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Abstract 
Effects of Brassica on the human gut microbiota 
 
 
Brassica vegetables, such as broccoli, are characterised by the presence of sulphur-
containing compounds, termed glucosinolates, which are associated with potential 
health benefits for humans. Glucosinolates are metabolised in the gut by members of 
the gut microbiota, producing biologically active breakdown products, such as 
isothiocyanates. The effects of consuming Brassica on the composition of the gut 
microbiota, and the bacterial mechanisms employed for glucosinolate metabolism, are 
unclear, and forms the basis of the research presented in this thesis. 
 
Culturing human faecal microbiotas in an in vitro batch fermentation model identified 
the bacterial-mediated reduction of glucoraphanin and glucoiberin to glucoerucin and 
glucoiberverin, respectively. An Escherichia coli strain was found to exhibit reductase 
activity on glucoraphanin and the broccoli-derived compound S-methylcysteine 
sulphoxide, through the reduction of the sulphoxide moiety. Within this fermentation 
model, the relative proportions of members of the genus Lactobacillus were found to 
significantly increase when the microbiota was repeatedly exposed to a broccoli 
leachate, and 16S rDNA sequencing identified these as L. fermentum. Metabolite 
analysis detected relatively high concentrations of lactate and short-chain fatty acids 
when faecal microbiotas were cultured in the presence of broccoli leachates, compared 
to a glucose control media. 
 
A human dietary study investigating the effects of Brassica on the microbiota 
composition revealed a significant association between dietary Brassica and changes 
to the relative proportions of a number of bacteria, many of which belong to the 
Clostridiales. Further studies are required to reveal the nature of this association, and 
whether the presence of glucosinolates may have been a factor. 
 
The work presented in this thesis highlights the strong connection between diet, the gut 
microbiota, and the potential health benefits to the host that may be derived from the 
bacterial metabolism of dietary compounds. 
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1. General introduction
 
 
 2 
1.1 Dietary Brassica vegetables 
The family Brassicaceae consists of approximately 3,500 species within 350 genera, 
including the genus Brassica [1]. Several important food crops are cultivars within the 
species Brassica oleracea, including broccoli (var. italica), cauliflower (var. botrytis), 
and cabbage (var. capitata). In addition, members of  B. rapa (e.g. pak choi), B. napus 
(e.g. swede), and B. juncea (e.g. mustard greens) are also regularly consumed 
worldwide [2]. Brassica vegetables are a rich source of fibres, vitamins, minerals, 
carotenoids, and phenolic compounds, and contain relatively high levels of sulphur-
containing compounds, such as S-methylcysteine sulphoxide (SMCSO) and 
glucosinolates, which add to the characteristic flavour and aroma of these vegetables 
[3, 4]. Traka et al performed total sulphur analysis on several broccoli cultivars, 
including the Beneforté® high-glucoraphanin hybrids, and found that much of the 
sulphur was incorporated into sulphate (29.4%), methionine-derived glucosinolates 
(21.4%), and SMCSO (13.6%) [5]. 
 
1.1.1 Glucosinolate structure 
Glucosinolates are typical of the order Capparales, but are also found in the genus 
Drypetes, of the family Putranjivaceae. There are between 120 and 200 known 
glucosinolates, which all share a basic chemical structure (Figure 1.1) [6, 7]. 
Glucosinolates are β-thioglucoside N-hydroxysulphates, with a sulphur-linked β-D-
glucopyranose moiety and a variable side-chain (R), which is derived from one of eight 
amino acids: alanine, phenylalanine, leucine, isoleucine, tyrosine, tryptophan, valine, 
methionine, and chain-elongated homologs of methionine and phenylalanine [7-10]. 
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Figure 1.1: The basic structure of the glucosinolate molecule, where R denotes the 
variable side-chain. 
 
Each glucosinolate contains a central carbon atom that is bound to a thioglucose group 
via a sulphur atom, to a sulphate group via a nitrogen atom, and to a side group [11]. 
The variation in side groups amongst glucosinolates is responsible for the varying 
biological activities of these compounds. Aliphatic glucosinolates are derived from 
alanine, leucine, isoleucine, methionine or valine, whereas those that are derived from 
phenylalanine or tyrosine are aromatic glucosinolates, and indole glucosinolates are 
derived from tryptophan [12]. The structures of some of the more abundant 
glucosinolates observed in nature can be found in Table 1.1 and Table 1.2. 
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Table 9.1: The most abundant aliphatic glucosinolates found in nature. 
Class Semi-systematic name Trivial name R group 
Aliphatic 
 
3-Butenyl Gluconapin 
GSL
2
 
(R)-2-Hydroxy-3-butenyl Progoitrin 
GSL
2
 
2-Propenyl Sinigrin 
GSL
2
 
4-Methylsulphinylbutyl Glucoraphanin 
3
GSL
 
3-Methylsulphinylpropyl Glucoiberin 
3
GSL
 
4-Methylthiobutyl Glucoerucin 3
GSL
 
3-Methylthiopropyl Glucoiberverin 
3
GSL  
4-Pentenyl Glucobrassicanapin 
GSL
2
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Table 1.2: The most abundant aromatic and indolic glucosinolates found in nature. 
Class Semi-systematic name Trivial name R group 
Aromatic 
 
Benzyl Glucotropaeolin 
GSL
 
2-Phenylethyl Gluconasturtiin 
GSL  
Indolic 
3-Indolylmethyl Glucobrassicin 
GSL
 
4-Hydroxy-3-indolylmethyl 4-hydroxyglucobrassicin 
GSL
 
4-Methoxy-3-indolylmethyl 4-Methoxyglucobrassicin 
GSL
3
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1.1.2 Biosynthesis of glucosinolates 
Biosynthesis of glucosinolates can be divided into three stages: chain elongation of 
pre-cursor amino acids (methionine & phenylalanine only), formation of the core 
glucosinolate structure, and secondary modifications of the amino acid side-chain. 
 
1.1.2.1 Chain elongation 
The largest group of chain-elongated glucosinolates are the methionine-derived 
glucosinolates [13]. Using the plant model, Arabidopsis thaliana, the first deamination 
reaction was identified as being performed by branched-chain amino acid 
aminotransferase 4 (BCAT4) [14, 15], whilst the transamination that yields 
homomethionine was accomplished by BCAT3 (Figure 1.2). 
 
 
Figure 1.2: The chain elongation stage in the biosynthetic pathway for aliphatic and 
indolic glucosinolates in Arabidopsis (adapted from [15]). Abbreviations: BCAT = 
branched-chain amino acid aminotransferase; BAT = bile acid transporter. 
 
BCAT4 is localised in the cytosol, whilst the remaining enzymes involved in chain 
elongation are localised in the chloroplast. The biosynthesis of the core glucosinolate 
structure occurs in the cytosol, indicating that 2-oxo acids are imported into the 
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chloroplast and the resulting chain-elongated amino acids are exported back out to the 
cytosol [12, 15, 16]. Based on co-expression analysis, and its transactivation by three 
aliphatic glucosinolate regulators (MYB28, MYB29 and MYB76), the chloroplast-
localised bile acid transporter BAT5 was identified as a candidate transporter [15, 17, 
18]. Work involving bat5 knockdown mutants, BAT5 amiRNA knockdown plants, and in 
planta feeding studies suggest that BAT5 functions as an importer of 2-oxo acids into 
the chloroplast, but the role of BAT5 has yet to be conclusively established [17-19]. 
 
1.1.2.2 Core structure 
The construction of the glucosinolate core begins with cytochromes P450, of the 
CYP79 family, converting the precursor amino acids to aldoximes (Figure 1.3) [15, 20-
23]. The aldoximes are oxidised to either nitrile oxides or aci-nitro compounds by 
cytochromes P450, of the CYP83 family. CYP83A1 converts the aliphatic aldoximes, 
and CYP83B1 metabolises the phenylalanine-derived and tryptophan-derived 
acetaldoximes [15, 24-26]. Following the conjugation of the activated aldoximes to a 
sulphur donor, these products are converted to thiohydroximates by the carbon-sulphur 
(C-S) lyase, SUR1 [27]. The thiohydroximates are then S-glycosylated by 
glucosyltransferases of the UGT74 family to form desulphoglucosinolates. Finally, the 
desulphoglucosinolates are sulphated by the sulphotransferases SOT16, SOT17 and 
SOT18 to form glucosinolates. SOT16 metabolises tryptophan- and phenylalanine-
derived desulphoglucosinolates, whilst SOT17 and SOT18 favour long-chained 
aliphatic substrates [28]. 
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Figure 1.3: Biosynthesis of the core glucosinolate structure for aliphatic (left) and 
aromatic/indolic glucosinolates (right) in Arabidopsis (adapted from [15]). Abbreviations: 
Glc = glucose; Gly = glycine; In = 3’-indolyl; γ-Glu = γ-glutamyl 
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1.1.2.3 Side-chain modification 
The biological activity of glucosinolates is largely determined by the structure of the 
side-chain. Secondary modifications for aliphatic glucosinolates include alkenylations, 
hydroxylations, oxygenations and benzoylations, whilst those of aromatic and indolic 
glucosinolates consist of hydroxylations and methoxylations [15]. Quantitative trait 
locus (QTL) analyses have identified four gene loci responsible for side-chain variability 
of aliphatic glucosinolates in Arabidopsis, named GS-ELONG (related to methionine 
side-chain elongation), GS-OX, GS-AOP and GS-OH [29]. Studies on the 
Brassicaceae-specific subgroup of flavin monooxygenase (FMO) genes (FMOGS-OX1-5) 
have shown that FMOGS-OX1-5 S-oxygenate short- and long-chained aliphatic 
glucosinolates, albeit with different chain-length specificity [15, 30, 31].  
 
1.1.2.4 Exploiting the regulatory gene MYB28 
A complex network of transcription factors regulates the biosynthesis of glucosinolates 
in response to both abiotic and biotic stress. Of these factors, the R2R3 MYB family are 
the best characterised and can be divided into two groups: high aliphatic glucosinolate 
(HAG) 1-3, and high indolic glucosinolate (HIG) 1-3. HAG 1-3 is comprised of MYB28, 
MYB76 and MYB29, which are specifically involved in the control of aliphatic 
glucosinolate synthesis [32-36]. High-glucoraphanin broccoli hybrids were developed 
by crossing standard broccoli cultivars with the wild broccoli species, Brassica villosa 
[5]. These hybrids were commercialised under the name Beneforté® broccoli, and 
contain 2.5 – 3 times the glucoraphanin content of standard broccoli cultivars. The 
increased glucoraphanin content is considered to be due to the hybrids being 
heterozygous for Myb28 B. villosa allele and a Myb28 broccoli allele [5]. The Myb28 
transcription factor has been demonstrated to play an important role in the biosynthesis 
of methionine-derived glucosinolates, and sulphate assimilation [33, 35, 37]. 
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1.1.3 Plant myrosinase enzymes 
Glucosinolates are hydrolysed by glycosylated thioglucosidases called myrosinases 
(E.C 3.2.1.147), which produce an unstable thiohydroximate-O-sulphonate (Figure 
1.4).  
 
 
Figure 1.4: The production of the thiohydroximate-O-sulphonate though the action of 
plant myrosinase. 
 
Glucosinolates are spatially separated from myrosinases within the plant, but tissue 
damage, such as can be caused by infection, pest attack, or mechanical damage, 
results in cellular breakdown and exposes the glucosinolates to the myrosinase 
enzyme. O-glycosidases are ubiquitous in plants, but myrosinase is the only known S-
glycosidase, and it is strongly activated by ascorbic acid [38]. Myrosinase is a member 
of the glycoside hydrolase family 1, but unlike other members of the family, it lacks the 
acid/base residue in its active site [39-41]. Although its active site resembles that of the 
O-glycosidases, they differ with respect to one of the catalytic residues: whereas O-
glycosidases have a carboxylate residue, which functions as the general base, 
myrosinase has a glutamine residue [39]. The hydrolysis of glucosinolates by 
myrosinases releases glucose and sulphate (via a Lossen-like rearrangement), and 
produces an isothiocyanate (ITC), thiocyanate, nitrile, epithionitrile, oxazolidine-2-
thione, or other less common products (Figure 1.5) [42, 43]. 
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Figure 1.5: The generation of glucosinolate hydrolysis products by myrosinase, via the 
formation of thiohydroximate-O-sulphonate. The conditions that are believed to favour 
particular hydrolysis products are indicated (adapted from [43]). Abbreviations: ESP = 
Epithiospecifier protein. 
 
1.1.4 Glucosinolate hydrolysis products 
Several factors influence the formation of different hydrolysis products, such as the 
glucosinolate structure, pH, and the presence of metal ions (e.g. Fe2+) or specifier 
proteins. For example, ITCs are generally produced at a neutral pH (~pH 7), whereas 
nitriles are thought to be favoured at a lower pH (~pH 4) [44]. A recent study observed 
nitrile production within a pH range of 3.7 – 7.6 during bacterial fermentations with 
glucosinolates, however it is possible that this may be reflective of differences between 
the plant and bacterial enzyme activities [45]. It has also been shown that nitriles are 
produced when glucosinolates undergo non-enzymatic hydrolysis catalysed by Fe2+ 
[46]. 
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The most prevalent products are ITCs, which result from a spontaneous Lossen-like 
rearrangement in the absence of the epithiospecifier protein (ESP) [42]. ITCs play an 
important part in plant defence and are toxic to a diverse range of organisms including 
insects, bacteria, fungi and nematodes. It has been shown that ITCs can cleave 
disulphide bonds and react with amino acids in vitro [47]. The volatility and polarity is 
determined by the molecular structure of the ITC and this enables access to different 
targets within an organism. An increase in molecular weight increases the toxicity, and 
aromatic ITCs have been found to be more toxic than aliphatic ITCs to various 
organisms [48-50]. Nitriles, epithionitriles, and organic thiocyanates are formed instead 
of ITCs when myrosinase and specifier proteins are both present. 
 
1.1.4.1 Epithiospecifier protein 
If ESPs are present during the myrosinase-catalysed hydrolysis of glucosinolates, 
these specifier proteins can redirect hydrolysis to generate nitriles or epithionitriles. It is 
believed that ferrous ions allow the formation of an intermediate between the 
thiohydroximate and ESP [42, 51-53]. Although the proteins do not form a stable 
complex, physical contact between ESP and myrosinase is necessary for epithionitrile 
formation to occur, and it has been predicted that ESPs contain a series of β-sheets 
called Kelch-motifs, which may play an important role in the interaction between ESP 
and myrosinase [54-56]. Another factor in the formation of nitriles or epithionitriles is 
the QTL named epithiospecifier modifier 1 (ESM1), which acts in concert with ESP to 
epistatically affect nitrile formation by repressing the production of nitriles in favour of 
the formation of ITCs from methionine-derived glucosinolates [57]. 
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1.1.4.2 Thiocyanate forming protein 
The formation of organic thiocyanates, via a thiocyanate forming protein (TFP), is not 
as prevalent as that of nitriles and epithionitriles. TFP activity has only been identified 
in a limited number of plant species including Thlaspi arvense, Eruca sativa, Alliaria 
petiolata, and Lepidium sativum [58]. The TFPs currently identified have differing 
substrate/product specificities, with some TFPs limited to benzylthiocyanate formation, 
and others limited to allylthiocyanate formation, from benzyl- and allylglucosinolate 
hydrolysis, respectively [58]. To date, organic thiocyanates have only been found to be 
generated from three glucosinolates: allylglucosinolate, benzylglucosinolate, and 4-
methylthiobutylglucosinolate [56]. As with ESP, TFP also contain Kelch repeats [59]. 
The structure of the glucosinolate is an important factor that contributes to whether 
ESP or TFP will generate epithionitriles or organic thiocyanates, respectively. 
Glucosinolates must have a terminal double bond in their side-chain for epithionitriles 
to be formed, and organic thiocyanate formation has only been found in glucosinolates 
that have side-chains that can form a stable carbocation [56]. If these structures are 
absent, simple nitriles will be generated upon myrosinase-catalysed hydrolysis in the 
presence of specifier proteins [60-64]. 
 
1.1.4.3 Nitrile specifier protein 
The nitrile specifier protein (NSP) was first identified in the larvae of Pieris rapae 
(cabbage white butterfly). It does not contain Kelch motifs, but it is made up of 
sequence repeats of approximately 200 amino acids each, and contains a signal 
peptide for excretion into the gut lumen. In the presence of NSP, myrosinase-catalysed 
hydrolysis of glucosinolates results in the generation of simple nitriles, instead of ITCs, 
which are not harmful to the larvae and are excreted in the faeces [56, 65, 66]. 
However, this protein did not display sequence similarity to plant ESP and, at the time, 
a comparable plant NSP had not been found. In 2009, six A. thaliana genes with a 
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relatively high degree of sequence similarity to A. thaliana ESP were identified and, of 
these, five were found to exhibit NSP activity (NSP1, NSP2, NSP3, NSP4, and NSP5). 
The sixth gene was deficient for specifier activity and was hypothesised to represent 
the ancestor of the gene family [52, 67]. A recent study performed phylogenetic 
analyses on putative specifier proteins in Brassicaceae, and concluded that ESPs likely 
evolved from NSPs at least 36 million years ago, with TFP activity evolving from ESPs 
[68]. Whilst ESP and TFP also have nitrile-specifier activity, NSP contributes 
exclusively to the formation of simple nitriles. 
 
 
1.2 Potential health benefits of glucosinolates 
Numerous studies have investigated the potential health benefits of Brassica 
vegetables, and glucosinolates specifically. Research indicates that the consumption of 
high levels of Brassica vegetables is associated with a decreased risk in developing 
various cancers, including lung, breast, prostate, pancreatic, and gastrointestinal 
cancers [69-73]. Other beneficial effects linked to a diet rich in Brassica include the 
maintenance of a healthy heart [74-77], a reduction in circulating levels of pro-
inflammatory cytokines [78], a reduced risk of type 2 diabetes [79-81], and the positive 
modulation of mitochondrial function [82]. The majority of the research on potential 
health benefits of glucosinolates has focused on the biological activity of sulforaphane, 
the ITC formed through the hydrolysis of glucoraphanin. 
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1.3 Bioavailability of glucosinolates 
Evidence indicates that the breakdown products of glucosinolates may have an impact 
on the risk of developing chronic diseases, but these compounds can only have an 
effect in vivo, if they are present at an appropriate site and at a sufficient concentration 
[83]. To ascertain their mechanisms of action and how they may influence health 
maintenance, it is necessary to consider which factors may limit the release of 
glucosinolates from the food matrix, the extent of absorption, and the fate of these 
compounds in an in vivo setting [83]. In general, the bioavailability of a dietary 
compound is dependent on several processes: Liberation, the release and dissolution 
of a compound from its food matrix; Absorption, the transfer of the compound from the 
site of administration to the blood circulation; Distribution, the diffusion of the 
compound or its transference to the extravascular space from the intravascular space; 
Metabolism, the biochemical conversion or transformation of the compound into forms 
that allow for efficient disposal; and Excretion, the disposal of metabolites/conjugates 
or unchanged compounds from the body through renal, biliary or pulmonary processes 
[83].  
 
1.3.1 Liberation of glucosinolates  
For efficient intestinal absorption to occur, compounds that reach the intestinal mucosal 
surface must be in a form that enables access to the enterocyte, or the ability to pass 
through the tight junctions of the epithelial layer [83]. As glucosinolates are encased 
within the plant tissue, it is necessary for this matrix to undergo disintegration to allow 
the dissolution of the glucosinolates into the intestinal milieu [83]. The amounts of 
glucosinolates present, methods of food processing, and the food matrix affects both 
liberation and absorption [84]. Chopping, cooking, and bacterial fermentation result in 
cell damage, degradation of glucosinolates, and the formation of different hydrolysis 
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products. Boiling has been found to cause a 30 - 60% reduction in glucosinolate 
content, whilst blanching only results in a minor reduction in glucosinolate levels, 
suggesting that the predominant reason for glucosinolate loss during cooking is the 
leaching of glucosinolates into the cooking liquor, rather than thermal degradation [83, 
85, 86]. The complexity of the food matrix can have a large effect on glucosinolate 
availability; glucosinolates present in a soup or juice will be more accessible than those 
embedded within plant tissue. In conjunction with ionisability and lipophilicity, aqueous 
solubility determines the dissolution of a compound and, due to the sulphate group and 
thioglucose moiety, intact glucosinolates are water-soluble [83]. 
 
The initial release of intact glucosinolates is likely to occur during the mastication of the 
vegetable. Due to the lack of myrosinase activity in human saliva, the formation of 
hydrolysis products from glucosinolates is dependent on the activity of the plant 
myrosinase during mastication. Whether glucosinolate hydrolysis occurs during 
mastication of cooked Brassica vegetables can depend on the choice of cooking 
method, as it has been shown that microwaving vegetables completely abolishes 
myrosinase activity [87, 88]. Processing techniques determines the degree of cell 
disruption, and ESP activity, as well as the activity of myrosinase [83]. A high level of 
thermal cell disruption results in a large release of glucosinolates, and whilst 
myrosinase is relatively heat stable, ESP is heat sensitive. After processing, if active 
myrosinase is present, the release of the glucosinolates via cell disruption allows for 
enzymatic glucosinolate hydrolysis, and relatively high amounts of the corresponding 
hydrolysis products.  
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1.3.2 Digestion of glucosinolates 
In a study evaluating the concentration of glucosinolates in the ileal digesta of pigs, it 
was proposed that approximately 60% of glucosinolates are able to reach the colon 
intact [89]. Similar results were found in two rat studies, with 55% of the initial dose of 
glucosinolates recovered from the gastrointestinal tract in one study, and the second 
study reporting 50% of the initial dose in the rat large intestine [90, 91]. It is thought that 
the losses of total glucosinolates during peptic and small intestinal digestion is due to 
three main processes: acidic hydrolysis, non-specific binding, and hydrolysis by plant 
myrosinase [83]. 
 
The majority of glucosinolates were found to be relatively stable when exposed to 
acidic conditions (pH 2) that mimic those found in the empty stomach [92]. A study 
examining the effects of incubating rapeseed meal with pepsin-HCL and the contents 
of porcine small intestine found a ~15% reduction in total glucosinolate contents after in 
vitro gastric digestion, and a 25 - 37% reduction when this was followed by an in vitro 
simulation of a 4-hour digestion in the small intestine [93]. The pepsin-HCL and porcine 
small intestinal treatments had a larger effect on glucosinolate content than was 
observed when glucosinolates were tested under acidic conditions [92, 93]. It was 
suggested that processes, such as non-specific binding and further degradation of the 
plant material, would have likely had a substantial effect on the observed glucosinolate 
losses [83]. 
 
A study examining the bioavailability of glucosinolates in rats observed a loss of the 
initial dose of glucosinolates in the intestinal contents (24%) and intestinal tissue 
homogenate (42%), which was suggested to be a result of non-specific binding of 
glucosinolates to the homogenised material [94]. A combination of the acidic conditions 
in the stomach and the activity of digestive enzymes, results in the lysis of vegetative 
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cells, and the subsequent release of glucosinolates and myrosinase [83]. Thus the 
hydrolysis of glucosinolates by active plant myrosinase, can occur during the passage 
of glucosinolates to the colon, leading to the production of the bioactive compounds in 
both the upper and lower gastrointestinal tract 
 
1.3.3 Absorption & distribution of glucosinolates 
It has been proposed that intact glucosinolates are absorbed through the gut epithelium 
[95-97]. This was later supported by a study that examined the transport of allyl 
glucosinolates in everted gut sacs from the small intestine and colon of rodents, in 
which the transport rate of intact glucosinolates was observed to be both structure and 
side-chain dependent [94]. This study suggested that intact glucosinolates could only 
be absorbed by passive diffusion or facilitated transport [94]. Recent research has 
reported the presence of intact glucosinolates in plasma, albeit at relatively low 
concentrations [98-102]. The permeation of tissue membranes must occur to enable 
the entry of ITCs, and this is thought to happen in the same manner as described for 
intestinal absorption [103]. ITCs must be present as unbound compounds or L-cysteine 
derivatives in order to passively diffuse into the cells, with passive diffusion being 
driven by GSH conjugation within the cell [103-106]. Studies on the cellular effects of 
ITCs in the presence or absence of excessive GSH or L-cysteine indicated that the 
equilibrium between bound and free ITC is an important factor in enabling the passage 
of cellular membranes, and that organ specific effects of ITCs in vivo may be linked to 
organ-specific differences in GSH concentration [83, 107]. After absorption into 
epithelial cells of the gut, ITCs spontaneously conjugate with GSH (typically present at 
concentrations of 1 – 10 mM), an action that may be promoted by glutathione 
transferases [108]. This is followed by the export of the GSH conjugate to the systemic 
circulation via the multidrug resistance associated protein-1 (MRP1), MRP2 and P-
glycoprotein-1 (Pgp-1) [108-110]. 
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1.3.4 Metabolism & excretion of glucosinolates and their products 
Even if there is a high degree of absorption for a compound, bioavailability may be 
restricted depending on the speed and degree of metabolism. It has been observed 
that the total urinary excretion of dithiocarbamates is higher following consumption of 
ITCs, compared to consumption of the corresponding intact glucosinolates [111-114]. 
Shapiro et al reported a 6-fold increase in the cumulative excretion of dithiocarbamates 
after ITC consumption, and a significantly faster peak excretion (4 hours vs 8 hours), 
when compared to glucosinolate consumption [114]. Several studies have reported 
variation between individuals regarding the excretion of glucosinolate hydrolysis 
products from a known dose of glucosinolates, with recovery rates ranging between 
~1% and 45% [91, 111-114]. 
 
Following intestinal absorption of ITCs, the liver is the second metabolic barrier [83]. 
Due to the high levels of GSH, and GST activity, the liver is a site of increased 
conjugation of GSH with ITCs, enabling the accumulation of ITCs [83, 104, 115]. A 
result of the accumulation of ITCs is a concomitant decrease of GSH, and elevation of 
the binding of ITCs to cellular macromolecules [106]. The ITC structure influences the 
extent of this binding and the rates of enzymatic and non-enzymatic conjugation with 
GSH [83, 115]. Several studies have indicated that the reduction of glucosinolates and 
ITCs may occur in the liver, with evidence that glucosinolates, ITCs, and ITC 
conjugates can undergo enterohepatic circulation [98, 116]. 
 
The formation of the corresponding mercapturic acids from the GSH conjugates 
predominantly takes place in the kidney. The isopeptide bond, between the γ-carbonyl 
of the glutamate residue and the amino group of cysteine, is cleaved through the 
activity of γ-glutamyltranspeptidase, with the resulting S-cysteinylglycine conjugate 
undergoing further breakdown by aminopeptidase M or cysteinylglycinase (Figure 1.6) 
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[83]. The resultant S-cysteine conjugate is N-acetylated into the equivalent N-acetyl-S-
cysteine conjugate through the activity of N-acetyltransferases (NAT), and excreted in 
the urine [83, 104, 117]. The formation of the mercapturic acid derivatives can occur 
prior to excretion in the kidney, due to the high concentrations of GSH in the liver, and 
high NAT activities in both the liver and kidney [83, 91, 116].  
 
 
Figure 1.6: The mercapturic acid pathway. Following the hydrolysis of glucosinolates, 
isothiocyanates conjugate with glutathione, and sequential cleavage reactions produce the 
mercapturic acids, which are excreted in the urine. 
 
The metabolism of specific ITCs, and their potential chemopreventive effects, may be 
influenced by polymorphisms within the genes encoding GST enzymes. It has been 
demonstrated that individuals with GSTM1 and/or GSTT1 null genotypes benefit from 
an increased protective effect of high cruciferous vegetable intake on the risk of lung 
cancer [118]. However, other studies suggest that GSTM1 positive individuals receive 
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an increased protection from cancer following the ingestion of cruciferous vegetables 
than GSTM1 null individuals, and that the GSTM1 null genotype is associated with a 
greater rate of excretion of sulforaphane metabolites [119-121]. It is likely that the 
effects of GST polymorphisms on cancer protection from cruciferous vegetables are 
more complex than first thought, and may differ dependent on which 
glucosinolates/ITCs are consumed.  
 
 
1.4 Bacterial metabolism of glucosinolates 
Through the use of in vitro experiments, in which pure or mixed cultures of bacteria 
were incubated with glucosinolates, it has been confirmed that various bacterial 
species that populate the human gut, such as Bacteroides thetaiotaomicron, 
Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Lactobacillus agilis, 
and particular Bifidobacterium sp. and Peptostreptococcus sp., are able to metabolise 
glucosinolates in culture [90, 122-126]. One of the earliest studies into this was 
performed in 1972 using papaya (Carica papaya L.) seeds, which are known to contain 
a high concentration of benzyl glucosinolates [127]. Homogenates of mature papaya 
seeds were found to produce an odour of hydrogen sulphide (H2S), and tested positive 
for sulphide after an overnight incubation at room temperature. Gram-negative, rod-
shaped bacteria were identified from the seed homogenates using microscopy 
techniques, and it was postulated that the production of H2S might have resulted from 
the microbial degradation of benzyl ITC (BITC) [127]. The addition of chloramphenicol, 
or heat-treating the homogenate, inhibited the formation of H2S [127]. Of the bacteria 
isolated from the BITC-enriched papaya pulp homogenates, 14 were classified as 
members of Enterobacter cloacae, with the remaining two classified as the genera 
Citrobacter and Hafnia from the family Enterobacteriaceae. The E. cloacae isolates 
were found to produce H2S from BITC, whilst the Citrobacter and Hafnia isolates, as 
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well as the E. cloacae type strain, were found to generate either minimal or no sulphide 
when tested. Further study with one of the E. cloacae isolates (strain P6A) identified 
that the kinetics of benzylamine formation from BITC corresponded to the production of 
H2S [127]. 
 
In 1995 a research group investigated 42 Lactobacillus strains for the ability to degrade 
sinigrin. Three of these strains (R16, KG25, and KG31) were linked to a decrease in 
sinigrin content, with Lactobacillus agilis R16 found to exhibit the greatest sinigrin-
degrading ability [125]. Experimental work with resting cells demonstrated that the 
sinigrin-degrading activity of L. agilis R16 could be induced by culturing the bacteria in 
the presence of sinigrin. Following incubation of the induced cells with a mixture of 
sinigrin and glucose, the glucose disappeared after 1 hour, whilst the sinigrin levels 
remained constant. After 4 hours, 80% of the sinigrin had been degraded, and after 24 
hours this too had been fully depleted [125]. The sinigrin-degrading activity was found 
to be associated with the presence of intact cells; when cell-free extracts were used, 
sinigrin degradation was not observed. This is supported by other work, such as that of 
Ohtsuru and Hata, in which it was found that the myrosinase-like enzyme obtained 
from the fungus Aspergillus niger was unstable, even in the presence of stabilising 
agents [128, 129]. This suggested that functioning bacterial myrosinase activity may 
either be cell-associated or intracellular [125]. 
 
Bifidobacterium species are commonly found in human faecal microflora and they are 
known to have beneficial effects on the host [123, 130, 131]. The ability to hydrolyse 
glucosinolates was investigated in three strains of Bifidobacterium species: B. 
adolescentis JCM 7045, B. longum JCM 7050, and B. pseudocatenulatum JCM 7040. 
This was performed in vitro, using sinigrin and glucotropaeolin, and the digestive 
products were analysed using gas chromatography-mass spectrometry (GC-MS) [123]. 
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Degradation of sinigrin and glucotropaeolin was observed with all three strains, and 
was associated with a decrease in the pH of the medium (7.1 to 5.2). The major 
products identified were the nitrile derivatives of the two glucosinolates, which may 
have been a result of the increasing acidity of the medium. Sinigrin degradation was 
found to be similar in all three strains, 20 - 48% and 72 - 83% of the initial amount of 
0.5 mM was degraded in the 24 and 48 hour cultivation, respectively, and the 
degradation of glucotropaeolin by B. adolescentis followed a similar pattern [123]. No 
sinigrin-digestive activity was seen when the supernatant of the 12 hour-cultured B. 
adolescentis was tested, indicating that any glucosinolate-digesting enzymes were 
unlikely to have been secreted into the medium. However, an apparent activity to 
degrade sinigrin was perceived in a cell-free extract prepared from sonically crushed 
cells of B. adolescentis [123]. This activity increased in the presence of 0.5 mM L-
ascorbic acid, which indicates that ascorbic acid may be an activator of bacterial 
myrosinase, as has been observed for plant myrosinase [123]. 
 
In 2001, proton nuclear magnetic resonance (1H NMR) spectroscopy was employed to 
study the biotransformation of sinigrin and glucotropaeolin by the human colonic 
microbiota in vitro [132]. Additionally, it was investigated whether glucosinolate 
metabolism by the gut microbiota would be hindered by the availability of glucose, by 
incubating stool samples with a mixture of sinigrin and glucotropaeolin in the presence, 
or absence, of glucose. They showed that sinigrin and glucotropaeolin were 
transformed by the human faecal flora into allylamine and benzylamine, respectively, 
and that the presence of glucose had no effect on the nature of the metabolites, or the 
rate of glucosinolate transformation [132]. These results contrasted with those of 
previous studies that showed that the human microbiota generated ITCs from 
glucosinolates [90, 91, 133]. The presence of allylamine and benzylamine, in 
conjunction with the low amounts of ITCs recovered (10 - 20%), may indicate that the 
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glucosinolates were degraded to form ITCs, and the ITCs were then hydrolysed to form 
allylamine and benzylamine. This is supported by work performed by Tang et al. that 
showed that BITC could be converted to benzylamine when incubated with a 
suspension of E. cloacae isolated from papaya pulp [127, 132]. 
 
Between 2009 and 2011, two human dietary studies were performed in an attempt to 
identify the relationship between the gut microbiota and the metabolism of 
glucosinolates, using terminal restriction fragment length polymorphism (tRFLP) [124, 
134]. In one study, urinary ITC levels of subjects were examined after a standardised 
broccoli meal, enabling the selection of high- and low-ITC excreters. Correlations 
between the levels of  urinary ITCs excreted and differences in the composition of the 
faecal microbiotas were then investigated [124]. Following a 48 hour anaerobic 
incubation with glucoraphanin, it was shown that the faecal bacteria from the high-ITC 
excreters were able to degrade more glucoraphanin than those from the low-ITC 
excreters. However, the overall bacterial community structure did not differ significantly 
between the two groups, either in faecal samples or in ex vivo faecal bacterial 
cultivation samples [124]. This may indicate functional redundancy in glucosinolate 
metabolism for gut bacteria; although not closely related phylogenetically, bacterial 
species may have the same metabolic function. This is supported by previous work, as 
bacteria that are able to hydrolyse glucosinolates have been found in several different 
phylogenetic families, including Actinobacteria, Firmicutes and Bacteroidetes [90, 122, 
123, 125, 126, 135]. It has been hypothesised that a relatively high level of lateral gene 
transfer may occur between bacterial species within the gut environment [136-138]. 
Lateral gene transfer could explain the diversity between gut-associated bacteria that 
exhibit glucosinolate hydrolysis activity, and suggest that metabolomic or 
metatranscriptomic approaches may be the best path towards understanding microbial 
glucosinolate hydrolysis. 
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The same group performed a human dietary study concerned with the effects of a 
Brassica diet on the composition of the gut microbiota. Participants were asked to 
consume a diet rich in Brassica, but restricted of other vegetables, fruits, high-fibre and 
whole grain foods [134]. tRFLP analysis of the composition of the faecal microbiotas 
after the Brassica diet, was compared to the microbiota composition after following the 
dietary restrictions without the supplementation of Brassica vegetables. Modifications 
to the microbiota composition associated with the Brassica diet was observed, with 
changes to the relative proportions of bacterial species putatively identified as 
Eubacterium hallii, Phascolarctobacterium faecium, Alistipes putredinis, and 
Eggerthella sp. [134]. However, it was not reported whether the proportions of these 
bacteria were positively or negatively associated with the consumption of the Brassica 
diet. The bacterial sequences obtained from the dietary study were compared to a 
reference set of 96 16S rDNA sequences, which were obtained from a faecal sample of 
a single individual. This reference set is unlikely to represent the less dominant 
members of the bacterial community, and does not take into consideration the 
variability of the gut microbiota between individuals. Therefore, limitations in the 
analysis suggests that further research would be required to elucidate the effects of 
Brassica diets on the community composition of the human gut microbiota. 
 
1.4.1 Bacterial reduction of glucosinolates 
Research into the bacterial metabolism of glucosinolates has indicated that gut bacteria 
are able to convert glucosinolates to their reduced form via a reduction reaction. A 
study performed by Kassahun et al showed interconversion between sulforaphane and 
erucin in a rat model [116]. When rats were dosed with erucin via intraperitoneal 
injection, urine analysis detected erucin N-acetylcysteine accounting for 28.5% of the 
initial dose, and sulforaphane N-acetylcysteine which represented 66.7% of the initial 
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ITC dose. However, dosing with sulforaphane led to the urinary excretion of 60.2% of 
the dose as sulforaphane N-acetylcysteine, and 11.6% in the form of erucin N-
acetylcysteine [139]. This suggested that although the reduction of sulforaphane 
occurred, the oxidation of erucin to sulforaphane was more prevalent. Another study 
investigated the metabolism of glucoraphanin in rats and detected the reduced 
analogue, glucoerucin, in the bile [98]. Thus indicating that glucoraphanin could be 
reduced in vivo, and that enterohepatic circulation may play a role in glucosinolate 
metabolism. A study performed in mice in 2014 reported that the reduction of 
sulforaphane to erucin was observed, and that erucin was the preferred form in the 
liver, kidney, and bladder [140]. Evidence for the interconversion of sulforaphane and 
erucin has also been reported in humans [141-143]. 
 
Direct evidence that the reduction of glucosinolates is performed by the human gut 
microbiota was first reported in 2012 [142]. A human faecal microbiota was cultured in 
a media containing glucoraphanin in an anaerobic batch fermentation model. 
Glucoerucin was observed in the media after 8 hours, with the amount increasing after 
24 hours, and erucin nitrile was also detected. The conversion of glucoraphanin did not 
occur with heat-sterilised faecal samples, indicating that the reduction of glucoraphanin 
was a bacterial-mediated reaction. Recently, two studies from independent research 
groups identified human-derived bacterial isolates that had the ability to reduce 
glucosinolates and ITCs under in vitro conditions [45, 144]. E. coli Nissle 1917, E. coli 
VL8, and E. cloacae reduced glucoraphanin and glucoiberin to glucoerucin and 
glucoiberverin, respectively. The reduction reaction targeted the sulphoxide group 
present on glucoraphanin and glucoiberin, and was not influenced by oxygen levels, or 
pH [144]. E. coli VL8 was shown to also convert sulforaphane to erucin, suggesting that 
the sulphoxide of ITCs are also a target of the reductase enzyme (Figure 1.7) [45]. 
Luang-In et al suggested that the glucosinolate core skeleton induced the reductase 
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reaction, and that the bacterial reduction of glucosinolates may reflect different 
mechanisms of glucosinolate metabolism by human gut bacteria [45]. To date, all 
bacteria exhibiting glucosinolate reductase activity are members of the 
Enterobacteriaceae, which may reflect a phylogenetic-specific mechanism of 
glucosinolate metabolism. 
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Figure 1.7: Potential methods of glucosinolate hydrolysis, and glucosinolate/ITC 
interconversion, by human gut bacteria. 
 
1.4.2 S-methylcysteine sulphoxide 
Both SMCSO and glucosinolates are thought to play a role in plant defence, largely 
through the biological activity of their hydrolysis products [145-148]. Although 
glucosinolates are often the focus of Brassica research, SMCSO is present at higher 
concentrations (1 - 2% dry weight) than glucosinolates (0.1 – 0.6% dry weight) in 
Brassica vegetables [149, 150]. However, as SMCSO is more prone to thermal 
degradation than glucosinolates, the difference in content may not be reflected in the 
gastrointestinal tract following the consumption of cooked vegetables [151]. 
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In 1973, SMCSO was linked to cases of severe haemolytic anaemia that was reported 
to develop in ruminants that were fed a diet consisting mainly of Brassica crops [150]. 
The effects of SMCSO consumption was found to be dependent on the amount 
consumed (~15 to 20 g SMCSO per 100 kg liveweight per day could produce a 
haemolytic response), and the species of the animal [150]. Cattle and goats were the 
most susceptible, with sheep, fowl, and rats also affected, whilst rabbits, mice, 
hamsters, and guinea pigs did not exhibit symptoms of anaemia following consumption 
of SMCSO-containing crops [3, 150, 152-157]. Further research indicated that the 
differential response between species was likely due to differences in bacterial 
metabolic activity in the digestive system [157-159]. It was proposed that the ruminal 
bacteria were able to degrade SMCSO to the causative agent, dimethyl disulphide, that 
led to the depletion of glutathione in erythrocytes, which were subsequently damaged 
by reactive oxygen species [150, 160, 161]. These studies culminated in the 
development of cultivars of Brassica species with significantly reduced levels of 
SMCSO that are now used as cattle fodder, and have led to a steep reduction in 
Brassica-associated anaemia [150, 162, 163]. 
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Figure 1.8: Metabolic schematic for the reduction or degradation of S-methylcysteine 
sulphoxide (SMCSO). Schematic displaying the metabolic products formed through the 
degradation of SMCSO by the action of cysteine lyase, and the reduced analogue of SMCSO. 
 
Members of the human gut microbiota have been reported to exhibit the cysteine 
sulphoxide lyase activity necessary to degrade SMCSO (Figure 1.8) [164-166]. 
However, the amount of SMCSO present in 150 g of Brassica, such as broccoli, 
cauliflower, or Brussel’s sprouts would represent a dose of ~0.5 g/100 kg body weight 
in a 70 kg individual [150]. Therefore, the levels of SMCSO that could be expected to 
be found in the human gut are far lower than the amounts that were observed to cause 
negative effects on cattle health. Conversely, there are indications that the bacterial 
degradation of low levels of SMCSO may produce beneficial effects on human health. 
SMCSO, and its breakdown product dimethyl thiosulphinate, were found to produce a 
33% reduction in micronucleus formation in mice treated with the carcinogen 
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benzo[α]pyrene [167]. Dimethyl thiosulphinate has also been associated with an 
increased life expectancy in mice inoculated with a fibrosarcoma cell line, and an 
inhibition of the in vitro proliferation of human colon and prostate cancer cell lines [150, 
168-170]. The SMCSO metabolite dimethyl thiosulphonate has been observed to exert 
anti-mutagenic effects against mitomycin C in Drosophila melanogaster and mice [171], 
and aflatoxin B1 in treated rat bone marrow cells [172]. Dimethyl thiosulphonate was 
also found to reduce the occurrence of aberrant crypt foci, and induce a regression of 
the associated lesions, in azoxymethane-treated rats [173, 174]. As well as anti-
mutagenic properties, SMCSO has also been reported to have cholesterol- and 
triglyceride-lowering effects, and anti-hyperlipidemic and anti-diabetic properties in rats 
[175-179].  
 
 
1.5 Human gut microbiota 
It has been suggested that there are tenfold more microbes in the human body than 
there are human cells, and that they encode 100-fold more unique genes than the 
human genome [180, 181]. The majority of these microbes reside in the gut and, as 
well as affecting human physiology, they contribute to energy harvest from food [182, 
183]. It has been approximated that the colon contains ~1.5 kg of bacteria, with an 
approximate density of 1012 cells per gram of intestinal content [184, 185]. In the early 
years of human development, the gastrointestinal tract is colonised by a myriad of 
microbes, dominated by bacteria, which are collectively known as the gut microbiota. 
Many of the bacteria are derived from the mother during birth, and the mode of delivery 
(vaginal or caesarean section) influences the early microbiota of the infant. Vaginal 
birth is associated with a microbiota containing Lactobacillus and Prevotella species, 
whilst the microbiota of babies delivered by caesarean section harbour increased 
numbers of Staphylococcus and Propionibacterium species [186-188]. 
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1.5.1 Effects of the gut microbiota on human health 
The gut bacteria interact intimately with our body and contribute to human health, 
playing a critical role in the development of the immune system [189-192]. An altered 
gut microbiota (dysbiosis) has been associated with inflammatory bowel disorders 
(IBD) [193], type 2 diabetes [194-196], irritable bowel syndrome (IBS) [197, 198], 
coeliac disease [199, 200], obesity [201, 202], and colorectal cancer [203]. Faecal 
microbiota transplantation (FMT) is a therapeutic strategy that aims to restore the 
balance of the microbiota, and reduce the risk of developing health issues associated 
with dysbiosis [204, 205]. At present this therapy has had most success against 
Clostridium difficile infections [206, 207], but has also shown promise in treating IBD 
and IBS [208, 209]. Although some health complaints may be linked to specific 
members of the microbiota [210, 211], others are thought to be associated with a 
reduction in species diversity [181, 196, 212-214]. A recent surge in research has 
focused on the gut-brain axis, with studies indicating that the gut microbiota may be 
associated with some brain disorders, and can influence mood and sociality, largely 
through bacterial metabolites and their effects on gut hormones [215-221]. 
 
‘Colonisation resistance’ is the name given to the microbial barrier, formed by the gut 
microbiota, which inhibits the colonisation of the gut by pathogenic organisms [222]. 
Members of the microbiota can provoke a physiological response from the host e.g. 
stimulation of peristalsis, chemically modify bile salts, or induce immunological 
processes [223]. Alternately, the bacteria can directly interact with the potential 
pathogens by i) occupying mucosal receptors and the mucin layer to inhibit colonisation 
[224, 225], ii) creating a physiologically restrictive environment through the production 
of short-chain fatty acids, lowering the pH, or altering the oxidation-reduction potential, 
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iii) successfully competing for growth factors and nutrients, or iv) producing 
antimicrobial substances [223]. 
1.5.2 Community composition of the gut microbiota 
Microbes in the gut are faced with a selective pressure from both the host and 
microbial competitors, which will generally lead to a homeostasis of the ecosystem in 
which some species will occur in high abundance, whilst many others will be present in 
a low abundance [226]. Members of two bacterial phyla, Firmicutes and Bacteroidetes, 
dominate the distal gut microbiota, constituting more than 90% of the bacteria present 
in the total microbiota, followed by species of Proteobacteria, Actinobacteria and 
Verrucomicrobia [181, 202, 227, 228]. The clostridial clusters IV and XIVa are the most 
abundant members of the Firmicutes, with a lower representation of the cluster IX 
group, and it is thought that bacteria belonging to these groups may comprise 
approximately 60% of the colonic microbiota [229]. In addition to bacteria, the gut 
ecosystem is also known to contain members of the methanogenic archaea, which 
have been suggested to be temporally stable members of the gut microbiota, viruses, 
and bacteriophages [181, 228]. It is known that certain life changes such as 
medication, illness, and travel can affect the microbiota homeostasis in a temporary 
manner. The temporal instability of the microbiota caused by overseas travelling may 
be due to a combination of factors, such as stress, exposure to new environmental 
microbes, or disturbances of the circadian rhythms [228]. 
 
Many studies have focused on identifying the composition of the human gut microbiota, 
based on the 16S ribosomal-RNA-encoding gene, or analysis of phylogenetic 
microarrays [181, 202, 226, 230-236]. These studies have found variation in community 
composition and relative abundances within and between individuals, but it appears 
that the gene pool is largely conserved, indicating functional redundancy within the 
ecosystem [181, 202, 226, 227, 237]. In 2010, Qin et al used metagenomic sequencing 
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to analyse the faecal samples of 124 European individuals [181]. In total the cohort 
contained 1,000 – 1,150 bacterial species, with each individual having a minimum of 
160 species [181]. They identified 75 species common to more than 50% of individuals, 
and 57 species common to more than 90% of individuals [181]. Another group 
performed metagenomic analysis of human faecal samples, and it was posited that the 
gut microbiota may be stratified into three groups, termed enterotypes, characterised 
by a dominance of either Bacteroides, Prevotella, or Ruminococcus species [226]. 
There is some evidence that these enterotypes may be the result of the effects of long-
term dietary intake, as individuals with high levels of Bacteroides are often associated 
with a diet high in protein and fat, whilst those rich for Prevotella tend to consume high 
levels of fibre [238, 239]. 
 
Although much can be learned from studying the abundant species or genera within 
the gut microbiota, this alone cannot reveal the entire functional complexity of the gut 
ecosystem. It has been reported that low-abundance E. coli within one individual 
contributed more than 90% of two abundant proteins, PapC (COG3188) and FimA 
(COG3539), which are associated with bacterial pilus assembly [226]. It is likely that 
some low-abundance species, such as methanogens, may perform specialised 
functions that are beneficial to the host [240, 241]. 
 
1.5.3 Intestinal lactic acid bacteria 
An example of important low-abundance species can be found in the lactic acid 
bacteria (LAB), which include Lactobacillus species. Along with the genus 
Bifidobacterium, lactobacilli are important early colonisers of the gut. A culture-based 
study performed in 1999 investigated differences in the gut microbiotas of infants 
delivered vaginally or by caesarean section [242]. It was found that the intestinal 
colonisation of Lactobacillus, Bifidobacterium, and Bacteroides species was delayed in 
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infants delivered by caesarean section, compared to the infants born vaginally. 
Maternally-derived Lactobacillus and Bifidobacterium have been shown to be present 
in breast milk, and the oligosaccharides present in the milk sustain the growth of the 
infant microbiota [243-245]. The genus Lactobacillus contains bacteria that are 
considered to be beneficial to human health, and yet they have been reported to 
constitute less than 1% of the total adult bacterial community [246].  
 
Human gut lactobacilli have been demonstrated to play a role in maintaining microbiota 
homeostasis through immunomodulatory properties, the elimination of intestinal 
pathogens, the release of acidic compounds that subsequently lowers the pH, and the 
production of anti-microbial/anti-inflammatory compounds [247-251]. The LAB includes 
Streptococcus, Weisella, Lactococcus, Enterococcus, and Leuconastoc, as well as 
Lactobacillus, and are classified as either homofermenters or heterofermenters based 
on the end-products of fermentation (Figure 1.9) [252]. The LAB are characterised by 
the production of lactate, which can be used by other intestinal bacteria to generate 
short-chain fatty acids (SCFA) [253]. These bacterial waste products are considered to 
have a beneficial impact on human health, and will be discussed in more detail in 
section 1.5.6. 
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Figure 1.9: Schematic displaying glucose fermentation strategies by the lactic acid 
bacteria. 
 
1.5.4 Dietary effects on the gut microbiota 
Diet has a substantial effect on the composition of the gut microbiota, and 
subsequently human health. Human dietary interventions have reported compositional 
changes to the gut microbiota after short periods [254-258], and long-term dietary 
habits have been implicated in shaping the stable microbiota structure [238, 239, 259]. 
A study performed in 2010 investigated differences in the composition of the gut 
microbiota in children living in the urban city of Florence, compared to children in a 
village in Burkino Faso (BF) [238]. Members of the Bacteroidetes and Actinobacteria 
were more abundant in the microbiotas of children from BF, whilst relative proportions 
of Proteobacteria and Firmicutes were higher in those of the Florentine children. 
Xylanibacter, Prevotella, Treponema, and Butyrivibrio species were only observed in 
the children of BF, and this was considered to be a consequence of the high plant-
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based diet consumed in BF, compared to the high-fat diets common in the Western 
world [238]. A higher total amount of SCFAs was found in the faeces of the BF 
children, compared to the Florentine children, and this would seem to correlate with the 
high-fibre plant-based diet consumed by the BF children. 
 
When the microbiotas of the Hadza hunter-gatherer tribes in Tanzania were 
sequenced, gender-based differences were found, and this was hypothesised to be a 
consequence of the tasks assigned to men and women within the tribes [259]. Whilst 
the male members of the tribe may travel far from the camp in search of honey and 
meat, the female members stay close to the camp foraging for plants and tubers. All 
the food that is gathered is shared between the other members of the tribe, but 
snacking throughout the day leads to an increased consumption of the foods obtained 
by each group [259]. This snacking pattern may be responsible for the higher levels of 
Treponema that were detected in the microbiota of the Hadza women, compared to the 
men. The genus Treponema contains species that are efficient degraders of cellulose 
and xylan, which would be present at relatively high levels in the female colon due to 
the increased consumption of plant material [259]. The diets of the BF children and 
Hadza tribal members are alike in terms of being high in fibre and low in fat, and this 
was reflected in enrichment for Prevotella, Treponema, and Butyrivibrio, and a 
depletion of Bacteroides in both cohorts, compared to the Florentine children tested 
[238, 259]. 
 
The effect of a short-term diet on the long-term human gut microbiota composition was 
recently investigated in two independent studies [239, 254]. In 2011, Wu et al 
examined how two 10-day diets, characterised as high-fibre/low-fat and low-fibre/high-
fat, would affect the composition of the gut microbiota in ten individuals [239]. The 
microbiotas of the subjects were characterised based on the proposed enterotype 
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hypothesis, and the observation that a dominance of Prevotella is associated with a 
high-fibre diet, whilst a large relative abundance of Bacteroides may be linked to a high 
fat/protein diet [240]. Within 24 hours of consuming either of the diets, notable changes 
in the microbiota were observed, but the changes were not significant enough to cause 
a switch between the enterotype clusters associated with high-fibre or high-protein/fat 
consumption [239]. The other human dietary study was performed by David et al in 
2014 to examine how a plant-based diet may affect the gut microbiota, compared to an 
animal-based diet [254]. As with the Wu et al study, notable changes in the microbial 
communities were observed after a single day; the animal-based diet caused a 
significant increase in β-diversity compared to the pre-intervention baseline samples. 
Of the two diets, it was observed that the animal-based diet had the greatest effect on 
the gut microbiota, including an increase in the relative proportions of Bilophila 
wadsworthia [254]. It was posited that this was a reflection of an increase in bile acid 
secretion, which is known to reflect a high fat intake [260]. Increased levels of bile acids 
have been linked to the inhibition of some members of the Bacteroidetes and 
Firmicutes, and experiments using mice indicate a possible connection to the 
development of IBD and cancer [261-263]. These studies highlight the importance of 
the diet regarding the gut microbiota and human health, which may enable the use of 
long-term dietary changes as a means to combat the development of disease. 
 
Several studies have investigated the differences in the gut microbiota between 
omnivorous, vegetarian, and vegan humans [264-268]. Vegan subjects have been 
found to exhibit lower microbial counts of Bifidobacterium, Bacteroides, E. coli, and 
other Enterobacteriaceae species, compared to omnivorous subjects [264, 268]. It has 
been suggested that the reduced numbers of both E. coli and Enterobacteriaceae may 
be linked to low levels of dietary protein and a lower gut pH, whilst an increase in 
Bacteroides species have been linked to a protein-rich diet [238, 268]. A vegan diet is 
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associated with a higher consumption of carbohydrates and a higher fibre intake 
compared to omnivores, and this is known to lower the stool pH [269]. 
 
1.5.5 Effect of pH changes on gut bacteria 
The bacterial fermentation of dietary fibres results in the production of acidic 
compounds, such as lactate and SCFAs, which lowers the pH of the intestinal milieu. 
Intestinal bacteria that are able to ferment fibres are generally more tolerant of acidic 
environments, than non-fermenting bacteria. Studies focusing on the effects of pH on 
bacterial communities have observed marked differences in community composition 
within a pH range of 5.5 – 6.7 [270, 271]. Experiments culturing bacterial isolates and 
faecal bacterial communities at varying pH within a range of 5.5 – 6.7, have observed 
differential growth, community shifts, and changes to bacterial metabolite production 
[270, 271]. At a pH of 5.5 increased proportions of 19 of 23 Gram-positive anaerobes 
tested, and specifically members of the Roseburia group, were observed, whilst the 
proportions of Bacteroides species and E. coli decreased [270, 271]. Conversely, the 
proportions of E. coli and members of the Bacteroides increased when the pH was 
altered to 6.7 [270, 271]. Eubacterium rectale, which had accounted for 50% of all 16S 
rDNA sequences at pH 5.5, was not detected at pH 6.7 [270]. pH-associated changes 
to the microbiota composition have been fund to correlate to changes in the production 
of SCFAs. Butyrate concentrations were higher at pH 5.5 compared to a pH of 6.5, and 
this was directly related to the decreased proportions of the butyrate-producing 
members of the Roseburia group [271]. Propionate levels peaked when the medium 
had a pH of 6.5, and this coincided with an increase in the levels of the genus 
Bacteroides, which have been reported to contain propionate-producing species [271-
273]. Relatively small changes in the colonic pH can significantly affect the composition 
of the gut microbiota, and this can occur through the fermentation of dietary fibres, and 
subsequent production of SCFAs. 
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1.5.6 Short-chain fatty acid production 
The most prevalent SCFAs found in the human colon and stools are acetate, butyrate, 
and propionate, which have been reported to be present at a molar ratio of 60:20:20 
[274-276]. Total colonic SCFA concentrations range from ~70 – 140 mM in the 
proximal colon, and ~20 – 70 mM in the distal colon, and this is dependent on the diet 
[277]. The diet and the gut microbiota are inextricably linked through the production of 
metabolites, such as SCFAs. The consumption of fibre leads to bacterial fermentation 
and the production of SCFAs, which lowers the pH of the intestinal milieu and aids in 
the prevention of overgrowth of pH-sensitive pathogenic bacteria, such as Clostridium 
and Enterobacteriaceae species [270, 278, 279]. There are multiple pathways that 
various bacteria can employ to generate SCFAs from hexoses, pentoses, fucose, and 
rhamnose sugars (Figure 1.10). 
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Figure 1.10: Schematic of microbial short-chain fatty acid (SCFA) production. Metabolism 
of sugars by the human gut microbiota may lead to the production of the SCFAs, acetate, 
butyrate, propionate, or valerate, by various metabolic pathways (the acrylate, propanediol, 
succinate, or Wood-Ljungdahl pathways) (adapted from Louis et al [280]). Abbreviations: DHAP 
= dihydroxyacetone phosphate ; PEP = phosphoenolpyruvate 
 
Although SCFAs are bacterial waste products, produced to balance redox equivalent 
production, these compounds can be absorbed from the gut lumen and elicit beneficial 
properties on human health [281]. The nature of these beneficial properties differs 
dependent on the SCFA. Acetate is the only SCFA to reach relatively high 
concentrations in the peripheral blood (0.10 – 0.15 mM) and serves as an energy 
source for peripheral tissues [282, 283]. Acetate has also been shown to cross the 
blood-brain barrier and act to suppress appetite by influencing central hypothalamic 
mechanisms [284]. Propionate has been implicated in the enhancement of satiety and 
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is used by the liver as an energy source, as well as exhibiting anti-inflammatory, anti-
carcinogenic, anti-lipogenic, and cholesterol-lowering activity [282, 285-287]. Butyrate 
is perhaps the most widely studied SCFA, and is utilised as an energy source by the 
colonic epithelia [282]. Butyrate has been shown to affect genes and pathways 
involved in epithelial integrity, fatty acid oxidation, and apoptosis, by inducing histone 
hypermethylation through the inhibition of histone deacetylases [288-290]. 
 
SCFAs have been shown to exert activities by binding to the G protein-coupled 
receptors (GPRs) GPR41 and GPR43 [291, 292]. GPR41 is activated by propionate 
and butyrate, which leads to the expression of Gi/o protein in the peripheral nervous 
system, adipocytes, and the gut, promoting activation and growth of the sympathetic 
nervous system [291-293]. Activated GPR43 has been linked to the decrease of 
inflammatory cytokines in the intestine, and is more responsive to propionate and 
acetate, rather than butyrate, activating both Gi/o and Gq proteins in the gut and adipose 
tissue [291-293]. The production of SCFAs has also been shown to affect energy 
homeostasis and levels of gut peptides. Butyrate has been associated with a decrease 
in the rate of digestion and intestinal transit, leading to an increase in plasma insulin 
and satiety promotion, through an increase in the plasma levels of gastric inhibitory 
peptide (GIP), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), insulin, and amylin 
[291-293]. Propionate has also been found to increase the plasma levels of GIP, 
insulin, and amylin, although to a lesser degree than observed for butyrate [291-293]. 
Whilst acetate has not been found to affect these hormones, it has been reported to 
increase the release of leptin from fat cells [291, 292]. 
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1.6 Bacterial reductases 
Bacterial reductases are multi-purpose enzymes that are key to various processes that 
are crucial to the survival of bacteria. Respiration is a fundamental process which 
involves the transfer of electrons from low-redox-potential donors, and concludes in the 
reduction of a high-redox-potential electron acceptor [294]. The greatest amount of 
respiratory flexibility is found in bacteria and archaea, due to the wide range of electron 
acceptors that they are able to utilise. It has been reported that these organisms are 
able to use halogenated organics [295-297], radionuclides [298, 299], transition metals 
[300], metalloid oxy-anions [301, 302], and a range of nitrogen-based [303-306] and 
sulphur-based compounds [307-309]. Simala-Grant and Weiner researched the 
substrate specificity of the dimethyl sulphoxide reductase, DmsABC, of E. coli and 
found that it has a very broad substrate specificity [310]. It was identified that the 
anaerobic growth of E. coli on sulphoxide compounds was solely due to the activity of 
this reductase [310]. 
 
Some bacterial reductase enzymes are able to protect proteins from oxidative damage. 
Methionine residues are primary targets for oxidation, and this can lead to the loss of 
biological activity [311]. Methionine sulphoxide reductases (Msr) A and B are a class of 
highly conserved enzymes that are able to reverse methionine oxidation, and restore 
the biological activity of oxidised proteins [312]. Msr was first discovered in the cytosol 
of E. coli, and recently it was identified that these protein repair mechanisms are also 
present in the bacterial cell envelope [313]. Methionine residues within the protein 
compartment of the bacterial signalling recognition particle, Ffh, have been shown to 
be prone to oxidation resulting in a perturbation of the targeting of membrane proteins 
[313, 314]. Experiments using E. coli msr knockout mutants identified that msr activity 
was essential for the normal functioning of Ffh during aerobic growth [314]. 
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Bacterial reductases are also involved in maintaining homeostasis through the 
modification of proteins [315], the synthesis of DNA [316, 317], xenobiotic metabolism 
[318], and detoxification processes [319, 320]. The bacterial reduction of dietary 
compounds, such as sulphoxide-containing glucosinolates and cholesterol have also 
been reported [45, 142, 144, 321]. The reduction of dietary compounds may increase 
the range of biologically active metabolites, potentially with different biological activities, 
derived from the parent compound, and lead to a variety of potential health benefits for 
the human host from a single compound. 
 
 
1.7 Thesis aims 
1. To use an in vitro batch fermentation model to culture human faecal microbiotas in a 
broccoli leachate-containing media, in order to investigate: 
i) The metabolic fate of broccoli-derived glucosinolates when exposed to the human 
faecal microbiota. 
ii) The effects on the human faecal microbiota following a repeated exposure to a 
broccoli leachate. 
iii) Changes to bacterial metabolism caused by a repeated exposure to a broccoli 
leachate. 
iv) The identity of human gut bacteria able to metabolise glucosinolates and 
SMCSO. 
 
2. To examine the effects of two Brassica diets on the human gut microbiota through 
the use of a human intervention study. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER TWO 
 
2  Materials and methods 
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2.1 General reagents 
A 0.02 M sodium acetate solution was generated by adding 1.2 ml acetic acid glacial 
(Cat. # 01074131, Biosolve) to 990 ml 0.22 μm filtered water, adjusted to a pH of 5.0 
using sodium hydroxide, and adding 0.22 μm filtered water to a total volume of 1 L.  
 
DEAE Sephadex A25 (Cat. # 17-0170-01) and SP Sephadex C25 (Cat. # 17-0230-01) 
were obtained from GE Healthcare Life Sciences, and prepared in the same manner. 
Sephadex (26 g) was added to 200 ml 0.02 M sodium acetate, and filtered with 
Whatman GF/D 15 cm filter paper (Cat. # WHA1823150, Sigma Aldrich). The solid 
fraction was resuspended in 200 ml 0.02 M sodium acetate, and filtered a second time 
before it was resuspended in 2x volume 0.02 M sodium acetate. 
 
Sinigrin hydrate was supplied from Sigma Aldrich (Cat. # 85440), and glucotropaeolin 
was obtained from Dr Shikha Saha at the Institute of Food Research. A 16 mM stock 
solution was prepared of each for use as internal standards by adding 63.6 mg of 
sinigrin hydrate, or 72 mg of glucotropaeolin, to 10 ml of 0.22 μm filtered water.  
 
Dulbecco’s phosphate-buffered saline, no calcium, no magnesium (Cat. # 14200-067) 
was purchased from Life Technologies, and aliquots were diluted 10-fold in 0.22 μm 
filtered water prior to use.  
 
Sulforaphane was obtained from LKT Laboratories (Cat. # S8045). The synthesis of the 
sulforaphane conjugates of nitrile, N-acetyl-cysteine, cysteine, cysteine-glycine and 
glutathione, and erucin N-acetyl-cysteine were all produced by Dr Paul Needs at the 
Institute of Food Research. A 1 mg/ml stock solution of each was prepared in 0.22 μm 
filtered water. 
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Acetonitrile (Cat. # 10407440) and methanol (Cat. # 10674922) were purchased from 
Fisher Scientific, and were of high-performance liquid chromatography (HPLC) grade 
with a purity of 95% or greater. 
 
Dansyl chloride reagent was prepared by dissolving 0.2691 g dansyl chloride in 100 ml 
HPLC grade acetonitrile (ACN). A 0.1 M boric acid solution was generated by 
dissolving 0.6183 g boric acid in 100 ml of 0.22 μm filtered water. 
 
A 20 mM borate buffer was produced by dissolving 3.8 g sodium tetraborate 
decahydrate in 500 ml of 0.22 μm filtered water, and the pH was adjusted to 9.2 using 
0.1 M boric acid solution. 
 
A 50 mM ammonium acetate buffer was prepared by dissolving 3.854 g ammonium 
acetate in 1 L of 0.22 μm filtered water, and adjusted to pH 5 using 0.1 M acetic acid. 
 
A 0.1% ammonium acetate buffer was generated by mixing two components; A1 and 
A2. A1 was produced by weighing 0.25 g of ammonium acetate (Cat. # 1161030250, 
Merck Millipore) and adding 0.22 μm filtered water to a final volume of 250 ml. A2 was 
produced by adding 250 μl glacial acetic acid to a volumetric flask, and adding 0.22 μm 
filtered water to a final volume of 250 ml. A1 was added to A2 until a pH of 4 was 
reached, before the buffer solution was filtered through 0.60 μm filter paper (Cat. # 
DAWP04700, Merck Millipore). 
 
ACN with 0.1% acetic acid was generated by adding 250 μl glacial acetic acid to a 
volumetric flask, and adding HPLC grade ACN to a final volume of 250 ml. 
 
Sulfatase (Type H-1 from Helix pomatia) (Cat. # S9626, Sigma Aldrich) was purified 
before use. Sulfatase (300 mg) was dissolved in ice-cold 0.22 μm filtered water (12 ml), 
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ice-cold ethanol (12 ml) was added, and the solution was mixed thoroughly. Following 
centrifugation (3,000 x g, 4˚C, 6 minutes), the supernatant was mixed with ice-cold 
ethanol (1.5x volume), and centrifuged under the same conditions as previously stated, 
the pellet was dissolved in 0.22 μm filtered water (8 ml). Aliquots (2 ml) were passed 
consecutively through columns of DEAE Sephadex A25 and SP Sephadex C25 and 
stored at -20˚C. 
 
 
2.2 Generating a broccoli leachate 
Beneforté® broccoli (purchased from Marks & Spencer) was steamed in 180 g batches 
on the second tier of a pre-heated domestic steamer for 3 minutes. Immediately after 
steaming, the broccoli was cooled on dry ice, and stored at -20˚C. The frozen broccoli 
was freeze-dried using a benchtop modulyo freeze drier (Edwards Vacuum), and milled 
using a domestic coffee-bean grinder. Two grams of powdered broccoli were added to 
tubes containing 40 ml of 0.22 μm filtered water (room temperature). The tubes were 
vortexed and incubated at room temperature for 60 minutes, prior to centrifugation at 
5,292 x g, 21˚C, for 10 minutes. The supernatant was passed through a Whatman 
GF/D filter under vacuum, and the water content was reduced approximately 10-fold 
using a BUCHI Rotavapor R-210 rotary evaporator set to 60˚C, 72 mbar. The 
concentrated broccoli leachate was filtered under vacuum through a succession of 
decreasing pore size filters in the following order: Whatman GF/A (Cat. # 1820125, 
Sigma Aldrich), Whatman GF/B (Cat. # 1821090, Sigma Aldrich), nitrocellulose 
membrane 60 μm (Cat. # DAWP04700, Merck Millipore), nitrocellulose membrane 40 
μm (Cat. # HAWP04700, Merck Millipore), and nitrocellulose membrane 0.22 μm (Cat. 
# GSWP04700, Merck Millipore). A 600 ul aliquot was analysed as described below 
(section 2.5). The remaining leachate was filtered through a Sartolab BT500 0.2 μm 
bottle top filter unit (Cat. # 18085E, Sartorius) into a sterile bottle and stored at 4˚C. 
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2.3 Bacterial media 
Chemostat nutrient media (CNM) is a medium designed to provide the nutrients 
necessary for the cultivation of bacteria found in the human gastrointestinal tract. Luria 
Broth (LB) is a widely used bacterial culture medium that is rich in nutrients, and often 
used to culture members of the Enterobacteriaceae. Man Rogosa Sharpe (MRS) is a 
medium that was designed for the cultivation of lactobacilli. Brain-heart infusion agar 
(BHI) is a general purpose solid growth medium that is rich in nutrients. The 
composition of each medium is shown in Table 2.1. 
 
Table 2.1: Compositions of bacterial culture media 
Media Compositions in 1 L H2O pH 
BHI 
agar 
12.5 g brain infusion solids, 5 g beef heart infusion solids, 10 g 
proteose peptone, 5 g sodium chloride, 2 g glucose, 2.5 g 
disodium phosphate, 10 g agar 
7.4 ± 0.2 
CNM 
2 g peptone water, 2 g yeast extract, 0.01 g NaCl, 0.04 g K2HPO4, 
0.04 g KH2PO4, 0.01 g MgSO4.6H2O, 0.01 g CaCl2.6H2O, 2 g 
NaHCO3, 0.5 g cysteine.HCL.H2O, 0.5 g bile salts, 2 ml Tween-
80, 0.005 g Hemin, 10 μl vitamin K1 
7.0 ± 0.2 
LB 
 
10g tryptone, 5g yeast extract, 10g NaCl 
 
7.0 ± 0.2 
MRS 
agar 
8 g peptone, 5 g yeast extract, 5 g CH3COONa.3H2O, 2 g 
K2HPO4, 2 g C6H17N3O7, 5 ml salt solution (0.2 g CaCl2 
anhydrous, 0.2 g MgSO4, 1 g K2HPO4, 1 g KH2PO4, 10 g 
NaHCO3, 2 g NaCl in 1 L), 1 ml Tween 80, 20 g glucose, 3 g agar  
6.5 ± 0.2 
 
CNM was the basal bacterial medium used in the production of the broccoli leachate-
containing (BL) media and the glucose (GL) media (chapter 3). These media were 
used for the in vitro batch fermentation culturing experiments using human faecal 
microbiotas (chapters 4, 5, and 6), and the faecal bacteria screening assays (chapter 
7). 
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In chapter 7, MRS was used to grow bacterial isolates for identification by 16S rDNA 
sequencing, and LB was used in the bacterial screening assays investigating 
glucoraphanin metabolism by human faecal bacteria. BHI agar was used as described 
in section 2.8.5. 
 
 
2.4 Liquid chromatography mass spectrometry analysis 
2.4.1 Glucosinolate hydrolysis product analysis 
Glucosinolate hydrolysis products and their conjugates were analysed by LC-MS/MS 
using a Phenomenex Luna C18(2) (100 x 2 mm id, 3 μm particle size) column 
connected to a model 1290 infinity 6490 Triple Quad LC-MS/MS system (Agilent 
Technologies) comprised of a degasser, binary pump, cooled autosampler, column 
oven, diode array detector and 6490 mass spectrometer. The samples were eluted at 
0.25 ml/min with a gradient of increasing acidified ACN: solvent A (0.1% ammonium 
acetate buffer), solvent B (ACN with 0.1% acetic acid). The gradient increased from 5% 
acidified ACN to 100% over 9.1 minutes, prior to re-equilibration to 5% acidified ACN 
for 2.9 minutes. The LC eluent flow was sprayed into the mass spectrometer interface 
without splitting. ITCs and their conjugates were monitored by tandem MS using 
multiple reaction monitoring (MRM) with electrospray ionisation source in the positive 
ion mode. Identification was achieved on the basis of retention time and product ions, 
and quantification was performed through the use of calibration standards. 
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2.4.2 S-methylcysteine sulphoxide analysis 
Cultured samples (100 μl) from the experiments using bacteria isolated from human 
faecal bacteria (chapter 7) were mixed with 250 μl dansyl chloride reagent (10 mM) and 
650 μl borate buffer (20 mM; pH 9.2).The samples were incubated at room temperature 
for 30 min, prior to centrifugation at 17,000 x g for 10 min at room temperature. The 
supernatants (~ 800 μl) were transferred to autosampler vials for LC-MS analysis. S-
methylcysteine sulphoxide (SMCSO) was analysed by LC-MS with a Waters 
Spherisorb ODS2 (4.6 x 250 mm id, 5 μm particle size) column connected to an 1100 
series Single Quad LC-MS system (Agilent Technologies) comprised of a 1200 series 
degasser, binary pump, cooled autosampler, column oven, diode array detector and 
G1956B  mass spectrometer. The samples were eluted at 0.9 ml/min with a gradient of 
increasing acidified methanol (MeOH): solvent A (50 mM ammonium acetate adjusted 
to pH 5 with 0.1 M acetic acid), solvent B (MeOH (1 L) containing 10 mM hydrochloric 
acid (826 μl 37% conc.)). The gradient increased from 30% acidified MeOH to 40% 
over 35 minutes, then increased from 40% to 75% over 25 minutes, and after 10 
minutes this re-equilibrated to 30% acidified MeOH for 5 minutes. The LC eluent flow 
was sprayed into the mass spectrometer interface without splitting. SMCSO isomers 
were monitored by MS using full scan acquisition with electrospray ionisation source in 
the positive ion mode. Identification was achieved on the basis of retention time, and 
quantification was performed through the use of calibration standards. 
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2.5 Glucosinolate analysis 
2.5.1 Desulphoglucosinolate extraction 
Glucosinolates were measured using an adapted method that converts glucosinolates 
to their corresponding desulphoglucosinolates [322]. Briefly, 200 μl of the samples 
were added to 4.8 ml of 70% MeOH (70˚C), and 50 μl of 16 mM sinigrin was added to 
act as an internal standard. Samples were mixed, and 3 ml aliquots were added to ion 
exchange columns. Once the samples had passed through, the columns were washed 
with 0.22 μm filtered water (2x 0.5 ml) and 0.02 M sodium acetate (2x 0.5 ml), prior to 
the addition of purified sulphatase (75 μl). Following an overnight incubation at room 
temperature, the desulphoglucosinolates were eluted by the consecutive application of 
0.22 μm filtered water (2x 0.5 ml and 0.25 ml), and the eluent was collected and 
analysed using HPLC. 
 
2.5.2 Analysis of desulphoglucosinolates by high-performance 
liquid chromatography 
The desulphoglucosinolates were analysed using a model 1100 HPLC system (Agilent 
Technologies) equipped with a degasser, binary pump, cooled autosampler, column 
oven and diode array detector, with a Waters Spherisorb ODS2 (4.6 x 250 mm id, 5 μm 
particle size) column attached. Filtered (0.22 μm) water and ACN were used as 
solvents with a flow rate of 1 ml/min, and a gradient of increasing ACN from 5% to 90% 
over 32 minutes, prior to re-equilibration to 5% for 14 minutes. Desulphoglucosinolate 
quantification was achieved, using absorbance at 229 nm, by comparison with the peak 
area ratio of the internal standard (sinigrin), and the relevant desulphoglucosinolate 
ultraviolet (UV) light relative response factor (Table 2.2).  
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Table 2.2: Desulphoglucosinolate UV relative response factors for HPLC analysis 
Desulphoglucosinolate Correction factor Ref. 
Desulphoglucobrassicin 0.29 [323] 
Desulphoglucoerucin 1.00 [324] 
Desulphoglucoiberin 1.13 [323] 
Desulphoglucoiberverin 0.80 [325] 
Desulphoglucoraphanin 1.13 [323] 
Desulphoglucotropaeolin 0.95 [326] 
Desulphogluconasturtiin 0.95 [326] 
Desulphoprogoitrin 1.09 [326] 
Desulphosinigrin 1.00 [326] 
Desulpho4-hydoxyglucobrassicin 0.28 [326] 
Desulpho4-methoxyglucobrassicin 0.20 [326] 
Desulpho4-methoxyindolylmethyl 0.25 [327] 
 
 
2.6 Metabolite analysis 
2.6.1 Sample preparation 
Cultured bacterial samples (2 ml) from the in vitro batch fermentation experiments were 
centrifuged at 9,600 x g at room temperature for 5 minutes. The supernatants were 
passed through a 0.2 μm syringe filter (Cat. # 16532K, Sartorius) into sterile tubes and 
stored at -20˚C. 
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 Prior to analysis, the samples were thawed at room temperature, 600 μl was added to 
70 μl of 0.4 mM phosphate buffer (K2HPO4 (2.82 g) and NaH2PO4 (0.54 g) [pH 7.4]) 
made up in 100% D2O (total volume 200 ml), containing 0.1% NaN3 (104 mg), and 2.5 
mM  sodium 3-(Trimethylsilyl)-propionate-d4, (TSP) (34 mg) as a chemical shift 
reference. The samples were mixed, and 600 μl was transferred into a 5 mm NMR tube 
for spectral acquisition. 
 
2.6.2 Proton nuclear magnetic resonance spectrometry analysis 
The 1H NMR spectra were recorded at 600 MHz on a Bruker Avance spectrometer 
(Bruker BioSpin GmbH) running Topspin 2.0 software and fitted with a cryoprobe and a 
60-slot autosampler. Each 1H NMR spectrum was acquired with 64 scans, a spectral 
width of 12,500 Hz, an acquisition time of 2.62 seconds, and a relaxation delay of 3 
seconds. The “noesypr1d” pre-saturation sequence was used to suppress the residual 
water signal with a low-power selective irradiation at the water frequency during the 
recycle delay and a mixing time of 10 ms. Spectra were transformed using the 
Chenomx NMR Suite software with a 0.3 Hz line broadening, and were manually 
phased, baseline corrected, and referenced by setting the TSP methyl signal to 0 ppm.  
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2.7 Glucoraphanin stability assay 
A broccoli leachate was prepared as described in section 2.2, and the glucoraphanin 
content was analysed in three technical replicates using HPLC (section 2.5). An aliquot 
of the broccoli leachate and CNM were added to six sterile 25 ml glass bottles to a 
volume of 19 ml, to produce a glucoraphanin concentration of 100 μM in a final 
inoculated volume of 20 ml. The tubes were transferred to an anaerobic cabinet (Don 
Whitley Scientific, UK) set at 37˚C to deoxygenate (85% nitrogen, 10% hydrogen, 5% 
carbon dioxide) for 12 hours. 
 
A 5 g portion of the faecal sample was placed into a stomacher bag (Cat. # 
BA6141/STR, Seward Ltd, UK) using a sterilised spatula. Deoxygenated sterile 1x PBS 
was added to the stomacher bag to obtain a mass of 50 g. The stomacher bag was 
placed into the Stomacher 400 circulator (Seward Ltd, UK) and the faecal matter was 
homogenised at 230 rpm, for 45 seconds. A 10 ml aliquot of the homogenised faecal 
suspension was transferred into a 20 ml sterile glass bottle and placed into an 
anaerobic cabinet set at 37˚C. The faecal suspension was mixed, prior to 1 ml being 
added to three of the six bottles of deoxygenated media. The inoculated media were 
gently mixed and incubated in the anaerobic cabinet (37˚C) for 24 hours. Control 
samples were generated through the addition of 1 ml 0.22μm filtered water, in place of 
1 ml faecal suspension, to the remaining three bottles of deoxygenated media. 2 ml 
aliquots were collected from each replicate, centrifuged at 9,600 x g for 5 minutes, and 
the supernatant was passed through a filter (0.2 μm) into a sterile tube. The filtered 
supernatants were stored at -20˚C prior to glucoraphanin analysis using HPLC (section 
2.5). 
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2.8 Culturing human faecal microbiotas 
2.8.1 Recruitment of faecal donors 
Faecal material was obtained from participants recruited onto a human study 
(ENGAGE; ClinicalTrials.gov: NCT01927666) who gave written informed consent for 
their stools to be used in these experiments. Details of the faecal donors are displayed 
in Table 2.3. The ENGAGE study protocol was approved by the Human Research 
Governance Committee at the Institute of Food Research and Hertfordshire Research 
Ethics Committee (HREC 12/EE/0483). All study participants were assessed for 
eligibility on the basis of a health questionnaire and the results of clinical laboratory 
tests. All participants produced a urine sample for urinalysis which was screened for 
protein, blood, leukocytes, nitrites, glucose, ketones, bilirubin and urobilinogen via a 
dipstick urine test (Multistix® SG; Siemens). 
The following exclusions applied: 
 suffering from or had previously suffered from any gastrointestinal disease, 
gastrointestinal disorders and/or surgery including regular diarrhoea or 
constipation (excluding asymptomatic hiatus hernia), or the study 
intervention/procedure was indicated to be inadvisable. 
 diagnosed with a long-term medical condition that may affect the study outcome 
e.g. cardiovascular disease, haemophilia, anaemia, diabetes, or glaucoma. 
 was or had been pregnant in the last 12 months, or breast-feeding. 
 on medication that may affect the study outcome. 
 used antibiotics within the previous month or on long-term antibiotic therapy. 
 regularly taking laxatives. 
 intermittently used pre- or probiotics unless willing to abstain for a set period 
(continued regular use, defined as >3 times per week, was acceptable). 
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 taking  certain dietary supplements or herbal remedies unless willing to abstain 
for a set period. 
 regular/recent use of colonic irrigation or other bowel cleansing techniques. 
 involved in another research project that includes dietary intervention and/or 
collection of blood. 
 given blood sample to another research project within a set period (dependent 
on total volume). 
 donated or intended to donate blood within a set period. 
 Body Mass Index (BMI) less than 20 kg/m2. 
 unwilling to provide details of General Practitioner (GP). 
 unable to provide written informed consent. 
 related to or living with a member of the study team. 
 unable to swallow capsules. 
 no access to a freezer. 
 clinical results at screening judged by the medical advisor to be indicative of a 
health problem or affect study outcome. 
 
Table 2.3: Age, gender, Body Mass Index (BMI), and smoking status of the faecal donors. 
Faecal donors Age (years) Gender BMI (kg/m2) Smoker 
Subject 1 44 Male 24.1 N 
Subject 2 24 Female 23.3 N 
Subject 3 52 Female 20.9 N 
Subject 4 50 Female 38.4 N 
Subject 5 61 Female 20.5 N 
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2.8.2 Preparation of broccoli leachate-containing media and 
glucose media 
Three technical replicates of the broccoli leachate stock solution (section 2.2) were 
analysed, as described in section 2.5, to identify the concentration of glucoraphanin. A 
sterile inoculating loop was used to streak the broccoli leachate on a BHI agar plate, 
which was incubated anaerobically at 37˚C, to confirm that the leachate was not 
contaminated. The volumes of CNM and broccoli leachate necessary to make a final 
solution of 30 μmoles glucoraphanin BL media were added to five 50 ml sterilised glass 
bottles in a laminar flow hood. The bottles containing the BL media were transferred to 
an anaerobic cabinet set at 37˚C to deoxygenate for 12 hours. The glucose medium 
was generated by adding 113.79 mg of glucose (Cat. # G-7528, Sigma Aldrich) to a 1 L 
bottle to produce a medium containing 30 μmoles of glucose, prior to being autoclaved. 
CNM was added to the bottle up to 1 L, mixed, and 47.5 ml was dispensed into each of 
the five 50 ml sterilised bottles in a laminar flow hood. The bottles containing the 30 
μmole GL medium were transferred to an anaerobic cabinet, set to 37˚C, to 
deoxygenate for 12 hours. 
 
2.8.3 Culturing human faecal microbiotas in a broccoli leachate-
containing media and a glucose media 
A 17 g portion of faecal material was placed into a Seward stomacher bag using a 
sterilised spatula. Deoxygenated 1x PBS was added to the stomacher bag to obtain a 
mass of 170 g. The stomacher bag was placed into the Stomacher 400 circulator and 
the faecal matter was homogenised at 230 rpm, for 45 seconds. A 100 ml aliquot of the 
homogenised faecal suspension was transferred into a 150 ml sterile glass bottle and 
placed into an anaerobic cabinet set at 37˚C. The faecal suspension was inverted 4 
times and 8 ml aliquots were transferred to sterile tubes for 16S rDNA phylogenetic 
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analysis. A 2 ml aliquot was taken from each of the four replicates of the BL and GL 
media for analysis of the pre-intervention samples. A 2.5 ml aliquot of the faecal 
suspension was added to the four replicates of each media, and these were gently 
mixed. The remaining bottle of the BL media and the GL media were not inoculated, 
and were incubated alongside the cultured media to act as indicators of possible 
contamination. Following 12 hours incubation, the cultured media were inverted 4 
times, and aliquots were removed from each replicate and placed in sterile tubes for 
analysis using multiple techniques. Fresh media was prepared (as described in section 
2.8.2) and seeded with a 2.5 ml aliquot from each replicate, to start the next cycle of 
culturing (Figure 2.1). 
 
 
Figure 2.1: Experimental design for culturing human faecal microbiotas. Broccoli leachate 
(BL) media (47.5 ml) and glucose (GL) media (47.5 ml) were seeded with a faecal suspension 
(2.5 ml) and cultured for 12 hr at 37˚C, under anaerobic conditions. After a 12 hr incubation 
period, samples were taken for HPLC, LC-MS/MS, 
1
H NMR spectroscopy, and 16S rDNA 
sequencing. A 2.5 ml aliquot was used to seed the respective fresh media, and this was 
repeated for four cycles of bacterial enrichment. This was performed identically for five human 
faecal microbiotas. 
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2.8.4 Sample storage 
Three 2 ml aliquots, collected from each replicate after each 12 hour cycle, were 
centrifuged at 9,600 x g for 5 minutes; and the supernatant was passed through a filter 
(0.2 μm) into a sterile tube. The filtered supernatants were stored at -80˚C for HPLC 
(section 2.5), LC-MS/MS (section 2.4.1), and 1H NMR spectroscopy (section 2.6) 
analysis. A further 8 ml aliquot, collected from each replicate after each 12 hour cycle, 
was centrifuged at 23,500 x g, at 4˚C, for 15 minutes. The supernatant was discarded 
and the pellets were stored at -80˚C for 16S rDNA phylogenetic analysis. This was 
repeated for each of the five cultured human faecal samples.  
 
2.8.5 Bacterial isolation from cultured microbiotas 
Following the fourth 12 hour cycle, each of the four replicates from both the BL and GL 
cultured media were streaked onto separate BHI agar plates. The plates were 
incubated in an anaerobic cabinet at 37˚C for 2 days. Twelve bacterial colonies were 
selected from each of the eight plates. Each bacterial colony isolated from the BL 
media was transferred to a single well of a 96-well microtitre plate containing 300 μl of 
30 μmole BL media. Bacterial colonies isolated from the GL media were transferred to 
wells containing 300 μl of 30 μmole GL media. The microtitre plate was incubated 
overnight in an anaerobic cabinet at 37˚C. The entire contents of each well were 
transferred to sterile tubes containing 500 μl of 50% glycerol, and these glycerol stocks 
were stored at -80˚C. 
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2.9  Phylogenetic analysis of cultured human faecal 
microbiotas 
2.9.1 Extracting bacterial DNA 
The bacterial pellets were thawed at room temperature, and the bacterial DNA was 
extracted using a FastDNA SPIN Kit for Soil (Cat. # 116560200, MP Biomedicals, UK) 
following a method adapted from Maukonen et al [328]. Briefly, 200 mg of sample was 
transferred to a sterile tube containing 978 μl sodium phosphate buffer and 122 μl MT 
buffer, vortexed, and incubated at 4˚C for 45 minutes. Samples were vortexed, 
transferred to Lysing Matrix E tubes, and mechanically disrupted three times with a 
FastPrep instrument (MP Biomedicals, UK) at 6.5 ms-1 for 60 seconds. The 
supernatant was transferred to a sterile tube containing 250 μl protein precipitation 
solution (PPS), mixed well, and centrifuged at 16,800 x g for 5 minutes. The 
supernatant was transferred to a sterile tube containing 1 ml Binding Matrix 
suspension, mixed for 2 minutes, then incubated at room temperature for 3 minutes. 
600 μl of the mixture was added to a SPIN filter tube, centrifuged at 14,500 x g for 1 
minute, then underwent three 500 μl DNase-free salt/ethanol wash solution (SEWS-M) 
wash steps, centrifuged at 14,500 x g for 1 minute between each step. DNA was eluted 
with 50 μl of DNase/Pyrogen free DNA elution solution (DES) and stored at -20˚C. 
 
2.9.1.1 Assessing bacterial DNA extraction 
A 1% (w/v) agarose solution was generated by adding 0.5 g agarose powder (Cat. # 
A9539, Sigma Aldrich) to 500 ml 0.5 mM Tris/borate/ethylenediaminetetraacetic acid 
(TBE) buffer, and microwaved (800 watts) for 2 – 3 min at full power until clear. The 1% 
(w/v) agarose solution was added to an electrophoresis gel tray in a horizontal gel 
electrophoresis system (Cat. # 1068BD, Life Technologies, Inc.), with a toothed comb 
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fitted (to a depth of ~6 mm) and left to set at room temperature (~30 min). TBE (5 mM) 
was added to a depth that covered the 1% (w/v) agarose gel. 2 μl Bioline Hyperladder I 
(Cat. # BIO-33053VTFP) was added to the outer well to act as a molecular weight 
marker, and 2 μl DNA and 0.5 μl 10x loading dye were added to the remaining wells. 
The gel was run at 100 volts (PPV 300/200.4, Northumbria Biologicals Ltd) until the 
samples had migrated towards the end of the gel (~45 min), as indicated by the loading 
dye. The gels were submerged in an ethidium bromide solution (5 μg-10 μg/ml 
ethidium bromide in water) for ~30 min and rinsed with water. DNA fragments were 
visualised and photographed using the AlphaImager HP system (Alpha Innotech) under 
UV trans-illumination. 
 
Total DNA was quantified using the NanoDrop ND-1000 UV/vis spectrophotometer 
(NanoDrop Technologies, Inc., USA) and the ND-1000 version 3.8.1 computer 
software. The nucleic acid, DNA-50 settings were selected, DNase/Pyrogen free water 
(1.2 μl) was used as a blank, and 1.2 μl of each sample was analysed. 
 
2.9.2 Amplification and high throughput 454 pyrosequencing of 
16S rDNA gene regions 
PCR amplification of the 16S rDNA gene and subsequent DNA sequencing was 
performed at the Animal Health and Veterinary Laboratories Agency (AHVLA) using 
454 pyrosequencing, as described by Ellis et al [329]. Briefly, universal primers for the 
V4 and V5 regions of the 16S rDNA gene were used to amplify the extracted DNA. The 
primers U515F (5’-GTGYCAGCMGCCGCGGTA) and U927R (5’-
CCCGYCAATTCMTTTRAGT) include at their 5’ end one of two adaptor sequences 
(adaptor A and B) used in the 454-sequencing library preparation. The adaptor 
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sequences are linked to a unique 10 base multiplex identifier (MID) tag barcode, with a 
minimum 2 base difference between each pair, to enable sample identification. 
FastStart HiFi polymerase (Roche Diagnostics Ltd) was used to amplify the ribosomal 
gene regions using the following conditions: 94˚C for 3 minutes; 30 cycles of 94˚C for 
30 seconds, 55˚C for 45 seconds, 72˚C for 1 minute; followed by one cycle of 72˚C for 
8 minutes. Amplicon purification was performed using Ampure XP magnetic beads 
(Beckman Coulter), and a Picogreen assay (Invitrogen) was used to measure the 
sample concentrations prior to normalisation. Samples were pooled into batches of 8 
and subjected to unidirectional sequencing from the forward primer on the GS FLX 
Titanium platform following the manufacturer’s instructions (Roche Diagnostics). 
 
2.9.3 Bioinformatic analysis of 16S rDNA 
Sequencing reads were analysed using the Quantitative Insights Into Microbial Ecology 
(QIIME) pipeline and Ribosomal Database Project (RDP) classifier [330, 331]. All 
sequences were filtered to meet the following criteria: read length within 200 and 1,000 
bp; a maximum of 6 ambiguous bases; a minimum average quality score of 25 within a 
50 bp window; and exact match to primer sequences. ChimeraSlayer was used to filter 
trimmed reads for chimeric sequences, and RDP classifier (version 2.10) was used for 
bacterial taxonomy assignment with a confidence value threshold of 50%, with trimmed 
reads clustered into OTUs at 97% identity level. Observed species (number of unique 
OTUs), PD whole tree (measure of phylogenetic diversity), chao1 (species richness), 
and the Shannon Index (species richness and evenness) were used to compute alpha 
diversity and rarefaction plots. Weighted and unweighted UniFrac distances were used 
to generate beta-diversity PCoA plots, which were visualised using the Emperor tool. 
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2.10  Identifying bacterial isolates 
2.10.1 Reviving glycerol stocks of bacterial isolates 
MRS agar plates were transferred to an anaerobic cabinet set at 37˚C, and placed on a 
grid template. Fifty glycerol stocks of bacterial isolates obtained from experiments 
culturing human faecal microbiotas (section 2.8.5), were transferred to the anaerobic 
cabinet. Two microliters were taken from each of the glycerol stocks and added to the 
two MRS agar plates, at a recorded grid position. One plate was incubated in the 
anaerobic cabinet at 37˚C, and the other was transferred to a static incubator set at 
37˚C. Both plates were incubated for 12 hours. 
 
2.10.2 Colony polymerase chain reaction 
Colony polymerase chain reaction (PCR) was performed on 19 colonies of the revived 
glycerol stocks that exhibited strong growth. Each colony was transferred to a 50 μl 
PCR tube containing 10 μl of 0.22 μm filtered water, and resuspended. The 
resuspended colonies were boiled in a pre-heated Hybaid PCR Sprint thermal cycler 
(Thermo Scientific) set at 95˚C, for 5 min. This was used as the template DNA for the 
following PCR reactions. The PCR reaction mixture was generated by adding the 
following together: 10 μl 5x colourless GoTaq reaction buffer (Cat. # M792A, Promega, 
UK), 0.4 μl (25 mM) deoxynucleotide triphosphate (dNTP) Mix (Cat. # 10180740, 
Thermo Fisher Scientific, Inc.), 1 μl (20 μM) universal forward primer (AmpF 5’- 
GAGAGTTTGATYCTGGCTCAG -3’) [332], 1 μl (20 μM) universal reverse primer 
(AmpR 5’- AAGGAGGTGATCCARCCGCA -3’) [332], 36.35 μl 0.22 μm filtered water, 1 
μl template DNA, and 0.25 μl GoTaq DNA polymerase (Cat. # M3175, Promega, UK), 
to make a final volume of 50 μl per reaction mixture. A negative control was generated 
as above with the template DNA replaced with filtered water. 
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The thermal cycler was programmed to perform the amplifications as previously 
described by Nueno-Palop & Narbad [333] with minor modifications: one cycle of 95˚C 
for 2 min followed by 25 cycles of 95˚C for 30 s, 55˚C for 30 s, and 72˚C for 60 s, and 
one cycle of 72˚C for 5 min. The PCR products were resolved by electrophoresis in a 
1% (w/v) agarose gel and visualised by ethidium bromide staining (section 2.9.1.1). 
PCR amplified products were cleaned using QIAquick PCR Purification Kit (Cat. # 
28104, Qiagen) according to the manufacturer’s instructions. Two 15 μl aliquots of 
each cleaned PCR amplicon was added to a Eurofins sequencing tube, with 2 μl of the 
AmpF primer added to one aliquot, and 2 μl of the AmpR primer added to the other 
aliquot. The tubes were sent to Eurofins for 16S rDNA sequencing. 
 
 
2.10.3 Bacterial isolate identification 
The FinchTV software (Geospiza, Inc.) was used for an initial assessment of the quality 
of the 16S rDNA sequencing data returned from Eurofins. The paired samples, 
sequenced with the AmpF and AmpR primers, were assembled to form a single contig 
using SeqMan (DNASTAR, Inc.). The contig of each sample was checked for errors or 
mismatches, the validity of which was evaluated through the use of FinchTV. The 
quality-checked aligned sequences were uploaded to the online RDP SeqMatch tool 
(http://rdp.cme.msu.edu/seqmatch/seqmatch_intro.jsp (RDP Data - release11_1; 
Seqmatch – version 3)). The search options enabled were type and non-type strains, 
environmental sequences and isolates, near full length sequences (≥ 1,200), and good 
quality sequences. The identification of the bacterial isolates was determined on the 
basis of the highest S_ab score [334]. 
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2.11 Bacterial screening assays 
2.11.1 Screening bacterial isolates for glucoraphanin reduction 
activity 
A 0.15 M glucoraphanin stock solution was generated by dissolving a purified 
glucoraphanin extract (Intertek Group plc) in either CNM or LB. This was further diluted 
in the same medium to produce a purified glucoraphanin extract media (~6 mM). 
Glycerol stocks containing bacterial isolates (section 2.8.5), and an Escherichia coli 
DH5α stock (kindly donated by Ms Fatma Cebeci), were mixed, prior to 5 μl of each 
being added to tubes containing the purified glucoraphanin extract media. Control 
samples were generated through the addition of 5 μl 0.22 μm filtered water in place of 5 
μl bacterial glycerol stock. Samples were incubated in either an aerobic or anaerobic 
cabinet set at 37˚C, for 24 hr or 72 hr, under static conditions. Optical density readings 
were taken at 600 nm wavelength using a 6715 UV/vis. spectrophotometer (Cat. # 671 
5B0, Jenway) with control samples used as blanks. Samples were centrifuged at 
21,100 x g for 5 minutes; and the supernatant was passed through a filter (0.2 μm) into 
a sterile tube. The filtered supernatants were stored at -20˚C for desulphoglucosinolate 
analysis by HPLC (section 2.5). 
 
2.11.2 Screening bacterial isolates for glucoerucin metabolism 
Glucoerucin (Carl Roth®) was dissolved in 0.22 μm filtered water to generate a 1 
mg/ml stock solution (2.37 mM). CNM had the glucoerucin stock solution added to 
generate a 0.3 mM glucoerucin media. The E. coli 1B04 glycerol stock (section 2.8.5) 
was mixed before 10 μl was added to the glucoerucin media. Filtered water was used 
in control samples in place of the E. coli 1B04 glycerol stock. The samples were placed 
in an anaerobic cabinet set at 37˚C for 24 hr. 
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The cultures were centrifuged at 21,100 x g for 5 minutes; and the supernatant was 
passed through a filter (0.2 μm) into a sterile tube. The filtered supernatants were 
stored at -20˚C prior to desulphoglucoerucin analysis using HPLC (section 2.5). 
 
2.11.3 Screening bacterial isolates for activity against S-
methylcysteine sulphoxide 
Powdered SMCSO (Cat. # M6626, Sigma Aldrich) was dissolved in filtered water to 
generate a 1 mg/ml stock solution (7.4 mM). The SMCSO stock solution was added to 
CNM to a final concentration of 0.3 mM. The E. coli 1B04 glycerol stock was mixed, 
and 5 μl was added to 995 μl of the SMCSO media. Control samples were generated 
through the addition of 0.22 μm filtered water in place of the E. coli 1B04 glycerol stock. 
The samples were placed in an anaerobic cabinet set at 37˚C for 24 hr. The samples 
were centrifuged at 21,100 x g for 5 minutes, and the supernatant was passed through 
a filter (0.2 μm) into a sterile tube. The filtered supernatants were stored at -20˚C prior 
to SMCSO derivative analysis using LC/MS (section 2.4.2), and 1H NMR spectroscopy 
analysis (section 2.6). 
 
 
2.12 Gas chromatography mass spectrometry analysis  
CNM containing either glucoraphanin (~6 mM) or SMCSO (0.3 mM) (section 2.11.1 
and 2.11.3, respectively) was inoculated with 2.5 μl of either E. coli 1B04 or E. coli 
DH5α, to a final volume of 0.5 ml. Filtered water was used in control samples in place 
of i) the tested substrate (glucoraphanin or SMCSO), ii) the bacterial strain (E. coli 
1B04 or E. coli DH5α), and iii) both the substrate and the bacterial strain. Samples 
were prepared in triplicate. Gas chromatography mass spectroscopy analysis was 
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performed by Mr Paul Brett. A 65 μm PDMS/DVB solid-phase microextraction (SPME) 
fibre was exposed in the headspace of samples at room temperature for 20 minutes. 
Gas chromatography mass spectrometry (GC-MS) was performed with an Agilent 6890 
series system, with the Agilent 5973 inert mass selective detector (Agilent 
Technologies, UK). A DB-WAX 30 m x 250 μm x 0.25 μm capillary column was used 
with helium as the carrier gas (splitless) at a constant flow of 1 ml/min. The SPME fibre 
was inserted into the GC-MS with the inlet temperature set to 250˚C. The oven 
temperature was kept at 40˚C for 2 minutes, so extracted compounds could be 
thermally desorbed, before increasing at a rate of 20˚C/min to a final temperature of 
200˚C, which was held for 5 minutes. Mass spectra were obtained by electron 
ionisation over a range of 30 – 500 atomic mass units with six scans performed every 
second. Ion source temperature was 230˚C, with the quadrupole temperature set to 
150˚C. Peaks were identified by comparing retention times, mass spectra and fragment 
ion fingerprints with the National Institute of Standards and Technology (NIST) library. 
 
 
2.13 Effects of Brassica on human gut lactobacilli human 
dietary intervention study 
Full details can be found in the Appendix in the form of annexes but, briefly, the study 
method was as follows. 
 
2.13.1 Study recruitment 
Ten participants were recruited onto the ‘Effects of Brassica on human gut lactobacilli’ 
(EBL) human study (ClinicalTrials.gov: NCT02291328), and gave written informed 
consent (Appendix: annex 6) for their biological samples to be used as described in the 
(Appendix: study protocol). The EBL study protocol was approved by the Human 
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Research Governance Committee at the Institute of Food Research and Norfolk 
Research Ethics Committee (14/EE/1078). All study participants were assessed for 
eligibility on the basis of a health questionnaire (Appendix: annex 7) and the results of 
clinical laboratory tests. All participants produced a urine sample for urinalysis which 
was screened for protein, blood, leukocytes, nitrites, glucose, ketones, bilirubin and 
urobilinogen via a dipstick urine test (Multistix® SG; Siemens). 
The following exclusions applied: 
 Those not within the range of 18 – 50 years old. 
 Those with a BMI outside the range of 19.5 and 30 kg/m2. 
 Women who are or have been pregnant within the last 12 months, or are 
lactating and/or breast feeding. 
 Those currently suffering from, or have ever suffered from, any diagnosed 
gastrointestinal disease, gastrointestinal disorders including regular diarrhoea 
and constipation (excluding hiatus hernia unless symptomatic) and/or have 
undergone gastrointestinal surgery, or the study intervention/procedure is 
contraindicated. 
 Have been diagnosed with any long-term medical condition that may affect the 
study outcome (e.g. diabetes, haemophilia, cardiovascular disease, glaucoma, 
anaemia). These will be assessed on an individual basis. 
 Those diagnosed with a long-term medical condition requiring medication that 
may affect the study outcome. 
 Those regularly taking self-prescribed over the counter medications for 
digestive/gastrointestinal conditions. 
 Those on long-term antibiotic therapy. Those who have been on a course of 
antibiotics are able to participate in/continue on the study once 4 weeks has 
elapsed from the end of the course of antibiotics, and this will be assessed on 
an individual basis. 
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 Those regularly taking laxatives (once a month or more). 
 Those intermittently using pre and/or probiotics unless willing to abstain for 1 
month prior to and during study period. If used regularly (3+ times a week, and 
for more than one month) and will continue throughout study period then do not 
exclude. 
 Those on a diet programme, or those who plan to start a diet programme during 
the study, that may affect the study outcome (e.g. the 5:2 fasting diet) unless 
willing to abstain for 1 month prior to and during study period. These will be 
assessed on an individual basis. 
 Those taking dietary supplements or herbal remedies (including those derived 
from Brassica plants) which may affect the study outcome – unless the 
participant is willing to discontinue taking them for 1 month prior to and during 
study period. Please note that some supplements may not affect the study and 
this will be assessed on an individual basis.  
 Regular/recent (within 3 months) use of colonic irrigation or other bowel 
cleansing techniques. 
 Recently returned to the UK following a period abroad, and who have suffered 
gastric symptoms during the period abroad or on return to the UK. These will be 
assessed on an individual basis. 
 Parallel participation in another research project which involves dietary 
intervention and/or sampling of biological fluids/materials. Sampling of certain 
biological samples, such as saliva, may not affect the study and this will be 
assessed on an individual basis.  
 Those who record blood in their stools or have two or more episodes of type 1, 
2, or 7 stools during the study. 
 Any person related to or living with any member of the study team. 
 Those who are unwilling to provide GPs contact details.  
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 Those who are unable to provide written informed consent. 
 Those who are not suitable to take part in this study because of their eligibility 
screening results. 
 Those who do not have access to a freezer. 
 Those who regularly consume more than 15 units of alcohol (women) or 22 
units of alcohol (men) a week. 
 Those who are allergic to any of the foods/ingredients within the diets supplied.  
 
Details of the participants that were enrolled onto the study are displayed in Table 2.4. 
 
Table 2.4: Age, gender, Body Mass Index (BMI), and smoking status of the EBL study 
participants. 
Participant 
code 
Age (years) Gender BMI (kg/m2) Smoker 
EBL16 35 Male 28.5 N 
EBL28 25 Female 23.5 N 
EBL51 25 Female 24.8 N 
EBL56 32 Female 21.1 N 
EBL74 39 Female 20.3 N 
EBL84 40 Male 24.4 N 
EBL88 36 Male 26.0 N 
EBL89 41 Female 25.3 Y 
EBL92 28 Male 27.5 N 
EBL97 34 Female 23.8 N 
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2.13.2 Effects of Brassica on human gut lactobacilli study design 
A randomised, two-phase crossover dietary intervention study (n = 10), with one phase 
representing a low-Brassica diet, and the other phase a high-Brassica diet (Figure 
2.2). The low-Brassica diet consisted of one portion of 84 g frozen broccoli and one 
portion of 84 g frozen cauliflower, purchased from a Sainsbury’s superstore (J 
Sainsbury PLC, UK). Portions were to be steamed following the instructions provided 
(Appendix: annex 18), and a single portion of the participant’s choice was to be 
consumed each week for two weeks. The high-Brassica diet consisted of six 84 g 
portions of frozen broccoli, six 84 g portions of frozen cauliflower, and six 300 g 
portions of a broccoli and sweet potato soup containing 84 g broccoli (Bakkavor Group 
Ltd, UK). Three portions of frozen broccoli, three portions of frozen cauliflower, and 
three broccoli and sweet potato soups were consumed each week, for a period of two 
weeks, prepared as instructed (Appendix: annex 18). 
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Figure 2.2: Design for the EBL human dietary intervention study. Randomised, two phase crossover, human dietary intervention study: n = 10. Following a 
successful eligibility screening appointment, participants produced a faecal sample before commencing a Brassica and glucosinolate-containing food diet restriction. 
After 2 weeks, a faecal sample (F) and urine (u) sample were collected, and the first 2 week intervention phase started (low- or high-Brassica diet).  All urine was 
collected for 24 hr (U) directly after consuming the first portion of broccoli or broccoli-based soup. Participants were restricted from eating further portions until the 
urine collection was completed. Upon conclusion of the first intervention phase, a faecal sample was collected, and the 2 week washout period began. A further faecal 
sample and urine sample were collected on completion of the washout period, and the second 2 week intervention phase started (alternative diet to that consumed in 
intervention phase 1). All urine was collected for 24 hr directly after consuming the first portion of broccoli or broccoli-based soup. Participants were restricted from 
eating further portions until the urine collection was completed. Upon conclusion of the second intervention phase, a faecal sample was collected and the diet 
restriction period ceased. After 2 weeks consuming their habitual diet, participants collected a final faecal sample, completing the study. During each intervention 
phase, and the habitual diet phase, stool charts and food diaries were completed for a period of seven consecutive days. * At the end of the 2 week wash-out period, 
8 participants were granted a short break from the study, for a period of no more than 6 weeks, to accommodate the Christmas period. Participants were required to 
resume the dietary restrictions for 2 weeks prior to producing an additional faecal sample, and starting the second intervention phase.
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Participants were required to restrict their diet of Brassica and other foods that contain 
glucosinolates (Appendix: annex 15) during the active study period, starting two weeks 
prior to the first intervention phase, and finishing upon completion of the second 
intervention phase. Six faecal samples were collected per participant, following the 
instructions provided (Appendix: annex 14), at the following stages in the study: before 
commencing the diet restriction, immediately prior to the two intervention phases, upon 
completion of each intervention phase, and two weeks after the diet restriction ceased. 
Participants that required the prescribed study break were required to produce an 
additional sample following a 2-week diet restriction period prior to the second 
intervention phase. Urine samples were collected immediately prior to the two 
intervention phases, and were used for diet restriction compliance testing. Upon 
consuming the first portion of broccoli or the broccoli-based soup in each dietary 
intervention phase, participants were asked to refrain from eating further portions until 
they had collected all of their urine produced during the following 24 hr period. These 
urine samples were analysed for excreted glucoraphanin hydrolysis products. 
 
Participants were asked to complete stool charts (Appendix: annex 12) to assess any 
effects of the diets on gut function, and to record fruit and vegetable consumption in 
food diaries (Appendix: annex 13). These were completed in consecutive 7-day periods 
during each intervention phase, and in the 2 week period following completion of the 
second intervention phase. 
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2.13.3 Effects of Brassica on human gut lactobacilli study sample 
analysis 
2.13.3.1 Phylogenetic analysis of human faecal microbiotas 
Approximate 2 g portions of faecal samples were collected in triplicate from each faecal 
sample, using sterilised spatulas and tubes, and stored at -80˚C. Bacterial DNA was 
extracted, visualised, and the DNA concentration was quantified following the method 
described in section 2.9.1. Bacterial DNA concentration was normalised to 1 ng/μl by 
dilution with DES (MP Biomedicals, UK) to produce a final volume of 20 μl. Normalised 
DNA samples were sent to the Centre of Genomic Research (Liverpool, UK) for PCR 
amplification of the 16S rDNA gene, and paired-end Illumina sequencing (2x 250 bp) 
on the MiSeq platform. Sequencing data were supplied in FASTQ format with adaptors 
already trimmed. 
 
Sequencing data were analysed using the Quantitative Insights Into Microbial Ecology 
(QIIME) pipeline and RDP 16S rDNA sequence database [330, 331]. All sequences 
met the following criteria: read length within 200 and 1,000 bp; an Illumina quality digit 
>0; and a minimum average quality score of 25 within a 50 bp window. ChimeraSlayer 
was used to filter trimmed reads for chimeric sequences, RDP classifier (version 2.10) 
was used for bacterial taxonomy assignment with a confidence value threshold of 50%, 
and trimmed reads clustered into OTUs at 97% identity level. Shannon, PD whole tree, 
chao1, and observed species were used to compute alpha diversity and rarefaction 
plots. Weighted and unweighted UniFrac distances were used to generate beta-
diversity PCoA plots, which were visualised using the Emperor tool. 
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2.13.3.2 Metabolite analysis of human faecal waters 
Approximately 100 mg of thawed faecal samples were added to sterile tubes. A 
phosphate buffer was generated by combining NaH2PO4.H2O (0.54 g), K2HPO4 (2.82 
g), NaN3 (100 mg), and TSP (34 mg) with 200 ml D2O. The faecal waters were 
generated by adding the phosphate buffer to samples in volumes 12-fold greater than 
the mass of the faecal sample. Faecal waters were homogenised using a Kimble 
Kontes pellet pestle motor (Cat. # Z359971, Sigma Aldrich) with sterilised pestles (Cat. 
# Z359947, Sigma Aldrich). Homogenised faecal waters were centrifuged at 16,200 x g 
at room temperature for 5 min. The supernatants were passed through a 0.2 μm 
syringe filter into sterile tubes, and 600 μl was transferred into a 5 mm NMR tube for 
spectral acquisition, as described in section 2.6.2. 
 
2.13.3.3 Urinary glucoraphanin hydrolysis product analysis 
Compliance urine samples were mixed, aliquoted and stored at -80˚C. 24 hr urine 
collections were returned in pre-weighed containers. The mass of the full containers 
were recorded, and the volume of urine was calculated by subtracting the mass of the 
empty containers from the mass of the full containers. The urine samples were mixed, 
aliquoted, and stored at -80˚C. Aliquoted urine samples were thawed at room 
temperature, mixed, and passed through a 0.2 μm syringe filter into sterile tubes. A 100 
μl aliquot of the filtered urine, 890 μl 0.1% ammonium acetate buffer, and 10 μl BITC 
were combined in sterile tubes and mixed. After centrifugation (17,000 x g, 4˚C, 10 
min), 800 μl of the supernatant was transferred to an autosampler vial for LC-MS/MS 
analysis as described in section 2.4.1. 
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2.14 Statistical analysis 
Data analysis, including calculation of average values, percentage products, standard 
deviations, and the student’s t-test or one-way ANOVA where applicable, was 
performed using GraphPad Prism 5 (version 5.04). Results were treated as significant 
if p≤0.05. 
 
The bacterial population data contained in chapter 8 underwent multivariate analysis 
prior to statistical analysis, which was performed by Dr Henri Tapp. A sub-set of 66 
bacterial taxa were selected, based on their detection (non-zero proportions) in a 
minimum of 45 of the 67 faecal samples. A small offset (0.00001) was added to the 
data to counteract the presence of zero values. The data was log transformed to 
enable clearer visualisation of the data, and variance scaled, as the data was unevenly 
distributed. Fourteen principal components were retained based on the Kaiser criterion 
(factors with an eigenvalue >1). A varimax rotation (orthogonal rotation of the factor 
axes to simplify interpretation) was applied to the retained components, and the new 
scores were rescaled such that the corresponding loading were of unit length. The 
correlations between the first and second rotated factor scores and each of the log-
transformed variates were plotted to identify bacterial taxa associated with the first 
rotated factor score. 
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Differences between the two diet intervention phases were investigated using 
sequential analysis of variance. The proportions of bacterial taxa were log-transformed 
following the addition of a small offset (0.00001). The response variable was the 
transformed post-high-Brassica diet bacterial proportion, and the four explanatory 
variables were, respectively: the transformed post-low-Brassica diet bacterial 
proportion (continuous), the participant code (n-level categorical), the study phase (2-
level categorical, first intervention and second intervention), and the dietary treatment 
order (2-level categorical, high - low, low - high). Carry-over was investigated using the 
sum of the two post-intervention measurements, and statistical analysis was performed 
using Matlab. Results were treated as significant if p≤0.05. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER THREE 
 
3 Characterisation of broccoli leachates and 
bacterial media 
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3.0 Summary 
Broccoli is a rich source of fibres, sugars, vitamins and minerals, such as sulphur. The 
majority of the sulphur is present in sulphate, glucosinolates, S-methylcysteine 
sulphoxide, glutathione, and the amino acids methionine and cysteine. This chapter 
details the process by which broccoli leachates are produced, characterised, and used 
to generate a broccoli leachate-containing (BL) medium. A glucose (GL) medium is 
also produced and characterised. The BL medium was found to contain a range of 
minerals, 21 amino acids and amino acid derivatives, and relatively high levels of 
sugars. The BL medium was also shown to be particularly rich in total sulphur, 
glutamine, glutamate, fructose, and glucose. The GL medium also contains multiple 
minerals, 19 amino acids and amino acid derivatives, and sugars, but generally at 
lower levels than seen in the BL medium. 
 
 
3.1 Introduction 
 
Two F1 broccoli hybrids, containing high levels of glucoraphanin, were developed 
during breeding programmes in which the wild broccoli species (Brassica villosa) was 
crossed with a double haploid broccoli breeding line [335]. These F1 hybrids contain a 
2.5 - 3-fold increase in glucoraphanin compared to standard broccoli cultivars [5]. This 
increase in glucoraphanin content is likely due to the presence of a B. villosa Myb28 
allele, which appears to increase sulphate assimilation, and channels a greater amount 
of sulphur into the biosynthesis of methionine-derived glucosinolates, such as 
glucoraphanin [5]. These high-glucoraphanin hybrids are commercially available as 
Beneforté® broccoli. 
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Broccoli is a rich source of sulphur, containing S-methylcysteine sulphoxide (SMCSO), 
sulphate, glutathione, and the sulphur-containing amino acids methionine and cysteine, 
as well as methionine- and tryptophan-derived glucosinolates. Broccoli also contains 
relatively high levels of potassium, dietary fibres, and vitamins, such as Vitamin C and 
E, carotene, folate, pantothenate, and riboflavin [336]. This complex mix of potential 
bacterial nutrients makes broccoli an attractive option as a substrate for human gut 
microbiota fermentation studies. 
 
Sulphur is an essential component of life, and is required for the bacterial biosynthesis 
of methionine and cysteine, as well as sulphur-containing co-enzymes [337]. Several 
research groups have shown that human gut bacteria are able to hydrolyse 
glucosinolates (releasing glucose, sulphate, and an aglycone), or modify glucosinolates 
through biotransformation reactions [45, 142, 338]. 
 
The formulation of bacterial media for use in fermentation studies with intestinal 
bacteria are designed to contain the essential nutrients for bacterial growth. Chemostat 
nutrient media (CNM) is a medium whose recipe has been used in multiple in vitro 
fermentation studies, in which the carbon source added to the medium is the substrate 
being investigated [339-343]. This allows the investigator to examine the metabolic 
effects associated with a single compound, whole food, or specific diet when cultured 
with a single species of bacteria, or a complex bacterial community. 
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3.2 Objectives 
The objective of the work contained in this chapter was to generate and characterise 
leachates derived from broccoli, which will be used to supplement a basal bacterial 
medium. The broccoli leachate-containing medium, and a medium supplemented with 
glucose, were analysed for glucosinolate, mineral, amino acid, and sugar content. 
 
 
3.3 Materials and methods 
Broccoli leachates were generated using commercially sourced Beneforté® broccoli as 
described in section 2.2, and the basal bacterial medium (CNM) used is detailed in 
section 2.3. LC-MS/MS (section 2.4) was used to confirm that processing of the 
broccoli had significantly reduced broccoli myrosinase activity. A desulphoglucosinolate 
extraction in conjunction with HPLC, was used to investigate the levels of 
glucosinolates contained within the broccoli leachates, as described in section 2.5. 1H 
NMR spectroscopy was used to identify the constituent parts of the broccoli leachates 
and the bacterial medium as explained in section 2.6.2. Samples were centrifuged and 
the supernatant filtered, prior to being mixed with a 0.4 mM phosphate buffer (section 
2.6.1). Sodium 3-(Trimethylsilyl)-propionate-d4 was used as a chemical shift reference, 
and metabolite quantification was carried out using the Chenomx NMR suite software. 
The broccoli leachates were combined with CNM to produce a broccoli leachate-
containing (BL) medium, and glucose was added to CNM to generate a glucose (GL) 
medium. These media were commercially analysed for mineral content by Eurofins, 
and 1H NMR spectroscopy was used to determine the concentrations of the amino 
acids and sugars within both media. 
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3.4 Results 
3.4.1 Producing a broccoli leachate for use in culturing human 
faecal microbiotas 
A broccoli leachate was chosen to act as the main substrate in the basal bacterial 
medium, rather than glucoraphanin alone, as the mix of plant compounds would better 
reflect the potential in vivo intestinal milieu following the consumption of broccoli. The 
BL media will be standardised to contain 30 μmoles of glucoraphanin. Beneforté® 
broccoli was selected as the starting substrate due to the increased levels of 
glucoraphanin compared to standard broccoli. Prior to making the broccoli leachates, it 
was necessary to investigate what processing would be required to significantly reduce 
the activity of the plant myrosinase enzyme. As broccoli is commonly steamed from 
fresh before human consumption, fresh Beneforté® broccoli was purchased and 
steamed for different durations, prior to lyophilisation. This was performed to identify 
the time necessary to significantly reduce myrosinase activity without negatively 
affecting the levels of glucoraphanin. When fresh broccoli was steamed for a minimum 
of 3 minutes, myrosinase activity was significantly reduced compared to unsteamed 
broccoli (Figure 3.1), and the levels of glucoraphanin remained high (Figure 3.2). 
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Figure 3.1: Effect of steaming on Beneforté® broccoli myrosinase activity. Fresh 
Beneforté® broccoli was steamed for different durations (0, 3, 5, 7 and 10 minutes) prior to 
lyophilisation and grinding. The powdered broccoli was rehydrated in purified water for 30 
minutes, and the supernatant was collected and analysed by LC-MS/MS. Data shown = mean ± 
SD of three biological replicates. Data was statistically analysed using one-way analysis of 
variance (ANOVA) followed by the Dunnett multiple comparisons test. ***p≤0.001 vs unsteamed 
broccoli control. 
 
 
Figure 3.2: Effect of steaming on glucoraphanin content in Beneforté® broccoli. Fresh 
Beneforté® broccoli was steamed for different durations (0, 3, 5, 7 and 10 minutes) prior to 
lyophilisation. The powdered broccoli was rehydrated in purified water for 30 minutes, and the 
supernatant was collected and analysed by HPLC. Data shown = mean ± SD of three biological 
replicates. Data was statistically analysed using one-way ANOVA followed by the Dunnett 
multiple comparisons test. ***p≤0.001 vs unsteamed broccoli control. 
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From these data, a steaming duration of 3 minutes was deemed sufficient to prepare 
the fresh Beneforté® broccoli, prior to generating the broccoli leachates for use in the 
culturing of human faecal bacteria. 
 
 
3.4.2 Identifying the constituents of the broccoli leachates 
3.4.2.1 Glucosinolate content in the broccoli leachates 
The broccoli leachates were concentrated through the use of evaporation techniques, 
and filtered before undergoing analysis to examine the glucosinolate profile (Figure 
3.3). The glucoraphanin content in the broccoli leachates were between 1517.24 
μmoles and 1845.44 μmoles. Lesser amounts of the glucosinolates glucoiberin (15.73 
μmoles to 538.82 μmoles) and 4-methoxyindolylmethyl (4-MIND) (1.6 μmoles to 456.43 
μmoles) were also present. 
 
Figure 3.3: Glucosinolate profile of a broccoli leachate. Broccoli leachates were passed 
through a sephadex column to extract the desulphoglucosinolates, prior to HPLC analysis. The 
figure shows a representative HPLC chromatogram of a broccoli leachate, indicating which 
glucosinolates were present in the broccoli leachate. Sinigrin was used as an internal standard. 
RT = retention time. GI = glucoiberin (RT: 3.8); GR = glucoraphanin (RT: 4.5); 4-MIND = 4-
methoxyindolylmethyl (RT: 29.3); SIN = sinigrin (RT: 5.4). 
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The broccoli leachates were used as stock solutions to generate the BL media, which 
were standardised to 30 μmoles of glucoraphanin. Although the levels of glucoiberin 
and 4-MIND varied between batches of BL media, the levels of glucoraphanin 
remained constant. The differences observed in the levels of glucosinolates in the 
broccoli leachates were likely due to seasonal variation and the different growing 
locations of the broccoli. 
 
3.4.2.2 Proton nuclear magnetic resonance spectroscopy analysis of the 
broccoli leachates  
Proton nuclear magnetic resonance (1H NMR) spectroscopy was used to identify the 
different constituents present in the broccoli leachates. The spectra from the lower end 
of the parts per million (ppm) spectrum (0 - 3.2 ppm) showed a range of amino acids, 
as well as lactate, citrate, choline, SMCSO, and glucoraphanin (Figure 3.4). 
 
 
Figure 3.4: The broccoli leachates contain various amino acids. 
1
H NMR analysis identifies 
various amino acids alongside several other compounds at the lower range of the ppm 
spectrum. arg: arginine; asn: asparagine; asp: aspartate; gln: glutamine; glu: glutamate; ile: 
isoleucine; leu: leucine; lys: lysine; pro: proline; pyro: pyroglutamate; SMCSO: S-methylcysteine 
sulphoxide; val: valine; ppm: parts per million. 
lactate 
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Between 3 and 6 ppm, the sugars glucose and sucrose are identified, along with the 
glucosinolates, glucoraphanin and glucoiberin (Figure 3.5). The mass of peaks seen at 
3.3 - 4.3 ppm are likely due to a polymer originating from the container used to store 
the broccoli leachates. Although this area masks peaks representing glucose, other 
peaks are present to enable the quantification of glucose in the broccoli leachates. 
 
 
Figure 3.5: The leachates contain sugars derived from broccoli. 
1
H NMR analysis identifies 
the sugars, glucose and sucrose, and the glucosinolates, glucoraphanin and glucoiberin 
between 3 - 6 ppm in the broccoli leachates. GI: glucoiberin; GR: glucoraphanin; ppm: parts per 
million. 
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At the higher end of the ppm range (5.9 – 9 ppm) a number of nucleosides and 
nucleotides were observed, as well as the amino acids tryptophan, tyrosine and 
phenylalanine. Formate, fumarate, and the indolic 4-MIND glucosinolate were also 
identified within this region of the 1H NMR spectra (Figure 3.6). 
 
 
Figure 3.6: The broccoli leachates contain a number of nucleosides and nucleotides. 
Nucleosides, nucleotides, amino acids, and other compounds including 4-MIND are identified at 
the upper parts per million (ppm) range. 4-MIND: 4-methoxyindolylmethyl glucosinolate; nucleo: 
nucleosides/tides; phe: phenylalanine; trp: tryptophan; tyr: tyrosine. 
 
Analysis using 1H NMR showed that the broccoli leachates were a complex mix of 
amino acids, sugars, glucosinolates, and other compounds that may be able to be used 
as substrates by the human faecal bacteria during culturing. 
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3.4.2.3 Proton nuclear magnetic resonance spectroscopy analysis of the 
chemostat nutrient media 
Analysis of the basal bacterial growth medium CNM, using 1H NMR identifies a range 
of amino acids, lactate, acetate, succinate, betaine, and the presence of lipids and 
steroids between 0 – 3.6 ppm (Figure 3.7). The peaks assigned to lipids and steroids 
likely originate from the presence of Tween 80 and bile salts, respectively, in CNM. 
 
 
Figure 3.7: The chemostat nutrient media contains a range of amino acids. 
1
H NMR 
analysis identifies a number of amino acids and other compounds at the lower parts per million 
(ppm) range within the basal medium (CNM). asn: asparagine; asp: aspartate; glu: glutamate; 
ile: isoleucine; leu: leucine; phe: phenylalanine; trp: tryptophan; tyr: tyrosine; val: valine. 
 
Towards the upper range (5.5 – 9 ppm), additional amino acids were identified, as well 
as nucleosides and nucleotides, uracil, formate, nicotinate and nicotinamide (Figure 
3.8). As observed in the broccoli leachates, CNM contained a range of amino acids as 
well as other compounds that are available to bacteria as nutrients. 
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Figure 3.8: The chemostat nutrient media contains a number of nucleosides and 
nucleotides. Several nucleosides/tides, amino acids, and other compounds are detected using 
1
H NMR at the upper parts per million (ppm) range for the basal medium. his: histidine; phe: 
phenylalanine; nic: nicotinamide; nico: nicotinate; nucleo: nucleosides/tides; trp: tryptophan; tyr: 
tyrosine; ura: uracil. 
 
3.4.3 Analysis of media for use in a batch fermentation model 
The broccoli leachate was added to CNM to produce a BL medium containing 30 
µmoles of glucoraphanin. Standard commercial broccoli contains approximately 1 
µmole of glucoraphanin per gram fresh weight prior to cooking [5]. The BL media was 
standardised to 30 µmoles as it was considered to be physiologically relevant to the 
amount of glucoraphanin that may reach the colon. This allowed for the loss of 
glucoraphanin through chopping and cooking a small portion of broccoli, as well as 
hydrolysis/absorption in the upper gastrointestinal tract. As the hydrolysis of 1 mole of 
glucoraphanin releases 1 mole of glucose, a control medium was produced by 
supplementing CNM to generate a 30 µmole glucose (GL) medium. The mineral 
content of these media was analysed commercially by Eurofins. The experimental 
volume of each medium will be 50 ml, and Table 3.1 displays the amounts of minerals 
present in 50 ml of both the BL and GL media. 
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Table 3.1: Mineral analysis of 50 ml of the BL and GL media. 
Mineral mass per 50 ml  BL medium GL medium 
Sodium (g) 0.061 (± 0.01) 0.063 (± 0.01) 
Potassium (g) 0.071 (± 0.01) 0.011 (± 0) 
Calcium (g) 0.005 (± 0) <0.0003 
Magnesium (g) 0.003 (± 0) <0.0003 
Phosphorus (g) 0.011 (± 0) 0.002 (± 0) 
Iron (mg) 0.064 (± 0.01) <0.05 
Zinc (mg) 0.122 <0.1 
Total sulphur (mg) 27.48 (± 3.22) 7.43 (± 0.67) 
 
With the exception of sodium, which is present at similar levels within the two media, 
increased amounts of the other minerals were found in the BL medium compared to the 
GL medium. In particular, the BL medium contained a higher amount of potassium, and 
total sulphur than the GL medium. The sulphur contained within the three 
glucosinolates and SMCSO in the BL medium accounted for 3.97 mg of the total 
sulphur (Table 3.2). The majority of the remaining sulphur in the BL medium may have 
been incorporated into sulphate, which was not measured. 
 
Table 3.2: Sulphur mass contributed by glucosinolates and SMCSO in 50 ml of the BL 
medium. 
 Glucoraphanin Glucoiberin 4-MIND SMCSO 
Molecular weight 436.50 422.47 478.50 151.19 
No˚ sulphur 
molecules 
3 3 2 1 
μmoles solute in 
50 ml 
30.05 3.7 7.41 8.06 
Mass of sulphur 
(mg) 
2.89 0.36 0.46 0.26 
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Analysis using 1H NMR spectroscopy indicated that supplementation of CNM with the 
broccoli leachate increased the concentrations of multiple amino acids and their 
derivatives in the BL medium, compared to the GL medium (Table 3.3). 
Table 3.3: Amino acid and amino acid derivative analysis of 50 ml of the BL and GL 
media. 
Amino acid (mM) BL medium GL medium 
Alanine 1.26 (± 0.32) 0.76 (± 0.19) 
Arginine 1.13 (± 0.86) 0.16 (± 0.06) 
Asparagine 0.75 (± 0.08) 0.15 (± 0.05) 
Aspartate 1.15 (± 0.40) 0.21 (± 0.06) 
Cystine 0.23 (± 0.02) 0.26 (± 0.34) 
Glutamate 2.78 (± 0.92) 0.87 (± 0.11) 
Glutamine 4.21 (± 1.81) 0.02 (± 0.01) 
Glycine 0.51 (± 0.15) 0.62 (± 0.23) 
Histidine 0.03 (± 0) 0.03 (± 0.03) 
Isoleucine 0.64 (± 0.21) 0.29 (± 0.10) 
Leucine 0.65 (± 0.07) 0.51 (± 0.18) 
Lysine 0.45 (± 0.15) 0.19 (± 0.04) 
Methionine 0.08 (± 0.03) 0.09 (± 0.01) 
Phenylalanine 0.45 (± 0.12) 0.22 (± 0.04) 
Proline 1.29 (± 0.66) 0 
Pyroglutamate 1.50 (± 1.01) 0.27 (± 0.05) 
Serine 1.54 (± 0.75) 0 
Threonine 0.68 (± 0.19) 0.20 (± 0.03) 
Tryptophan 0.09 (± 0.01) 0.04 (± 0) 
Tyrosine 0.23 (± 0.11) 0.08 (± 0.01) 
Valine 1.21 (± 0.46) 0.41 (± 0.13) 
 
The proline and serine detected in the BL medium originates from the broccoli 
leachate, whilst glutamate, glutamine, and pyroglutamate are present at notably higher 
concentrations in the BL medium, compared to the GL medium. These data indicate 
that the sulphur-containing amino acids, cystine (derived from oxidised cysteine) and 
methionine, are supplied to both media through CNM. 
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Table 3.4: Sugar content in 50 ml of the BL and GL media 
 Sugars (mM)  BL medium GL medium 
Fructose 10.44 (± 3.30) 0 
Glucose 8.92 (± 1.87) 0.73 (± 0.04) 
Sucrose 1.15 (± 0.33) 0 
Trehalose 0.22 (± 0.01) 0.24 (± 0.06) 
 
The BL medium contained a larger range, and higher concentration, of sugars than the 
GL medium, with fructose, glucose, and sucrose originating from the broccoli leachate 
(Table 3.4). Trehalose, present in both media, would likely have originated from the 
yeast extract used to generate CNM. These analyses indicate that the BL medium was 
a richer source of minerals, amino acids, and sugars than the GL medium. 
 
 
3.5 Discussion 
3.5.1 Reduction of broccoli myrosinase activity 
Beneforté® broccoli was used to generate broccoli leachates containing high levels of 
glucoraphanin. It was necessary to inactivate, or significantly reduce, the activity of the 
broccoli myrosinase enzyme to prevent glucosinolate hydrolysis. It was determined that 
a steaming duration of 3 minutes was sufficient to significantly reduce the activity of the 
myrosinase enzyme (Figure 3.1), whilst minimising glucosinolate loss through 
excessive heat treatment or leaching (Figure 3.2). There was little difference in the 
levels of sulforaphane or glucoraphanin in the broccoli steamed for any of the times 
tested, but steaming for a shorter duration may preserve the volatile sulphur-containing 
compound, SMCSO. 
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3.5.2 Broccoli leachate characterisation 
The concentrated broccoli leachates were analysed for glucosinolate content, and they 
were found to contain glucoraphanin, glucoiberin, and 4-MIND glucosinolate (Figure 
3.3). These glucosinolates were detected in all the broccoli leachates produced, but 
were present at varying levels. This was likely due to the broccoli being grown in 
different locations, with different soils and weather conditions, as well as seasonal 
variations. The main focus of the experiments will be on the metabolic fate of 
glucoraphanin, therefore the BL media will be standardised for glucoraphanin content. 
 
1H NMR spectroscopy of the broccoli leachates indicated the presence of SMCSO 
(Figure 3.4). Broccoli is known to also contain sulphur in the form of methionine, 
cysteine, and glutathione [5], however these compounds were not detected using 1H 
NMR spectroscopy. This may have been due to the degradation of these compounds 
during steaming or the broccoli leachate processing steps, which entailed an extended 
evaporation procedure at 60˚C, at a pressure of 72 mbar. Cooking foods can lead to 
the release of sulphur-containing volatile compounds, with the breakdown of cysteine, 
methionine, and derivatives, such as glutathione, considered to be the prime source for 
simple organic sulphur compounds [344, 345]. In addition, it has been shown that the 
thermal degradation of glutathione produces several products including pyroglutamate, 
therefore the breakdown of glutathione may have accounted for a portion of the 
pyroglutamate detected in the BL media [346]. Sulphate accounts for a large proportion 
of the sulphur present in broccoli, and the leachate characterisation would have been 
strengthened through performing sulphate analysis. 
 
The broccoli leachates were found to contain sugars (Figure 3.5), and a variety of 
amino acids (Figure 3.4 and Figure 3.6). In addition, choline, citrate, lactate, formate, 
fumarate, and trigonelline were also detected (Figure 3.4 and Figure 3.6). The broccoli 
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leachates contain a large number of compounds that can be used as a nutrient source 
for human faecal bacteria. 
 
3.5.3 Chemostat nutrient media characterisation 
As with the broccoli leachates, CNM contains a variety of amino acids, formate, and 
lactate (Figure 3.7 and Figure 3.8). In addition, CNM also contains acetate, succinate, 
betaine, uracil, nicotinate, and nicotinamide (Figure 3.7 and Figure 3.8). Nicotinate 
and nicotinamide can be used by bacteria as precursors for the production of the co-
enzymes NAD+ and NADP+ [347]. Lipids and steroids were also detected in the CNM 
(Figure 3.7), and are available for hydrolysis or biotransformation by gut bacteria [348]. 
 
3.5.4 Characterisation of BL and GL media 
The BL and GL media were produced to a volume of 50 ml and analysed for mineral, 
amino acid, and sugar content. The BL medium was found to be a richer source of 
multiple minerals, various amino acids, and total sugars, than the GL medium. The 
most notable difference between the media, detected by mineral analysis, was that 
there was approximately 3.5-fold greater amounts of total sulphur present in the BL 
medium (27.48 ± 3.22), compared to that found in the GL medium (7.43 ± 0.67) (Table 
3.1). The sulphur contained within the GL medium would also be present in the BL 
medium at approximately the same mass. This is because sulphur would have been 
present in the CNM, which was used to make both media types. The remaining sulphur 
(~20.05 mg) would have originated from the broccoli leachate. 
 
The glucosinolates and SMCSO present in the BL medium accounted for 3.97 mg 
(19.8%) of the total sulphur derived from the broccoli leachate in the BL medium (Table 
3.2), leaving approximately 16.08 mg unaccounted for. Detailed total sulphur analysis 
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of the F1 broccoli hybrids 1199 and 1639 (commercialised as Beneforté®), performed 
by Traka et al, indicated that approximately half of the total sulphur within the broccoli 
was present as sulphate (29.4%), methionine (10.6%), cysteine (8.7%), and glutathione 
(1.8%) [5]. This accounted for 50.5% of the total sulphur within the broccoli, with the 
remaining sulphur incorporated into SMCSO (13.6%) and total glucosinolates (28.9%), 
and 7.2% unaccounted for. If the total sulphur proportions of sulphate, methionine, 
cysteine, glutathione, and the missing sulphur present in the broccoli tested were 
similar in the BL medium, it would leave 4.51 mg unaccounted for.  
 
It is a limitation of the broccoli leachate characterisation process that sulphate was not 
quantified, as this could have been performed using validated anion-exchange 
chromatography techniques [349]. The total sulphur analysis performed by Traka et al 
was accomplished through the analysis of fresh broccoli florets, whereas the broccoli 
leachate was generated using steamed broccoli florets. It has been reported that mild 
heating can lead to the formation of sulphur-containing volatiles, which may be formed 
from methionine, cysteine, and glutathione [350, 351]. These compounds are 
responsible for the odours associated with cooked broccoli, and SMCSO is particularly 
prone to thermal degradation [151]. Therefore, part of the missing total sulphur in the 
BL media may be attributed to the loss of sulphur-containing volatiles generated during 
the heating processes necessary to produce the broccoli leachate. The effects of 
processing the broccoli leachate could have been investigated. Analysis of samples 
before and after steaming the broccoli and the evaporation technique, may have 
allowed a greater understanding of the fate of the sulphur-containing compounds. 
 
1H NMR spectroscopy indicated that the GL medium contained a wide range of amino 
acids, though at lower concentrations than detected in the BL medium (Table 3.3). The 
BL medium contained notably higher concentrations of glutamine, glutamate, and 
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pyroglutamate, compared to the GL medium. As well as being used by bacteria in 
protein synthesis, glutamine acts as a nitrogen donor in various biosynthetic reactions, 
and has a role as a signalling molecule in the regulation of bacterial nitrogen 
metabolism [352]. 
 
Glutamate is also involved in a wide range of bacterial metabolic processes, and plays 
an important role in bacterial stress responses [353, 354]. Pyroglutamate can be 
formed from glutamine or glutamate, or hydrolysed to produce glutamate, and is also 
an intermediate metabolite in glutathione degradation [355, 356]. It is possible that the 
processing steps, necessary to generate the broccoli leachates, promoted glutathione 
degradation, as indicated by the relatively high concentrations of pyroglutamate and 
glutamate within the BL medium. Proline and serine were present in the BL medium, 
but absent from the GL medium, indicating that these amino acids originated from the 
broccoli leachate. Proline is derived from glutamate, whilst serine is a precursor in the 
synthesis of multiple amino acids by bacteria, and can be degraded to form pyruvate, 
an important molecule in bacterial metabolic processes [357]. 
 
The BL medium was found to contain high concentrations of fructose and glucose, with 
lesser amounts of sucrose and trehalose (Table 3.4). In comparison, the GL medium 
contained the glucose that was added to the CNM to generate the GL medium, and a 
similar concentration of trehalose to that observed in the BL medium. Much of the 
trehalose detected in both media would have likely originated from the yeast extract, 
which was used to make CNM. The high levels of sugars, amino acids and minerals, 
such as sulphur and potassium, found in the BL medium, makes this medium a rich 
source of nutrients and utilisable metabolites for human faecal bacteria. 
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3.6 Conclusions 
Beneforté® broccoli was heat-treated and further processed to generate broccoli 
leachates for use in culturing human faecal bacteria. The broccoli leachates were 
analysed and found to contain three glucosinolates, a range of amino acids, sugars, 
and other compounds that could be utilised by bacteria. The broccoli leachates were 
used to supplement the basal bacterial medium, CNM. Therefore, CNM was also 
analysed and was found to contain multiple amino acids, lipids, steroids, and other 
compounds, including the metabolically important nicotinamide and nicotinate. Broccoli 
leachates were added to CNM to produce a BL medium standardised to contain 30 
μmoles of glucoraphanin. A GL medium was produced by supplementing CNM with 30 
μmoles of glucose. Both of these media were then characterised for mineral, amino 
acid, and sugar content. In comparison to the GL medium, the BL medium was found 
to be a particularly rich source of total sulphur, glutamine, glutamate, pyroglutamate, 
and sugars. The next chapter will detail the use of the BL medium to investigate the 
metabolic fate of glucosinolates, when cultured with human faecal microbiotas in a 
static batch fermentation model. 
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4 Dietary broccoli and the gut microbiota: 
Investigations into the metabolic fate of 
glucosinolates  
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4.0 Summary 
The majority of glucosinolates from cooked Brassica vegetables reach the colon intact, 
where they can be metabolised by the gut microbiota. It has previously been shown 
that some bacteria are able to directly hydrolyse glucosinolates, whilst other bacteria 
convert glucosinolates to the reduced analogue via a bacterial-mediated reduction 
reaction of the sulphoxide group at the terminal R group. This chapter investigates the 
metabolic fate of glucosinolates in a broccoli leachate when cultured with human faecal 
microbiotas. The main bacterial activity observed was the reduction of glucoraphanin 
and glucoiberin, to glucoerucin and glucoiberverin, respectively. Although LC-MS/MS 
analysis does not indicate a notable degree of glucosinolate hydrolysis, a portion of the 
glucosinolates are unaccounted for and may have been metabolised to unknown 
products. 
 
 
4.1 Introduction 
Chapter 3 described the production and characterisation of a broccoli leachate-
containing (BL) media. This chapter describes the metabolic fate of glucosinolates 
contained within this media, when cultured with human faecal microbiotas. 
 
Links between the diet, gut microbiota, and health-promoting effects have led to an 
increased interest in identifying functional foods that promote the growth of beneficial 
bacteria. As discussed in chapter 3, cooking can inactivate the plant myrosinase found 
in Brassica vegetables. Therefore, we rely entirely on the myrosinase-like activity of the 
gut microbiota to hydrolyse glucosinolates, forming the bioactive breakdown products. 
Investigations into the microbial metabolism of glucosinolates have included the use of 
in vitro models (isolated bacterial strains or bacterial communities) [90, 123, 125, 358], 
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rodent models [98, 135, 338], and human intervention studies [84, 134, 142]. Research 
has shown that single strains of human gut bacteria from a range of phyla have the 
ability to hydrolyse glucosinolates [90, 123, 125, 358], that bacterial glucosinolate 
metabolism occurs in vivo with a potential role for enterohepatic recycling [91, 98], and 
that there are inter-individual differences in glucosinolate metabolism, as evidenced by 
variation in urinary ITC excretion [111, 124, 359]. 
 
Recent studies have determined that human gut bacteria are able to convert 
glucosinolates via the reduction of a sulphoxide group [45, 142, 144]. This bacterial-
mediated reduction reaction has been shown to convert glucoraphanin to glucoerucin, 
and glucoiberin to glucoiberverin. It has been postulated that the reduction of 
glucosinolates may be a mechanism employed by some bacteria to overcome steric 
hindrance, caused by the presence of the sulphoxide groups rendering the β-
thioglucosidic bonds inaccessible to bacterial myrosinase-like enzymes [45]. It was 
shown that Escherichia coli VL8 did not exhibit the ability to hydrolyse glucosinolates 
until after it had converted them to their reduced analogues [45]. This indicates that 
there may be multiple mechanisms by which the human gut microbiota can hydrolyse 
glucosinolates. 
 
 
4.2 Objectives 
The hypothesis of the research presented in this chapter is that glucosinolates in a 
broccoli leachate-containing (BL) media would be metabolised by human faecal 
bacteria when cultured in vitro under anaerobic conditions. 
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4.3 Materials and methods 
The faecal material used in this work originated from five healthy human participants 
(Table 4.1). All participants consented to have their biological samples used for these 
experiments as part of ‘The conversion of encapsulated glucoraphanin, gut microbiota 
phylogeny and genotype’ (ENGAGE) human intervention study (ClinicalTrials.gov: 
NCT01927666). The study was managed by Dr J. F. Doleman at the Institute of Food 
Research. A broccoli leachate was generated using commercially sourced Beneforté® 
broccoli as described in section 2.2, and the basal bacterial medium used is detailed in 
section 2.3. The human faecal bacteria were cultured in the BL media and GL media, 
as described in detail in section 2.8.3, and summarised in Figure 4.1. Glucosinolate 
levels within the BL media were measured prior to inoculation, and after each of four 
consecutive 12 hr incubations with human faecal bacteria. A glucosinolate extraction 
was performed prior to HPLC analysis as described in sections 2.5.1 and 2.5.2, 
respectively. Identification of glucosinolate hydrolysis products contained within the BL 
media was performed using LC-MS/MS (section 2.4). 
 
Table 4.1: Age, gender, and Body Mass Index (BMI) of the faecal donors. 
Faecal donors Age (years) Gender BMI (kg/m2) Smoker 
Subject 1 44 Male 24.1 N 
Subject 2 24 Female 23.3 N 
Subject 3 52 Female 20.9 N 
Subject 4 50 Female 38.4 N 
Subject 5 61 Female 20.5 N 
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Figure 4.1: Schematic of experimental design. Broccoli leachate (BL) media (47.5 ml) and 
glucose (GL) media (47.5 ml) were seeded with a faecal suspension (2.5 ml) and cultured for 12 
hr at 37˚C, in anaerobic conditions. After a 12 hr incubation period, samples (2 ml) were taken 
for glucosinolate and isothiocyanate (ITC) analysis, and a 2.5 ml aliquot was used to seed the 
respective fresh media. This was repeated for four cycles of bacterial enrichment. 
 
 
4.4 Results 
4.4.1 Evaluating glucoraphanin stability in the bacterial medium 
Prior to receiving the faecal samples that would be used for the experiments that are 
the focus of this chapter, small-scale experiments were performed to evaluate the 
optimal time for each cycle of bacterial incubation, and whether the glucoraphanin 
would remain stable in the chemostat nutrient media (CNM). Repeated experiments 
using the BL medium and human faecal samples indicated that glucoraphanin was 
stable in the media (Figure 4.2). 
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Figure 4.2: Glucoraphanin is stable in an aqueous media over a period of 24 hours. A 
human faecal microbiota was cultured in a broccoli leachate-containing media for 24 hours at 
37˚C, under anaerobic conditions. Glucoraphanin was converted to desulphoglucosinolates 
prior to HPLC analysis. Data shown = mean ± SD of three technical replicates. 
 
The levels of glucoraphanin in the samples that were inoculated with faecal bacteria 
started to decrease after 6 hours, and the glucoraphanin was completely depleted by 
24 hours. However, the glucoraphanin levels remained constant throughout the entire 
24 hour period in the control samples that had 0.22 μm filtered water added in place of 
the faecal bacteria. It was concluded that 12 hours was an appropriate length of time 
for each cycle, and that glucoraphanin was stable in the BL media. 
 
4.4.2 Analysis of glucosinolates in human faecal bacteria cultures 
Five independent human faecal microbiotas were cultured in a BL medium to assess 
how the human gut bacteria may contribute to the metabolic fate of glucosinolates. 
Samples were taken to determine whether these microbial communities were 
metabolising the glucosinolates derived from the broccoli. HPLC analysis indicated 
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that, of five independent experiments, four cultured faecal bacterial communities 
(subjects 1, 3, 4, and 5) exhibited the ability, to varying degrees, to biotransform 
glucoraphanin, converting it to glucoerucin, the reduced analogue of glucoraphanin. 
Figure 4.3 shows the level of glucoraphanin conversion to glucoerucin performed by 
the faecal microbiota of subject 3. 
 
 
Figure 4.3: Conversion of glucoraphanin to glucoerucin when cultured with human faecal 
bacteria. Human faecal microbiotas were cultured separately with a broccoli leachate-
containing media for four 12 hr cycles at 37˚C, under anaerobic conditions. The figure shows 
the conversion of glucoraphanin to glucoerucin by the faecal microbiota of subject 3, which is 
representative of the observations of the microbiotas of subjects 1, 3, 4, and 5. The y-axis refers 
to the number of μmoles in the total culture volume. Glucosinolates were converted to 
desulphoglucosinolates prior to HPLC analysis. GR; Glucoraphanin: G-ERN; Glucoerucin. Data 
shown = mean ± SD of four technical replicates. The data was statistically analysed using 
paired Student’s t-tests (two-tailed). *p<0.05; ***p<0.001 zero hr vs 12 hr. 
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Although the conversion of glucoraphanin to glucoerucin accounts for a large 
proportion of the glucoraphanin that disappears during each 12 hour cycle, a small 
portion of glucoraphanin is still unaccounted for. Of the five faecal microbiotas tested, 
the cultured microbiota of subject 2 did not convert glucoraphanin to glucoerucin 
(Figure 4.4). 
 
 
Figure 4.4: Changes in glucoraphanin levels when cultured with human faecal bacteria. 
Human faecal microbiotas were cultured with a broccoli leachate-containing media for four 12 hr 
cycles at 37˚C, under anaerobic conditions. The graph details the results obtained from the 
cultured microbiota of subject 2. The y-axis refers to the number of μmoles in the total culture 
volume. Glucosinolates were converted to desulphoglucosinolates prior to HPLC analysis. Data 
shown = mean ± SD of four technical replicates. The data was statistically analysed using 
paired Student’s t-tests (two-tailed). *p<0.05; **p<0.01; ***p<0.001 zero hr vs 12 hr. 
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The bacterial community of subject 2 does not seem to have the ability to reduce 
glucoraphanin to glucoerucin, but as with the other four faecal microbiotas tested, a 
decrease in glucoraphanin levels were observed across each 12 hour cycle. 
Glucoraphanin was the most prevalent glucosinolate in the culture medium, but the 
glucosinolates glucoiberin and 4-MIND were also present and available to the cultured 
faecal bacteria. As previously mentioned in section 3.4.2.1, the BL media was 
standardised for glucoraphanin in each experiment, but varied in the levels of 
glucoiberin and 4-MIND. When culturing the five independent faecal microbiotas, the 
levels of glucoiberin in the starting media (50 ml) ranged from 4.39 μmoles to 19.07 
μmoles, but were consistent within each separate experiment. Glucoiberin was 
converted to the reduced analogue glucoiberverin by three of the faecal microbiotas 
tested (subjects 1, 3, and 5). Figure 4.5 illustrates the reduction of glucoiberin that 
occurred whilst culturing the microbiota of subject 5 in the BL media.  
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Figure 4.5: Reduction of glucoiberin to glucoiberverin when cultured with human faecal 
bacteria. Human faecal microbiotas were cultured separately with a broccoli leachate-
containing media for four 12 hr cycles at 37˚C, under anaerobic conditions. This figure shows 
the conversion of glucoiberin to glucoiberverin by the faecal microbiota of subject 5, which is 
representative of the observations of two other microbiotas tested (subjects 1, 3 and 5). The y-
axis refers to the number of μmoles in the total culture volume. Glucosinolates were converted 
to desulphoglucosinolates prior to HPLC analysis. GI; Glucoiberin: GIV; Glucoiberverin. Data 
shown = mean ± SD of four technical replicates. The data was statistically analysed using 
paired Student’s t-tests (two-tailed). *p<0.05; **p<0.01; ***p<0.001 zero hr vs 12 hr. 
 
The bacterial-mediated reduction of glucoiberin occurred in the cultured microbiotas of 
subjects 1, 3, and 5, in which the reduction of glucoraphanin had been previously 
observed. Of the two remaining cultured faecal microbiotas (subjects 2 and 4) where 
glucoiberverin was not detected, these microbiotas exhibited the least (subject 4) or no 
(subject 2) reduction activity on glucoraphanin. 
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Figure 4.6 displays data indicating a lack of reductase activity on glucoiberin by the 
faecal microbiota of subject 2, which is representative of the activity observed for the 
cultured faecal microbiota of subject 4. 
 
 
Figure 4.6: Changes in glucoiberin levels when cultured with human faecal bacteria. 
Human faecal microbiotas were cultured with a broccoli leachate-containing media for four 12 hr 
cycles at 37˚C, under anaerobic conditions. This figure shows that glucoiberin was not 
converted to glucoiberverin by the faecal microbiota of subject 2, which is representative of the 
observations for the microbiotas of subjects 2 and 4. The y-axis refers to the number of μmoles 
in the total culture volume. Glucosinolates were converted to desulphoglucosinolates prior to 
HPLC analysis Data shown = mean ± SD of four technical replicates. The data was statistically 
analysed using paired Student’s t-tests (two-tailed). *p<0.05; **p<0.01 zero hr vs 12 hr. 
 
As with the glucoiberin content, the levels of 4-MIND varied (0.48 μmoles to 7.15 
μmoles) in the starting media (50 ml), but were stable within each experiment. A 
statistically significant decrease in the levels of 4-MIND in the BL media was observed 
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when each of the five microbiotas were cultured, although no reduction occurred as this 
particular glucosinolate does not have an oxide group available for enzymatic 
reduction. Figure 4.7 displays data from the cultured microbiota of subject 5, which is 
representative of the data for all five cultured microbiotas. 
 
 
Figure 4.7: Changes in 4-MIND levels when cultured with human faecal bacteria. Human 
faecal microbiotas were cultured with a broccoli leachate-containing media for four 12 hr cycles 
at 37˚C, under anaerobic conditions. This figure shows the decrease in levels of 4-MIND when 
cultured with the faecal microbiota of subject 5, which is representative of the observations for 
all five cultured microbiotas. The y-axis refers to the number of μmoles in the total culture 
volume. Glucosinolates were converted to desulphoglucosinolates prior to HPLC analysis.  Data 
shown = mean ± SD of four technical replicates. The data was statistically analysed using 
paired Student’s t-tests (two-tailed). **p<0.01; ***p<0.001 zero hr vs 12 hr. 
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Table 4.2 summarises the metabolic fate of glucoraphanin, glucoiberin, and 4-MIND when human faecal microbiotas were cultured in the BL 
media. The amount of each glucosinolate remaining in the BL media, converted to the reduced analogue, or unaccounted for during each of the 
four 12 hr cycles was averaged over each experiment and displayed as a percentage of the starting levels of each glucosinolate. 
 
Table 4.2: Metabolic fate of the glucosinolates in the BL media cultured with human faecal microbiotas, averaged across all four 12 hr cycles. 
Source of 
microbiota 
Glucoraphanin Glucoiberin 4-MIND 
% remaining % converted % missing % remaining % converted % missing % remaining % converted % missing 
Subject 1 55.1 31.1 13.8 55.4 1.1 43.5 64.8 0 35.2 
Subject 2 78.9 0 21.1 89.6 0 10.4 68.4 0 31.6 
Subject 3 57.7 15.1 27.2 55.9 8.8 35.3 60.5 0 39.5 
Subject 4 81.2 5.1 13.7 84.6 0 15.4 78.7 0 21.3 
Subject 5 56.7 20.2 23.1 40.2 15.9 43.9 64.0 0 36.0 
 
Chapter 4 
   
 
111 
 
4.4.3 Analysis of glucoraphanin hydrolysis products in human 
faecal bacteria cultures 
Samples were taken for LC-MS/MS analysis of glucoraphanin hydrolysis products 
before the BL media was inoculated with human faecal microbiotas, and following 
twelve hours of anaerobic growth, for each of four cycles. Although some of the 
decreases in glucoraphanin levels were due to its conversion to glucoerucin, a portion 
of glucoraphanin was still unaccounted for within each experiment. LC-MS/MS was 
used to identify whether the missing glucoraphanin had been hydrolysed to form 
glucosinolate breakdown products by the bacterial communities. Low levels of the ITC 
sulforaphane (SF), derived from glucoraphanin, was present in the starting media, and 
SF levels decreased within each 12 hr cycle, during all five experiments (Figure 4.8). 
 
 
 
Figure 4.8: Levels of sulforaphane in the BL media when cultured with a human faecal 
microbiota. Human faecal microbiotas were cultured with a broccoli leachate-containing (BL) 
media for four 12 hr cycles at 37˚C, under anaerobic conditions. This figure shows the μmoles 
of sulforaphane in the BL media when cultured with the faecal microbiota of subject 5, which is 
representative of the observations of all five microbiotas tested. The y-axis refers to the number 
of μmoles in the total culture volume.  Glucoraphanin hydrolysis products were measured using 
LC-MS/MS. T0; prior to inoculation: T12; 12 hours post-inoculation. Data shown = mean ± SD of 
four technical replicates. The data were statistically analysed using paired Student’s t-tests 
(two-tailed). **p<0.01; ***p<0.001 zero hr vs 12 hr. 
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Glucoraphanin hydrolysis, whether non-enzymatically or due to bacterial myrosinase 
activity, may have led to the production of conjugated SF products as well as free SF, 
and these are also identifiable through the use of LC-MS/MS. SF nitrile was found to be 
the most abundant glucoraphanin hydrolysis product in the starting media (Figure 4.9). 
 
 
Figure 4.9: Presence of sulforaphane nitrile in the BL media when cultured with a human 
faecal microbiota. Human faecal microbiotas were cultured with a broccoli leachate-containing 
(BL) media for four 12 hr cycles at 37˚C, under anaerobic conditions. This figure shows the 
μmoles of sulforaphane nitrile in the BL media when cultured with the faecal microbiota of 
subject 5, which is representative of the observations of all five microbiotas tested. The y-axis 
refers to the number of μmoles in the total culture volume.  Glucoraphanin hydrolysis products 
were measured using LC-MS/MS. T0; prior to inoculation: T12; 12 hours post-inoculation. Data 
shown = mean ± SD of four technical replicates. The data were statistically analysed using 
paired Student’s t-tests (two-tailed). ***p<0.001 zero hr vs 12 hr. 
 
As with free SF, SF nitrile was present in the starting media and decreased within each 
12 hour cycle. The conjugated ITC products, SF-cysteine, SF-cysteine-glycine, SF-
glutathione, SF-N-acetylcysteine and erucin-N-acetylcysteine were identified at trace 
levels (Figure 4.10 and Figure 4.11). 
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Figure 4.10: Levels of sulforaphane conjugates in the BL media when cultured with a 
human faecal microbiota. Human faecal microbiotas were cultured with a broccoli leachate-
containing (BL) media for four 12 hr cycles at 37˚C, under anaerobic conditions. This figure 
shows the presence of sulforaphane conjugates at low levels in the BL media when cultured 
with the faecal microbiota of subject 5, which is representative of the observations of all five 
microbiotas tested. The y-axis refers to the number of μmoles in the total culture volume. 
Glucoraphanin hydrolysis products were measured using LC-MS/MS. A. SF-cysteine-glycine; B. 
SF-cysteine; C. SF-glutathione. T0; prior to inoculation: T12; 12 hours post-inoculation. Data 
shown = mean ± SD of four technical replicates. The data were statistically analysed using 
paired Student’s t-tests (two-tailed). ***p<0.001 zero hr vs 12 hr. 
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Figure 4.11: Levels of isothiocyanate N-acetylcysteine conjugates in the BL media when 
cultured with a human faecal microbiota. Human faecal microbiotas were cultured with a 
broccoli leachate-containing (BL) media for four 12 hr cycles at 37˚C, under anaerobic 
conditions. This figure shows the presence of ITC N-acetylcysteine conjugates at low levels in 
the BL media when cultured with the faecal microbiota of subject 5, which is representative of 
the observations of all five microbiotas tested. The y-axis refers to the number of μmoles in the 
total culture volume. Glucosinolate hydrolysis products were measured using LC-MS/MS. A. SF-
N-acetylcysteine; B. Erucin-N-acetylcysteine. T0; prior to inoculation: T12; 12 hours post-
inoculation. Data shown = mean ± SD of four technical replicates. The data were statistically 
analysed using paired Student’s t-tests (two-tailed). ***p<0.001 zero hr vs 12 hr. 
 
Combining the HPLC and LC-MS/MS data of glucoraphanin, glucoerucin, and their 
related hydrolysis products over each 12 hour culturing period, does not account for the 
entire amount of glucoraphanin and associated breakdown products present in the 
starting media. The average percentage of glucoraphanin and its related products 
unaccounted for by the end of each cycle in each experiment was 26.65% (SD 
12.69%). Interestingly, the average percentage unaccounted for in each 12 hour 
culturing period for the experiments in which glucoraphanin was biotransformed to 
glucoerucin is 31.06% (SD 10.94%), whilst only 13.39% (SD 7.33%) was unaccounted 
for in the one experiment where glucoraphanin was not reduced to glucoerucin. 
Performing a Student’s t-test (unpaired, 2-tailed) on the percentage of missing starting 
material in the cultured microbiota where reductase activity was absent, against those 
experiments where reductase activity occurred shows that there is a statistically 
significant difference (p = 0.01). 
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4.5 Discussion 
4.5.1 Stability of glucoraphanin in the aqueous medium 
The initial objective of this experiment was to establish whether glucoraphanin would 
remain stable in the BL media under the proposed experimental conditions. The 
stability of glucoraphanin in CNM was confirmed across a 24 hr period, at 37˚C under 
anaerobic conditions. The glucoraphanin levels in the BL media remained constant in 
the absence of faecal bacteria (Figure 4.2). The samples cultured with faecal bacteria 
exhibited a decrease in glucoraphanin after 6 hours, and the glucoraphanin was fully 
depleted in the media after 24 hours. These data indicated that a period of 12 hours 
would be suitable to investigate the metabolic fate of glucosinolates when cultured with 
human gut bacteria, and that any change to the levels of glucoraphanin could be 
attributed to bacterial metabolic activity. 
 
4.5.2 Reduction of glucosinolates 
When human faecal microbiotas were cultured in a BL media, decreases in the levels 
of glucoraphanin were recorded for each experiment. A concomitant appearance of 
glucoerucin was observed in four of the five experiments (Figure 4.3). Glucoraphanin 
can be converted to glucoerucin via the reduction of the sulphoxide present on the R 
group of glucoraphanin (Figure 4.12). As it had already been shown that glucoraphanin 
was stable under these experimental conditions, it can be inferred that the reduction of 
glucoraphanin was bacterial-mediated. The reduction of glucosinolates by a human 
faecal microbiota [142], and bacteria isolated from human faecal material [45] has 
previously been reported. 
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Figure 4.12: Schematic indicating the bacterial reduction of glucoraphanin. The 
sulphoxide (circled) on the R group of glucoraphanin can be reduced by human intestinal 
bacteria to produce the reduced analogue, glucoerucin. 
 
The BL media contained lesser amounts of glucoiberin and 4-MIND, compared to 
glucoraphanin levels. Glucoiberin was also observed to be converted to glucoiberverin 
via the reduction of the sulphoxide group (Figure 4.5). The reduction of both 
glucoraphanin and glucoiberin occurred in experiments using the faecal microbiotas of 
subjects 1, 3, and 5, suggesting that they were modified by the same bacterial reaction, 
as reported in other studies [45, 144]. Furthermore, this implies that the cultured 
microbiota in which the reduction reaction was not observed for either glucosinolate, 
may have lacked the bacteria able to perform a reduction reaction. The amount of 4-
MIND decreased by an average of 32.7% during 12 hr incubation cycles using the five 
faecal microbiotas (Figure 4.7). This could not be due to a reduction reaction as this 
glucosinolate lacks an oxide group, but a portion of 4-MIND may have been 
metabolised by bacteria contained within the faecal microbiota to unidentified 
metabolites. 
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4.5.3 Glucoraphanin hydrolysis products 
Low levels of glucoraphanin hydrolysis products were present in the starting media, 
which may have been the result of non-enzymatic glucosinolate hydrolysis [46, 360], 
the action of the broccoli myrosinase enzyme prior to steaming, or because the 
myrosinase enzyme was not completely abolished during the preparation of the 
broccoli leachate. The amount of sulforaphane (Figure 4.8) and sulforaphane nitrile 
(Figure 4.9) in the BL media decreased within each 12 hour culturing period. The loss 
of these compounds may have been due to the inherent instability of ITCs in an 
aqueous medium [125], or due to bacterial metabolism. Furthermore, some of the 
glucoraphanin and glucoiberin were unaccounted for during the experimental periods, 
and it is unknown whether these were hydrolysed by the cultured microbiotas, and 
subsequently metabolised further to unidentified products. The hydrolysis of 
glucoerucin, or the reduction of sulforaphane or sulforaphane nitrile, can produce 
erucin or erucin nitrile. These are volatile compounds, which may accumulate in the 
headspace of the sample vessel. Additional information regarding the missing 
glucoraphanin may have been gained through the analysis of samples for volatile ITC 
products. GC-MS can analyse the gaseous space to identify volatile and semi-volatile 
compounds using thermal desorption. Therefore, the conclusions derived from this 
experimental work could have been strengthened through the use of GC-MS to 
determine whether erucin and erucin nitrile were present in the cultured BL media. 
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4.6 Conclusions 
Using a static batch fermentation model, differential metabolism of glucosinolates by 
independent human faecal microbiotas was observed. It was determined that the 
sulphoxide group, which forms part of the structure of both glucoraphanin and 
glucoiberin, could be reduced by bacterial communities originating from the human gut 
to form glucoerucin and glucoiberverin, respectively. However, this bacterial reductase 
activity was not observed in one of the five microbiotas tested. This may indicate that 
bacteria that possessed the ability to reduce glucosinolates were not present in that 
sample. The total amount of the three glucosinolates present in the BL media 
(glucoraphanin, glucoiberin, and 4-MIND) could not be fully accounted for at the end of 
each of the experiments, indicating the possible formation of unidentified metabolites. 
To complement these results, the next chapter will detail how the community 
composition of the faecal microbiotas used in these experiments was modified by 
growth in the BL media. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FIVE 
 
5 Dietary broccoli and the gut microbiota: 
Bacterial community modulation through 
repeated exposure to a broccoli leachate 
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5.0 Summary 
The diet has modulatory effects on the composition of the human gut microbiota. 
Bacterial fermentation of dietary carbohydrates can lead to the production of metabolic 
end-products, such as short-chain fatty acids, which are beneficial to human health. 
These acidic compounds can alter the pH of the colonic microenvironment, giving acid-
tolerant bacteria a competitive advantage. This chapter investigates how microbial 
growth in a medium supplemented with a broccoli leachate, may modulate the 
composition of human faecal microbiotas, compared to a medium containing glucose. 
Bacterial communities cultured in a broccoli leachate-containing (BL) media were 
enriched for lactic acid bacteria (LAB), particularly Lactobacillus, compared to 
communities cultured in a glucose (GL) media. LAB enrichment was associated with a 
decrease in pH, which would likely have given this group of bacteria a competitive 
advantage. 
 
 
5.1 Introduction 
The previous chapter focused on how human faecal microbiotas influenced the 
metabolic fate of glucosinolates, when cultured in a BL media. This chapter details how 
the community compositions of the faecal microbiotas were modified through a 
repeated exposure to either a BL media or a GL media. 
 
The structure of the human gut microbiota is influenced by multiple factors, such as the 
birthing method [187], age [230, 361], host genotype [362-364], antibiotic treatment 
[365-367], environmental factors [368], and diet [238, 254, 259, 369, 370]. As such, a 
large variation in the gut microbiota composition has been observed between 
individuals [180, 202]. The enterotype hypothesis proposes that the human gut 
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microbiota can be stratified into three distinct clusters according to the relative 
abundance of Bacteroides, Prevotella, or Ruminococcus [226]. It has been suggested 
that the enterotype clustering may be primarily driven by the ratio of Prevotella to 
Bacteroides [239, 371]. Although the analysis of several datasets have indicated the 
presence of these enterotypes [181, 202], other studies were unable to confirm these 
bacterial clusters [368, 372].  
 
The diet is considered to be one of the most influential chronic factors determining the 
composition of the human gut microbiota [239, 373, 374]. It has been suggested that 
an individual’s microbial profile is strongly associated with their long-term dietary habits 
[239]. Studies indicate that a long-term diet rich in fibre correlates with an increased 
abundance of Prevotella, whilst a long-term diet containing high levels of protein and 
fat is associated with higher levels of Bacteroides [238, 239]. Short-term dietary 
interventions are able to produce rapid changes to the composition of the gut 
microbiota, but the community reverts to the original composition within days of the 
intervention ending [239, 254]. This illustrates the elasticity and the range of functional 
capabilities within the microbiota. As the nutrient profile of the intestinal environment 
changes, the composition of the bacterial community alters to maximise nutrient 
utilisation. 
 
In some cases it may be more relevant to group the gut microbiota by metabolic 
function rather than composition [181, 202, 226]. Lactic acid bacteria (LAB) have 
limited biosynthetic capabilities, but are efficient metabolisers of carbohydrates [375]. 
The major fermentation product is lactic acid, which can be further metabolised to 
produce short-chain fatty acids (SCFAs) [376]. Although SCFAs are bacterial waste 
products, these compounds have been shown to have beneficial properties on human 
health [377]. 
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The human colon has a pH gradient ranging from mildly acidic within the proximal 
colon, to a neutral pH at the distal colon [378, 379]. It is understood that the proximal 
colon is the favoured site of substrate fermentation, and the production of weakly acidic 
bacterial fermentation products lowers the luminal pH [380]. Many Firmicutes, including 
LAB, have evolved to be tolerant of the acidic microenvironments that are generated at 
the sites of substrate fermentation [270, 381, 382]. Acid-tolerance can give these 
bacteria a competitive advantage over bacteria, such as Bacteroides and strains of 
Escherichia coli, whose growth have been shown to be inhibited at a physiologically 
relevant pH of 5.5 [270]. 
 
 
5.2 Objectives 
The hypothesis for the research contained within this chapter, was that the community 
composition of the human faecal microbiotas would be altered through the bacterial 
metabolism of compounds contained within a broccoli leachate media. 
 
 
5.3 Materials and methods 
The samples tested in this work originated from the experiment detailed in section 
2.8.3, and summarised in Figure 5.1. Details of the faecal donors are displayed in 
Table 5.1, and the samples analysed were obtained at the same time-points as the 
samples discussed in chapter 4. The bacterial DNA was extracted, using a bead-
beating technique, following the method in section 2.9.1, with the effectiveness of the 
extraction technique determined by gel electrophoresis, and the DNA yield and purity 
examined using a NanoDrop spectrophotometer (section 2.9.1.1). 16S rDNA was 
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amplified by PCR, and sequenced commercially using a 454 pyrosequencing platform, 
as detailed in section 2.9.2. Bioinformatic analysis was performed on the sequencing 
output files using the QIIME 1.9.0 pipeline, with RDP as the reference sequence 
database (section 2.9.3). 
 
 
Figure 5.1: Schematic of experimental design. Broccoli leachate (BL) media (47.5 ml) and 
glucose (GL) media (47.5 ml) were seeded with a faecal suspension (2.5 ml) and cultured for 12 
hr at 37˚C, under anaerobic conditions. Samples of the cultured media were taken for 
sequencing analysis of the variable V4 and V5 regions within the 16S rDNA gene. An aliquot of 
the cultured media was used to seed the respective fresh media. This was repeated for four 
cycles of bacterial enrichment. 
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Table 5.1: Age, gender, Body Mass Index (BMI), and smoking status of the faecal donors. 
Faecal donors Age (years) Gender BMI (kg/m2) Smoker 
Subject 1 44 Male 24.1 N 
Subject 2 24 Female 23.3 N 
Subject 3 52 Female 20.9 N 
Subject 4 50 Female 38.4 N 
Subject 5 61 Female 20.5 N 
 
 
5.4 Results 
5.4.1 Extracting bacterial DNA 
Bacterial DNA was extracted from the samples collected from the batch fermentation 
model experiments (section 2.8.3) using a FastDNA SPIN Kit for Soil, following a 
method adapted from Maukonen et al (section 2.9.1) [328]. The extraction of bacterial 
DNA was confirmed using agarose gel electrophoresis (Figure 5.2) and a NanoDrop 
spectrophotometer as described in section 2.9.1.1. 
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Figure 5.2: Representative image of a 1% agarose gel containing bacterial DNA extracted 
from cultured faecal microbiotas. Human faecal microbiotas were cultured with a broccoli 
leachate-containing media and a glucose media for four 12 hr cycles at 37˚C, under anaerobic 
conditions. Bacterial DNA was extracted using the FastDNA SPIN Kit for Soil (MP Biomedicals), 
run on a 1% agarose gel, and visualised, after ethidium bromide staining, under UV trans-
illumination. The image is representative of the visualised agarose gels of all of the bacterial 
DNA extracted. L = Bioline Hyperladder I (10 Kb). 
 
5.4.2 Phylogenetic analysis of human faecal microbiotas 
The bacterial DNA obtained from the cultured faecal microbiotas and the original faecal 
samples had the V4 and V5 variable regions of the 16S rDNA gene amplified 
commercially using PCR to generate amplicons. The amplicons were then sequenced 
commercially using 454 pyrosequencing, and analysed using the QIIME pipeline 
(section 2.9.2 and 2.9.3). Faecal samples from 5 healthy humans, aged 24 - 61 years 
with a mean age of 46 years and an average BMI of 25.4 kg/m2, were collected and 
sequenced. This produced 453,810 high-quality reads, with an average of 5,403 ± 
3,019 reads per subject, which clustered into 10,503 operational taxonomic units 
(OTUs) at 97% identity.  
L L Samples 
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5.4.2.1 Microbiota composition 
The relative abundance of bacterial taxa within each sample is represented as a 
proportion of each taxonomic unit within the microbiota. Differences in the relative 
abundance of reads assigned to taxonomic groups within the microbiotas were 
observed, and are displayed at both the phylum and genus levels (Figure 5.3 and 
Figure 5.4, respectively). 
 
 
Figure 5.3: Firmicutes are highly represented in the human faecal microbiotas. Bacterial 
DNA from faecal samples obtained from 5 healthy human subjects (numbered 1 - 5) was 
extracted, and the V4 and V5 regions of the 16S rDNA gene were sequenced. Bioinformatic 
analysis was performed using QIIME 1.9.0, and the bar chart displays the proportion of OTUs 
per faecal microbiota classified at the phylum level. 
 
Across the five microbiotas, the Firmicutes were highly represented at an average 
proportion of 73% (SD 14.5%) along with Bacteroidetes at 24.1% (SD 15%), together 
accounting for an average of 97.2% (SD 1.3%) of the bacteria present in the faecal 
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communities. The standard deviations indicate that although there is variability in the 
proportions of Firmicutes and Bacteroidetes among the five microbiotas, the proportion 
of both phyla combined is relatively consistent. Other phyla present are Tenericutes 
(0.8%; SD 0.9%), Actinobacteria (0.8%; SD 0.4%), Proteobacteria (0.7%; SD 0.9%), 
and Euryarchaeota (0.04%; SD 0.1%), with 0.4% of phylum OTUs unclassified. 
 
 
Figure 5.4: The genera Faecalibacterium and Prevotella are most abundant amongst the 
human faecal microbiotas. Bacterial DNA from faecal samples obtained from 5 healthy human 
subjects (numbered 1 - 5) was extracted, and the V4 and V5 regions of the 16S rDNA gene 
were sequenced. Bioinformatic analysis was performed using QIIME 1.9.0, and the bar chart 
displays the proportion of OTUs per faecal microbiota. The key reads from top left to bottom 
right, and consists of genera with a relative abundance ≥0.5% in at least one faecal microbiota. 
* represents unclassified OTU reported at a higher taxonomic level.  
 
The genera most represented amongst the faecal microbiotas were Faecalibacterium 
(22.2%; SD 9.8%), Prevotella (17.7%; SD 13.8%), Ruminococcus of the 
Ruminococcaceae family (8.6%; SD 7.6%), Blautia (5.7%; SD 1.2%), and Eubacterium 
(4.4%; SD 6.9%). Interestingly, the data indicates that subjects 2 and 5 may share a 
highly similar microbiota, characterised by a smaller proportion of Prevotella (1 - 4%) 
and increased abundance of Clostridiales, compared to subjects 1, 3, and 4. These 
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inter-individual similarities appear to be present at the phylum level, with reduced levels 
of Bacteroidetes, and an increased abundance of Firmicutes and Tenericutes in 
subjects 2 and 5, compared to the other microbiotas sequenced (Figure 5.3). 
 
5.4.2.2 Faecal microbiota alpha diversity 
Bacterial diversity within the microbiotas (alpha diversity) was measured using four 
metrics: Observed Species, Phylogenetic Distance (PD), Chao1, and the Shannon 
Index. The Observed Species metric produces a count of the number of unique OTUs 
within each sample, whilst PD requires a phylogenetic tree to be generated from the 
samples, and uses the branch lengths that separate the taxa within a community to 
estimate diversity [383, 384]. Chao1 estimates species richness within a sample, and 
the Shannon Index accounts for both species richness and distribution (evenness), via 
quantification of the entropy associated with the OTU abundances [385]. Alpha 
rarefaction plots depicting the diversity within each of the faecal microbiotas show that 
the number of unique OTUs, species richness, and phylogenetic diversity within all 
faecal samples increase as the number of sequences obtained for each sample 
increases (Figure 5.5 and Figure 5.6). The faecal microbiota of subject 5 contains the 
largest number of unique OTUs (609.5 in 3,010 sequences) and highest level of 
species richness (1,927.4 in 3,010 sequences) (Figure 5.5 A). The lowest quantity of 
unique OTUs (412.4 in 3,010 sequences) and degree of species richness (1,149.9 in 
3,010 sequences) was observed in the faecal microbiota of subject 1, with similar 
numbers obtained from the microbiota of subject 3 (428.1 and 1,312.7 in 3,010 
sequences, respectively) (Figure 5.5). The faecal microbiotas of subjects 2 and 4 have 
a comparable number of unique OTUs (526.2 and 492.7 in 3,010 sequences, 
respectively) and measure of species richness (1,633.3 and 1,513.1 in 3,010 
sequences, respectively).  
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Figure 5.5: Faecal microbiota of subject 5 contains the greatest number of unique OTUs 
and highest level of species richness. Alpha diversity rarefaction plots of (A) number of 
unique OTUs, and (B) species richness within the human faecal microbiota samples (subjects 1 
- 5). The y-axis is a measure of diversity within each community, whilst the x-axis represents the 
number of sequences used in the diversity calculation. Rarefaction plots were generated using 
QIIME 1.9.0. 
 
Chapter 5 
   
 
130 
 
 
Figure 5.6: Greater phylogenetic diversity within the faecal microbiota of subject 5, and 
increased species richness and evenness in subjects 4 and 5. Alpha diversity rarefaction 
measures of (A) phylogenetic diversity and (B) species richness and evenness within the 
human faecal microbiota samples (subjects 1 - 5). (A) The y-axis is a measure of phylogenetic 
diversity within each community, whilst the x-axis represents the number of sequences used in 
the diversity calculation. (B) The y-axis represents the Shannon Index value associated with 
species richness and evenness at 3,010 samples per sequence. The microbiotas of the five 
subjects are plotted along the x-axis. The rarefaction plot was generated using QIIME 1.9.0, and 
the bar graph was produced using GraphPad Prism 5. 
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The greatest phylogenetic diversity is found in the faecal microbiota of subject 5 (24.0 
in 3,010 sequences), with the microbiota of subject 1 exhibiting the least phylogenetic 
diversity (16.4 in 3,010 sequences) (Figure 5.6 A). The results from the analysis 
performed using the Shannon Index gives a similar score to the faecal microbiotas of 
subjects 4 and 5 (6.48 and 6.54, respectively), with subject 1 receiving the lowest score 
(5.07) (Figure 5.6 B). 
 
5.4.2.3 Faecal microbiota beta diversity 
Bacterial diversity between the microbiotas (beta diversity) was measured using QIIME 
and the UniFrac metric, with the results displayed as a principal coordinates analysis 
(PCoA) plot generated using the Emperor tool. The taxa present in each of the samples 
are mapped onto a phylogenetic tree, and the distance between the samples is 
calculated using their UniFrac measure to generate a PCoA plot to visualise the 
dissimilarities between microbiotas. The unweighted UniFrac calculation is based on 
which taxa are present and shared between microbiotas, and does not take the relative 
abundance of each of the taxa within the communities into consideration. Calculating 
the phylogenetic distance between the five faecal microbiotas using the unweighted 
UniFrac metric indicated that the microbiotas of the five subjects did not share a large 
range of taxa (Figure 5.7). 
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Figure 5.7: Faecal microbiotas were not phylogenetically similar. Unweighted beta diversity 
analysis of faecal microbiotas (subjects 1 - 5) using the UniFrac metric, visualised as a 3D 
PCoA plot. Beta diversity analysis performed using QIIME 1.9.0, and plotted using Emperor. 
 
The weighted UniFrac calculation factors in the relative abundance of each of the taxa 
within the communities, alongside which taxa are shared amongst the samples. 
Calculating the phylogenetic distance between the five faecal microbiotas using the 
weighted UniFrac metric suggests that the microbiotas of subjects 2 and 5 are most 
similar to one another (Figure 5.8). The similarity between the microbiotas of subjects 
2 and 5 concurs with the observations made based on the bar chart displaying the 
proportions of genera present in the faecal microbiotas (Figure 5.4). 
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Figure 5.8: Faecal microbiotas of subjects 2 and 5 are phylogenetically similar when 
relative abundance of taxa is considered. Weighted beta diversity analysis of faecal 
microbiotas (subjects 1 - 5) using the UniFrac metric, visualised as a 3D PCoA plot. Beta 
diversity analysis performed using QIIME 1.9.0, and plotted using Emperor. 
 
 
5.4.3 Phylogenetic analysis after culturing of the microbiotas 
The five faecal microbiotas were used in independent experiments to test whether 
culturing in a broccoli leachate-containing (BL) media would modify the microbiota 
composition, compared to a glucose (GL) media control (detailed in section 2.8, and 
summarised in Figure 5.1). All experiments were performed with four replicates, under 
anaerobic conditions at 37˚C. The broccoli leachates were tested for sterility, both 
before and during each experiment, to confirm that any bacterial growth observed 
originated from the human faecal suspension. The faecal bacteria were cultured for 12 
hours in both media before samples were taken for phylogenetic analysis, and aliquots 
were used to seed the respective fresh media. This procedure was repeated for four 12 
hour cycles. Phylogenetic analysis was performed on samples taken from both cultured 
media types after the completion of cycle 1 and cycle 4, to identify the effects of 
repeated exposure to the broccoli leachate on bacterial community composition. 
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5.4.3.1 Variation amongst biological replicates 
Phylogenetic analysis of four biological replicates for both the cultured BL media and 
the GL media, across all five independent experiments, indicated a high level of 
similarity in the community composition between the experimentally linked replicates. 
Figure 5.9 shows the similarity between replicates for the cultured microbiota of 
subject 1 at the genus level.  
 
 
Figure 5.9: Minimal variation between four replicates at the genus level under both 
conditions at two time-points. Five human faecal samples were cultured independently in a 
broccoli-leachate-containing (BL) media and a glucose (GL) media. Bacterial DNA was 
extracted, and the variable V4 and V5 regions within the 16S rDNA gene were sequenced. 
Bioinformatic analysis was performed using QIIME 1.9.0. The bar chart displays the proportion 
of OTUs per cultured faecal microbiota of subject 1 after the first cycle (1) and the last cycle (4). 
These data are representative of the level of similarity observed between the replicates of each 
of the five cultured microbiotas. The key reads from top left to bottom right, and consists of 
genera with a relative abundance ≥0.5% in at least one sample. * represents unclassified OTU 
reported at a higher taxonomic level. 
 
The strong similarity between replicates at the genus level allowed each set to be 
grouped and averaged to form a single dataset for the subsequent analyses. 
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5.4.3.2 Modification of microbiotas through culturing in a BL and GL media 
The community compositions of the faecal microbiotas were differentially modified 
when cultured in a BL media and a GL media. Figure 5.10 shows the changes at the 
phylum level when the microbiota of subject 1 was cultured in the BL and GL media. 
 
 
Figure 5.10: The faecal microbiota was differentially modified at the phylum level when 
cultured in two media types. Five human faecal samples were cultured independently in a 
broccoli-leachate-containing media (BL) and a glucose media (GL). Bacterial DNA was 
extracted, and the 16S rDNA gene V4 and V5 regions were sequenced. Bioinformatic analysis 
was performed using QIIME 1.9.0. The bar chart displays the proportion of OTUs per cultured 
faecal microbiota of subject 1 after the first cycle (1) and the last cycle (4), and is representative 
of all five cultured microbiotas. The key consists of phyla with a relative abundance ≥0.5% in at 
least one sample. 
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Across the five cultured microbiotas, the average proportion of Bacteroidetes 
decreased after cycle 1, from 24.1% (SD 15%) to 18.4% (SD 2.9%) in the BL media 
and 21.8% (SD 4.3%) in the GL media. After cycle 4 Bacteroidetes were present at a 
proportion of 0.1% (SD 0.04%) in the BL media, and 8.6% (SD 1.2%) in the GL media. 
Conversely, an increase in the proportion of Proteobacteria, averaging 0.7% in the 
faecal microbiotas, was observed in the BL media and GL media at cycle 1 (5.6% (SD 
3.4%) vs 19.6% (SD 8.8%), respectively) and cycle 4 (26.8% (SD 11.4%) vs 38.2% 
(SD 2.5%), respectively). The proportion of Firmicutes, which were present at an 
average of 73% in the faecal microbiotas, were modified differently, and this was 
dependent on the media. The proportion of Firmicutes remained relatively stable in the 
BL media (72% (SD 11.4%) after cycle 4), whilst a decrease in the proportion of this 
phylum was seen when cultured in the GL media (50.4% (SD 1.6%). On average, 
Actinobacteria proportionally increased from 0.8% (SD 0.4%) in the faecal microbiotas 
to 12.3% (SD 1.6%) in the BL media after cycle 1, before decreasing to 1% (SD 0.4%) 
after cycle 4. In the GL media, the average proportion of Fusobacteria increased to 
1.8% (SD 0.7%) of the cultured microbiota after cycle 4, from <0.1% in the faecal 
starting material, and was absent from the cultured BL media. The cultured microbiotas 
were investigated for modification of the community at the genus level to gain a deeper 
understanding of the effect of the broccoli leachate (Figure 5.11). 
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Figure 5.11: The proportion of the genus Lactobacillus increases after culturing faecal 
microbiotas in the media containing a broccoli leachate. Five human faecal samples were 
cultured independently in a broccoli-leachate-containing (BL) media and a glucose (GL) media. 
Bacterial DNA was extracted, and the V4 and V5 regions of the 16S rDNA gene were 
sequenced. Bioinformatic analysis was performed using QIIME 1.9.0. The bar chart displays the 
proportion of OTUs per cultured faecal microbiota of subject 1 after the first cycle (1) and the 
last cycle (4). This figure is representative of the observations that lactobacilli proportionally 
increased in the BL media for four of the five cultured microbiotas (subjects 1 - 3 and 5).  The 
key reads from top left to bottom right, and consists of genera with a relative abundance ≥0.5% 
in at least one sample. * represents unclassified OTU reported at a higher taxonomic level. 
 
At the genus level, the greatest effect observed was an increase in Lactobacillus in the 
cultured BL media. The average proportion of lactobacilli present in the initial faecal 
samples was 0.5% (SD 0.7%). Culturing these faecal microbiotas in the BL media, 
caused the average proportion of lactobacilli to increase to 10.2% (SD 20.6%) after 
cycle 1, and 42.0% (SD 31.4%) after cycle 4. As a similar bloom of lactobacilli were not 
seen in the GL media (cycle 1, 1% (SD 2%); cycle 4, 0.2% (SD 0.3%)), this indicated 
that the increased growth was due to constituents of the broccoli leachate, rather than 
the experimental conditions or basal media. 
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In experiments with four of the five human faecal microbiotas (subjects 1 - 3, and 5) 
cultured in the BL media, the proportion of the genus Lactobacillus increased to 
between 22% and 94% of the microbial community at the end of cycle 4. The only 
experiment in which lactobacilli were present in the GL media after cycle 4 (0.8%), was 
when the media was cultured with the microbiota of subject 3. In the experiment using 
the microbiota of subject 4, the proportion of lactobacilli cultured in the BL media 
increased to 4.3% at the end of cycle 4, compared to 0.8% in the faecal material. 
However, this bacterial community was dominated by another genus of the lactic acid 
bacteria, Streptococcus (Figure 5.12). 
 
 
Figure 5.12: The faecal microbiota cultured in the broccoli leachate-containing media is 
highly represented by the genus Streptococcus. Five human faecal samples were cultured 
in a broccoli-leachate-containing (BL) media and a glucose (GL) media. Bacterial DNA was 
extracted, and the V4 and V5 regions of the 16S rDNA gene were sequenced. Bioinformatic 
analysis was performed using QIIME 1.9.0, the bar chart displays the proportion of OTUs per 
cultured faecal microbiota of subject 4 after the first cycle (1) and the last cycle (4). The key 
reads from top left to bottom right, and consists of genera with a relative abundance ≥0.5% in at 
least one sample. * represents unclassified OTU reported at a higher taxonomic level. 
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At the end of the experiment, the faecal microbiota of subject 4 cultured in the BL 
media largely consisted of the genus Streptococcus (77.4% (SD 18.3%)), with 
Lactobacillus present at 4.3% of the microbiota. Unlike previously, when lactobacilli 
were enriched, members of Streptococcus were also present at a relatively high 
proportion in the GL media at this time-point (21.9% (SD 0.5%)). This may indicate that 
the basal media and/or experimental conditions favoured the growth of streptococci, 
and that this effect was enhanced by the presence of the broccoli leachate. Other 
notable changes to the microbiota composition that were seen repeatedly, concerned 
the genera Bacteroides and Escherichia. The average proportion of the Bacteroides 
that were observed in the faecal samples was 3.4% (SD 2.2%). Growth in the BL media 
caused a reduction of all Bacteroidetes by cycle 4, with the average proportion of 
Bacteroides decreasing to 0.03% (SD 0.04%). However, an increase in Bacteroides at 
cycle 4 was observed when the faecal microbiotas were cultured in the GL media 
(9.4% (SD 2.8%)). Coupled with the information obtained regarding changes at the 
phylum level (Figure 5.10), this would suggest that growth in the presence of the 
broccoli leachate favoured members of the Firmicutes. 
 
The proportions of the genus Escherichia were found to increase regardless of whether 
they were grown in the BL or GL media. On average, Escherichia was proportionally 
represented at 0.3 (SD 0.6%) of the initial faecal material, and increased to 25.4% (SD 
2.4%) in the BL media and 31.2% (SD 7.9%) in the GL media, by the end of the fourth 
growth cycle. This indicates that the growth of Escherichia species was likely due to the 
experimental model and/or basal media, rather than a specific effect of the broccoli 
leachate. This reflects the ease at which Escherichia species grow in a laboratory 
environment under the conditions tested here. 
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5.4.3.3 Microbial diversity within cultured microbiotas 
Diversity analysis was performed on the cultured faecal microbiotas to determine how 
within-sample diversity differed between cultured media types and the initial community 
composition. As discussed previously (section 5.4.2.2), alpha rarefaction methods were 
employed to investigate diversity within the microbial communities, using the Observed 
Species, PD, Chao1, and Shannon Index metrics. Fewer unique OTUs and a reduction 
in species richness were observed in samples cultured in both media types, compared 
to the starting faecal material (Figure 5.13). Analysis of the faecal material, at 3,796 
sequences per sample, recorded 446 unique OTUs and a species richness measure of 
1,358.1. When cultured for four cycles in the GL media, the number of unique OTUs 
decreased to 140.9 ± 8.9, with fewer present in the cultured BL media (31.7 ± 1.9). 
Effects of culturing on species richness within the microbiota followed the same trend 
at cycle 4, with a lower richness found in the BL media cultured community (78.9 ± 
11.6) compared to the community grown in the GL media (333.9 ± 25.6).  
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Figure 5.13: A lower number of unique OTUs, and reduced species richness is found in 
the microbiota cultured with the broccoli leachate media. Alpha diversity rarefaction plots of 
(A) number of unique OTUs, and (B) species richness within the faecal microbiota of subject 1 
cultured in a broccoli leachate-containing (BL) media or glucose (GL) media. Data plotted 
represents diversity within the communities after the first cycle (1) and the last cycle (4). (A) The 
y-axis is a measure of diversity within each community, whilst the x-axis represents the number 
of sequences used in the diversity calculation. Rarefaction plots generated using QIIME 1.9.0. 
Data = mean ± SD of four technical replicates for the cultured samples, whilst the data for the 
uncultured faecal sample is from a single sample. 
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Figure 5.14: Faecal microbiota cultured with a broccoli leachate exhibits a reduced 
phylogenetic diversity and lower species richness and evenness. Alpha diversity 
rarefaction plots of (A) phylogenetic diversity, and (B) species richness and evenness within the 
faecal microbiota of subject 1 cultured in a broccoli leachate-containing (BL) media or glucose 
(GL) media. Data plotted represents diversity within the communities after the first cycle (1) and 
the last cycle (4), and is representative of the five cultured microbiotas. (A) The y-axis is a 
measure of phylogenetic diversity within each community, whilst the x-axis represents the 
number of sequences used in the diversity calculation. (B) The y-axis represents the Shannon 
Index value associated with species richness and evenness at 2,534 samples per sequence. 
The initial faecal microbiota and cultured microbiotas of subject 1 are plotted along the x-axis. 
The rarefaction plot was generated using QIIME 1.9.0, and the bar graph was produced using 
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GraphPad Prism 5. Data = mean ± SD of four technical replicates for the cultured samples, 
whilst the data for the uncultured faecal microbiota is from a single sample. 
Both media had similar effects on the phylogenetic diversity, and combined species 
richness and evenness, within the cultured microbiotas (Figure 5.14). A decrease in 
phylogenetic diversity was observed for microbiotas cultured in BL media (2.2 ± 0.11) 
and GL media (7.5 ± 0.3) after cycle 4, compared to the original faecal microbiota 
(17.2). When the relative microbial abundance is considered in the calculation for 
species richness (Shannon Index), the microbiota cultured in the BL media retains a 
lower diversity measure than the microbiota grown in the GL media (cycle 4: 2.04 ± 
0.04 vs 3.58 ± 0.5), and the uncultured faecal microbiota (4.73). Analysis using all four 
metrics (Figure 5.13 and Figure 5.14) indicates that modification of the microbiotas 
occurs rapidly, with large changes seen after the first 12 hours of culturing (cycle 1). A 
combination of the Chao1 and Shannon Index analyses implies that the first cycle of 
growth in the GL media produced a more even distribution of bacterial genera within 
the cultured microbiota. This hypothesis appears to be corroborated by the bar chart 
displaying the proportion of each genus within the bacterial community (Figure 5.11).  
 
Unweighted beta diversity analysis indicated a clear divergence in community 
composition between microbiotas cultured in the two media types (Figure 5.15). 
Twelve hours growth in the BL media or GL media was sufficient to modify the initial 
faecal community to form two distinct microbiotas. 
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Figure 5.15: Media-dependent modulation of faecal microbiotas. Unweighted beta diversity 
analysis of the faecal microbiota of subject 1, cultured in a broccoli leachate-containing (BL) 
media and glucose (GL) media, after the first cycle (1) and the last cycle (4). This is 
representative of the five cultured microbiotas. Beta diversity calculated using UniFrac distances 
through QIIME 1.9.0, and visualised as a 3D PCoA plot using Emperor.  
 
Weighted beta diversity analysis was performed to examine whether differences in the 
relative abundance of taxa would affect the level of diversity between the cultured 
microbiotas (Figure 5.16). The weighted analysis suggested a greater divergence of 
the cultured microbiotas from the original faecal sample following the first twelve hours 
of growth. The inclusion of relative abundance into the beta diversity calculation did not 
report a notably altered level of diversity between the cultured microbiotas at the end of 
the experiment, comparable to the unweighted analysis. 
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Figure 5.16: Diversity between cultured faecal microbiotas is not abolished when relative 
abundance is considered. Weighted beta diversity analysis of the faecal microbiota of subject 
1, cultured in a broccoli leachate-containing (BL) media and glucose (GL) media, after the first 
cycle (1) and the last cycle (4). This is representative of the five cultured microbiotas. Beta 
diversity calculated using UniFrac distances through QIIME 1.9.0, and visualised as a 3D PCoA 
plot using Emperor. 
 
The effects on beta diversity were greater on the microbiotas cultured in the BL media, 
highlighting the strong selection pressure that the broccoli leachate exerted on the 
microbial communities. 
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5.4.4 Changes in pH during culturing with human faecal bacteria 
Members of the Lactobacillus and Streptococcus are known producers of lactic acid. It 
was hypothesised that the production of lactic acid may have reduced the pH of the 
medium, and inhibited the growth of bacteria sensitive to acidic conditions.  In respect 
of this, the pH values of the faecal microbiota cultures were recorded at the end of the 
first and fourth cycles (Figure 5.17). 
 
 
Figure 5.17: The pH of both media types after the first and fourth 12 hr culturing periods 
with faecal bacteria. Human faecal microbiotas were cultured with a broccoli leachate-
containing (BL) media and a glucose (GL) media for four 12 hr cycles at 37˚C, in anaerobic 
conditions. The pH values of both cultured media types were recorded after the first (cycle 1) 
and fourth (cycle 4) 12 hr incubation period. The figure shows the pH values of the cultured 
microbiota of subject 5, and is representative of the four microbiotas tested (subjects 2 – 5). 
Data shown = mean ± SD of four technical replicates. The data was statistically analysed using 
two-way ANOVA followed by Bonferroni multiple comparisons test. ***p<0.001 BL media vs GL 
media. 
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The above graph (Figure 5.17) is representative of the changes in pH observed in the 
culturing experiments using the faecal microbiotas of subjects 2 – 5, the pH of the 
cultured microbiota of subject 1 was not measured. Both the BL media and the GL 
media had a pH of 7.0 ± 0.02 prior to inoculation with human faecal bacteria. 
Combining the data from the experiments using the microbiotas of subjects 2 - 5, the 
pH of the BL media dropped from 7.0 to 4.52 ± 0.22 at the end of cycle 1, and was an 
average of 4.87 ± 0.43 at the end of cycle 4. Conversely, the pH of the cultured GL 
media remained relatively stable throughout the experiments; cycle 1 = 7.14 ± 0.13, 
and cycle 4 = 7.02 ± 0.21. 
 
 
5.5 Discussion 
5.5.1 Optimising bacterial DNA extraction 
The protocol for the FastDNA SPIN kit for soil DNA extraction kit was modified based 
on the current literature. Zoetendal et al reported the presence of an extra amplicon 
following a period of bead-beating for 3 minutes, suggesting the presence of bacteria 
that were difficult to lyse [236]. Recently, it was identified that an increase in the 
mechanical disruption of cells, through the use of bead-beating, from 30 seconds to 2 
minutes increased the detection of all bacterial groups [386]. Faecal samples subjected 
to 5 minutes bead-beating were associated with a decrease in the detection of bacterial 
taxa, likely due to the degradation of DNA during this extended time. Therefore, the 
DNA extraction method used maximised the detection of bacterial taxa, whilst 
minimising the loss of DNA. 
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5.5.2 Microbial composition of faecal microbiotas 
Phylogenetic analysis of the five faecal microbiotas indicated a dominance of 
Firmicutes and Bacteroidetes at the phylum level (Figure 5.3). This concurs with the 
findings of other studies using 16S rDNA gene sequencing methods, where Firmicutes 
and Bacteroidetes have been found to constitute >90% of the distal gut microbiota, at 
an approximate ratio of 2.8:1 [227, 238, 371, 387]. The microbiotas of subjects 1, 3, 
and 4 contained the highest proportion of Bacteroidetes. An examination of the 
community composition at the genus level indicates that this is principally due to a 
relatively large proportion of Prevotella in these microbiotas (Figure 5.4). Prevotella are 
known to degrade cellulose and a variety of complex glycans [374]. Decreased levels 
of Prevotella have been reported to correlate with increased energy intake and 
adiposity, and to be associated with a diet low in carbohydrates [238, 388]. The genus 
Faecalibacterium contains one known species, F. prausnitzii, which is reportedly the 
most abundant bacterium found in the gut microbiota of healthy humans, representing 
5 - 15% of the total bacterial community [389, 390]. Faecalibacterium were the most 
prevalent genera amongst the faecal samples tested, and the relative abundances 
correlated with the proportions observed in previous work. F. prausnitzii is a major 
butyrate producer [391], with anti-inflammatory and immunomodulatory capabilities 
[392, 393]. Decreased levels of this bacterium has been associated with Crohn’s 
disease [394] and ulcerative colitis [395].  
 
5.5.3 Diversity analysis of faecal microbiotas 
The alpha diversity scores, measuring the diversity within faecal microbiotas, indicated 
increased diversity within the faecal microbiota obtained from subject 5 (Figure 5.5 and 
Figure 5.6), compared to the faecal microbiotas of subjects 1 - 4. As the Chao1 
analysis indicated that the faecal microbiota of subject 5 exhibited increased species 
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richness versus that of subject 4 (1,927.4 vs 1,513.1) (Figure 5.5 B), the Shannon 
Index score (Figure 5.6 B) suggests a more even distribution of bacterial taxa within 
the microbiota of subject 4. Comparing the Shannon Index score against the Chao1 
measurement for subject 3 versus that of subject 2 (5.66 vs 5.83), indicates that the 
bacterial taxa are more evenly distributed within the microbiota of subject 3, compared 
to the microbiota of subject 2 (Figure 5.5 B and Figure 5.6 B). The faecal microbiota of 
subject 1 was consistently scored as having the lowest diversity, but the alpha diversity 
measurements for all microbiotas were similar to previously reported scores [396-398]. 
Unweighted beta diversity analysis indicated that the microbiotas of the five subjects 
were dissimilar based on the level of shared taxa (Figure 5.7). However, the weighted 
analysis, which also computes the similarity between the relative abundance of taxa 
between communities, suggested that the microbiotas of subjects 2 and 5 were 
phylogenetically similar (Figure 5.8). It has been proposed that the human gut 
microbiota can be stratified into clusters known as enterotypes, principally by the levels 
of Prevotella and Bacteroides present in the microbiota [226, 239]. There was no 
evidence that the microbiotas of subjects 2 and 5 correlated with any of the proposed 
enterotypes. 
 
5.5.4 Effect of broccoli leachate on gut microbiota community 
After the first cycle of growth, the cultured microbiotas of both media types differed 
from the original faecal microbiota composition, and these differences were enhanced 
by the end of the fourth cycle. At the phylum level, microbiotas cultured in either the BL 
or GL media exhibited a decrease in Bacteroidetes, and an increase in Proteobacteria 
(Figure 5.10) in all five microbiotas tested. An increase in the proportion of Firmicutes 
was observed in the microbiotas cultured in the BL media. 
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The differential effects of the culture medium on the microbiotas can be clearly seen at 
the genera level (Figure 5.11). At the end of four of the five experiments, the 
microbiota cultured in the BL media was dominated by Lactobacillus, whilst this genus 
was only observed in the GL media at low levels (0.8%) after one experiment. This was 
observed in four of the five experiments and would seem to indicate that nutrients 
available in the BL media favoured the growth of members of the Lactobacillus. In a 
recent study performed by Filannino et al, the metabolism of phenolic compounds by 
Lactobacillus sp. was investigated using a broccoli puree [399]. All strains tested 
exhibited good growth, and it was found that two strains of Lactobacillus (L. fermentum 
FUA3165 and L. reuteri FUA3168) were able to reduce quinic acid, which was 
postulated to give these organisms an energetic advantage through NAD+ regeneration 
[399]. Multiple in vitro and in vivo studies have indicated that dietary components may 
have the potential to increase beneficial intestinal lactobacilli [400-408]. In the 
experiment where a bloom of Lactobacillus was not observed, Streptococcus was 
present at the largest proportion (Figure 5.12). Lactobacillus and Streptococcus are 
from the order Lactobacillales, and are considered core members of the LAB. This 
group of Gram-positive bacteria are found in the small intestine and colon, where they 
metabolise dietary carbohydrates. Broccoli is rich in galacturonic acid, glucose, 
galactose, and arabinose, with lesser amounts of mannose, xylose, rhamnose and 
fucose also present [409]. This source of carbohydrates may have provided 
Lactobacillus and Streptococcus with a competitive advantage over other members of 
the microbiota. 
 
5.5.5 Effect of broccoli leachate on gut microbiota diversity 
Alpha diversity analysis, using a range of metrics, indicated that both of the cultured 
microbiotas exhibited a decrease in diversity compared to the bacterial communities 
present in the original faecal material (Figure 5.13 and Figure 5.14). It is believed that 
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approximately 60 - 80% of the intestinal bacteria identified by metagenomic analyses 
have yet to be cultured, although recent advances in culturomics may help to overcome 
this deficiency [410-412]. Therefore, the decrease in diversity seen within the cultured 
microbiotas, compared to that of the initial faecal microbiota, were likely partly due to 
the experimental conditions not supporting the growth of the less robust members of 
the microbiota. The strong selection pressure exerted by the broccoli leachate is 
illustrated in the reduced diversity observed within the microbiota cultured in the BL 
media, compared to that of the GL media. Beta diversity analysis highlights the 
similarity between replicates, and the effect of the media type on bacterial community 
modulation (Figure 5.15 and Figure 5.16). Changes from the initial bacterial 
community composition occurred within the first 12 hours of growth, and these changes 
were media-dependent. The divergence between the cultured microbiotas increased 
following the fourth cycle of growth, although the similarity between the replicates 
remained high. 
 
5.5.6 Effect of pH on growth environment 
A decrease in pH was observed in the cultured BL media (mean final pH of 4.87), 
whilst the cultured GL media remained at a neutral pH (Figure 5.17). The major 
metabolic end-product of carbohydrate fermentation by LAB, such as Lactobacillus or 
Streptococcus, is lactic acid [413]. The production of lactic acid, or other acidic 
metabolites (e.g. SCFAs), may have been responsible for the increased acidity of the 
BL media. Culturing Lactobacillus strains in a broccoli puree has been shown to cause 
a decrease in pH from 6.51 – 4.28 [399]. Previous work has shown that the growth of 
Bacteroides species and Escherichia coli were negatively affected at a pH of 5.5 [270]. 
The consistent loss of Bacteroides from the microbiota cultured in the BL media may 
have been influenced by the acidity of the growth medium. Conversely, Bacteroides 
were consistently observed in the cultured GL media, which retained a neutral pH. 
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Although Escherichia were present in the BL media at the completion of the fourth 
cycle, they were present at a lower proportion than observed in the GL media. Many 
Firmicutes are tolerant of acidic conditions, and it would be reasonable to expect that 
these bacteria would have gained a competitive edge in the acidic conditions of the 
cultured BL media. In vitro studies have shown that a difference in pH of 1 unit is 
sufficient to alter the bacterial community composition and metabolic output [270, 271]. 
Therefore, the batch fermentation model used for this research has limitations. A pH 
controlled continuous fermentation model would have allowed for a constant influx of 
media, mitigating any effects on the bacterial community caused by the carbon source 
being depleted, and removing the advantage to acid-tolerant bacteria by maintaining a 
stable pH. These experimental conditions would have better reflected the environment 
that the human gut microbiota inhabits. 
 
 
5.6 Conclusions 
The results presented in this chapter detail how the compositions of human faecal 
microbiotas were modulated differentially by growth in a BL media or a GL media. The 
nutrients available in the BL media favoured the growth of Lactobacillus species, which 
was associated with an increase in the acidity of the culture medium. These acidic 
conditions would enhance the growth of acid-tolerant bacteria, such as Lactobacillus, 
whilst simultaneously inhibiting the growth of other bacteria within the microbiota. 
Neither a notable presence of Lactobacillus, nor a decrease in pH was observed in the 
cultured GL medium. The next chapter will detail the use of metabolomic analyses to 
determine a) whether the change in pH was linked to the production of lactic acid, b) 
whether SCFAs accumulated in the BL and GL media, and to what degree, and c) how 
the metabolic profiles may have differed between cultured microbiotas.
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER SIX 
 
6 Dietary broccoli and the gut microbiota: 
Production of bacterial metabolites after 
repeated exposure to a broccoli leachate 
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6.0 Summary 
Bacterial carbohydrate fermentation produces weakly acidic products, such as lactic 
acid, which can lower the luminal pH of the colon. Lactate can be utilised by bacteria in 
metabolic processes that generates SCFAs, which are thought to be beneficial to the 
host. This chapter investigates which bacterial metabolites were produced when 
human faecal microbiotas were cultured in BL and GL media. The cultured BL media 
contained high concentrations of lactate, which was largely absent from the cultured 
GL media. Higher concentrations of numerous SCFAs were present in the cultured BL 
media, compared to the GL media. When the microbiota of subject 1 was cultured in 
the BL media, relatively high levels of propionate and valerate were observed, which 
were associated with relatively low levels of lactate. It is suggested that this is due to 
the activity of members of the genus Megasphaera. Comparison of the fermentation 
intermediates and SCFAs produced by the cultured microbiota of subject 4 is 
suggestive of a switch in Streptococcus fermentation activity, when cultured in the GL 
media. Metabolite analysis indicates that the observed decrease in pH of the cultured 
BL media was likely due to lactate produced by the LAB, which may have been further 
metabolised to generate SCFAs. 
 
 
6.1 Introduction 
The previous chapter detailed how the community compositions of the faecal 
microbiotas were modified through repeated exposure to BL and GL media. This 
chapter will investigate whether the observed decreases in pH of the cultured BL media 
was associated with the presence of lactate. In addition, samples will be analysed for 
the presence of SCFAs, and differences between the bacterial metabolic profiles of the 
cultured human faecal microbiotas will be explored. 
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The fermentation of carbohydrates by the human gut bacteria leads to decreases in the 
luminal pH of the colon. This is due to the production of weakly acidic bacterial 
metabolites, such as lactate and SCFAs (Figure 6.1). The lactic acid bacteria (LAB) 
are a group of bacteria considered beneficial to human health, whose major metabolic 
end-product is lactate, which is a good substrate for the growth of many intestinal 
bacteria, and can be utilised to form SCFAs [414-416]. LAB can be classified as 
heterofermenters (Weisella, Leuconostoc, and some lactobacilli) or homofermenters 
(Streptococcus, Pediococcus, Lactococcus, and some lactobacilli) based on the end-
products of fermentation [252]. Whilst homofermenters produce lactate as the major, or 
sole, fermentation end-product, heterofermenters produce equimolar amounts of 
lactate, ethanol, and CO2 [252]. Some bacteria can switch fermentation strategies, and 
this is dependent on nutrient availability [417]. 
 
SCFAs are bacterial waste products, which are necessary to balance redox equivalent 
production in the anaerobic environment of the human gut [281]. The most 
physiologically prevalent SCFAs in the human gut are acetate, propionate, and 
butyrate, all of which are potential end-products of lactate metabolism [273, 418-420]. 
In the human colon and stool, acetate, propionate, and butyrate are found in an 
approximate molar ratio of 60:20:20 [274-276]. SCFA production is closely associated 
with diet, and total SCFA concentrations have been found to range between ~70 – 140 
mM in the proximal colon, decreasing to ~20 – 70 mM in the distal colon [277]. 
Following absorption, SCFAs are used as an energy source by the host, and are 
believed to have multiple beneficial effects in humans. These physiological effects 
include regulating immune responses [421], maintaining intestinal homeostasis [422-
425], functioning as signalling molecules [284, 285, 426, 427], and anti-inflammatory 
and anti-carcinogenic activity [286, 287, 428-430]. 
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Figure 6.1: Schematic of microbial short-chain fatty acid production. Metabolism of sugars 
by the human gut microbiota can lead to the production of the short-chain fatty acids (acetate, 
butyrate, propionate, or valerate), by various metabolic pathways (the acrylate, propanediol, 
succinate, or Wood-Ljungdahl pathways) (adapted from Louis et al [280]). Abbreviations: DHAP 
= dihydroxyacetone phosphate ; PEP = phosphoenolpyruvate 
 
 
6.2 Objectives 
The hypothesis for the research presented in this chapter was that the presence of 
acidic compounds, such as lactate, would link the increase in proportions of the genera 
Lactobacillus and Streptococcus with the decrease in pH of the BL media. Additionally, 
it was hypothesised that culturing human faecal microbiota in the BL and GL media 
would result in different metabolic profiles, due to the increased nutrient availability in 
the BL media.  
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6.3 Materials and methods 
The samples analysed in this work originated from the experiment detailed in section 
2.8, and summarised in Figure 6.2. Details of the faecal donors are displayed in Table 
6.1. The samples were collected at the same time-points as those discussed in 
chapters 4 and 5. The samples were centrifuged and the supernatant filtered, prior to 
being mixed with a 0.4 mM phosphate buffer (section 2.6.1). 1H NMR spectroscopy 
was performed as detailed in section 2.6.2, with sodium 3-(Trimethylsilyl)-propionate-d4 
used as a chemical shift reference. Metabolite quantification was carried out using the 
Chenomx NMR Suite software.  
 
 
Figure 6.2: Schematic of experimental design. Broccoli leachate (BL) media (47.5 ml) and 
glucose (GL) media (47.5 ml) were seeded with a faecal suspension (2.5 ml) and cultured for 12 
hr at 37˚C, under anaerobic conditions. After a 12 hr incubation period, samples (2 ml) were 
taken for 
1
H NMR spectroscopy, and a 2.5 ml aliquot was used to seed the respective fresh 
media. This was repeated for four cycles of bacterial enrichment. 
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Table 6.1: Age, gender, Body Mass Index (BMI), and smoking status of the faecal donors. 
Faecal donors Age (years) Gender BMI (kg/m2) Smoker 
Subject 1 44 Male 24.1 N 
Subject 2 24 Female 23.3 N 
Subject 3 52 Female 20.9 N 
Subject 4 50 Female 38.4 N 
Subject 5 61 Female 20.5 N 
 
 
6.4 Results 
6.4.1 Analysis of lactate production 
Samples obtained from experiments using five human faecal microbiotas cultured in a 
BL media and a GL media, were examined using 1H NMR spectroscopy. This analysis 
was performed to determine whether the production of lactic acid by LAB may have 
been responsible for the increased acidity of the cultured BL media. 
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Figure 6.3: Lactate accumulated in the BL media when cultured with human faecal 
microbiotas. Five human faecal suspensions were cultured independently in a broccoli-
leachate-containing (BL) media and a glucose (GL) media. Aliquots of the cultured media 
supernatant were mixed with a 0.4 mM phosphate buffer, and subjected to 
1
H NMR 
spectroscopy. Sample analysis was performed using the Chenomx NMR Suite software. The 
figure shows the concentration of lactate in the pre-inoculated BL media, and cultured BL media 
after cycle 1 and cycle 4 for the microbiotas obtained from subjects 2 - 5. Data shown = mean ± 
SD of four technical replicates. A. = subject 2; B. = subject 3; C. = subject 4; D. = subject 5. The 
data was statistically analysed using one-way ANOVA followed by Bonferroni multiple 
comparisons tests. **p≤0.01; ***p≤0.001. 
 
In experiments using four of the five microbiotas (subjects 2 - 5), high levels of lactate 
(21.33 – 34.38 mM) were observed in the cultured BL media after cycle 4 (Figure 6.3). 
A relatively high decrease in the levels of lactate in the cultured BL media between 
cycles 1 and 4 was observed for the cultured microbiota of subject 1 (Figure 6.4). 
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Figure 6.4: Lactate levels decreased in the BL media after cycle 4 when cultured with the 
faecal microbiota of subject 1. A human faecal suspension was cultured in a broccoli-
leachate-containing (BL) media and a glucose (GL) media. Aliquots of the cultured media 
supernatant were mixed with a 0.4 mM phosphate buffer, and subjected to 
1
H NMR 
spectroscopy. Sample analysis was performed using the Chenomx NMR Suite software. The 
bar chart displays the concentration of lactate in the pre-inoculated BL media, and cultured BL 
media after cycle 1 and cycle 4 for the microbiota obtained from subject 1. Data shown = mean 
± SD of four technical replicates. The data was statistically analysed using one-way ANOVA 
followed by Bonferroni multiple comparisons tests. ***p≤0.001 cultured BL media cycle 1 vs 
uncultured BL media. 
 
The decrease in lactate concentration observed between cycle 1 and cycle 4 may have 
been due to increased lactate utilisation by the cultured microbiota of subject 1. 
Although lactate was detected in the GL media after cycle 1, following inoculation with 
three of the faecal microbiotas (subjects 3 - 5), it was only present in low amounts (0.07 
- 0.84 mM). Lactate was not present in the GL media after cycle 4 when cultured with 
the faecal microbiotas of subjects 1 – 4. Lactate was detected at a low concentration in 
the GL media after cycle 4 when cultured with the microbiota of subject 5 (Table 6.2).  
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Table 6.2: Proportions of Lactobacillus (Lb) and Streptococcus (Str) in the BL and GL 
media after cycle 4, and the corresponding concentrations of lactate. 
Source of 
microbiota 
BL media 
Lb (%)      Str (%)    Lactate (mM) 
GL media 
Lb (%)      Str (%)    Lactate (mM) 
Subject 1 53.4 0 0.84 (± 0.28) 0 0.1 0 
Subject 2 94.1 0 36.31 (± 2.12) 0 0 0 
Subject 3 35.9 0.9 23.49 (± 3.78) 0.8 1.6 0 
Subject 4 4.3 77.4 31.16 (± 2.59) 0 21.9 0 
Subject 5 22.5 0.3 24.53 (± 2.15) 0 0 0.17 (± 0.19) 
 
As lactate was present at a high concentration in the BL media cultured with the 
microbiota of subject 4, it may be a little surprising that lactate was not detected in the 
corresponding GL media. LAB can be divided into two groups based on the 
fermentation pathways utilised for hexose metabolism: homofermenters and 
heterofermenters. Whilst the former produce lactate as the sole or major end-product, 
heterofermenters produce smaller quantities of lactate, but also produce acetate, 
ethanol and CO2 [252]. Analysis of acetate and ethanol, alongside lactate, may help to 
explain the absence of lactate in the GL media cultured with the microbiota of subject 4 
(Table 6.3). 
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Table 6.3: Products obtained from two LAB fermentation pathways. 
Source of 
microbiota 
BL media GL media 
Acetate 
(mM) 
Ethanol 
(mM) 
Lactate 
(mM) 
Acetate 
(mM) 
Ethanol 
(mM) 
Lactate 
(mM) 
Subject 1 
21.37 
(± 0.26) 
1.75 
(± 0.09) 
0.84 
(± 0.28) 
10.61 
(± 2.35) 
1.65 
(± 0.28) 
0 
Subject 2 
20.27 
(± 1.46) 
18.42 
(± 1.32) 
36.31 
(± 2.12) 
8.68 
(± 0.23) 
1.21 
(± 0.02) 
0 
Subject 3 
24.68 
(± 7.23) 
7.79 
(± 0.50) 
23.49 
(± 3.78) 
7.45 
(± 1.24) 
1.18 
(± 0.13) 
0 
Subject 4 
3.79 
(± 2.78) 
0.75 
(± 0.71) 
31.16 
(± 2.59) 
7.52 
(± 0.09) 
0.67 
(± 0.03) 
0 
Subject 5 
16.46 
(± 2.68) 
3.53 
(± 0.20) 
24.53 
(± 2.15) 
6.68 
(± 1.05) 
0.97 
(± 0.09) 
0.17 
(± 0.19) 
 
Acetate and ethanol were present at relatively low concentrations in the BL media 
cultured with the microbiota of subject 4, which was dominated by Streptococcus. This 
may suggest that homofermentation was the primary fermentation activity. The data 
obtained from the corresponding cultured GL media was less suggestive, and may be 
indicative of a switch to heterofermentation due to the depletion of glucose from the 
media. 
 
6.4.2 Short-chain fatty acid analysis of cultured media 
Lactate can be used in bacterial metabolic processes to generate bacterial waste 
products, termed SCFAs. 1H NMR spectroscopy was used to identify the 
concentrations of the most physiologically prevalent SCFAs (acetate, butyrate, and 
propionate) in both the cultured BL and GL media (Figure 6.5). 
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Figure 6.5: Concentrations of short-chain fatty acids differ in the BL media and GL media 
when cultured with human faecal microbiotas. Five human faecal suspensions were cultured 
independently in a broccoli-leachate-containing (BL) media and a glucose (GL) media. Aliquots 
of the cultured media supernatant were mixed with a 0.4 mM phosphate buffer, and subjected to 
1
H NMR spectroscopy. Sample analysis was performed using the Chenomx NMR Suite 
software. The figure shows the concentration of acetate, butyrate, and propionate in the pre-
inoculated media, and cultured BL and GL media after cycle 1 and cycle 4 for the microbiota 
obtained from subject 1. These results are representative of the differences between the media 
observed with all five cultured faecal microbiotas. A. Acetate, butyrate, and propionate 
concentrations in cultured BL media; B. Acetate, butyrate, and propionate concentrations in 
cultured GL media. Data shown = mean ± SD of four technical replicates. The data was 
statistically analysed using one-way ANOVA followed by Bonferroni multiple comparisons tests. 
*p≤0.05; **p≤0.01; ***p≤0.001 cultured media vs uncultured media. 
 
Acetate, butyrate, and propionate were present at higher concentrations in the cultured 
BL media, compared to the cultured GL media. On average, across all five faecal 
microbiotas, there was a 2.2-fold increase in total yield of SCFAs in the cultured BL 
media compared to the cultured GL media. The increased levels of the SCFAs found in 
the cultured BL media, likely reflects the increased availability of nutrients derived from 
the broccoli leachate, but will be directly linked to the metabolic capabilities of the 
bacteria within the cultured microbiotas. 
 
Chapter 6 
   
 
164 
 
6.4.3 Comparing SCFA profiles between microbiotas cultured in a 
BL media 
It has been demonstrated that inter-individual variability exists within the metabolic 
potential, as well as in the composition, of the human gut microbiota [418]. Variability in 
SCFA production, between the five human faecal microbiotas cultured in the BL media 
for four 12 hr cycles, was investigated using 1H NMR spectroscopy (Table 6.4). 
 
Table 6.4: Mean short-chain fatty acid concentrations in the BL media after cycle 4, when 
cultured with human faecal microbiotas. 
Source of 
microbiota 
Acetate Butyrate Formate Propionate Valerate Total 
Subject 1 
21.37 
(± 0.26) 
8.55 
(± 0.26) 
2.25 
(± 0.14) 
16.53 
(± 1.05) 
11.54 
(± 0.28) 
60.24 
Subject 2 
20.27 
(± 1.46) 
0 
1.16 
(± 0.06) 
0 0 21.43 
Subject 3 
24.68 
(± 7.23) 
4.94 
(± 1.34) 
5.03 
(± 0.68) 
2.64 
(± 2.85) 
0.21 
(± 0.41) 
37.5 
Subject 4 
3.79 
(± 2.78) 
0 
2.59 
(± 2.21) 
0.06 
(± 0.12) 
0 6.44 
Subject 5 
16.46 
(± 2.68) 
0 
1.69 
(± 0.10) 
0 0 18.15 
 
The cultured microbiota of subject 1 produced a variety of SCFAs, as well as the 
highest total yield of SCFAs (60.24 mM). Valerate was only detected in the cultured 
samples from subjects 1 and 3, whilst subjects 2 and 5 formed neither butyrate, nor 
propionate. The lowest total yield of SCFAs was observed in the samples derived from 
subject 4 (6.44 mM), and this largely consisted of acetate and formate. All sugars 
present in the starting BL media were metabolised by subjects 1 - 3, however relatively 
high concentrations of fructose were identified in the cultured samples from subjects 4 
and 5 (6.91 mM and 2.18 mM, respectively).  
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6.5 Discussion 
6.5.1 Lactate production by gut bacteria in the presence of a 
broccoli leachate 
Human faecal microbiotas cultured in a BL media exhibited a proportional increase in 
LAB, and this was associated with a decrease in the pH of the media from 7.0 to an 
average of 4.87 (Figure 5.17). 1H NMR spectroscopy was used to test the hypothesis 
that the decrease in pH was associated with the production of lactic acid by the LAB. 
Samples obtained from the cultured BL media indicated that lactate was present at 
high concentrations after the first 12 hours growth with all five faecal microbiotas. High 
levels of lactate were observed after cycle 4 in the BL media of four of the five cultured 
faecal microbiotas (subjects 2 - 5) (Figure 6.3). The cultured BL media with the 
microbiota obtained from subject 1, contained levels of lactate which were not 
significantly greater than that found in the starting media (Figure 6.4). It seems likely 
that the lactate was being utilised in metabolic processes by members of this 
microbiota. 
 
6.5.2 Metabolic activity of Streptococcus in the glucose media 
Lactate was only detected in the GL media at low levels in three of the cultured 
samples (subjects 3 - 5) following the first 12 hours of growth, and was only present in 
the cultured microbiota obtained from subject 5 after cycle 4 (Table 6.2). The 
microbiota of subject 4 exhibited an increased proportion of the potential LAB, 
Streptococcus, when cultured in both the BL and GL media (Figure 5.12). Lactate was 
absent in the corresponding cultured GL media. This may be a consequence of the 
different fermentation pathways between LAB, and an effect of glucose-limiting 
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conditions in the GL media, as higher levels of glucose were present in the BL media 
compared to the GL media. 
 
Streptococcus is classified as a homofermentative LAB; lactic acid is the sole or major 
end-product of glucose fermentation [252]. Some lactobacilli are homofermentative, 
whilst others, such as L. fermentum, are heterofermenters, producing lactate, acetate, 
ethanol and CO2 from hexose sugars [252]. These data indicate that, when cultured in 
the BL media, the microbiota of subject 4 produced high levels of lactate, but less 
acetate and ethanol than the other cultured microbiotas (Table 6.3). However, when 
the same microbiota was cultured in the GL media, the profile of acetate, ethanol, and 
lactate resembled that of the other microbiotas tested. This may be explained by the 
differences in sugar content between the two media. The BL media was richer in 
sugars than the GL media (Table 3.4). The glucose within the GL media had been fully 
depleted at this time-point, and this may have provided conditions in which it was 
favourable for Streptococcus to switch to a heterofermentative state. Thomas et al 
previously showed that under certain growth conditions, such as glucose-limited 
conditions, lactic streptococci switch to heterofermentation activity [417]. Therefore, it 
may be that lactate was being produced in smaller amounts in the GL media, and 
subsequently utilised by members of the cultured microbiota due to the depletion of the 
preferred carbon source, glucose. 
 
6.5.3 Short-chain fatty acid production by cultured microbiotas 
Lactate is the major metabolic end-product of carbohydrate fermentation by LAB, and 
can be subsequently utilised by other members of the gut microbiota to generate 
bacterial metabolites, such as SCFAs (Figure 6.1). The physiologically prevalent 
SCFAs (acetate, butyrate, and propionate) were detected in cultured samples from 
both the BL media and GL media (Figure 6.5). However, on average there was a 2.2-
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fold increase in the total yield of these SCFAs in the cultured BL media, compared to 
the cultured GL media. The microbiotas cultured in the BL media may have used some 
of the available lactate for metabolic processes, which could lead to a greater yield of 
SCFAs. 
 
Acetate was the primary SCFA produced from all cultured microbiotas, as has been 
observed in the human colon and faecal material [274-276]. Acetate or butyrate can be 
produced through the utilisation of pyruvate, which can be formed through the oxidation 
of lactate [419, 431]. Lactate can be used directly in the acrylate pathway to generate 
propionate [273]. Relatively high concentrations of propionate were only detected in the 
BL media cultured with the microbiota obtained from subject 1 (Table 6.4). This may 
indicate that lactate was being produced by this microbiota during cycle 4, but was 
subsequently utilised to produce propionate. The microbiota of subject 1 contained a 
relatively high proportion of the genus Megasphaera, which was not detected in the 
other microbiotas cultured (Figure 5.11). Megasphaera elsdenii is known to be present 
in the human intestine, and is an important rumen bacterium, which converts lactate to 
propionate via the acrylate pathway [432]. When glucose and lactate are both 
available, M. elsdenii produces increasing amounts of butyrate and valerate, with a 
concomitant decrease in the production of propionate [433]. When the glucose is 
depleted, the lactate is metabolised to produce propionate. The presence of 
Megasphaera in the BL media cultured with the faecal microbiota of subject 1 may be 
at least partly responsible for the relatively high concentration of both propionate and 
valerate, as well as the production of butyrate (Table 6.4). 
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6.6 Conclusions 
Metabolite analysis using 1H NMR spectroscopy indicated that lactate was the major 
bacterial metabolite produced when human faecal microbiotas were cultured in the BL 
media. At the end of the experimental period, lactate was only detected in the GL 
media cultured with the microbiota of subject 5, and was only present at relatively low 
concentrations. Levels of lactate, acetate, and ethanol in the cultured microbiota of 
subject 4 suggested that growth in the GL media may have caused Streptococcus 
species to switch from homofermentation to heterofermentation. This was likely due to 
the depletion of glucose from the GL media. Although SCFAs were detected in all the 
cultured media, the total yield of SCFA was higher in the BL media compared to the GL 
media. The types and concentrations of SCFAs produced in the cultured BL media 
differed between the microbiota. The microbiota of subject 1 produced the largest yield 
of SCFAs when cultured in the BL media, with relatively high concentrations of 
propionate and valerate. This microbiota contained a relatively high proportion of the 
genus Megasphaera, which has previously been shown to utilise lactate and glucose to 
produce propionate and valerate. The low pH of the cultured BL media was likely due 
to the increased levels of lactate and SCFAs, which were produced during bacterial 
carbohydrate fermentation. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER SEVEN 
 
7 Bacterial identification and screening 
assays 
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7.0 Summary 
This chapter discusses the identification of bacteria isolated from the in vitro 
fermentation experiments detailed in chapter 5, and the use of these isolates in 
screening assays to investigate the bacterial metabolism of broccoli compounds. 16S 
rDNA sequencing of eighteen bacterial isolates identified all lactobacilli tested to be 
Lactobacillus fermentum. Pure culture screening assays using glucoraphanin 
discovered several Escherichia species able to reduce glucoraphanin to a similar 
degree. The extent of glucoraphanin reduction was not dependent on the levels of 
oxygen, but differed between bacterial culture media. The E. coli DH5α laboratory 
strain was able to reduce glucoraphanin, suggesting that the bacterial reduction of 
glucosinolates may not be restricted to intestinal bacteria. The reduction of S-
methylcysteine sulphoxide (SMCSO) by an isolated E. coli strain (1B04) suggests that 
the reduction reaction is not specific to glucosinolates. GC-MS analysis using E. coli 
1B04 and E. coli DH5α, cultured in media containing glucoraphanin or SMCSO, 
identified degradation products of both compounds due to the activity of each E. coli 
strain. These results suggest that although the bacterial reduction reaction was the 
primary metabolic activity, E. coli 1B04 is able to degrade glucoraphanin and SMCSO. 
 
 
7.1 Introduction 
 
Lactobacillus fermentum species are an indigenous resident of the human gut 
microbiota, with several strains currently used as probiotics. These acid-tolerant 
bacteria have been shown to strongly adhere to intestinal epithelial cells, have 
antimicrobial activity against pathogenic bacteria, and immunomodulatory properties 
[247, 250, 251]. In addition, L. fermentum strains have been linked to an increased 
production of SCFA, and cholesterol-lowering properties associated with bile salt 
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hydrolase activity [434-436]. Investigations into the beneficial properties of L. 
fermentum strains is an ongoing area of research. 
 
E. coli have evolved to be highly efficient at exploiting its environment to maximise 
energy sources, with reductases central to many of these processes. Reductases are 
involved in multiple important biological processes, such as the protection of proteins 
from oxidative damage [314, 437, 438], altering the biological activities of proteins to 
maintain homeostasis [315], involvement in the synthesis of DNA [316, 317], and are 
central in respiratory pathways [294, 439]. The high level of flexibility built into the 
respiratory pathways of E. coli enables its growth in aerobic and anaerobic 
environments, as well as the utilisation of a diverse range of electron acceptors [294, 
439, 440]. The E. coli dimethyl sulphoxide (DMSO) reductase, DmsABC has been 
found to be able to utilise multiple sulphoxides as electron acceptors during anaerobic 
growth [310, 441]. 
 
Within the plant, S-methylcysteine sulphoxide is thought to function as a phytoalexin, 
providing protection against microbial pathogens and herbivores, through its 
degradation by cysteine sulphoxide lyases (Figure 7.1) [150, 442, 443]. Bacterial 
cysteine β-lyase activity has been detected within gastrointestinal bacteria, and has 
been attributed to a diverse range of bacteria, including E. coli [164-166, 444-448]. The 
bacterial cysteine lyase has broad substrate specificity, and is able to cleave the C-S 
bonds of a range of S-alkyl-cysteine molecules, in a manner similar to the plant 
cysteine lyases [150]. Research into the beneficial effects of SMCSO and its metabolic 
products have indicated that this dietary compound may exhibit protective effects 
against cancer [167-174, 449, 450], diabetes [177, 179, 451], and cardiovascular 
disease [175, 176, 178, 452]. 
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Figure 7.1: Metabolic schematic for the reduction or degradation of S-methylcysteine 
sulphoxide. Schematic displaying the metabolic products formed through the degradation of 
SMCSO by the action of cysteine lyase, and the reduction of SMCSO to S-methylcysteine. 
 
 
7.2 Objectives 
The hypothesis of the work contained in this chapter was that bacteria, isolated from 
the in vitro fermentation experiment (chapter 5), that were able to reduce glucoraphanin 
and SMCSO would be identified through pure culture experiments. 
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7.3 Materials and methods 
Bacteria were isolated from experiments in which human faecal microbiotas were 
cultured in BL media, as summarised in Figure 7.2, and described in section 2.8.5. The 
16S rDNA, of a selection of these bacterial isolates, were amplified using colony PCR 
(section 2.10.2), and sequenced commercially at Eurofins. The FinchTV and SeqMan 
software were used for DNA sequence quality checking and contig assembly, 
respectively, and the online Ribosomal Database Project (RDP) tool SeqMatch, was 
used for bacterial species identification, as detailed in section 2.10.3. Bacterial isolates 
were cultured in media containing ~6 mM glucoraphanin (section 2.11.1), or 0.3 mM 
glucoerucin (section 2.11.2). The analysis of glucosinolates within culture supernatants 
was performed using HPLC (section 2.5). A bacterial isolate was cultured in the 
presence of 0.3 mM SMCSO (section 2.11.3), and analysis of SMCSO concentrations 
in the culture supernatants was performed using LC-MS (section 2.4.2) and 1H NMR 
spectroscopy (section 2.6). GC-MS was used to further investigate the products of 
glucoraphanin and SMCSO metabolism (section 2.12). 
 
Chapter 7 
   
 
174 
 
 
Figure 7.2: Schematic of experimental design. Broccoli leachate (BL) media (47.5 ml) and 
glucose (GL) media (47.5 ml) were seeded with a faecal suspension (2.5 ml) and cultured for 12 
hr at 37˚C, under anaerobic conditions. Samples were taken for sequencing analysis of the 
variable V4 and V5 regions within 16S rDNA, and an aliquot was used to seed the respective 
fresh media. This was repeated for four cycles of enrichment. 
 
 
7.4 Results 
7.4.1 Amplification of the 16S rDNA gene from bacterial isolates 
Fifty bacterial isolates, obtained from human faecal microbiotas that had been cultured 
in the BL media (section 2.8.5), were selected for further investigation. Following 
growth of colonies on MRS agar medium, 19 bacterial isolates were chosen for species 
identification based on growth and morphological characteristics. The 16S rDNA gene 
was amplified for each of these bacterial isolates, using colony PCR (section 2.10.2), 
and visualised using agarose gel electrophoresis (section 2.9.1.1). 
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Figure 7.3: A 1% agarose gel showing the amplification of the 16S rDNA gene from 
bacteria isolated from the cultured BL media. Human faecal microbiotas were cultured with a 
broccoli leachate-containing (BL) media for four 12 hr cycles at 37˚C, under anaerobic 
conditions, and bacteria were isolated and stored in glycerol at -80˚C. The 16S rDNA gene (1.5 
Kb) was amplified through colony PCR, and visualised using agarose gel electrophoresis and 
ethidium bromide staining. The figure shows an imaged gel of 11 amplicons, which is 
representative of all the amplicons visualised. L = Bioline Hyperladder I (10 Kb); -C = negative 
control (PCR reaction mixture without DNA). 
 
Visualisation of the agarose gel suggested that PCR amplification of the 16S rDNA 
gene had been successful, as indicated by the presence of bands at the 1.5 Kb 
molecular weight marker (Figure 7.3). 
 
7.4.2 Identification of bacterial isolates 
Amplified PCR products of the nineteen isolates were sent to Eurofins in duplicate for 
sequencing of the 16S rDNA gene, each containing 2 μl of either the forward or reverse 
primer used in the PCR reaction. The sequences obtained were quality checked. 
Based on the data obtained, one of the isolates was considered as potentially 
contaminated and removed from further analysis. The sequence data for the remaining 
eighteen isolates were submitted to RDP SeqMatch for comparison to known 16S 
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rDNA sequences compiled in the RDP database. Taxonomic identification was based 
on the S_ab score (fraction of shared 7-base sequence fragments between query and 
reference sequences) [334]. 
 
Table 7.1: Identification of bacterial isolates based on the RDP SeqMatch S_ab score, and 
the number of unique oligomers within each query sequence. 
Isolate 
code 
Taxonomic 
rank 
Species name S_ab score 
Unique 
oligomers 
1A09 Species Lactobacillus fermentum 1.000 1384 
1B02 Genus Escherichia 1.000 1350 
1B03 Genus Escherichia 0.995 1334 
1B04 Species Escherichia coli 1.000 1325 
1C03 Species Enterococcus faecium 1.000 1367 
1C04 Species Lactobacillus fermentum 1.000 1375 
1C05 Species Lactobacillus fermentum 1.000 1381 
1C06 Genus Escherichia 1.000 1035 
My-0101 Species Lactobacillus fermentum 1.000 1382 
My-0103 Species Lactobacillus fermentum 0.998 1398 
My-0105 Species Enterococcus durans 1.000 1371 
My-0201 Species Lactobacillus fermentum 0.997 1380 
My-0204 Species Lactobacillus fermentum 1.000 1384 
My-0205 Species Lactobacillus fermentum 1.000 1391 
My-0302 Species Lactobacillus fermentum 1.000 1391 
My-0303 Species Lactobacillus fermentum 1.000 1391 
My-0401 Species Lactobacillus fermentum 0.995 1385 
My-0404 Species Lactobacillus fermentum 0.993 1383 
Chapter 7 
   
 
177 
 
Of the eighteen isolates, twelve were identified as Lactobacillus fermentum, two 16S 
rDNA sequences were considered as belonging to Enterococcus species, and the 
remaining four isolates were identified as belonging to the genus Escherichia (Table 
7.1).  
 
7.4.3 Screening for glucoraphanin reduction activity 
Ten identified bacterial isolates were selected and screened for their ability to convert 
glucoraphanin to glucoerucin in pure cultures (section 2.11.1). 
 
 
Figure 7.4: Four bacterial isolates, identified as Escherichia, have the ability to form 
glucoerucin via the reduction of glucoraphanin. Ten bacterial isolates (5 μl) were cultured in 
CNM containing ~6 mM purified glucoraphanin extract (total volume of 1 ml) for 24 hr at 37˚C, 
under anaerobic conditions. The control sample consisted of CNM containing ~6 mM purified 
glucoraphanin extract (995 μl) with sterile water (5 μl) added in place of the bacterial inoculum. 
Glucosinolates were converted to desulphoglucosinolates and measured using HPLC. GR = 
Glucoraphanin; G-ERN = Glucoerucin. 
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Of the ten bacterial isolates tested, four identified as belonging to the genus 
Escherichia were able to significantly reduce glucoraphanin to glucoerucin (74 – 85%) 
(Figure 7.4). The remaining six isolates, that did not exhibit the ability to reduce 
glucoraphanin, consisted of bacteria from the order Lactobacillales: four L. fermentum 
isolates and two Enterococcus species. Two Escherichia isolates were cultured with 
glucoraphanin under aerobic conditions to test whether the ability to reduce 
glucoraphanin was associated with the reduced environment in the anaerobic cabinet. 
 
 
Figure 7.5: Reduction of glucoraphanin to glucoerucin by Escherichia isolates is not 
linked to a reduced environment. Two Escherichia isolates (5 μl) were cultured in CNM 
containing ~6 mM purified glucoraphanin extract media (total volume of 1 ml) for 24 hr at 37˚C, 
under aerobic conditions. The control sample consisted of CNM containing ~6 mM purified 
glucoraphanin extract (995 μl) with sterile water (5 μl) added in place of the bacterial inoculum. 
Glucosinolates were converted to desulphoglucosinolates and measured using HPLC. GR = 
Glucoraphanin; G-ERN = Glucoerucin. 
 
The reduction of glucoraphanin to glucoerucin occurred to a similar extent when 
Escherichia isolates were cultured with purified glucoraphanin extract under aerobic 
conditions, compared to an anaerobic environment (Figure 7.5). Luria broth (LB) is a 
nutritionally rich medium, which is commonly used for the cultivation of E. coli [453]. 
Isolate E. coli 1B04 was cultured in both CNM and LB, supplemented with a purified 
glucoraphanin extract to a concentration of ~6 mM, to investigate whether differences 
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in media would affect bacterial reductase activity. No significant difference in reductase 
activity was observed between aerobic or anaerobic conditions within each media type, 
but the conversion of glucoraphanin to glucoerucin was lower in the cultured LB 
samples, compared to the cultured CNM samples (Figure 7.6). 
 
 
Figure 7.6: The ratio of glucoraphanin to glucoerucin differs between the LB and CNM 
media when cultured with Escherichia coli 1B04, irrespective of levels of oxygen. E. coli 
1B04 (5 μl) was cultured in two media (CNM and LB) containing ~6 mM purified glucoraphanin 
extract media (total volume of 1 ml) for 24 hr at 37˚C, under both anaerobic and aerobic 
conditions. The control samples consisted of the equivalent media containing ~6 mM purified 
glucoraphanin extract (995 μl) with sterile water (5 μl) added in place of the bacterial inoculum. 
Glucosinolates were converted to desulphoglucosinolates and measured using HPLC. GR = 
Glucoraphanin; G-ERN = Glucoerucin; CNM = Chemostat nutrient media; LB = Luria broth. 
Data shown = mean ± SD of two technical replicates. The data for the ratios of glucoraphanin 
and glucoerucin between samples were statistically analysed using two-way ANOVA; a and b 
are statistically significantly different from one another (p<0.001). The data for the analysis of 
total glucosinolates in cultured samples vs the associated control sample were analysed using 
Student’s t-tests (two-tailed); *p<0.05, **p<0.01. 
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Optical density (OD600) readings indicated that E. coli 1B04 exhibited stronger growth in 
LB compared to CNM, in both anaerobic and aerobic conditions (Table 7.2). 
 
Table 7.2: Mean absorbance readings of E. coli 1B04 when grown in either CNM or LB, 
containing ~6 mM purified glucoraphanin extract, over 24 hours. 
Media Conditions Time (hr) Optical density (OD600) 
CNM 
Anaerobic 
8 0.297 
12 0.699 
24 0.806 
Aerobic 
8 0.298 
12 0.799 
24 0.970 
LB 
Anaerobic 
8 0.954 
12 1.279 
24 1.726 
Aerobic 
8 0.943 
12 1.180 
24 1.502 
 
Taken together, Table 7.2 and Figure 7.6 would seem to suggest that there is a 
negative correlation between the growth of E. coli 1B04 and the degree to which 
glucoraphanin is reduced. To investigate this relationship, E. coli 1B04 was cultured in 
both CNM and LB, containing ~6 mM purified glucoraphanin extract, over 72 hours in 
anaerobic conditions. 
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Figure 7.7: Similar levels of glucoraphanin and glucoerucin are observed within both 
media cultured with E. coli 1B04, following an extended period of culturing. E. coli 1B04 (5 
μl) was cultured in two media (CNM and LB) containing ~6 mM purified glucoraphanin extract 
media (total volume of 1 ml) for 72 hr at 37˚C, under anaerobic conditions. The control samples 
consisted of the equivalent media containing ~6 mM purified glucoraphanin extract (total volume 
of 995 μl) with sterile water (5 μl) added in place of the bacterial inoculum. Glucosinolates were 
converted to desulphoglucosinolates and measured using HPLC. GR = Glucoraphanin; G-ERN 
= Glucoerucin; CNM = Chemostat nutrient media; LB = Luria broth; 1B04 = Escherichia coli 
1B04. Data shown = mean ± SD of two technical replicates. 
 
Extending the culturing period of E. coli 1B04 in both CNM and LB, containing ~6 mM 
purified glucoraphanin extract, from 24 hours to 72 hours resulted in similar levels of 
glucoraphanin reduction between the media (Figure 7.7). There was no statistically 
significant difference between the levels of glucoraphanin or glucoerucin within the two 
media, or the total glucosinolate content between the cultured samples and their 
respective control samples. The OD600 values indicated that increased growth of E. coli 
1B04 was observed when cultured in LB (1.400), compared to CNM (0.798). 
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7.4.4 Can Escherichia coli 1B04 metabolise glucoerucin? 
It had been determined that E. coli 1B04 was able to reduce glucoraphanin to form 
glucoerucin. Many bacterial reduction reactions are reversible; therefore a small-scale 
experiment was performed to investigate whether this strain was able to form 
glucoraphanin through the oxidisation of glucoerucin. 
 
 
Figure 7.8: Glucoerucin is neither oxidised nor hydrolysed by E. coli 1B04. E. coli 1B04 (5 
μl) was cultured in CNM containing 0.3 mM glucoerucin (total volume of 1 ml) for 24 hr at 37˚C, 
under anaerobic conditions. The control samples consisted of CNM containing 0.3 mM 
glucoerucin (995 μl) with sterile water (5 μl) added in place of the bacterial inoculum. 
Glucosinolates were converted to desulphoglucosinolates and measured using HPLC. GR = 
Glucoraphanin; G-ERN = Glucoerucin; CNM = Chemostat nutrient media; 1B04 = Escherichia 
coli 1B04; T0 = prior to inoculation; T24 = 24 hr post-inoculation. Data shown = mean ± SD of 
three technical replicates. 
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Glucoraphanin was not detected in either the control or test samples, demonstrating 
that, under the conditions tested, E. coli 1B04 did not convert glucoerucin to 
glucoraphanin via an oxidation reaction (Figure 7.8). The levels of glucoerucin in the 
control and test samples were not statistically significantly different, indicating that E. 
coli 1B04 did not hydrolyse glucoerucin. 
 
7.4.5 Glucoraphanin reduction by Escherichia coli DH5α 
The E. coli strain DH5α was developed as a laboratory cloning strain. E. coli DH5α was 
cultured in CNM containing glucoraphanin to assess whether a laboratory-associated 
strain of E. coli possessed the ability to reduce glucoraphanin.  
 
 
Figure 7.9: The laboratory strain, Escherichia coli DH5α, has the ability to convert 
glucoraphanin to glucoerucin. E. coli DH5α (5 μl) was cultured in CNM containing ~7.5 mM 
purified glucoraphanin extract media (total volume of 1 ml) for 24 hr at 37˚C, under anaerobic 
conditions. The control sample consisted of CNM containing ~7.5 mM purified glucoraphanin 
extract (995 μl) with sterile water (5 μl) added in place of the bacterial inoculum. Glucosinolates 
were converted to desulphoglucosinolates and measured using HPLC. GR = Glucoraphanin; G-
ERN = Glucoerucin; CNM = Chemostat nutrient media; DH5α = Escherichia coli DH5α. Data 
shown = mean ± SD of three technical replicates. 
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Although E. coli DH5α grew relatively poorly in the media (OD600 = 0.286), this 
laboratory strain was able to convert glucoraphanin to its reduced analogue, 
glucoerucin (Figure 7.9). CNM was designed to contain the essential nutrients required 
for the growth of human intestinal bacteria. The weak growth of this strain may reflect 
the differences in nutrient requirements between gut-adapted E. coli and the laboratory 
strain DH5α. Enhanced growth of E. coli DH5α may have been observed if it had been 
grown in a nutrient rich media, such as LB media, and shaken under aerobic 
conditions. As E. coli DH5α was able to reduce glucoraphanin, this may suggest that 
the ability of E. coli to reduce sulphoxide groups could be a general metabolic process 
rather than a glucosinolate-specific process. 
 
7.4.6 Is the bacterial sulphoxide reduction specific to 
glucosinolates? 
Sulphoxide-containing compounds can be found in various foods that form part of a 
normal diet. To investigate whether the observed putative reductase activity was 
glucoraphanin-specific, E. coli 1B04 was cultured in a media containing SMCSO, which 
is also a broccoli-derived compound that contains a sulphoxide moiety.
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Figure 7.10: Levels of S-methylcysteine sulphoxide decreased when incubated with 
Escherichia coli 1B04. E. coli 1B04 (5 μl) was cultured in CNM containing 0.3 mM SMCSO 
(total volume of 1 ml) for 24 hr at 37˚C, under anaerobic conditions. The control samples 
consisted of CNM containing 0.3 mM SMCSO (995 μl) with sterile water (5 μl) added in place of 
the bacterial inoculum. Derivatisation of the samples (100 μl) was performed by mixing with a 10 
mM dansyl chloride reagent (250 μl) and a 20 mM borate buffer (650 μl). SMCSO derivative 
analysis was performed using LC-MS. SMCSO = S-methylcysteine sulphoxide; CNM = 
Chemostat nutrient media; 1B04 = Escherichia coli 1B04; T0 = prior to inoculation; T24 = 24 hr 
post-inoculation. Data shown = mean ± SD of three technical replicates. 
 
Levels of SMCSO decreased considerably over a period of 24 hours when exposed to 
E. coli 1B04 (Figure 7.10). SMCSO remained stable in the control samples devoid of 
bacteria, indicating that the lower concentration of SMCSO in the cultured samples was 
due to the presence of E. coli 1B04. A 200 μl aliquot was taken from the remaining 
supernatant of each of the control samples to form a pooled control sample with a total 
volume of 600 μl, and the same was performed for the cultured samples. The pooled 
samples were not derivatised prior to analysis using 1H NMR spectroscopy, due to 
concerns that the derivatisation reagents may cause significant chemical shifts or 
severe line broadening. 
 
Chapter 7 
   
 
186 
 
 
Figure 7.11: Presence of S-methylcysteine in the cultured sample confirms S-
methylcysteine sulphoxide was reduced. E. coli 1B04 (5 μl) was cultured in CNM containing 
0.3 mM SMCSO (total volume of 1 ml) for 24 hr at 37˚C, under anaerobic conditions. The 
control samples consisted of CNM containing 0.3 mM SMCSO (995 μl) with sterile water (5 μl) 
added in place of the bacterial inoculum. Aliquots (600 μl) of the samples were mixed with 70 μl 
of a 0.4 mM phosphate buffer, and 600 μl was analysed using 
1
H NMR spectroscopy. SMCSO = 
S-methylcysteine sulphoxide; SMC = S-methylcysteine; CNM = Chemostat nutrient media; 1B04 
= Escherichia coli 1B04. 
 
S-methylcysteine, the reduced analogue of SMCSO, was only detected in the SMCSO-
containing CNM sample incubated with E. coli 1B04, indicating that SMCSO was 
reduced by a bacterial-mediated reaction (Figure 7.11). In the control sample, SMCSO 
was present at a concentration of 0.12 mM. The SMCSO peak in the cultured sample 
was too small to accurately quantify, but S-methylcysteine was quantified at 0.11 mM. 
The concentration of SMCSO is lower than recorded by LC-MS (Figure 7.10), and this 
may indicate loss of these volatile compounds due to the samples not being derivatised 
prior to analysis. 
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7.4.7 Detection of metabolic products using gas chromatography 
mass spectrometry 
E. coli 1B04 and DH5α were cultured anaerobically for 24 hours in two media: CNM 
containing glucoraphanin (~6 mM), and CNM containing SMCSO (0.3 mM). Gas 
chromatography mass spectrometry (GC-MS) was used to investigate product 
formation by comparing retention times, mass spectra, and fragment ion fingerprints 
with the National Institute of Standards and Technology (NIST) library. Compounds 
common to controls (CNM + water, CNM + substrate, and CNM + bacterium) and test 
samples (CNM + substrate + bacterium) are omitted from Table 7.3, as they likely 
originate from CNM. 
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Table 7.3: Metabolic products of glucoraphanin and S-methylcysteine sulphoxide, 
identified using GC-MS, following culturing with two individual strains of Escherichia 
coli. Abbreviations: E. coli = Escherichia coli; SMCSO = S-methylcysteine sulphoxide. 
E. coli 
strain 
Substrate 
Retention time 
(min) 
NIST ID 
Probability 
(%) 
1B04 Glucoraphanin 
1.9 Carbon disulphide 94.4 
11.0 Erucin nitrile 89.9 
DH5α Glucoraphanin 
1.9 Carbon disulphide 51.9 
11.0 Erucin nitrile 96.9 
1B04 SMCSO 
1.8 Methanethiol 96.6 
3.4 Ethanol 78.7 
4.8 Dimethyl disulphide 95.6 
5.8 2-heptanone 59.9 
5.9 3-methyl-1-butanol 55.7 
7.5 Dimethyl trisulphide 58.3 
9.2 1-nonanol 5.0 
DH5α SMCSO 
1.8 Methanethiol 98.2 
3.4 Ethanol 90.2 
4.4 1-propanol 88.5 
4.8 Dimethyl disulphide 95.6 
5.8 2-heptanone 66.2 
5.9 3-methyl-1-butanol 48.8 
7.5 Dimethyl trisulphide 98.0 
  9.2 1-nonanol 17.5 
 
GC-MS analysis indicated that culturing either E. coli 1B04 or DH5α in CNM containing 
glucoraphanin, led to the production of carbon disulphide and, the glucosinolate 
hydrolysis product, erucin nitrile (Table 7.3). As erucin nitrile was only present in the 
samples containing both glucoraphanin and either E. coli strain, this indicates that both 
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E. coli strains have the ability to degrade glucosinolates. However, only relatively low 
amounts of glucoraphanin were unaccounted for when each strain was cultured in 
glucoraphanin-containing media (Figure 7.6 and Figure 7.9), suggesting that 
glucosinolate reduction was the primary bacterial reaction. This indicates that any 
glucosinolate hydrolysis performed by these bacterial strains, under the conditions 
tested, occurred at a relatively low level. When E. coli 1B04 or DH5α were cultured in 
CNM containing SMCSO, a larger range of metabolic products were identified (Table 
7.3). Except for the presence of a ketone (2-heptanone) these metabolic products 
could be classified as either alcohols or sulphur-containing compounds. 
 
 
7.5 Discussion 
7.5.1 Identification of Lactobacillus fermentum 
Chapter 5 details experiments in which culturing human faecal microbiotas in a BL 
media led to the enrichment of Lactobacillus species. Bacteria isolated from these 
experiments were identified using 16S rDNA sequencing. Analysis of isolates derived 
from the BL media cultured faecal microbiotas of subjects 1 and 2 led to the 
identification of all twelve Lactobacillus isolates as Lactobacillus fermentum (Table 
7.1). L. fermentum is an acid-tolerant, heterofermentative LAB, which has repeatedly 
been detected in human samples, often found in faecal samples and oral swabs [454]. 
Several strains of L. fermentum have been marketed as probiotics, and are considered 
to have antimicrobial and antioxidative activities [455-458]. 
 
Chapter 7 
   
 
190 
 
7.5.2 Identification of Escherichia species able to reduce 
glucoraphanin 
Ten bacterial isolates were tested for the ability to convert glucoraphanin to the 
reduced analogue, glucoerucin (Figure 7.4). Four of these isolates exhibited putative 
reductase activity, all of which were identified as members of the genus Escherichia 
(Table 7.1). It is interesting to note that the BL media cultured faecal microbiota of 
subject 2, which did not convert glucoraphanin to glucoerucin, was the only cultured 
microbiota that did not contain Escherichia bacteria at the end of cycle 4. It was 
determined that the reduced atmosphere of the anaerobic environment did not play a 
role in the bacterial reduction of glucoraphanin by E. coli 1B04 (Figure 7.5). 
 
However, the choice of culture media was found to affect the rate at which 
glucoraphanin was converted to glucoerucin, with lower levels of glucoerucin seen in 
LB, compared to CNM (Figure 7.6). Higher OD600 readings were observed when E. coli 
1B04 was cultured in LB, compared to CNM, indicating stronger growth in LB. This may 
suggest that the reduction of glucoraphanin was linked to nutrient availability, but a 
difference in potential co-factors between the media may be a more plausible 
explanation. It was recently reported that Mg2+ and either NAD+ or NADP+ were 
necessary for the reduction of sulphoxide-containing glucosinolates by an E. coli strain 
[45]. Nicotinamide and nicotinate were identified following analysis of CNM (Figure 
3.8), and these compounds can be utilised by bacteria as precursors for the production 
of NAD+ or NADP+ [347]. 
 
GC-MS analysis of glucoraphanin-containing CNM cultured with E. coli 1B04 indicated 
that erucin nitrile was present in the cultured samples, but absent from the control 
samples (Table 7.3). The data presented in this chapter indicates that the reduction of 
glucoraphanin, rather than glucosinolate hydrolysis, was the primary metabolic activity 
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of E. coli 1B04. As the hydrolysis of glucoerucin was not observed (Figure 7.8), the 
presence of erucin nitrile indicates that this bacterial strain likely has the ability to 
hydrolyse glucoraphanin, and may have produced erucin nitrile through the subsequent 
reduction of SF or SF nitrile. The lack of glucoerucin hydrolysis may suggest that the 
reduction reaction itself, rather than the reduced product, was advantageous to E. coli 
1B04. Work performed by Simala-Grant and Weiner showed that the anaerobic growth 
of E. coli, on various sulphoxides, was only supported following the reduction of these 
compounds by the DmsABC reductase [310]. This enabled the sulphoxides to act as 
electron acceptors, which can be used by E. coli to generate energy to drive ATP 
synthesis through anaerobic respiration. Therefore, the difference in the rate of 
glucoraphanin reduction observed in Figure 7.6 may reflect the presence of electron 
acceptors in the LB media that were preferred to the sulphoxide, which were reduced 
by other enzymes. 
 
E. coli can express a wide range of reductases for a variety of activities, such as 
terminal reductases used in anaerobic respiration [439], methionine sulphoxide 
reductases which counteract damage that can be caused by reactive oxygen species 
[314, 315], the reduction of xenobiotics [318], and ribonucleotide reductases which are 
involved in the synthesis of DNA [316, 317]. In a study performed by Lee and Renwick, 
the authors postulated that E. coli may possess at least five cytosolic enzyme systems 
capable of reducing sulphoxide-containing drugs, such as sulindac [318]. As the 
laboratory strain E. coli DH5α was able to reduce glucoraphanin (Figure 7.9), this 
suggests that the enzyme responsible for the glucosinolate reduction may be present in 
all E. coli strains. It should be considered that this reduction reaction may be possible 
through the activity of more than one reductase. It is not unreasonable to conclude that 
sulphoxide reduction in anaerobic environments may provide electron acceptors for 
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anaerobic respiration, whilst similar reductase activity in an aerobic environment may 
serve to protect E. coli from oxidative damage.   
 
7.5.3 Metabolism of S-methylcysteine sulphoxide 
To test the hypothesis that the observed glucoraphanin reduction was not 
glucosinolate-specific, E. coli 1B04 was cultured in CNM containing SMCSO. A 
dramatic decrease in the levels of SMCSO was observed in the presence of E. coli 
1B04, when the culture supernatants were analysed by LC-MS (Figure 7.10). 1H NMR 
analysis indicated that a large proportion of SMCSO was converted to the reduced 
analogue, S-methylcysteine, by E. coli 1B04 (Figure 7.11). GC-MS analysis of 
SMCSO-containing CNM incubated with E. coli 1B04 or E. coli DH5α, highlighted 
multiple metabolic products derived from SMCSO due to the activity of the E. coli 
strains (Table 7.3). Amongst these products were sulphur-containing compounds, 
which are indicative of SMCSO degradation (Figure 7.1). SMCSO is degraded in 
plants through the action of cysteine lyases [442, 443]. Multiple gastrointestinal 
bacteria, including members of the human gut microbiota, have been shown to exhibit 
cysteine β-lyase activity, which cleaves C-S bonds of S-alkyl-cysteine molecules in a 
similar manner to the plant cysteine lyases [164-166, 444-448]. The reduction of 
SMCSO to S-methylcysteine appears to have been the primary reaction mediated by 
E. coli 1B04, however the degradation of SMCSO also occurred, to some degree, 
when cultured with both E. coli strains. Although it is possible that glucoraphanin and 
SMCSO were reduced by the actions of different enzymes, it is likely that the activity of 
a single enzyme with broad substrate specificity is responsible for the sulphoxide 
reductions of both of these compounds (Figure 7.12). 
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Figure 7.12: Schematic indicating the bacterial reduction of S-methylcysteine sulphoxide 
and glucoraphanin. The sulphoxide moieties (circled) on SMCSO and glucoraphanin can be 
reduced by human intestinal bacteria to produce the reduced analogues, S-methylcysteine and 
glucoerucin, respectively. 
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7.6 Conclusions 
Lactobacillus isolates, obtained from culturing two human faecal microbiotas in BL 
media, were identified as L. fermentum, a known human intestinal bacterium. L. 
fermentum isolates were unable to reduce glucoraphanin, but four Escherichia isolates 
did exhibit the ability to convert glucoraphanin to glucoerucin. Further analysis was 
focused on E. coli 1B04, and it was determined that the bacterial reduction of 
glucoraphanin occurred in both aerobic and anaerobic environments. The rate of 
glucoraphanin reduction was found to be affected dependent on the media used for 
culturing the bacteria, and this may have been linked to nutrient, co-factor, or electron 
acceptor availability. There were no indications that E. coli 1B04 was able to further 
metabolise glucoerucin, and it may be that the sulphoxides are used as electron 
acceptors as part of anaerobic respiration. The laboratory strain, E. coli DH5α, was 
also able to reduce glucoraphanin, which may suggest that this reaction is common 
amongst all E. coli strains. E. coli 1B04 was found to also have the ability to convert 
SMCSO to its reduced analogue, S-methylcysteine, but it is unclear whether the 
reduction of both SMCSO and glucoraphanin is by the action of a single enzyme. GC-
MS analysis detected breakdown products of both glucoraphanin and SMCSO, but it 
appears that the reduction of these compounds is the primary metabolic reaction, 
under the conditions tested. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER EIGHT 
 
8 Human intervention study investigating 
the effects of a low- and high-Brassica 
diet on the gut microbiota 
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8.0 Summary 
Although the human gut microbiota is relatively stable, short-term dietary interventions 
have been shown to alter the microbiota composition. This chapter presents the results 
of a human intervention study designed to investigate the effects of a low- and high-
Brassica diet on the composition and metabolic activity of the human gut microbiota. 
Variation between microbiotas was observed to be larger than variation within 
microbiotas across time, as has been reported in other dietary studies. Statistical 
analysis identified ten bacterial taxa significantly associated (p<0.05) with an increase 
in relative proportions following the low-Brassica diet, and a proportional decrease after 
the high-Brassica diet, compared to proportions present prior to the respective diet 
phase. The association of five of these taxa to the Brassica diets were strongly 
significant (p<0.01), and these were identified as members of the Rikenellaceae 
(Bacteroidales), Ruminococcaceae (Clostridiales), Mogibacteriaceae (Clostridiales), 
Clostridium (Clostridiales), and an unclassified Clostridiales. No associations between 
the faecal metabolite profiles and the Brassica diets were observed, and the results of 
the urinary excretion of glucoraphanin hydrolysis products were inconclusive. 
 
 
8.1 Introduction 
 
Studies indicate that although humans share a core gut microbiota, there is a greater 
amount of variation in community composition between individuals than within 
individuals across time [181, 202, 372, 459, 460]. The structure of the gut microbiota is 
largely formed during early life, and remains relatively stable for the majority of adult life 
[461]. Although stable, the structure of the microbiota exhibits a relatively large degree 
of plasticity, which allows for the adaptation to its environment [236, 459, 462, 463]. 
Small fluctuations in the abundances of different bacteria can enable the efficient 
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extraction of nutrients from various dietary compounds. Short-term dietary interventions 
have illustrated the effects of diet on the composition of the human gut microbiota [254, 
401, 408, 464-467]. Diet also affects the production and utilisation of metabolites in the 
intestines, and this can be monitored through analysis of biological material, such as 
urine and stools [468-470]. 
 
A study by Li et al investigated the effects of cruciferous vegetables on the human gut 
microbiota through a controlled diet devoid of other vegetables, fruits, whole-grains, 
and high-fibre foods [134]. Bacteria putatively assigned as Eubacterium hallii, 
Phascolarctobacterium faecium, Alistipes putredinis, and Eggerthella sp. were reported 
to be associated with the consumption of cruciferous vegetables, however the nature of 
the association was unexplained. Studies investigating the urinary excretion of 
glucosinolate hydrolysis products, as markers of microbial glucosinolate metabolism, 
observed variation between individuals, with recovery ranging from approximately 1 – 
45% of the initial dose of glucosinolates [111-114]. One study in which participants 
were retested over a period of two and a half years also reported intra-individual 
variation amongst urinary excretion results over time [111].  
 
 
8.2 Objectives 
The hypothesis for the work contained in this chapter was that a low- and/or high-
Brassica diet would alter the gut microbiota composition. It was also hypothesised that 
changes to the proportions of gut lactobacilli would be observed, based on the in vitro 
work in chapter 5. It was considered that these dietary interventions would alter the 
microbial metabolite profile, and that the excretion of glucoraphanin hydrolysis products 
in the urine would differ between individuals. 
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8.3 Materials and methods 
Ten participants were recruited onto the ‘Effects of Brassica on human gut lactobacilli’ 
(EBL) study, which investigated the differential effects of consuming a low- or high-
Brassica diet on the composition of the gut microbiota, and the proportions of intestinal 
lactobacilli (section 2.13). The two-phase crossover study design is summarised in 
Figure 8.1, and details of the study participants are compiled in Table 8.1. Analysis of 
the Brassica foods used in the diets was performed using HPLC (section 2.5). 1H NMR 
spectroscopy analysis (section 2.6.2) was performed on faecal waters to investigate 
changes to microbial metabolic profiles associated with the Brassica diets (section 
2.13.3.2). Urine samples were collected to act as indicators of compliance to the 
dietary restrictions, and 24 hr urine collections were used to assess differences in 
urinary glucoraphanin hydrolysis product excretion rates between and within 
participants. All urine samples were prepared as described in section 2.13.3.3, prior to 
analysis via LC-MS/MS (section 2.4.1). The bacterial composition of faecal samples 
were determined using 16S rDNA paired-end sequencing (2x 250 bp) on the Illumina 
MiSeq platform, and bioinformatic analyses were performed using the QIIME pipeline 
(section 2.13.3.1). The data was modelled using multivariate analysis, prior to statistical 
analysis by sequential analysis of variance (section 2.14).  
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Figure 8.1: Design for the EBL human dietary intervention study. Randomised, two phase crossover, human dietary intervention study: n = 10. Following a 
successful eligibility screening appointment, participants produced a faecal sample before commencing a Brassica and glucosinolate-containing food diet restriction. 
After 2 weeks, a faecal sample (F) and urine (u) sample were collected, and the first 2 week intervention phase started (low- or high-Brassica diet).  All urine was 
collected for 24 hr (U) directly after consuming the first portion of broccoli or broccoli-based soup. Participants were restricted from eating further portions until the 
urine collection was completed. Upon conclusion of the first intervention phase, a faecal sample was collected, and the 2 week washout period began. A further faecal 
sample and urine sample were collected on completion of the washout period, and the second 2 week intervention phase started (alternative diet to that consumed in 
intervention phase 1). All urine was collected for 24 hr directly after consuming the first portion of broccoli or broccoli-based soup. Participants were restricted from 
eating further portions until the urine collection was completed. Upon conclusion of the second intervention phase, a faecal sample was collected and the diet 
restriction period ceased. After 2 weeks consuming their habitual diet, participants collected a final faecal sample, completing the study. During each intervention 
phase, and the habitual diet phase, stool charts and food diaries were completed for a period of seven consecutive days. * At the end of the 2 week wash-out period, 
8 participants were granted a short break from the study, for a period of no more than 6 weeks, to accommodate the Christmas period. Participants were required to 
resume the dietary restrictions for 2 weeks prior to producing an additional faecal sample, and starting the second intervention phase.
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Table 8.1: Age, gender, Body Mass Index (BMI), and smoking status of the EBL study 
participants. 
Participant 
code 
Age (years) Gender BMI (kg/m2) Smoker 
EBL16 35 Male 28.5 N 
EBL28 25 Female 23.5 N 
EBL51 25 Female 24.8 N 
EBL56 32 Female 21.1 N 
EBL74 39 Female 20.3 N 
EBL84 40 Male 24.4 N 
EBL88 36 Male 26.0 N 
EBL89 41 Female 25.3 Y 
EBL92 28 Male 27.5 N 
EBL97 34 Female 23.8 N 
 
 
8.4 Results 
8.4.1 Analysis of the Brassica diet 
Participants were asked to consume a total of seven 84 g portions of cauliflower, seven 
84 g portions of broccoli, and six 300 g portions of broccoli and sweet potato soup 
(manufactured using 84 g of broccoli per portion) across the two dietary intervention 
phases. The soups were manufactured by Bakkavor for use in the ESCAPE study 
(REC ref: 13/EE/0110), performed at the IFR, and had been shown to be a rich source 
of glucoraphanin. Each of the portions were analysed for total glucosinolate content 
using HPLC (Table 8.2 and Table 8.3). 
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Table 8.2: Mean μmoles of glucosinolates per 84 g portion of steamed cauliflower from 5 different batches. Refer to page 4 and 5 (section 1.1.1) for 
glucosinolate structures and semi-systematic names. 
Batch 
code 
Cauliflower - glucosinolates (mean μmoles/84 g cooked portion) 
Glucoiberin Gluconasturtiin Progoitrin Glucoraphanin Sinigrin Glucoiberverin Glucobrassicin 
4-
MIND 
4-methoxy 
glucobrassicin 
Total 
DF4217 
13:58 
1.00 7.09 0.79 0.80 7.68 8.24 22.56 1.30 3.93 53.38 
DF4217 
13:59 
1.04 6.22 0.19 0.94 7.17 8.80 10.63 1.20 1.39 37.59 
DF4217 
07:09 
1.03 7.81 2.81 0.93 11.10 3.37 32.00 1.79 4.81 65.68 
DF4217 
16:28 
0.94 13.23 2.75 1.40 12.90 2.35 20.72 1.13 1.92 57.34 
DF4217 
12:56 
0.92 8.25 1.97 1.40 6.55 1.78 33.29 1.64 3.71 59.50 
 
Table 8.3: Mean μmoles of glucosinolates per 84 g portion of steamed broccoli from 3 different batches, and 300 g portion of a single batch of the 
microwaved broccoli and sweet potato soup. Refer to page 4 and 5 (section 1.1.1) for glucosinolate structures and semi-systematic names. 
Batch code 
Broccoli based foods - glucosinolates (mean μmoles/cooked portion) 
Glucoiberin Glucoraphanin Glucobrassicin 4-MIND 4-methoxyglucobrassicin 4-hydroxyglucobrassicin Total 
Broccoli - 
DF4231 18:18 
7.91 65.66 28.50 4.63 9.31 1.44 117.46 
Broccoli - 
DF4231 20:37 
7.71 61.64 21.13 2.31 6.55 1.45 100.80 
Broccoli - 
DF4232 15:55 
9.17 53.61 25.30 4.33 8.85 2.02 103.29 
Soup – 302 (3) 93.79 158.98 13.18 2.47 20.04 0 288.46 
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The cauliflower portions were found to contain a relatively high level of glucobrassicin 
(Table 8.2), but fewer total μmoles of glucosinolates than present in the broccoli 
portions. The most prevalent glucosinolate in the broccoli portions and the broccoli-
based soup was glucoraphanin, with the soup containing approximately 2.5-fold higher 
levels than the frozen broccoli (Table 8.3). The increased glucoraphanin levels in the 
broccoli-based soup is likely associated with the broccoli being cultivated in Spain 
under optimal growing conditions, with high quality fresh broccoli florets used to 
generate the soup. The frozen broccoli florets were grown in England, and purchased 
from a Sainsbury’s superstore. 
 
8.4.2 Urinary glucoraphanin hydrolysis product profiles 
Each participant collected their urine for 24 hours following consumption of the first 
portion, of either the broccoli or the broccoli and sweet potato soup, for each of the 
Brassica diet phases. The urine was analysed for glucoraphanin hydrolysis products 
using LC-MS/MS, and the total percentage excreted was calculated (Figure 8.2). 
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Figure 8.2: Differences in urinary glucoraphanin hydrolysis product excretion was 
observed between and within individuals. Ten participants collected their urine for 24 hr after 
eating the first portion of broccoli or the broccoli and sweet potato soup. Aliquots of urine were 
filtered (0.2 μm), and analysed using LC-MS/MS. Total percentage of glucoraphanin hydrolysis 
products were calculated based on the glucosinolate analysis of the dietary foods (Table 8.3). S 
signifies that the urine was collected following consumption of the broccoli-based soup, all other 
data was collected following consumption of steamed broccoli. 
 
A general trend in 8 of 10 participants was observed for a higher percentage of 
glucoraphanin hydrolysis products to be excreted in the urine following consumption of 
the first portion of the high-Brassica diet (Figure 8.2). The urine obtained from the 
remaining two participants (EBL74 and EBL84) show a similar percentage of excreted 
glucoraphanin hydrolysis products following consumption of the first portion of either 
Brassica diet. 
  
Chapter 8 
   
204 
 
8.4.3 Proton nuclear magnetic resonance spectroscopy analysis of 
metabolite profiles in faecal waters 
In total 68 faecal samples were collected from the 10 participants over the duration of 
the study. Each of the 68 faecal samples were homogenised in a 0.4 mM phosphate 
buffer to produce faecal waters (section 2.13.3.2). 1H NMR spectroscopy analysis was 
performed on the supernatant of the centrifuged faecal waters to detect Brassica diet-
induced changes to the metabolite profile. 
 
8.4.3.1 Variation in metabolite profiles due to portion sampling of faecal 
material 
It was decided to ascertain whether a single aliquot taken from a faecal sample was 
representative of the metabolite profile of the entire sample. Two aliquots of 54 faecal 
samples were taken from random positions of each sample and used to generate two 
separate faecal waters. The two faecal sample replicates of the 54 faecal samples 
were analysed using 1H NMR spectroscopy to identify the level of repeatability between 
different areas of the faecal sample (Figure 8.3). 
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Figure 8.3: Different areas of faecal samples are representative of one another regarding 
the metabolite profile. Two aliquots were taken from random positions of 54 faecal samples, 
homogenised in a 0.4 mM phosphate buffer, and analysed using 
1
H NMR spectroscopy. Each 
different number (1 – 54) represents one of the 54 faecal samples, and data-points with the 
same number denote replicates. The plot was generated using Matlab. 
 
Strong repeatability was seen between the two replicates of each of the 54 faecal 
samples, indicating that a single aliquot of a faecal sample is likely representative of 
the metabolite profile of the entire sample. As such, it was not deemed necessary to 
analyse the remaining 14 samples for portion sampling effects. 
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8.4.3.2 Effects of Brassica diets on metabolite profile 
The metabolite profiles of the 68 faecal waters showed a tendency to cluster based on 
the participant, indicating a low level of intra-individual variability over time (Figure 8.4). 
 
 
Figure 8.4: Between-individual variation of the metabolite profile is generally stronger 
than the within-individual variation over time. An aliquot of 68 faecal samples were each 
homogenised in a 0.4 mM phosphate buffer, and analysed using 
1
H NMR spectroscopy. The ten 
symbols represent the ten participants (as denoted in the key), and the numbers (1 – 3) indicate 
the type of sample: 1 = non-intervention faecal sample, 2 = faecal sample after the high-
Brassica diet, 3 = faecal sample after the low-Brassica diet. The plot was generated using 
Matlab. 
 
No association between the low- or high-Brassica diets and the faecal metabolite 
profile were detected on the first 10 principal components. Figure 8.5 shows the first 
two principal components. 
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Figure 8.5: The Brassica diets were not associated with significant changes to the faecal 
metabolite profile. An aliquot of 68 faecal samples were each homogenised in a 0.4 mM 
phosphate buffer, and analysed using 
1
H NMR spectroscopy. Red triangles = non-intervention 
faecal sample, green crosses = faecal sample after the high-Brassica diet, blue stars = faecal 
sample after the low-Brassica diet. The plot was generated using Matlab. 
 
8.4.4 Community analysis of human faecal microbiotas 
Faecal samples were collected during the study from 10 healthy participants, aged 25 – 
41 years with a mean age of 34 years, and an average BMI of 24.5 kg/m2. The DNA 
was extracted (section 2.9.1), and visualised and quantified (section 2.9.1.1), prior to 
normalisation to 1 ng/μl (section 2.13.3.1). The normalised DNA samples were sent to 
the Centre of Genomic Research (Liverpool, UK), where variable regions of the 16S 
rDNA gene were amplified using PCR, and sequenced using the paired-end Illumina 
MiSeq platform, for downstream analysis using the QIIME pipeline (section 2.13.3.1). 
This produced 6,503,134 high-quality reads, with an average of 95,634 ± 28,729 reads 
per sample, which clustered into 21,563 operational taxonomic units at 97% identity. 
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No associations were observed between the consumption of either of the Brassica 
diets and the relative proportions of Lactobacillus (≤0.2% in all samples). Unweighted 
(Figure 8.6) and weighted (Figure 8.7) beta-diversity analysis suggested that the 
consumption of a Brassica-rich (high) diet or a Brassica-poor (low) diet did not lead to a 
strong alteration of the faecal microbiotas towards a common composition. 
 
 
Figure 8.6: Consumption of the Brassica diets did not correlate with a common gut 
microbiota composition. Unweighted beta-diversity analysis of faecal microbiotas from ten 
study participants; each participant collected 4 – 5 non-intervention samples, a single sample 
following a 2 week low-Brassica diet, and a single sample following a 2 week high-Brassica diet. 
Analysis was performed using the UniFrac metric, and visualised as a 3D PCoA plot. Beta-
diversity analysis was performed using QIIME 1.8.0, and plotted using Emperor. 
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Figure 8.7: No association between gut microbiota composition and Brassica diets was 
observed when accounting for bacterial relative abundance. Weighted beta-diversity 
analysis of faecal microbiotas from ten study participants; each participant collected 4 – 5 non-
intervention samples, a single sample following a 2 week low-Brassica diet, and a single sample 
following a 2 week high-Brassica diet. Analysis was performed using the UniFrac metric, and 
visualised as a 3D PCoA plot. Beta-diversity analysis was performed using QIIME 1.8.0, and 
plotted using Emperor. 
 
Performing the unweighted (Figure 8.8) and weighted (Figure 8.9) beta-diversity 
analysis with samples colour-coded for each participant, indicated that the samples 
obtained from each individual clustered together. 
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Figure 8.8: Unweighted beta-diversity analysis shows clustering of faecal microbiotas 
based on the individual. Unweighted beta-diversity analysis of faecal microbiotas from ten 
study participants; each participant collected 4 – 5 non-intervention samples, a single sample 
following a 2 week low-Brassica diet, and a single sample following a 2 week high-Brassica diet. 
Analysis was performed using the UniFrac metric, and visualised as a 3D PCoA plot. Beta-
diversity analysis was performed using QIIME 1.8.0, and plotted using Emperor. The EBL code 
in the key refers to different participants. 
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Figure 8.9: Increased variation within individuals is observed when relative abundance of 
bacteria within the microbiotas is considered. Weighted beta-diversity analysis of faecal 
microbiotas from ten study participants; each participant collected 4 – 5 non-intervention 
samples, a single sample following a 2 week low-Brassica diet, and a single sample following a 
2 week high-Brassica diet. Analysis was performed using the UniFrac metric, and visualised as 
a 3D PCoA plot. Beta-diversity analysis was performed using QIIME 1.8.0, and plotted using 
Emperor. The EBL code in the key refers to the 10 different participants. 
 
The unweighted beta-diversity analysis calculates the similarities between samples, 
based on which bacterial taxa are shared amongst the microbiotas. Figure 8.8 
suggests that the greatest degree of similarity between faecal microbiotas can be found 
amongst the samples that originated from each individual. The faecal microbiotas of 
EBL56 and EBL92 would appear to differ from one another, and are less similar to the 
microbiotas of the other eight participants, due to a lower number of shared bacterial 
taxa. 
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Weighted beta-diversity analysis considers the similarity between the relative 
abundance of the bacterial taxa, alongside which taxa are shared between microbiotas. 
Figure 8.9 indicates an increased variability amongst the faecal microbiotas of 
individuals due to small fluctuations in the relative abundance of bacterial taxa. The 
effects of relative abundance are seen most strongly for the samples obtained from 
EBL28 and EBL97. Alpha-diversity analysis was performed to identify whether the 
variation observed for the samples from EBL28 and EBL97 were true indicators of 
natural fluctuations in the microbiota, or artifacts that reflect poor sequencing output 
(Figure 8.10). 
 
 
Figure 8.10: Alpha-diversity analysis indicates that at least one sample obtained from 
EBL97 contains poor sequencing data. Alpha-diversity rarefaction plot of species richness 
within the human faecal microbiota samples grouped for each of the ten individuals. The y-axis 
is a measure of diversity within each community, whilst the x-axis represents the number of 
sequences used in the diversity calculation. Rarefaction plots were generated using QIIME 
1.8.0. The EBL code in the key refers to the 10 different participants. The arrow points to the 
diversity analysis output for participant EBL97 (brown line), which indicates that at least one 
sample did not contain enough sequences to accurately reflect the true microbiota. 
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Alpha-diversity analysis suggested that a minimum of one sequencing data file from the 
faecal samples of EBL97 did not produce a number of sequences large enough for use 
in further analysis, as indicated by the arrow (Figure 8.10). Interrogation of the raw 
sequencing data isolated a file containing only 18,731 sequencing reads, which 
correlated to the DNA sample obtained from the faecal sample produced by EBL97 
following the two week low-Brassica diet intervention phase. This sample can be seen, 
positioned apart from the other samples, alongside the second principal component 
axis in Figure 8.7 and Figure 8.9, indicating that the number of sequencing reads was 
insufficient for this sample to be used in further analysis. Each of the remaining files, 
including the file corresponding to the isolated sample of EBL28 (Figure 8.7 and 
Figure 8.9), contained sufficient sequencing reads to reflect the true composition of the 
microbiotas. Therefore, the subsequent analysis was performed on the data obtained 
from the 67 samples that were considered to be reliable, and the data corresponding to 
the sample collected from EBL97 following the low-Brassica diet was excluded. 
 
8.4.5 Brassica diet-associated changes to bacterial taxa within the 
gut microbiota 
 
Although the consumption of a low- or high-Brassica diet were not sufficient to show 
large changes to the gut microbiota community composition, smaller diet-associated 
alterations to members of individual bacterial taxa may still have occurred. Multivariate 
analysis was performed on the bacterial taxa that were present at a proportion >0 in a 
minimum of 45 of the 67 faecal microbiotas (excluding the poorly sequenced sample of 
EBL97). This criterion designated 66 of the total 385 bacterial taxa as candidates for 
further analysis, with this subset accounting for >90% of the total population in 64 of 67 
faecal microbiotas. After the data was log-transformed to allow for a clearer 
visualisation of the data-points, and variance scaled to account for the uneven 
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distribution, 14 principal components were retained based on the Kaiser criterion 
(factors with an eigenvalue >1). A varimax rotation (orthogonal rotation of the factor 
axes to simplify interpretation) was performed on the 14 principal components to 
produce principal component analysis (PCA) factor scores that correlated with the 66 
bacterial taxa within each participant’s faecal microbiotas. The variance explained by 
the retained 14 principal components and the varimax-rotated factors are displayed in 
Table 8.4. 
 
Table 8.4: Variance and cumulative percentage variance explained by the first 14 
principal components, and the corresponding values for the varimax-rotated factors. 
PCA factor Variance 
Cumulative 
(%) 
Rotated axis 
variance 
Cumulative 
(%) 
1 15.3 23.2 13.9 21.1 
2 7.7 34.9 5.3 29.2 
3 6.7 45.0 5.4 37.4 
4 5.1 52.8 3.7 43.0 
5 3.5 58 3.2 47.9 
6 3.1 62.7 3.2 52.8 
7 2.6 66.7 2.5 56.6 
8 2.6 70.5 3.4 61.8 
9 2.2 73.9 2.3 65.4 
10 2.0 76.9 2.3 68.9 
11 1.5 79.1 4.5 75.7 
12 1.2 81.0 2.1 78.8 
13 1.1 82.7 2.0 81.8 
14 1.0 84.2 1.6 84.2 
 
The 66 bacterial taxa were plotted as a single variate for each of the 67 faecal 
samples, against the first two varimax-rotated factors in the form of a score-plot. This 
highlighted a trend, in which the 66 bacterial taxa were associated with lower first factor 
scores after participants consumed the high-Brassica diet, compared to the 
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corresponding taxa following consumption of the low-Brassica diet (Figure 8.11). In 
addition, samples from the same participants were observed to form clusters, although 
these often overlapped.  
 
 
Figure 8.11: Variates corresponding to 66 bacterial taxa within faecal samples collected 
after the high-Brassica diet are associated with a lower first factor score than those 
collected after the low-Brassica diet. Score-plot of the first two varimax-rotated factors: black 
dots signify scores of 66 bacterial taxa within non-intervention faecal samples, filled red circles 
represent scores faecal samples collected after the high-Brassica diet, filled blue circles denote 
scores of 66 bacterial taxa within faecal samples collected after the low-Brassica diet. Scores 
labelled with the same number (1 – 10) correspond to a single individual, and scores obtained 
for the low- and high-Brassica diet for each individual are connected by a black line. As the data 
from the sample collected after the low-Brassica diet for EBL97 (10) was excluded, no 
connecting line is present for the samples of this participant. 
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As a consequence of this perceived trend, correlations between the first and second 
varimax-rotated factor scores and each of the log-transformed variates were examined 
to identify which log-transformed variates were most strongly associated with the first 
factor score. Those variates in which the greater amount of variance was explained by 
the first factor score were selected as the most likely candidates to have had a 
significant association with the Brassica diets. This allowed the identification of 19 
bacterial taxa with a strong association with the first factor score (listed in Table 8.5): 
18 bacterial taxa were positively associated, whilst a member of the genus Veillonella 
was negatively associated. 
 
Sequential analysis of variance was performed using Matlab to identify whether there 
were any statistically significant changes to the log-transformed proportions of the 19 
bacterial taxa, following the consumption of the Brassica diets (Table 8.6). No 
significant difference was detected for the order in which the participants consumed the 
diets. 
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Table 8.5: Bacterial taxa associated with the first factor score (Veillonella (19) was the only taxa negatively associated), and the maximum (Max.) 
proportion of each in the total population, obtained from 67 faecal samples. p = phylum, c = class, o = order, f = family, g = genus. 
Identifier Bacterial taxa 
Max. 
proportion 
1 Unclassified bacteria 1.64% 
2 p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Rikenellaceae 1.23% 
3 p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Rikenellaceae 2.53% 
4 p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Rikenellaceae; g_Alistipes 0.37% 
5 p_Bacteroidetes; c_Bacteroidia; o_Bacteroidales; f_Barnesiellaceae 1.94% 
6 p_Firmicutes 1.26% 
7 p_Firmicutes; c_Clostridia 0.12% 
8 p_Firmicutes; c_Clostridia; o_Clostridiales 5.53% 
9 p_Firmicutes; c_Clostridia; o_Clostridiales; f_Christensenellaceae 4.41% 
10 p_Firmicutes; c_Clostridia; o_Clostridiales; f_Dehalobacteriaceae; g_Dehalobacterium 0.23% 
11 p_Firmicutes; c_Clostridia; o_Clostridiales; f_Ruminococcaceae 11.88% 
12 p_Firmicutes; c_Clostridia; o_Clostridiales; f_Ruminococcaceae 4.0% 
13 p_Firmicutes; c_Clostridia; o_Clostridiales; f_Ruminococcaceae; g_Anaerotruncus 0.22% 
14 p_Firmicutes; c_Clostridia; o_Clostridiales; f_Ruminococcaceae; g_Clostridium 0.07% 
15 p_Firmicutes; c_Clostridia; o_Clostridiales; f_Ruminococcaceae; g_Oscillospira 4.45% 
16 p_Firmicutes; c_Clostridia; o_Clostridiales; f_Ruminococcaceae; g_Ruminococcus 18.15% 
17 p_Firmicutes; c_Clostridia; o_Clostridiales; f_Mogibacteriaceae 0.38% 
18 p_Firmicutes; c_Clostridia; o_Clostridiales; f_Mogibacteriaceae 3.11% 
19 p_Firmicutes; c_Clostridia; o_Clostridiales; f_Veillonellaceae; g_Veillonella 0.88% 
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Table 8.6: Summary statistics and modelling results for 19 bacterial taxa associated with the first factor score. Identifier = numerical code assigned to 
bacterial taxa in Table 8.5; Day 0 and Day 15 = values obtained before and after each dietary intervention phase; Diff = paired differences between values 
obtained before and after each dietary intervention phase; Day 15 high – Day 15 low = paired differences between values obtained after the high- and low-
Brassica diet intervention phases; P = significance of Brassica diet in analysis of variance model, with bold values indicating p<0.05. Bacterial proportions 
expressed as the natural logarithm of the fractional proportion of population after the addition of a small offset (0.00001) to counter zero-proportions. 
Identifier 
Low-Brassica diet High-Brassica diet  
Day 0 Day 15 Diff Day 0 Day 15 Diff Day 15 high – Day 15 low 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD P 
1 -8.12 1.56 -8.39 1.37 -0.27 0.84 -8.90 1.45 -8.37 2.14 0.53 1.16 0.02 1.71 0.1879 
2 -6.17 1.00 -5.76 0.72 0.42 0.79 -6.24 1.18 -6.58 1.39 -0.33 1.40 -0.82 1.03 0.0295 
3 -5.06 0.87 -4.69 0.59 0.38 0.83 -5.09 1.14 -5.35 1.03 -0.26 1.02 -0.66 0.77 0.0078 
4 -7.85 1.45 -7.28 1.31 0.57 0.76 -8.29 1.44 -8.38 1.60 -0.09 1.51 -1.10 0.88 0.0254 
5 -7.08 1.84 -6.84 1.82 0.24 0.83 -6.97 2.03 -7.07 2.12 -0.11 1.18 -0.23 1.66 0.4902 
6 -7.15 2.17 -6.88 1.71 0.26 0.88 -7.41 1.41 -7.80 1.74 -0.38 1.11 -0.91 1.04 0.0206 
7 -9.05 1.35 -9.11 0.82 -0.06 0.72 -9.51 1.07 -10.03 1.42 -0.51 0.91 -0.92 1.31 0.1230 
8 -5.02 2.12 -4.93 2.05 0.09 0.68 -5.10 1.56 -5.75 1.89 -0.64 1.29 -0.82 0.93 0.0037 
9 -6.92 2.60 -6.94 3.01 -0.02 1.22 -7.48 2.53 -8.32 2.68 -0.85 0.79 -1.39 1.73 0.2320 
10 -8.84 1.76 -8.72 1.90 0.12 0.52 -9.46 1.79 -9.42 1.79 0.04 1.18 -0.69 0.86 0.0206 
11 -3.55 1.19 -3.43 1.06 0.12 0.37 -3.64 1.05 -3.67 0.84 -0.03 0.32 -0.24 0.35 0.0917 
12 -6.35 2.34 -5.86 2.29 0.49 0.80 -6.95 2.34 -7.23 2.38 -0.28 0.79 -1.37 1.26 0.0001 
13 -9.17 1.65 -8.97 1.63 0.20 1.27 -9.67 1.42 -9.38 1.29 0.29 0.53 -0.41 0.66 0.1336 
14 -8.98 0.83 -9.17 0.96 -0.20 1.07 -9.42 0.87 -9.94 1.19 -0.53 0.70 -0.77 0.45 0.0059 
15 -4.32 0.82 -4.17 0.74 0.15 0.43 -4.30 0.72 -4.66 1.15 -0.36 0.63 -0.50 1.10 0.1677 
16 -2.75 0.55 -2.77 0.51 -0.02 0.39 -2.82 0.58 -3.26 1.16 -0.44 0.97 -0.49 0.97 0.1384 
17 -7.83 1.65 -7.90 1.81 -0.07 0.84 -8.31 1.61 -8.60 1.76 -0.29 0.82 -0.70 0.77 0.0360 
18 -5.86 1.31 -5.57 1.15 0.29 0.49 -5.99 1.15 -6.31 1.30 -0.31 0.31 -0.74 0.36 0.0024 
19 -8.31 1.84 -9.10 0.91 -0.79 1.62 -8.02 1.64 -8.43 2.15 -0.41 1.76 0.68 1.44 0.2591 
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The p-values obtained though the statistical analysis indicated that 10 members of the 
selected 19 bacterial taxa were present at significantly different relative proportions 
(p<0.05), when comparing the endpoint of each Brassica diet intervention phase. Table 
8.6 indicates that the relative proportions of members of these taxa were lower after the 
high-Brassica diet, compared to after the low-Brassica diet. In addition, the proportions 
of the members of these taxa were often found to be lower at the end of the high-
Brassica diet compared to the beginning, whilst the reverse was observed for the low-
Brassica diet. The log-transformed proportions of the members of the 5 bacterial taxa 
with a p-value<0.01 after each of the Brassica dietary interventions are shown for the 9 
participants analysed, in Figure 8.12. 
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Figure 8.12: Decreased proportions of the strongly significant members of the bacterial 
taxa associated with the Brassica diets (p<0.01) are observed in most of the 9 
participants tested after consuming the high-Brassica diet, compared to the low-Brassica 
diet. Population proportions of members of the 5 bacterial taxa significantly associated with 
consumption of the Brassica diets (p<0.01) in 9 participants after the low-Brassica (blue) and 
high-Brassica (red) diets. The lower right sub-plot shows the summed proportions of the 18 
bacterial taxa positively associated with the first varimax-rotated factor in 9 participants after 
each Brassica diet. The proportions are presented on a log scale and have had a small offset 
(0.00001) added. The plots were produced using Matlab. 
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8.5 Discussion 
8.5.1 Differences in urinary glucoraphanin hydrolysis product 
excretion profiles between and within participants 
Participants were asked to collect their urine for 24 hours following the consumption of 
the first portion of Brassica for each of the two diets, and the percentage of 
glucoraphanin hydrolysis products excreted in the urine were calculated (Figure 8.2). 
Differences in the proportions of glucoraphanin hydrolysis products excreted in the 
urine were observed between and within individuals. Variation in urinary excretion 
profiles between individuals has been observed in several other studies, ranging from 1 
– 45% of the initial glucosinolate dose [111-114]. Fahey et al observed intra-individual 
differences when participants were re-tested between a period of a few days and two 
and a half years [111]. As the urinary excretion rate of glucosinolate hydrolysis 
products is likely to directly reflect the microbial conversion of glucosinolates, this could 
be linked to minor fluctuations in the relative abundances of certain gut bacteria able to 
metabolise glucosinolates. 
 
A limitation of the study that forms the basis of this chapter was that participants were 
free to consume either a portion of steamed broccoli or a broccoli and sweet potato 
soup, prior to the 24 hour urine collection. Interpretation of the urinary excretion data 
would be more reliable if all participants had consumed the same type of food prior to 
the urine collection period. The soup contained approximately 2.5-fold higher levels of 
glucoraphanin, and differences in the food matrix between the steamed broccoli and 
the soup may affect absorption, gut transit time, and microbial accessibility to 
glucosinolates. 
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8.5.2 Changes to faecal metabolite profiles associated with Brassica 
diets 
Metabolite analysis, using two replicates from 54 faecal samples, suggested that two 
distinct areas of the faecal samples tested contained a similar metabolite profile, and 
indicated good reproducibility of the technique (Figure 8.3). This mirrors the results 
from a study performed by Mai et al, which concluded that a pea sized aliquot of faecal 
material could be taken from any part of a faecal sample and that this would give an 
accurate representation of the entire stool with regards to both the composition of the 
microbiota and the microbial diversity [471]. 
 
When the metabolite profiles of all 68 faecal samples collected throughout the study 
were analysed, samples tended to cluster based on the participant (Figure 8.4). 
Statistical analysis indicated no significant association between the Brassica diets and 
the metabolite profile of the participants (Figure 8.5). However, this is not entirely 
unexpected as the components of the Brassica diet will have only represented a 
fraction of the daily food intake of the participants, and any effects may be transient. In 
addition, the metabolite profiles of faecal samples may not always be fully 
representative of activity in the colon. An increase in the production of metabolites may 
not be reflected in the faecal metabolite profile, if there is a corresponding increase in 
the utilisation of these metabolites by the gut microbiota or human host.  
 
8.5.3 Effects of the Brassica diets on the relative proportions of 
intestinal lactobacilli 
The relative proportions of Lactobacillus were observed to range between <0.1% and 
0.2% of the total bacterial populations, and were not found to be associated with the 
consumption of either of the Brassica diets. This suggests that the results obtained 
from the in vitro batch fermentation model, discussed in chapter 5, do not correlate with 
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the in vivo effects of consuming broccoli. This is likely due to the continuous flow of 
contents through the intestines, which does not allow for extreme changes to pH 
occurring in localised areas for extended periods of time. 
 
8.5.4 Bacterial community diversity analysis 
Phylogenetic analysis of the faecal microbiotas of 10 participants was performed to 
determine whether the consumption of a low- or high-Brassica diet was associated with 
an alteration in the gut bacterial community composition. It was observed that the 
faecal samples clustered by participant (Figure 8.8), indicating the unique nature and 
inherent stability of an individual’s gut microbiota. This appears to reflect the low intra-
individual variability across time that was also observed with the faecal metabolite 
profiles (Figure 8.4). Inter-individual differences in the composition of gut bacterial 
communities have been observed in other studies [134, 201, 227]. Weighted beta 
diversity analysis suggested that the microbiotas clustered, but that there was variation 
in the abundances of bacteria within the communities over time (Figure 8.9). This likely 
reflects the dynamic nature of the gut microbiota, which is able to adapt to 
environmental alterations, such as a change of dietary habits, while retaining its core 
structure.  
 
In a previous study by Li et al, changes to the composition of human gut bacterial 
communities were reported following a ‘double-cruciferous diet’ (basal diet + 14 g 
cruciferous vegetables/kg body weight per day), versus the basal diet [134]. As the 
basal diet was devoid of other vegetables, fruits, whole-grains and high-fibre foods, this 
would mean that the addition of a large portion of cruciferous vegetables would provide 
a range of nutrients, which the bacterial community may not have been able to obtain 
from other dietary sources. The study described in this chapter only required the 
participants to restrict their diet of Brassica vegetables, thereby allowing the 
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consumption of other foods that may contain similar vitamins, minerals, and fibres. 
Consumption of the Brassica diets did not appear to alter the composition of the gut 
microbiotas in a uniform direction (Figure 8.6 and Figure 8.7). This is not surprising 
considering that any effects of the Brassica diet would need to be strong enough to be 
detectable over the background of other foods containing similar nutrients, and the 
natural fluctuations of the microbiota. 
 
8.5.5 Statistical analysis of Brassica diet-associated changes to gut 
bacteria 
Data modelling and statistical analysis identified a tendency for the relative proportions 
of members of ten bacterial taxa to be higher following the consumption of the low-
Brassica diet, compared to the high-Brassica diet (p<0.05) (Table 8.6). Additionally, the 
relative proportions of the members of these ten bacterial taxa were often found to 
increase following the consumption of the low-Brassica diet, compared to the 
proportions measured prior to the low-Brassica diet phase, with the opposite trend 
observed for the high-Brassica diet. Three members of these bacterial taxa belonged to 
the Bacteroidales order, whilst six taxa were members of the Clostridiales order, and 
the remaining taxon could not be classified at a greater level than the phylum 
Firmicutes. The association of members of five of these taxa to the Brassica diets were 
found to be strongly significant (p<0.01): Rikenellaceae (Bacteroidales), 
Ruminococcaceae (Clostridiales), Mogibacteriaceae (Clostridiales), Clostridium 
(Clostridiales), and an unclassified Clostridiales. 
 
The cruciferous vegetable study performed by Li et al (discussed in section 8.5.4) 
found four terminal restriction fragment length polymorphism (tRFLP) fragments that 
were significantly associated with the double cruciferous diet intervention [134]. 
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However, it was not reported whether the identified fragments were positively or 
negatively associated with the cruciferous diet. These fragments were putatively 
assigned to Eubacterium hallii, Phascolarctobacterium faecium, Alistipes putredinis, 
and an Eggerthella species. Both E. hallii and P. faecium belong to the Clostridiales 
order, whereas A. putredinis is a member of the Rikenellaceae family. This may 
indicate that the Brassica diets described in this chapter affected similar bacterial taxa 
to those reported in the study of Li et al. Additionally, in this study the diet–bacteria 
association was observed whilst participants were able to consume other vegetables, 
fruits, whole-grains, and high-fibre foods, suggesting that the effects on the members of 
these bacterial taxa were associated with the Brassica diets, rather than nutritious 
foods in general. 
 
It is unclear why the high-Brassica diet was associated with a decrease in the relative 
proportions of the members of the bacterial taxa observed, but one explanation may be 
an inhibitory effect caused by relatively high concentrations of sulphur-containing 
compounds. Brassica and Allium, such as broccoli and garlic, respectively, are known 
to contain relatively large amounts of sulphur-containing compounds, compared to 
plants from other genera [472]. A study performed by Filocamo et al investigated the 
effects of garlic powder on pure cultures of human gut bacteria, and found a strong 
inhibitory effect on Clostridium nexile [473]. However, further research would be 
necessary to determine whether members of the order Clostridiales are sensitive to 
sulphur-containing compounds when present at relatively high concentrations. 
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8.6 Conclusions 
A human pilot dietary intervention study was performed to investigate the effects of a 
low- and high-Brassica diet on the human gut microbiota. It was shown that each 
participant had a unique bacterial community with small fluctuations in the relative 
abundances of bacterial members. Data modelling and statistical analyses identified 
members of ten bacterial taxa whose relative proportions were significantly altered 
following consumption of the Brassica diets. Members of these taxa tended to be 
present at higher proportions following the consumption of the low-Brassica diet, 
compared to before the low-Brassica diet intervention, and after consuming the high-
Brassica diet. Of these taxa, five members were strongly associated with the Brassica 
diet: Rikenellaceae (Bacteroidales), Ruminococcaceae (Clostridiales), 
Mogibacteriaceae (Clostridiales), Clostridium (Clostridiales), and an unclassified 
Clostridiales. Faecal metabolite profiles were similar within individuals, but no changes 
were detected following the consumption of the Brassica diets. Inter- and intra-
individual variation was observed in the urinary excretion of glucoraphanin hydrolysis 
products amongst participants over time, but an accurate interpretation of these results 
are complicated due to the different sources of glucoraphanin. 
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9 General discussion 
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9.1 Summary of findings 
The overall aim of this research was to investigate the effects of Brassica on the 
human gut microbiota composition, through the use of an in vitro batch fermentation 
model and a human intervention study. It has been established that short-term dietary 
interventions, using dietary components, whole foods, or different types of diet are able 
to alter the composition of the human gut microbiota [373]. The work presented in this 
thesis aimed to determine what effects broccoli may have on the microbiota community 
composition and metabolic output of human faecal bacteria when cultured in an in vitro 
batch fermentation model. These results formed the basis of a human study 
investigating what effects dietary Brassica may produce in vivo, with a focus on 
changes to the composition of the gut microbiota. 
 
9.1.1 Bacterial reduction of glucosinolates 
The bacterial metabolism of glucosinolates has been reported when human faecal 
bacteria have been cultured in media containing single glucosinolates [45, 124, 142], or 
a purified glucosinolate extract [144]. However, to the best of my knowledge the use of 
a broccoli leachate, containing components of broccoli in addition to glucosinolates, 
has not been previously explored. The data presented in chapter 4 indicated that the 
aliphatic glucosinolates, glucoraphanin and glucoiberin, were converted to their 
reduced analogues, glucoerucin and glucoiberverin, respectively, by human faecal 
microbiotas cultured in a media containing a broccoli leachate (page 104 and 107). 
Chapter 7 discusses the isolation of bacteria from these in vitro microbiota 
experiments, and presents data indicating that Escherichia coli 1B04, and the 
laboratory strain E. coli DH5α, were able to convert glucoraphanin to glucoerucin 
through the reduction of the sulphoxide moiety (page 177 and 183, respectively). 
Previous studies observed the reduction of glucoraphanin to glucoerucin by human 
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faecal microbiotas, but did not identify the bacteria responsible [124, 142]. Research in 
two independent groups identified three bacteria of human origin that were able to 
convert glucoraphanin and glucoiberin, to glucoerucin and glucoiberverin, respectively 
[45, 144]. All three bacterial species were members of the Enterobacteriaceae: E. coli 
Nissle 1917, E. coli VL8, and Enterobacter cloacae ATC13047. 
 
9.1.2 Is the bacterial reduction of glucosinolates substrate-specific? 
E. coli DH5α is a bacterial strain that was developed specifically for laboratory work. 
The ability of this strain to reduce glucoraphanin raises the question of whether the 
reduction of sulphoxide-containing glucosinolates is an outcome of a general bacterial 
reductase reaction, rather than a reaction specific to glucosinolates. The query 
regarding the specificity of the glucosinolate reduction reaction led to investigations into 
the metabolism of the plant secondary metabolite SMCSO (chapter 7). It was found 
that SMCSO was reduced by E. coli 1B04 to produce S-methylcysteine (page 186), 
and that both E. coli 1B04 and E. coli DH5α were able to degrade SMCSO (page 188). 
Multiple studies have indicated that bacteria, many of them residents of the 
gastrointestinal tract of animals, have the ability to degrade SMCSO via cysteine β-
lyase activity [444-448], but no evidence could be found for previous reports of SMCSO 
reduction by human gut bacteria. 
 
A previous study showed that E. coli is able to use sulphoxides as electron acceptors 
to generate energy for ATP synthesis, through their reduction by the DMSO reductase, 
DmsABC [310]. In another study, which focused on the reduction of sulphoxide-
containing drugs by an E. coli strain, the thioredoxin system was implicated in the 
reduction of sulindac. The authors concluded that there were likely to be a minimum of 
five different cytosolic enzyme systems present in E. coli that were able to reduce the 
sulphoxide-containing drugs tested [318]. As E. coli 1B04 did not metabolise 
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glucoerucin when cultured in a glucoerucin-containing medium (page 182), it may 
indicate that this bacterium benefits from the reaction rather than the product of the 
reaction. Although further characterisation of the bacterial reductase activity against 
sulphoxide-containing glucosinolates and SMCSO would be necessary, it seems 
unlikely that the reduction of glucosinolates is a substrate-specific bacterial reaction. 
 
9.1.3 In vitro effect of the broccoli leachate on the microbiota 
composition 
In chapter 5 it was identified that the repeated exposure of human faecal microbiotas to 
broccoli leachates, led to multiple observations of an increase in the relative 
proportions of lactobacilli (page 137), and in one experiment the potential LAB 
Streptococcus (page 138). Sequencing of bacterial isolates obtained from the cultured 
BL media indicated that all of the lactobacilli tested were L. fermentum (page 176). The 
increased relative proportions of the genus Lactobacillus observed in the cultured BL 
media was associated with a decrease in the pH of the media (page 146). The major 
end-product of Lactobacillus fermentation is known to be lactate [474], and analysis 
indicated relatively high levels of lactate accumulation in the BL media, with only a 
small amount observed in the GL media (page 161). 
 
Although LAB are acid-tolerant, it is known that some intestinal bacteria are sensitive to 
changes in pH [270, 271]. The decrease in pH will have likely inhibited the growth of 
some bacteria in the BL media, and killed those most sensitive to acidic conditions, 
while providing Lactobacillus and Streptococcus species with a growth advantage. 
However, lactobacilli generally account for ≤1% of the human gut microbiota [246], 
which was reflected in the pre-cultured faecal samples, so it is likely that the broccoli 
leachate contained nutrients that allowed the increased growth of 
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Lactobacillus/Streptococcus, prior to the effects of a decrease in pH. There would likely 
have been strong competition amongst the bacteria to metabolise the sugars contained 
within the media, but the broccoli leachate may have contained compounds less 
desirable to bacteria other than Lactobacillus. A study was recently published 
investigating the metabolism of phenolic compounds in a broccoli puree by various 
species of Lactobacillus [399]. A strain of L. fermentum was found to be an effective 
metaboliser of all of the measured phenolic compounds in the broccoli puree, with the 
exception of caffeic acid. It was hypothesised that the catabolism of phenolic 
compounds would provide these bacteria an energetic advantage through NAD+ 
regeneration [399]. 
 
9.1.4 Influence of broccoli leachate on SCFA production 
In chapter 6, metabolite analysis indicated a variation in the range and concentrations 
of SCFAs produced by the cultured microbiotas (page 164). Higher concentrations of 
SCFAs were observed in the cultured BL media, compared to the cultured GL media 
(page 163), and there is some evidence that the production of SCFAs may have been 
enhanced by lactate metabolism. Lower levels of lactate and a higher total 
concentration of SCFAs were detected in the BL media at the end of the experiment 
with the faecal microbiota of subject 1, compared to the other cultured microbiotas 
(page 159 and 164, respectively). This microbiota contained relatively high proportions 
of the genus Megasphaera (page 137), which includes the known ruminal lactate-
utilising species Megasphaera elsdenii [475, 476]. Megasphaera was only observed in 
the microbiota of subject 1, which fits in with the current literature suggesting that levels 
of Megasphaera are variable amongst human intestinal populations [237, 477-481]. 
Relatively high concentrations of propionate and valerate, in addition to acetate and 
butyrate, were only detected in samples from the Megasphaera-containing microbiota 
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cultured in the BL media (page 164). This genus is known to contain species able to 
utilise lactate and generate butyrate, propionate, and valerate, with the final product 
dependent on environmental conditions, such as pH and the availability of lactate and 
glucose [432, 475]. SCFAs in general are associated with positive effects on human 
health, with individual SCFAs linked to different beneficial properties [284-287, 421-
430]. 
  
9.1.5 In vivo effects of Brassica on the human gut microbiota 
Human intervention studies allow in vitro driven hypotheses to be tested in an in vivo 
environment. Chapter 8 presented a randomised, 2-phase crossover, human dietary 
intervention study, in which the effects of a low- and high-Brassica diet on the gut 
microbiota of 10 participants was investigated (page 199). Changes to the relative 
proportions of members of ten bacterial taxa were significantly associated with the 
Brassica diets, with five members showing a strongly significant association (p<0.01): 
Rikenellaceae (Bacteroidales), Ruminococcaceae (Clostridiales), Mogibacteriaceae 
(Clostridiales), Clostridium (Clostridiales), and an unclassified Clostridiales (page 218). 
The relative proportions of the members of these taxa were found to generally increase 
after consumption of the low-Brassica diet, and decrease following consumption of the 
high-Brassica diet, compared to the proportions measured prior to each diet (page 
220). 
 
Similar results were obtained from a study performed by Li et al, in which participants 
were asked to consume a basal diet (devoid of vegetables, fruits, whole-grain foods, 
and high-fibre foods) and a double-cruciferous diet (basal diet supplemented with 14 g 
cruciferous vegetables/kg body weight per day) [134]. Significant associations were 
observed between the double-cruciferous diet and bacteria putatively assigned as 
Eubacterium hallii, Phascolarctobacterium faecium, Alistipes putredinis, and an 
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Eggerthella species, compared to the basal diet. However, it was not reported whether 
these bacterial species increased or decreased in proportion following consumption of 
the double-cruciferous diet [134]. The Rikenellaceae family includes A. putredinis, 
whilst E. hallii and P. faecium are members of the Clostridiales order, thus this 
represents similar observations of diet-bacteria associations in both studies. 
 
The greatest differences between the study of Li et al and the human study presented 
in this thesis are found in the diets and the analysis method used. During the double-
cruciferous dietary phase, participants on the study performed by Li et al, were not 
consuming other vegetables, fruits, or high-fibre and whole-grain foods [134]. 
Throughout the duration of the study presented in this thesis, participants were asked 
to restrict their diet of all glucosinolate-containing foods, but could otherwise continue 
to eat their normal diet. Therefore any changes in the gut microbiota would be against 
a background of effects caused by dietary fibres, lignans, vitamins, minerals, 
polyphenols and other compounds obtained from vegetables and fruit in general. This 
strengthens the hypothesis that the observed effects on the gut microbiota were due to 
the Brassica vegetables specifically, rather than components of vegetables in general. 
The structure of the human gut microbiota is known to be unique between individuals, 
as was observed in chapter 8 of this thesis, and has been shown in numerous other 
studies [134, 201, 227]. In conjunction with this, analysis performed in 2010 indicated 
that faecal samples obtained from a cohort of 124 Europeans contained between 1000 
– 1150 different bacterial species, with each individual harbouring a minimum of 160 
bacterial species in their gut microbiota [181]. The Li et al study identified bacterial 
species corresponding to tRFLP fragments, based on a library of 96 16S rDNA genes 
obtained from a single individual [134]. Therefore, accurate identification of bacterial 
16S rDNA sequences may have been limited to the number of shared species amongst 
the participants, and may have overlooked bacterial species present at low 
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abundances. A strength of the dietary study presented in this thesis, was that the 
analysis of the bacterial populations was carried out using the Illumina sequencing 
platform in conjunction with the RDP classifier. This provided a high level of 
sequencing depth that maximised the ability to include the less abundant members of 
the bacterial communities, and allowed the comparison of bacterial sequences to a 
database currently containing 3,224,600 high-quality 16S rDNA sequences [331]. 
 
9.1.6 Brassica, the gut microbiota, and health 
The diet, gut microbiota, and human health are inextricably linked. Research indicates 
that the administration of probiotic bacteria can have beneficial effects on human 
health, such as helping to alleviate the symptoms of IBS [482-484], preventing 
antibiotic-associated diarrhoea [485, 486], reducing the duration of infectious diarrhoea 
[487-489], reducing hypercholesterolemia [490], and preventing necrotising 
enterocolitis in pre-term infants [491-493]. However, the gut microbiota of a healthy 
individual is stable, and therefore more resistant to changes in composition compared 
to that of a diseased individual. The ‘healthy’ gut microbiota likely contains bacteria that 
have probiotic effects on the host, and their growth can be encouraged through the use 
of prebiotics. Prebiotics were recently defined as “a selectively fermented ingredient 
that results in specific changes in the composition and/or activity of the gastrointestinal 
microbiota, thus conferring benefit(s) upon host health” [494]. Brassica vegetables 
contain components, such as fibres, that are resistant to digestion and enter the large 
intestine, thereby potentially having a prebiotic effect on the indigenous microflora. 
Coupled with the potential beneficial effects on human health that have been attributed 
to the hydrolysis products of glucosinolates, dietary Brassica may positively impact on 
human health in different ways, through the bacterial metabolism of fibres and 
glucosinolates. 
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9.1.7 Completion of thesis aims 
The aims of this thesis can be separated into two parts: 
1. To culture human faecal microbiotas in media containing a broccoli leachate 
using an in vitro batch fermentation system to investigate the bacterial 
metabolism of glucosinolates, and the effects of the broccoli leachate on the 
microbiota composition and bacterial metabolite profiles. In addition, to use 
bacteria isolated from these experiments to test for the ability to perform the 
reduction of the sulphoxide moieties on glucoraphanin and SMCSO.  
Under in vitro conditions, glucoraphanin and glucoiberin were converted to their 
reduced forms by a bacterial-mediated reaction in four of the five experiments. The 
exposure of human faecal microbiotas to a broccoli leachate resulted in an increase in 
the relative proportions of LAB, particularly the genus Lactobacillus, and an associated 
increase in lactate, which led to an enhanced production of SCFAs. An E. coli strain, 
designated E. coli 1B04, was isolated from the in vitro experiments, and was observed 
to exhibit the ability to reduce glucoraphanin and SMCSO.  
 
2. To perform a human intervention study to investigate the effects of two Brassica 
diets on the human gut microbiota. 
The results from the human intervention study indicated a trend for the low-Brassica 
diet to be associated with an increase in the relative proportions of certain gut bacteria, 
with the inverse relationship observed when the high-Brassica diet was consumed. 
Four of the five bacterial taxa most strongly associated with these effects were 
members of the order Clostridiales, with the family Rikenellaceae also represented. 
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9.2 Limitations of the research 
The characterisation of the broccoli leachates, discussed in chapter 3, could have been 
enhanced by the measurement of sulphate through the use of techniques, such as 
anion-exchange chromatography. This would have allowed a greater understanding of 
the partitioning of the sulphur measured within the BL media. In addition, it may have 
been informative to investigate how the processes used to generate the broccoli 
leachates may have affected constituents, particularly sulphur-containing compounds, 
within the leachates. Cysteine, methionine, and glutathione are known constituents of 
broccoli, however they were not detected in the final broccoli leachates when analysed. 
The most plausible explanation is that these compounds were degraded during the 
steps necessary to process the broccoli leachates, most likely through thermal 
degradation when the broccoli was steamed, or when the broccoli leachates were 
concentrated at a temperature of 60˚C using a rotary evaporator. 1H NMR analysis of 
samples collected before and after steaming the broccoli and evaporating the broccoli 
leachate, may have provided information regarding the fate of these sulphur-containing 
compounds during the process of generating the broccoli leachates. 
 
The design of the glucose control (GL) media was based on the hypothesis that a large 
degree of glucoraphanin hydrolysis by human faecal bacteria would be observed. The 
hydrolysis of one mole of glucoraphanin releases one mole of an unstable aglycone, 
and one mole of glucose. Therefore, supplementing the basal media with 30 μmoles of 
glucose would control for the presence of glucose in the BL media, following the full 
conversion of 30 μmoles of glucoraphanin. However, the presence of sugars in the BL 
media, derived from broccoli, was not taken into consideration. The GL media would 
have been a more robust control media if it had matched the content of glucose, 
sucrose, and fructose found in the BL media. 
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A limitation of chapter 4 was that the potential production of erucin and erucin nitrile 
was not investigated. Within each of the five independent experiments, a portion of 
glucoraphanin, or glucoraphanin hydrolysis products, present in the starting BL media 
was unaccounted for at the end of the experimental period. Although glucoraphanin 
hydrolysis products, such as SF and SF nitrile, were analysed, the glucoerucin 
hydrolysis products were not investigated. The reduction of glucoraphanin produced 
glucoerucin, which may have been further metabolised by the faecal microbiotas to 
generate products, such as erucin or erucin nitrile. In addition, it has been reported that 
SF or SF nitrile can be reduced by human gut bacteria to form erucin or erucin nitrile, 
respectively [45]. Therefore, erucin or erucin nitrile may have been present in the 
cultured BL media, and analysis of the samples for these products using GC-MS may 
have allowed a greater understanding of the fate of the missing glucoraphanin. 
 
In chapter 5, the main limitation was that the pH was not controlled during the culturing 
of the faecal microbiotas in the BL and GL media. Batch fermenters are often used due 
to their simplicity, affordability, and ease of which several can be run in parallel [481]. 
However, with the continuous flow of nutrients, and ability to control the pH, continuous 
culture fermenters produce a more accurate simulation of the luminal conditions of the 
human colon. The decision to use an in vitro batch model system meant that the acidic 
products produced during the culturing experiments accumulated in the media, causing 
the pH to become lower than is physiologically relevant in the colon. However, although 
a continuous culture system would be a more accurate model, it would have 
necessitated the production of a greater amount of the broccoli leachate, which was a 
time-consuming process and may have ultimately limited the number of faecal 
microbiotas that could have been tested. 
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During the human dietary intervention study (chapter 8), participants were asked to 
collect their urine across a 24 hour period in each of the diet phases, after consuming a 
single portion of the Brassica diets. The participants were asked to consume either a 
portion of the steamed broccoli, or a portion of the broccoli and sweet potato soup, 
prior to the urine collection. The study design would have been strengthened if all of 
the participants had been requested to collect their urine after consumption of the 
steamed broccoli. As the soup was not a component of the low-Brassica diet, all 
participants collected their urine after consumption of steamed broccoli in this diet 
phase, but many of the participants consumed the broccoli-based soup prior to the 
urine collection in the high-Brassica diet phase. The results of the urine analysis were 
difficult to interpret, and this may be partly due to the different food matrixes and the 
increased amount of glucoraphanin in the broccoli-based soup. Standardisation of the 
diet would have allowed for a greater interpretation of the urinary excretion results. 
 
 
9.3 Future research 
The data presented in this thesis identified an E. coli strain (1B04) isolated from human 
faeces, and an E. coli strain (DH5α) developed for laboratory cloning techniques, that 
were able to form glucoerucin via the reduction of glucoraphanin. However, it is unclear 
whether this is a metabolic reaction that is specific to glucosinolates, or a general 
mechanism of Escherichia species. Pure culture screening assays of a large range of, 
both pathogenic and commensal, E. coli strains (isolated from humans, animals, soil, 
and food sources) in a glucoraphanin media could help to identify whether this 
reduction reaction is a common metabolic process amongst E. coli. Should isolates be 
identified that are unable to convert glucoraphanin to glucoerucin, it may be possible to 
group reducers and non-reducers by environment, suggesting an environmental 
adaptation. Whereas, should all E. coli tested exhibit reductase activity on 
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glucoraphanin, it may indicate enzymic activity common to E. coli regardless of 
environment. 
 
Further pure culture screening assays using glucoraphanin could be performed using a 
range of phylogenetically diverse human gut isolates, associated with the colonic 
lumen or the mucosa. This may help to identify whether the reduction of glucoraphanin 
is widespread amongst the human gut microbiota, or restricted to a single phylogenetic 
group, as presently, all bacteria that have been shown to have the ability to reduce 
glucosinolates belong to the Enterobacteriaceae [45, 144]. 
 
E. coli 1B04 was also shown to have the ability to reduce SMCSO to form S-
methylcysteine, but it was not identified whether the reduction of the sulphoxide group 
of glucoraphanin and SMCSO were the result of the action of a single enzyme, or 
whether the activity is restricted to sulphoxides. The sulphoxide specificity could be 
tested using compounds that contain other oxide groups, such as the glucosinolate 7-
methylsulphinyl-3-oxoheptyl, which contains a sulphoxide moiety and a carbon oxide. If 
the reduction only occurs at the sulphoxide moiety, this may indicate that the reductase 
is sulphoxide-specific. To identify whether the reduction of glucoraphanin and SMCSO 
is performed by a single enzyme, gene expression analysis followed by gene knockout 
experiments could be performed. Growth of E. coli 1B04 in a i) glucoraphanin media, ii) 
glucoerucin media, iii) SMCSO media, and iv) S-methylcysteine media, followed by 
RNA-Seq analysis, may enable the identification of common reductases expressed 
during glucoraphanin and SMCSO reduction. This could be followed by E. coli 1B04 
gene knockout experiments to identify which gene(s) may be responsible for the 
reduction of glucoraphanin and/or SMCSO. If appropriate, growth of E. coli 1B04 and 
the associated knockout strain with a range of sulphoxide-containing dietary 
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compounds may help to elucidate the potential role of commensal E. coli in the 
formation of dietary metabolites within the human colon. 
 
The three-stage continuous culture system could be used to culture identified probiotic 
strains, such as lactobacilli and Bifidobacterium strains, in a glucoraphanin-containing 
media to identify whether glucoraphanin can be metabolised by bacteria beneficial to 
human health. Should probiotic bacteria with the ability to hydrolyse glucoraphanin be 
identified, this could form the basis of a synbiotic, whose efficacy could be tested in 
human intervention studies with the aim of commercialisation to improve human health.   
 
The results of the phylogenetic and statistical analyses of faecal microbiotas obtained 
from the human dietary study, indicated an association between the Brassica diets and 
five bacterial taxa: four members of the Clostridiales, and a member of the 
Rikenellaceae family. The nature of the association between the members of these 
taxa and the Brassica diets is unclear, but may be indicative of an inhibitory effect 
caused by the exposure to relatively high levels of sulphur-containing compounds. This 
hypothesis could be tested by culturing a range of human intestinal Clostridiales, 
reflecting the bacterial groups identified by the statistical analysis, and Rikenellaceae in 
media containing increasing amounts of a broccoli extract, in which concentrations of 
sulphur-containing compounds are measured. If an inhibitory effect was observed, the 
affected strains could be cultured in media containing each individual compound (e.g. 
sulphate, SMCSO, glucoraphanin, etc) to identify the minimum inhibitory concentration, 
and whether any inhibitory effects were due to a single compound or total sulphur. 
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9.4 Conclusion 
In conclusion, the research presented in this thesis provides evidence that the bacterial 
reduction of sulphoxide-containing glucosinolates may not be a glucosinolate-specific 
reaction, or limited to bacteria that have adapted to an intestinal environment. The use 
of an in vitro model, combining phylogenetic and metabolite analysis, provided an 
interesting view of the importance of bacterial cross-feeding during the production of 
bacterial metabolites beneficial to human health. Results from a human intervention 
study highlighted the importance of testing in vitro result-driven hypotheses in an in 
vivo model, and identified gut bacterial taxa whose members are potentially associated 
with the consumption of Brassica vegetables. This urges further exploration into the 
effects of dietary Brassica on the human gut microbiota and human health. 
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Background 
 
Numerous studies indicate that the health-promoting effects that can be obtained 
through eating a diet rich in Brassica vegetables are likely due to the biological 
activities of isothiocyanates (ITCs), which are the breakdown products of 
glucosinolates [1, 2]. Glucosinolates are sulphur-rich plant secondary metabolites that 
can be found in Brassica food crops, such as broccoli (Brassica oleracea L. var. 
italica), cabbage (Brassica oleracea var. capitata) and oilseed rape (Brassica napus) 
[3, 4]. Glucosinolate-containing plants also contain β-thioglucosidase enzymes 
(myrosinases) which are spatially separated from glucosinolates within the plant cells, 
however tissue damage, such as can be caused by chewing, results in cellular 
breakdown and exposes the glucosinolates to the enzyme. Myrosinase is then able to 
hydrolyse the thioglucose bond of the glucosinolate, causing the formation of a 
hydrolysis product, the most common of which are ITCs, and the release of glucose 
and sulphate [5, 6].  
 
3
Sulforaphane
Myrosinase
Glucosinolate
s
Isothiocyanate
s
Glucoraphanin
e  
Figure 1. The isothiocyanate sulforaphane is generated via the hydrolysis of the 
aliphatic glucosinolate glucoraphanin, by the myrosinase enzyme. 
 
There are >120 known glucosinolates, all of which contain the same core structure but 
vary by their side-chain which is derived from different amino acids. It is thought that 
this side-chain variation may be responsible for the different biological activity of ITCs. 
Brassica plants have different glucosinolate profiles, therefore affecting which ITCs are 
formed, for instance the prevalent glucosinolate found in broccoli is glucoraphanin and 
this is hydrolysed to form the ITC sulforaphane (SF) (Figure 1). Proposed beneficial 
effects of SF include anti-inflammatory and anti-oxidant effects, reduction of cholesterol 
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levels and systolic blood pressure, and a possible role in modulating the mitochondrial 
function [7-10]. However, when Brassica are cooked the myrosinase enzyme is 
denatured due to the heat, and some of the glucosinolates are able to pass intact 
through the gastrointestinal tract (GIT) to the colon.  
 
In recent years it has become clear that the GIT plays a larger role in the metabolism of 
dietary compounds than previously thought. The main reason behind this is the 
realisation that the complex microbial ecosystem housed within the human intestine 
play a large role in human health, largely due to its metabolic potential. The human 
colon alone contains an estimated 200g of living cells, at a concentration of 
approximately 1011-1012 cells/ml [11]. The large number of bacteria present in the colon 
are not reflected in the microbial diversity, with over 90% of the intestinal microbiota 
belonging to the Firmicutes and Bacteroidetes [12]. Despite this, it is estimated that the 
microbial gene catalogue residing in the gut consists of approximately 3 million genes, 
which is in the region of 100 times more than their host [13]. 
 
In contrast to the diversity of organisms, the bacterial genes present are highly diverse, 
in particular the genes that code for metabolic enzymes [14]. This is largely due to the 
range of non- or partly-digested food components that reach the colon, such as 
carbohydrates, proteins and phytochemicals. The carbohydrates that reach the colon 
undigested undergo bacterial fermentation, generating bacterial waste products (short-
chain fatty acids) that are beneficial to the host. In contrast to this, colonic protein 
fermentation can lead to the generation of toxic products, such as phenols and amines 
[15]. Phytochemicals are exposed to a range of possible metabolic processes, which 
may affect their final biological activity. Upon entering the small intestine, a portion of 
the phytochemicals may be absorbed through the cell wall into the liver. These may 
undergo conjugation with glucuronic acid or sulphate before entering the bloodstream, 
or being recycled back to the intestine through the bile as glucuronides and/or 
sulphates [16, 17]. Therefore, both the parent phytochemicals and those that have 
been bioconverted can enter the colon where they may be absorbed or act as a 
substrate for the colonic bacterial community with their extensive metabolic potential 
[14]. Previous studies have shown that some colonic bacteria can produce a 
myrosinase-like enzyme which can metabolise the glucosinolate to produce the 
corresponding ITC [18], whilst other bacteria have been found to exhibit reductase 
activity, converting the glucosinolate to its reduced form [19-21]. Although it has been 
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shown that gut bacteria from a range of phyla have the ability to metabolise 
glucosinolates to their corresponding ITCs, the conversion of glucosinolates to their 
reduced analogue has so far only been seen in bacteria from the Enterobacteriaceae 
family [22-25]. 
 
As well as playing a large role in human nutrition, our gut bacteria also have a profound 
impact on human physiology and immunology. It is thought that alterations in the 
composition of our gut bacteria, known as gut dysbiosis, may be associated with some 
diseases, such as colon cancer and inflammatory bowel disease, as well as metabolic 
disorders such as obesity [26, 27]. It is currently thought that preserving the appropriate 
compositional balance of the gut microbiota, may help to maintain the health of the 
host. With this in mind, there has been an increase in research relating to probiotic 
bacteria. The World Health Organization defines probiotics as “live microorganisms 
which when administered in adequate amounts confer a health benefit on the host”, the 
most common of which are Lactobacillus and Bifidobacterium strains [28]. Although the 
precise molecular mechanisms by which probiotic bacteria confer beneficial effects on 
the host are unclear, there is a body of evidence that indicates that it is generally via 
modulation of the host’s immune response, strengthening of the intestinal barrier, or 
the antagonism of pathogens by either the competition of mucosal binding sites, or the 
production of antimicrobial compounds [29]. 
 
The surge in commercially available probiotic supplements was preceded by increased 
research into these beneficial bacteria. A recent study using rats found that there was a 
higher abundance of both Lactobacillus and Bifidobacterium in diabetes-resistant rats 
compared to diabetes-prone rats, suggesting that an altered gut microbiota may be 
associated with the progression of type 1 diabetes [30]. Other studies, using 
Lactobacillus casei Shirota in experimental mouse models of immune disorders, have 
shown that this particular strain may be able to suppress the progression of arthritis, 
type 1 diabetes [31], chronic inflammatory bowel disease [32], and murine lupus [33]. A 
study using 135 human volunteers found that the daily consumption of a probiotic drink 
containing three lactic acid bacteria (2 of which were Lactobacillus) during a course of 
antibiotics led to a significant decrease in both antibiotic-associated diarrhoea and 
Clostridium difficile associated diarrhoea compared to the placebo group [34]. It is 
known that Lactobacillus spp. dominate the infant gut [35] and that enteric lactobacilli 
have been detected in adult human faecal samples, but they have also been found at 
Study protocol   EBL   Version 3   16/10/2014 
 278 
 
high levels in the stomach and small intestine [36-38]. Comparative genomics has been 
used to identify differences in milk-adapted and intestinal lactobacilli, which seem to 
reveal specific intestinal adaptation. Whilst, the lactobacilli from milk environments 
contained various genes used for growth on lactose, intestinal lactobacilli were found to 
have genes necessary for sugar-uptake systems and mucus-binding proteins, and 
certain lactobacilli are predicted to encode typical intestinal enzymes such as bile salt 
hydrolase [39-42]. This would seem to suggest that lactobacilli have adapted to survive 
in various niches throughout the human GIT, and modulation of their numbers may 
offer health benefits to the host. 
 
An alternative method of altering the human gut microbiota is through the use of 
prebiotics, which promote the selective growth of beneficial indigenous gut bacteria. 
Prebiotics are defined as “selectively fermented ingredients that allow specific changes, 
both in the composition and/or activity in the gastrointestinal microflora that confer 
benefits upon host wellbeing and health” [43]. A prebiotic effect requires three criteria: 
a resistance to gastric acidity and hydrolysis by mammalian enzymes and 
gastrointestinal absorption; the ability to be fermented by intestinal microflora; and that 
it selectively stimulates the growth and/or activity of intestinal bacteria associated with 
health and wellbeing [43]. Studies using prebiotics suggest that they have the potential 
to reduce the symptoms and severity of Crohn’s disease and ulcerative colitis [44, 45], 
help treat diarrhoea [46, 47], and enhance calcium absorption and bone health [48, 49]. 
Alongside this, there is interest in whether prebiotics may have beneficial effects on 
immunomodulation of the gut immune system [50], lipid metabolism, gut hormones, 
glycaemic control, weight loss and satiety [51], as well as behavioural effects and 
obesity [52]. Numerous studies focusing on prebiotic effects use purified 
oligosaccharides, for example fructans and galactans, but many foods, whole-grains, 
fruits, and vegetables in particular, are naturally high in prebiotics such as fibre. As 
such, in the last decade there has been an increase in human dietary studies focused 
on changes in the gut microbiota caused by diet. 
 
There have been several studies that have looked at the differences in ITC excretion 
between individuals, but as yet there have not been any links found with an individual’s 
gut bacteria [18, 24, 53-57]. A recent study attempted to correlate in vivo glucosinolate 
metabolism with ex vivo glucosinolate degradation from a small number of volunteers, 
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but was unable to uncover any direct links with specific bacterial species, although they 
did not examine whether any particular genes may have been responsible [24]. 
 
This study is primarily focused on whether a diet rich in Brassica vegetables can 
modulate the human gut microbiota by stimulating the growth of the beneficial 
lactobacilli. Experiments carried out during my PhD have indicated that components 
found within Brassica vegetables may specifically stimulate the growth of lactobacilli 
(unpublished data). In addition, there is evidence from a previous human intervention 
study that a diet rich in Brassica vegetables can cause a change in the composition of 
the gut microbiota compared to a fruit and vegetable free diet, however the study did 
have several limitations [58]. The amount of Brassica vegetables that the participants 
were asked to consume daily was based on their body weight and ranged from 660 to 
1080g/d for the high Brassica arm, therefore the intake of glucosinolates and fibre 
varied between individuals. Terminal restriction fragment length polymorphism (tRFLP) 
was used to analyse the differences in the participants’ gut microbiota following the 
consumption of the two different diets. A limitation of this method is that relies on 
comparing fragments of the 16S rRNA genes present in the samples, to a generated 
bacterial 16S rRNA gene clone library. For this study, the clone library was established 
from one faecal sample from one individual and therefore does not allow for the 
variability of gut bacteria between individuals. Also, as the library only consisted of 96 
rRNA gene sequences, it is possible that only the dominant members of the community 
were selected for phylogenetic analysis. I plan to overcome these limitations by giving 
each participant a set number of portions of Brassica vegetables, irrespective of body 
weight, and use Illumina sequencing techniques to analyse the bacterial communities. 
Illumina is far more powerful than tRFLP as it doesn’t rely on a clone library, instead it 
compares the sequences obtained from the samples analysed, to a database 
containing thousands of known sequences from different origins. 
Alongside this, I will also investigate any changes in short chain fatty acids, bile acids, 
and bacterial gene expression due to the intervention, and attempt to associate 
different urinary ITC excretion rates with the composition of the faecal microbiota. 
 
 
Hypothesis 
 
A diet rich in Brassica vegetables will cause a change in the composition of the gut 
microbiota, and specifically an increase in the proportion and number of lactobacilli 
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commensals, compared to both the baseline faecal sample and a diet low in Brassica 
vegetables. 
 
 
Objectives: 
 
Primary 
 
To investigate whether eating a diet rich in Brassica vegetables for two weeks will 
cause an increase in human gut lactobacilli, compared to the number of lactobacilli 
present in the participants’ normal gut microbiota. 
Secondary 
 
To ascertain whether eating a diet rich in Brassica vegetables modulates the gut 
microbial community as a whole, as compared to the consumption of a low Brassica 
diet, and the participants’ normal gut microbiota. 
 
To determine whether the consumption of a high and/or low Brassica vegetable diet 
causes a change in short chain fatty acids and bile acids in the faeces. 
 
To determine whether the consumption of a high and/or low Brassica vegetable diet 
causes a change in bacterial gene expression in the faeces. 
 
To determine the extent of glucosinolate conversion to ITCs from Brassica vegetables, 
as measured by ITC excretion in the urine. 
 
To determine the gut microbiota of participants and relate these data to the amount of 
urinary ITCs following the consumption of high and low Brassica diets. 
 
 
Study design 
 
A randomised, two-phase crossover dietary intervention study (Figure 2) will be 
undertaken to assess whether Brassica vegetables have the potential to cause an 
increase in the proportion and/or numbers of the beneficial lactobacilli in the human gut 
Study protocol   EBL   Version 3   16/10/2014 
 281 
 
microbiota. In this study, male and female participants aged between 18 and 50 years 
will be recruited until 10 complete the study, as this was the number deemed sufficient 
to see an increase in lactobacilli within the gut microbiota based upon power 
calculations (detailed on page 33 of this protocol). 
 
In one phase, the participants will consume a low Brassica diet for 2 weeks, consisting 
of one 84g portion of broccoli (or cauliflower) in week one, followed by one 84g portion 
of cauliflower (or broccoli) in week two, with a minimum period of five days between 
each portion. In the other phase, the participants will consume a high Brassica diet for 
2 weeks, consisting of three 84g portions of broccoli, three 84g portions of cauliflower, 
and three broccoli and sweet potato soups (300g with a broccoli content of 84g), in 
each of the 2 weeks, eating a minimum of one portion per day. The broccoli and sweet 
potato soups were made by Bakkavor for another human intervention study (ESCAPE; 
REC Ref: 13/EE/0110), which is currently being run at the IFR. These two dietary 
phases will be separated by a minimum two week washout phase, with the option of a 
break period before commencing the second diet phase. 
 
The participants will be asked to provide six faecal samples, this will increase to seven 
should they require the optional break period, during their involvement in the study: 
after the screening appointment, prior to starting each test phase, the first bowel 
movement after completing each 2 week test phase, and at the end of the study. This 
will allow for comparisons between the participants baseline gut microbiota to the 
composition present following both the low and the high Brassica diet, as well as 
determining any differences in the gut microbiota between the two Brassica diets. The 
faecal sample obtained at the end of the first two week diet restriction will determine 
any effects on the gut microbiota caused by the diet restriction, the faecal sample 
between the two test phases will be used to ascertain whether any effects on the gut 
microbial community seen at the end of test phase 1 have disappeared, and the faecal 
sample obtained at the end of the study will be compared with the baseline faecal 
sample to ascertain whether the gut microbiota has reverted back to its original 
composition. If participants require the optional break period (described earlier) it will 
be necessary for the participant to provide an additional faecal sample once the break 
period has finished and participants have undertaken an additional two week dietary 
restriction period. This extra faecal sample will act as the baseline sample to determine 
whether the second dietary phase has caused a change in the numbers of lactobacilli, 
or modulated the gut community composition as a whole.  
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The participants will be asked to provide a urine sample, prior to each test phase, 
which will be used to test compliance to the dietary restriction, and two 24 hour urine 
collections, which will start after eating the first portion of Brassica in each of the two 
test phases. The 24 hour urine collection samples will be used to analyse the amount 
of ITCs excreted in the participant’s urine after consuming a single portion of Brassica. 
The participants will be asked to eliminate all Brassica vegetables and ITC-containing 
food (except those provided) from their diet for a minimum of 8 weeks: two weeks prior 
to test phases 1 and 2, as well as during the full 2 weeks of each test phase. There will 
be an additional minimum 2 weeks dietary restriction, should the study break be 
required. In order to assess the compliance of the participants to the dietary 
intervention and monitor any dietary changes during the study, they will be asked to 
keep food diaries for a consecutive 7-day period in each 2 week test phase, and for the 
last seven days in the 2 week period following the second test phase, in which the 
participants will be asked to eat their habitual diet with no dietary restrictions. The 
purpose of the dietary restriction is to ensure that set amounts of Brassica are being 
consumed during the test phases, therefore all of the ITCs recovered from the urine 
during the test phases should originate from the Brassica vegetables provided.  
 
The study will be carried out at the Institute of Food Research (IFR) in Norwich and will 
be led by Professor Richard Mithen and run by Mr Lee Kellingray with assistance from 
Dr Joanne F Doleman where necessary. Dr Shikha Saha will be responsible for some 
of the sample analysis carried out at IFR. Students on placements may also help with 
supervised administrative and simple laboratory duties associated with the study at the 
IFR. 
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Information sheet (PIS) sent to potential participants (18 -50 years old) identified by HNU database & advertisements. 
 
Response from potential participant to study team. Book study talk. 
 
Study talk 
Study discussion and opportunity to ask questions with study team member at the HNU. 
Potential participants supplied with a small clean container and a copy of the Bristol Stool Chart. 
 
Minimum 72 hrs consideration, after which potential participant contacts the study team and 
screening appointment is made, appointment card is posted to participant. 
Eligibility screening appointment   (HNU - Visit 1) 
Consent form signed and copy given to participant. Urine analysed by nurse at HNU using urine dipstick patch test. 
Medical declaration form signed and copy given to participant. Screening questionnaire completed with participant 
by HNU nurse; measurements for pulse, blood pressure, height, weight, body mass index taken and recorded. 
- If the above is successful and participant wishes to continue:  Participant given faecal collection kit. 
 
Participant returns home & produces faecal sample which is collected by/delivered to study team 
member. 
Participant supplied with container for baseline urine sample and a new faecal collection kit. 
 
Weeks 1-2 prior to start of Test phase 1 
Diet restriction: Eliminate all Brassica and ITC-containing food from diet. 
After a minimum of 2 weeks, participant produces faecal sample which is collected by/delivered to study team member. 
Day 1 of Test phase 1 (HNU - Visit 2) 
Deliver baseline urine sample produced that day, collect Brassica diet for Test phase 1 and a 24-hr urine collection 
container. 
Test phase 1 
Maintain diet restriction for entire test phase and complete the food diary and stool chart for a consecutive 7 day period. 
Participant consumes supplied Brassica diet for 2 weeks at home. 
Following consumption of the first portion of Brassica, the first 24hr urine sample collection starts and is collected 
by/delivered to study team member when completed. 
Participant is given a new faecal collection kit. 
Following completion of the 2 week test phase, a faecal sample is produced which is collected by/delivered to study 
team member. 
Participant delivers the completed food diary and stool chart and is supplied with a new faecal collection kit and a 
container for baseline urine sample. 
Figure 2: Flow diagram of EBL study 
Day 1 of Test phase 2 (HNU - Visit 3) 
Deliver baseline urine sample produced that day, collect Brassica diet for Test phase 2 and a 24-hr urine collection container. 
 
Washout phase 
Maintain the diet restriction. 
After a minimum of 2 weeks a faecal sample is produced & is collected by/delivered to a study team member. 
 
Test phase 2 
See Test phase 1. 
Participant delivers the completed food diary and stool chart and is supplied with a new faecal collection kit. 
 
Habitual diet phase 
Consume habitual diet with no diet restrictions for a minimum of 2 weeks and complete the food diary and 
stool chart for the last 7 days of the 2 week period 
After a minimum of 2 weeks a faecal sample is produced and is collected by/delivered to a study team 
member along with outstanding food diaries and stool charts. Participants' involvement in the study 
completed. 
 
Optional study break 
A break from all study-related activities for a maximum of 6 weeks. 
Restart the diet restriction: Eliminate all Brassica and ITC-containing food from diet. 
After a minimum of 2 weeks, participant produces faecal sample which is collected by/delivered to study team member. 
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Approach 
 
The study is a randomised human dietary intervention cross-over study and will require 
the participants to consume both a low and a high Brassica vegetable diet. For the low 
Brassica diet test phase, the participants will be provided with one 84g portion of frozen 
broccoli and one 84g portion of frozen cauliflower, to be consumed across a period of 
two weeks. The participants will be asked to consume one of these portions of Brassica 
(either broccoli or cauliflower) in week one, and then consume the remaining portion of 
Brassica in week two, with a minimum of 5 days between consuming the two portions. 
When on the high Brassica diet test phase, the participants will be provided with six 
84g portions of frozen broccoli, six 84g portions of frozen cauliflower, and six 300g 
portions of frozen broccoli and sweet potato soups (each with a broccoli content of 
84g), to be consumed across a period of two weeks. The participants will be asked to 
consume three portions of broccoli, three portions of cauliflower, and three portions of 
the broccoli and sweet potato soups each week for two weeks, consuming a minimum 
of one portion per day. The Brassica diet test phases will be separated by a washout 
period, which will be a minimum of 2 weeks. 
 
The participants will be asked to restrict their diet of Brassica vegetables and ITC-
containing foods for a period which includes 2 weeks prior to test phases 1 and 2, as 
well as during the full 2 weeks of each test phase. The participants will be asked to 
provide faecal samples, urine samples, complete food diaries and stool charts at 
various stages throughout the intervention. This is described in more detail below. 
Participants will be asked to complete a food diary, recording the consumption of all 
fruits and vegetables, for a consecutive seven day period, during each of the two test 
phases (test phases 1 and 2), and for the entire seven days of the last week of the 
study when consuming their habitual diet. Participants will also need to be willing to 
complete stool charts noting the frequency and consistency of their bowel movements. 
Participants who do not have a BMI between 19.5 and 30 kg/m2 will be excluded on the 
grounds that their gut microbiota will be negatively affected, as studies have shown that 
the gut microbiota of individuals with a BMI between 18.5 and 30 kg/m2 are significantly 
different to obese or underweight individuals [26, 59]. 
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Recruitment strategy 
 
The study population will consist of men and women between the ages of 18 and 50 
who meet the study inclusion criteria, and recruitment will continue until 10 participants 
complete the study. If a potential participant registers an interest in taking part in the 
study, and we are near to ten participants completing the study, the potential 
participant may be asked if they would be happy to be placed on a standby list. Those 
placed on the standby list will neither be consented nor screened until they are 
recruited onto the study, and will be notified if their participation is not required. Those 
on the standby list may ask to be removed from the list at any time. The HNU volunteer 
database will be accessed by the HNU Senior Research nurse and it is anticipated that 
this will be the prime source of participant recruitment for the study. Apparently healthy 
potential participants from the HNU volunteer database, who meet the basic inclusion 
criteria, will be sent a letter of invitation (Annex 1) to participate in the study. This will 
be supported by the Participant Information Sheet (PIS, Annex 2) and a response slip 
and pre-paid envelope will be included for returning the slip if they are interested and 
wish for further information. The HNU volunteer database contains names and contact 
details of approximately 1600 people above the age of 18 years who have registered 
an interest for participating in human studies at IFR. Initial contact with potential 
participants from the database, including the posting of the invitation letter and PIS, is 
carried out solely by the HNU Senior Research nurse. The available numbers for 
recruitment on the database are subject to variation as a result of the recruitment of 
participants by other studies. 
 
Along with using the database as a source of recruitment, advertisements (Annex 3a & 
3b) will be placed around the Norwich Research Park (University of East Anglia (UEA), 
John Innes Centre (JIC), The Genome Analysis Centre (TGAC) and IFR), in the local 
press and other appropriate locations for example, supermarkets, social clubs, church 
newsletters, golf and other sporting clubs, gymnasiums and leisure facilities within the 
local area (a 40 mile radius of IFR). The posters advertising this study may have tear 
off contact slips attached to the poster in order to facilitate participant recruitment. If 
required, we will also obtain radio (and television) coverage, and place advertisements 
in the local press to raise local awareness of the project. Social networking sites like 
Facebook and Twitter may also be used to either display the ethically approved advert 
for the study, or to direct potential participants to an IFR website containing the 
ethically approved advertisement and contact details of members of the study team. A 
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member of the study team will send interested responders a letter of invitation (Annex 
4) and a copy of the PIS (Annex 2) with accompanying response slip and pre-paid 
envelope in which to return the completed response slip to the study manager, if 
interested in taking part in the study. 
 
Following an expression of interest, potential participants will be contacted by 
telephone or e-mail by a member of the study team (study manager or study scientist) 
to arrange an appointment for a pre-study talk. This talk, in which all aspects of the 
study will be discussed, will take place in the HNU by a member of the study team, and 
will involve visual aids to increase understanding of what will be required from the 
participant should they decide to take part in the study. The potential participants will 
be encouraged to ask questions at this point, prior to making any commitment. At the 
end of the talk all potential participants will be given a minimum of 72 hours to consider 
whether they wish to participate in the study, and during this consideration period they 
will not be contacted. If, following this period of consideration, the participant still 
wishes to take part they will be asked to contact the investigator named on the PIS. If 
however, potential participants have decided after the talk that they are keen to take 
part in the study and request to book their eligibility screening appointment, the 
screening appointment will be made for a minimum of 72 hours after the study talk. 
Before leaving the HNU, all potential participants will be supplied with a small clean 
container and a copy of the Bristol Stool Chart. Should the potential participant wish to 
take part in the study, the container will be used for a midstream urine sample from 
within 2 hours of their eligibility screening appointment. The potential participant will be 
told that should they decide to take part in the study, the HNU nurse will go through the 
Bristol Stool Chart with them at their eligibility screening appointment and ask them 
what their typical stool type is using the Bristol Stool Chart as a guide. Therefore, the 
potential participants will be advised that they will need to assess their typical stool 
type, referring to the Bristol Stool Chart, prior to their eligibility screening appointment. 
The potential participant will be informed that should they decide against taking part in 
the study, they may dispose of these as they see fit. On booking an eligibility screening 
appointment, a member of the study team will post an appointment card (Annex 5) to 
the potential participant.  
 
All those responding positively following this period of consideration will be invited to 
attend the HNU for an eligibility screening. Participants will be reminded to bring a 
midstream sample of urine in the container supplied to them following their pre-study 
talk. Participants will need to collect their urine sample from within 2 hours prior to the 
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screening appointment as this is a required specification for the validity of the urine 
dipstick patch test (this will not be tested until after the consent form has been signed). 
Participants will also be reminded to bring with them details of any prescribed 
medication, herbal remedies or dietary supplements (i.e. name of medication, dose 
taken). The HNU is situated on the main site of the IFR, however it is independent of 
the main building. The HNU facilities include a clinical room; diet kitchen; a 
lounge/dining area; a laboratory, interview rooms/rest rooms; anthropometry/PWV 
room, temperature monitored food fridges/freezers/walk in food freezer and dedicated 
parking area. The unit is permanently staffed by a registered general nurse, however 
on screening days, members of the study team will also be present. 
 
 
Eligibility screening (HNU - Visit 1) 
 
On arrival at the HNU the participant will be taken into a confidential room where a 
member of the study team (study manager or study scientist) or the HNU Senior 
Research Nurse will go through the consent form (Annex 6) with the participant and 
encourage any questions they may have at this stage. Participants will then be asked 
to sign the consent form agreeing to participate in the study and to all their eligibility 
screening results being sent to their GP. The participants will also be asked to sign a 
medical declaration form (Annex 16) agreeing to inform the study team of any 
medication they may have to take, illnesses suffered, or if they become pregnant 
during the study. A signed copy of both the consent form and medical declaration form 
will be given to the participant to keep, and each participant will be assigned a unique 
eligibility screening code number. 
 
Following consent, the HNU nurse will test the urine sample using Multistix ® SG urine 
dipstick patch test strips (Siemens Healthcare Diagnostics). The nurse will then 
complete a screening questionnaire with the participant (Annex 7), measure and record 
blood pressure (BP), pulse, height (cm) and weight (kg) and calculate Body Mass Index 
(BMI, kg/m2). The screening questionnaire contains specific questions pertaining to 
stools, the HNU nurse will explain the Bristol Stool Chart and should the participant 
indicate that their typical stool type is abnormal (type 1, 2, or 7), they may be referred 
to their GP and will be excluded from the study. The urine dipstick results will be known 
immediately. If any of the results for the urine dipstick patch test are flagged, the 
nurses will refer to the HNU Protocol ‘For the referral of abnormal urinalysis results at 
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screening’ which provides advice on exclusion or re-screening of the participant. This 
protocol has been authorised by the HNU medical advisor. In the event of a flagged 
urinalysis indicating a re-screen is appropriate, the HNU nurse will speak to the 
participant regarding their results and they will be advised to visit their GP/practice 
nurse prior to returning for a re-screen. If the urinalysis results are flagged on the 
second occasion the participant may be excluded depending on the tests flagged. If 
blood is flagged in the urine sample of female participants they will be asked if they are 
menstruating or have just finished menstruating, if they answer yes to either they will 
be asked to provide a second urine sample for testing 5 days after finishing 
menstruation. In the event of a flagged urinalysis on the second occasion, which 
indicates they may be re-screened, the HNU nurse will speak to the participant and 
they will be advised to speak to their GP regarding their results prior to coming back to 
the HNU for a re-screen. 
 
If the flagged urine results indicate exclusion from the study is appropriate, the HNU 
nurse will speak to the participant, they will be excluded from the study and the 
participant will be advised to speak to their GP regarding their results. Although 
participants will be given a copy of their flagged urine results to take with them to their 
GP, a member of the study team will send a copy of all the eligibility screening results 
(blood pressure, pulse, weight, BMI, and urinalysis results) to the GP (Annex 10), and 
this will be supported with a letter to their GP detailing their clinical results (urine 
analysis, blood pressure, pulse, weight and BMI) (Annex 11). 
 
The GPs of those successfully recruited onto the study will be informed of their 
patient’s participation in the study by letter (Annex 8) along with a study description 
(Annex 9). It is expected that all participants who successfully pass the screening, and 
who wish to continue, will commence on the study within six weeks of their screening 
appointment otherwise a re-screen will be necessary. 
 
Once recruited onto the study, the participant’s code number, which they were 
assigned at screening, will be used on all of their samples (faecal and urine). Only the 
members of the study team named in the approved documentation will be able to link 
the codes to participants’ names, however the code may be broken in the event of a 
medical emergency as deemed appropriate and necessary by the HNU Senior 
Research Nurse, the HNU medical advisor, or a UEA doctor who provides emergency 
medical cover. All personal information will be kept confidential and known only to the 
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chief investigator, members of the study team, HNU nurses, HNU medical advisor and 
the participant’s GP. 
 
 
Inclusion criteria 
 
 Men and women aged between 18 and 50. 
 Smokers and non-smokers. 
 Those with a body mass index (BMI) between 19.5 and 30 kg/m2. 
 Those that live within a 40 mile radius of Norwich. 
 
 
Exclusion criteria 
 
 Women who are or have been pregnant within the last 12 months, or are 
lactating and/or breast feeding. 
 Those currently suffering from, or have ever suffered from, any diagnosed 
gastrointestinal disease, gastrointestinal disorders including regular diarrhoea 
and constipation (excluding hiatus hernia unless symptomatic) and/or have 
undergone gastrointestinal surgery, or the study intervention/procedure is 
contraindicated. 
 Have been diagnosed with any long-term medical condition that may affect the 
study outcome (e.g. diabetes, haemophilia, cardiovascular disease, glaucoma, 
anaemia). These will be assessed on an individual basis. 
 Those diagnosed with a long-term medical condition requiring medication that 
may affect the study outcome. 
 Those regularly taking self-prescribed over the counter medications for 
digestive/gastrointestinal conditions. 
 Those on long-term antibiotic therapy. Those who have been on a course of 
antibiotics are able to participate in/continue on the study once 4 weeks has 
elapsed from the end of the course of antibiotics. This will be assessed on an 
individual basis. 
 Those regularly taking laxatives (once a month or more). 
 Those intermittently using pre &/or probiotics unless willing to abstain for 1 
month prior to and during study period. (If used regularly (3+ times a week, and 
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for more than one month) and will continue throughout study period then do not 
exclude). 
 Those on a diet programme or those who plan to start a diet programme during 
the study that may affect the study outcome (e.g. the 5:2 fasting diet) unless 
willing to abstain for 1 month prior to and during study period. These will be 
assessed on an individual basis. 
 Those taking dietary supplements or herbal remedies (including those derived 
from Brassica plants) which may affect the study outcome – unless the 
participant is willing to discontinue taking them for 1 month prior to and during 
study period. Please note that some supplements may not affect the study and 
this will be assessed on an individual basis.  
 Regular/recent (within 3 months) use of colonic irrigation or other bowel 
cleansing techniques. 
 Recently returned to the UK following a period abroad, and who have suffered 
gastric symptoms during the period abroad or on return to the UK. These will be 
assessed on an individual basis. 
 Parallel participation in another research project which involves dietary 
intervention and/or sampling of biological fluids/materials. Sampling of certain 
biological samples, such as saliva, may not affect the study and this will be 
assessed on an individual basis. 
 Those who record blood in their stools or have two or more episodes of type 1, 
2, or 7 stools during the study. 
 Any person related to or living with any member of the study team. 
 Those who are unwilling to provide GPs contact details.  
 Those who are unable to provide written informed consent. 
 Those who are not suitable to take part in this study because of their eligibility 
screening results. 
 Those who do not have access to a freezer. 
 Those who regularly consume more than 15 units of alcohol (women) or 22 
units of alcohol (men) a week. 
 Those who are allergic to any of the foods/ingredients within the foods supplied.  
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Study procedures: 
 
Stool chart 
 
During the study the participants will be asked to keep a record of the frequency and 
consistency of their bowel movements using the Bristol Stool Chart as a guide (Annex 
12). The participants will be asked to keep this record for a period of seven consecutive 
days during each of the two test phases (test phases 1 and 2), as well as the seven 
days that constitute the final week of the study. These scores will be used as an 
estimate of gut function. If the participants stool chart indicates an abnormal stool 
pattern, they may be advised by the HNU Senior Research Nurse to speak to their GP, 
who will receive a copy of the participants stool chart. Any participant who records two 
or more episodes of type 7 stools, or the presence of blood in their stools, on their stool 
chart, will be excluded and a copy of their stool chart will be sent to their GP. 
 
 
Food diary 
 
During the study the participants will be asked to record the types and amounts of 
fruits, and vegetables they have consumed in a food diary (Annex 13). The participants 
will be asked to keep this record for a period of seven consecutive days during each of 
the two test phases (test phases 1 and 2), as well as for the seven days that constitute 
the final week of the study. The participant will be asked to complete this diary on the 
same days as the stool chart, but if for any reason this is not possible, then the 
participant will be free to complete the diary on days within the set periods that are 
suitable for them. This will be used to discern whether the participants’ customary food 
intake may influence the effects seen during test phases 1 and 2, and to help confirm 
compliance to the dietary restriction. The food diaries will be analysed within the IFR 
using software such as Dietplan 6, which has been used successfully in previous 
human intervention studies at the IFR. 
 
 
Faecal collection 
 
Participants who successfully pass the eligibility screening will be provided with a 
faecal collection kit. The faecal collection kit will consist of an IFR carrier bag 
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containing a faecal collection pot, freezer blocks or ice cube bags, an autoclavable 
sample bag for collecting the faeces in, a plastic clip (for sealing the autoclavable bag), 
nappy sack and an insulated container for transporting the sample securely back to 
IFR. The participant will also be provided with study specific instructions (Annex 14) as 
to how to collect and store the faecal sample and how to contact members of the study 
team or HNU nurse regarding arrangements for collection or delivery of the faecal 
sample to the HNU, for processing at the IFR.  
 
Prior to collecting the faecal sample each participant will be required to either a) place 
the provided freezer blocks in their own freezer overnight, or b) fill the provided ice 
cube bag with water and place in their own freezer overnight, ready to place in the 
insulated container with their faecal sample. Detailed instructions will be provided as to 
how to collect their faecal sample directly into the labelled plastic autoclavable sample 
bag in the collection pot. Once the sample has been collected the autoclavable sample 
bag should then be sealed closed with the plastic clip, removed from the collecting pot 
and placed into the nappy sack which should be closed by tying the handles in a 
double knot. The tied nappy sack, containing the sample bag and the previously 
prepared freezer blocks/ice cube bags should be placed into the insulated container 
which should then be sealed shut. Participants will be advised to wash their hands after 
collecting the samples. Participants will be asked to write the date and time of sample 
collection on a label on the lid of the insulated container and contact a member of the 
study team to arrange delivery or collection of the sample.  
 
All containers used for faecal collections will be sterilised prior to being given to the 
participant, to prevent contamination and minimise infection risk. The importance of 
hand washing after sample collection by participants will be reiterated in the faecal 
collection instruction sheet. 
 
It is hoped that the participants will be able to bring their faecal sample to a member of 
the study team at the HNU, however it may be that a participant requires a member of 
the study team to collect their faecal sample, and this will be arranged on an individual 
basis.  
 
When receiving a faecal sample, a member of the study team will collect the entirety of 
the faecal collection kit from the participant, except for the sample collection pot which 
will have been disposed of. Once the first faecal sample has been received by a 
member of the study team, an appointment will be booked with each participant for the 
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start of test phase 1. The appointment will be booked for a minimum of two weeks after 
the faecal sample delivery in order to allow the participant to commence the Brassica 
dietary restriction, two weeks of which must be complete before the start of test phase 
1 (optional appointment card Annex 5). In total there will be an eight-week dietary 
restriction: 2 weeks prior to, and during, each 2 week test phase (1 and 2). However, 
should participants require the optional study break this will increase to a 10 week diet 
restriction in total. Each participant will be supplied with a new faecal collection kit and 
a small clean container for the urine sample. The participants will be reminded that the 
urine sample they provide must be from the first day of test phase 1, i.e. after the first 
two weeks of the dietary restriction period. 
 
Identical faecal collection kits and instructions will be provided to the participants prior 
to the collection point of all further faecal samples, and participants will be asked to 
collect the faecal samples in an identical manner to the first faecal sample. Should any 
participant suffer from diarrhoea during the study, they will be required to contact a 
member of the study team and will be asked to refrain from collecting a faecal sample 
for a minimum of 48 hours after the last episode of diarrhoea. Should the diarrhoea 
persist for more than 72hrs, the participant may be advised by the HNU Senior 
Research Nurse to speak to their GP and will be excluded from the study. 
 
 
2 weeks prior to test phase 1 – Weeks 1-2 of diet restriction 
 
Participants will be asked to eliminate all Brassica vegetables and other ITC-containing 
foods from their diet for two weeks prior to test phase 1. Following a minimum period of 
two weeks, the participant will collect a faecal sample in the collection kit provided. This 
faecal sample will be delivered to the HNU by the participant, or collected by a study 
team member if necessary. This will help to interpret any changes in the participants 
gut microbiota that are caused by the dietary restriction. A separate sheet detailing 
foods to be avoided will be provided to each participant (Annex 15), as well as the 
information being found in the PIS (Annex 2).  
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Test phase 1 (HNU - Visit 2) 
 
Participants will be asked to visit the HNU and bring both their faecal sample, if they 
have not already done so, and a urine sample from that day in a container that will 
have been provided with their faecal collection kit. The scientist will check with the 
participant that the urine was produced that day and that they are happy to continue on 
the study. Should the participant forget to bring the sample with them, they will be given 
the opportunity to produce one at the HNU. The participant will be asked to complete 
both the food diary and stool chart for seven consecutive days during the two week 
intervention period, and a container for the 24hr urine collection will be provided. The 
participant will receive either two or eighteen portions of frozen Brassica 
vegetables/soups, dependent on whether they have been randomly assigned to the low 
or high Brassica diet in test phase 1, and will be asked to store them in their home 
freezer. In addition, the participant will be supplied with a steamer and will be asked to 
use this to steam the provided Brassica vegetables following detailed instructions 
which will be provided (Annex 18). The participant will be asked to refrain from 
steaming other items in the steamer at the same time as the supplied diet. If the 
participant does not have enough room in their freezer for the two week supply of 
Brassica, they may take one week’s supply and collect the remainder towards the end 
of the first week. Those randomly assigned to the low Brassica diet will receive one 
portion of frozen broccoli (84g) and one portion of frozen cauliflower (84g). Those 
randomly assigned to the high Brassica diet will receive six portions of frozen broccoli 
(84g), six portions of frozen cauliflower (84g), and six portions of broccoli and sweet 
potato soups (300g with a broccoli content of 84g). The participant will be asked to 
consume either 1 (low Brassica diet) whole portion, or 9 (high Brassica diet) whole 
portions of these vegetables/soups a week, for a two week period. Participants on the 
low Brassica diet will be asked to leave a minimum of five days between consuming 
each portion, whilst those on the high Brassica diet will be asked to consume a 
minimum of one portion a day, across the 2 week period. The participants will be 
provided with instructions for cooking the vegetables & soups (Annex 18). 
 
Following the consumption of the first portion of Brassica, the participant will be asked 
to collect all the urine they produce over the next 24 hours in the urine container 
provided. The urine containers for the 24hr urine collections will contain approximately 
1g of powdered ascorbic acid (vitamin C) as a stabilising agent to prevent rapid 
deterioration of the urine. The participants will be advised to keep the containers away 
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from children and pets, and should they get the powder on their skin they should wash 
it off as soon as possible. The participants will be reminded to maintain their Brassica 
vegetable and ITC-containing food dietary restriction. The participants will be asked to 
refrain from consuming any further Brassica until the 24hr urine collection is complete. 
The participants will return to the HNU with their 24hr urine collection once completed, 
however it may be that a participant requires a member of the study team to collect 
their 24hr urine collection, and this will be arranged on an individual basis. Upon return 
of the 24hr urine collection, the participant will be given a faecal collection kit (as 
described in Study procedures: Faecal collection). Following the completion of test 
phase 1, the participant will be asked to collect their first bowel movement as described 
in Study procedures: Faecal collection. Once collected, the faecal sample, along with 
the food diary and stool chart, will be delivered to the HNU by the participant, or 
collected by a study team member if necessary. 
 
 
Washout phase 
 
Upon return of the faecal sample from the end of test phase 1, the participant will be 
reminded to continue the Brassica vegetable and ITC-containing food dietary 
restriction. The participant will be provided with a faecal collection kit and a small clean 
container for the urine sample required on the first day of test phase 2. The participant 
will be asked to provide a faecal sample (as described in Study procedures: Faecal 
collection) after a minimum of two weeks following the end of test phase 1. If, shortly 
after this two week period, the participant has not contacted the study team, a member 
of the study team will contact the participant to ascertain whether the participant would 
like to continue with the study. Upon delivery of the faecal sample to the HNU, the 
participant will be reminded that the urine sample they provide must be from the first 
day of test phase 2. Following the delivery of the faecal sample, there is an opportunity 
for a break in the study, should this have been previously agreed between the 
participant and the study team. This would allow the participant to cease the dietary 
restrictions for a maximum of six weeks, providing they are willing to restrict their diet 
for a minimum of 2 weeks and produce a faecal sample prior to continuing the study. 
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Test phase 2 (HNU - Visit 3) 
 
See test phase 1 for description. 
 
 
Habitual diet phase 
 
Once the faecal sample, food diaries, and stool charts from test phase 2 have been 
delivered to the HNU or collected by a study team member, the participant will be 
reminded that the Brassica vegetable and ITC-containing food dietary restriction has 
ended and to consume their normal diet. The participant will be provided with a faecal 
collection kit and will be asked to provide a faecal sample (as described in Study 
procedures: Faecal collection) after a minimum of two weeks on their normal diet 
following the end of test phase 2. During the last week of this two week period, the 
participant will be asked to complete both the food diary and stool chart for the entire 7 
days. If, shortly after this period, the participant has not contacted the study team, a 
member of the study team will contact the participant to ascertain whether the 
participant would like to complete the study. Upon delivery of the faecal sample, food 
diaries and stool charts to the HNU, the participant will have completed the study. 
 
 
Completion of the study 
 
Upon completion of the study, the general findings of the study will be reported back to 
the participants in the form of a basic brief summary. 
 
 
Adverse event (AE) and Serious adverse events (SAE) 
 
Any Adverse Events and Serious Adverse Events/Reactions will be reported in 
accordance with The National Research Ethics Service (NRES) and International 
Conference on Harmonisation – Good Clinical Practice (ICH-GCP) rules and the 
appropriate NRES form will be used to report the occurrence of any SAEs/Serious 
Adverse Reactions (SARs). All adverse events/reaction and SAEs/SARs will be 
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documented in the participant-specific case report form (Annex 17), signed by the HNU 
Medical Advisor and Chief Investigator, and held on file at the IFR. The report will 
include, the nature of the event, severity (mild, moderate or severe), and relationship to 
the study (definitely, probably, possibly, not related). Advice will be given by the HNU 
Medical Advisor as to the cause, relationship and any required further action 
(depending on the type of reaction); duration (dates and times), interventions and 
outcomes. 
 
A serious adverse event (SAE) is defined by ICH GCP as an untoward occurrence that: 
 Results in death 
 Is life threatening 
 Requires hospitalisation or prolongation of existing hospitalisation 
 Results in persistent or significant disability or incapability 
 OR, for IFR purposes, is otherwise considered medically significant by the HNU 
medical advisor 
 
The participant will only be deemed to have suffered an adverse event/reaction or a 
serious adverse event/reaction if the participant has taken part in any of the 
intervention. The Chief Investigator will report all SAEs/SARs to the research ethics 
committee (REC) and human research governance committee (HRGC) as soon as 
they become aware, using the standard NRES form. Reports of SAEs/SARs will be 
provided to the REC within 15 days of the event being reported to a member of the 
study team. Once the incident has been resolved, both REC and HRGC will be 
informed of the outcome. However, as participants are asked questions relating to 
allergy at screening, no adverse events or reactions are expected. 
 
 
Methods: 
 
Study sample urine analysis 
 
The total volume of urine collected will be recorded, mixed thoroughly and sub samples 
totalling no more than 40ml will be stored at –80°C until analysis. The remaining urine 
will be discarded. 
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ITC analysis 
 
ITCs will be analysed in 2 ways: 
 
1. A cyclocondensation assay will be used to quantify the total ITCs (PEITC, BITC, 
SF & ER and their conjugates; glutathione, cysteine-glycine, cysteine and N-
acetyl cysteine) in the urine samples according to the method stated in Ye et al 
[60] 
 
2. A validated liquid chromatography-mass spectrometry method will be used to 
measure the profile of the ITCs in the urine samples via an adapted method 
from Gasper et al [61]. The following ITCs and their conjugates will be 
measured: phenyl ethyl isothiocyanate (PEITC); benzyl isothiocyanate (BITC); 
sulforaphane (SF) and erucin (ER) and their conjugates; nitrile, glutathione, 
cysteine-glycine, cysteine and N-acetyl cysteine. Authentic standards of the 
conjugates are already available at the IFR laboratory.  
 
 
Assessment of dietary restriction compliance 
 
The urine samples collected prior to test phases 1 and 2 will be analysed for ITCs in 
the same way as the 24hr urine collection. It is hoped that this will provide baseline 
‘ITC free’ urine samples for each participant. The presence of urinary ITCs in the 
baseline samples would indicate the participant’s non-compliance with the Brassica 
vegetable and ITC-containing food dietary restriction period, prior to the test phases. 
Should non-compliance be evident, any data generated from that participant will be 
removed from the study analysis. From our previous experience with human dietary 
intervention studies we expect that the vast majority of participants will comply with the 
dietary restriction and do not foresee that it will be necessary to recruit further 
participants to compensate for the lack of data from any non-compliant participants.  
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Faecal sample analysis: 
 
Phylogenetic analysis 
 
The faecal samples produced by the participant will either be delivered to a member of 
the study team by the participant, or a member of the study team will arrange to go and 
collect the samples. Upon receipt of a faecal sample, part of it will be divided up into 
aliquots totalling no more than 10g, and stored at –80°C until analysis. The DNA will be 
extracted from faecal aliquots using the FastDNA spin kit for soil (MP Biomedicals) 
according to the method of Maukonen et al [62] and stored at –20°C. Part of the 
extracted DNA from the faecal samples will have the 16S rDNA genes amplified by 
PCR, prior to being commercially sequenced using a Next Generation platform such as 
Illumina. Faecal bacterial phylogenetic analysis will give both the bacterial genera 
present and the relative proportions of each genus within the sample. This will make it 
possible to observe shifts in the proportions of lactobacilli within the faecal microbiota 
of each participant, due to a) the consumption of the different Brassica diets compared 
to one another, and b) the consumption of the different Brassica diets compared to the 
baseline sample obtained at the start of the study. This information can then be 
compared with the ITC excretion data and used to try and determine whether the faecal 
microbiota composition correlates to the rates of ITC excretion. 
 
 
Bacterial enumeration 
 
Quantitative polymerase chain reaction (qPCR) is a validated laboratory technique 
which can be used to identify the numbers of specific bacteria present in a sample. 
This technique will enable an examination of how the consumption of the two Brassica 
diets may have caused a change in the actual numbers of lactobacilli, rather than 
proportions of lactobacilli, within the faecal bacterial communities, compared to one 
another, and compared to the baseline faecal sample. qPCR will be used to amplify the 
16S rDNA genes using lactobacilli-specific primers to give the number of lactobacilli 
present in the samples. This will be performed using DNA extracted from faecal 
aliquots, which will be precipitated and concentrated before being washed and the 
resultant pellet re-suspended in 20μl buffer TE for use as the qPCR template.  
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Faecal metabolite analysis  
 
Short chain fatty acids are bacterial waste products that are beneficial to the host, and 
as such can be considered a biomarker of good gut health. Nuclear magnetic 
resonance spectroscopy (NMR) will be used to determine the profile of metabolites 
such as short chain fatty acids and bile acids from faecal aliquots. Faecal aliquots will 
be diluted 10-fold using PBS, centrifuged at 10000rpm and the supernatant passed 
through a 0.2um filter. 70ul of a buffer solution will be added to 630ul of the filtered 
supernatant. This will be vortexed and 600ul will be added to an NMR tube for spectral 
acquisition. Data analysis will be performed at the IFR. 
 
 
Metatranscriptomic analysis 
 
If differences are seen in the phylogenetic, metabolomic, or ITC excretion rate between 
participants which warrant further investigation, metatranscriptomic analysis will be 
performed to monitor changes in bacterial gene expression. Metatranscriptomics is an 
approach which allows an examination of which genes are expressed at a given time, 
and to what extent. Metatranscriptomic analysis will use faecal aliquots which have had 
20% v/v phenol/ethanol buffer added, before being mixed and incubated on ice for 30 
minutes. The samples will then be centrifuged and the pellet will be re-suspended 
using an aliquot of the supernatant, prior to being stored at –80°C until analysis. The 
samples will be homogenised using a FastPrep instrument (MP Biomedicals), and 
centrifuged to obtain the supernatant from which the total RNA will be extracted. mRNA 
enrichment, cDNA synthesis and, if necessary, cDNA amplification may be performed 
at the IFR, prior to the samples being commercially sequenced. 
 
 
Statistics: 
Power calculations 
 
The average expected population of lactobacilli in human faecal samples, and the 
expected change due to a dietary intervention has been estimated using data 
contained in the paper by Tannock et al [63]. These data suggest that the mean 
lactobacilli present in human faecal samples are 4.57 (log10 bacteria/g) with a standard 
deviation of 2.8 (log10 bacteria/g). 
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The proposed study design will use participants as their own controls by measuring the 
lactobacilli present in their faecal sample prior to the test phases (control) and 
comparing this to the lactobacilli present in their faecal samples produced after 
completing each two week test phase (intervention). 
 
For the sample size calculation, we set the power to be 80% and alpha (α) to be 0.05 
(2-tailed). Using the information from Tannock et al [63], the study would require 10 
participants (in total) to detect a significant difference in the number of lactobacilli (2.79 
log10 bacteria/g) present in faecal samples, between the normal diet (baseline faecal 
sample) and the high Brassica diet intervention. 
 
 
Analysis of data 
 
The data obtained from analysis of the urine and faecal samples, except the 
metatranscriptomic data, will be analysed using a paired t-test or non-parametric 
equivalent. The correlation analysis of ITC excretion rates and the gut microbiota 
composition will be performed using a Pearson product-moment correlation with a test 
for significance versus zero correlation (r=0). All analysis will be carried out in the R 
statistical package [64]. The metatranscriptomic analysis will be carried out using the R 
statistical package with the use of add-on packages, such as Bioconductor, which are 
specifically designed for RNA analysis. The data analysis will be undertaken by IFR’s 
own statisticians, including Dr Jack Dainty who performed the power calculations for 
this study.  
 
 
Ethical considerations: 
Informed Consent 
 
Before participation in the intervention study, all participants will be asked to give 
written informed consent. Prior to consent being given, the participant will be provided 
with the Participant Information Sheet, which provides all the information about their 
involvement in the study and we will ensure that all their questions are answered. The 
ability of participants to give informed consent will depend on them receiving enough 
information about the study, the participant exercising their right to choose, the 
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participants ability to understand the information and the ability of the participant to 
make a decision.  
 
Food safety  
The HNU follows local Environmental Health Guidelines for the preparation and 
storage of food for study participants. All staff handling, preparing or delivering food for 
the participants will hold Level 2 Food Safety Certificates or will be supervised by a 
member of staff who holds a Level 2 Food Safety Certificate.  
 
Toxicity  
There is no evidence from animal or human studies that a diet rich in Brassica is 
harmful. In the Li et al study [58], 17 participants were asked to consume between 660 
and 1080g per day for 14 days when on the high Brassica diet, and they did not report 
any tolerability issues. For the high Brassica diet in this study, we will be asking 
participants to consume 504g of Brassica vegetables and 900g of soup, containing 84g 
of broccoli per soup, per week. That is a total of 756g of Brassica vegetables per week 
for a period of two weeks, which is lower than the daily amount some of the participants 
in the Li et al study were asked to consume. We therefore do not expect any tolerability 
issues with the amount of Brassica consumed in this study.  
 
 
Participant’s expenses/inconvenience payments    
 
Eligibility screening urine sample (x1)                                  
£2 
Urine sample on first day of test phases (x2)  2 x £2                                          £4 
24hr urine collection (x2)  2 x £10                                           £20 
Individual stool collection (x6)  6 x £5                                  
£30 
8 week diet restriction  8 weeks at £14 per week                                               £112 
21 day ‘Household measures’ food diary  21 days at £5 per day completed     £105 
21 day Stool chart  21 days at £2 per day completed                                         £42 
20x Brassica consumption  20 portions at £1 per portion consumed                 £20 
 
 
TOTAL =  £335 
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Participants will receive £335 as an inconvenience payment if the study is completed; if 
the participant withdraws or is excluded from the study, payment will be pro-rata. 
However, if the participant undergoes rescreening the inconvenience payment could 
total £339. Furthermore, if it is necessary for there to be a study break (as described 
previously), an additional £33 will be paid in recognition of the added inconvenience, 
due to the extra 2 weeks dietary restriction and faecal sample. Participants travelling by 
car will be reimbursed travel expenses to and from the HNU (at IFR). This will be 
reimbursed at the IFR's current mileage rate. Those participants travelling by public 
transport will be reimbursed costs on production of a ticket or receipt. If participants 
require transport, the study can provide a taxi to and from HNU. This is paid for by the 
study. 
 
 
Study partners 
 
The study will be sponsored by the IFR and funded through the NAT4LIFE project by 
the Danish Council for Strategic Research. 
 
The study will be led by Professor Richard Mithen and run by Mr Lee Kellingray with 
assistance from Dr Joanne F Doleman. 
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Date 
 
 
 
Dear_______________, 
 
 
Thank you for your interest in studies at the Institute of Food Research. 
 
 
I have sent you the details of, 
 
 
Effects of Brassica on human gut Lactobacilli 
(EBL study) 
 
 
which is one of the studies in progress at present, as your details currently held on the 
database indicate that you may fit the criteria for this study. If you are interested in 
participating in this study, please complete and return the reply slip in the enclosed 
participant information sheet. If you have any further questions, please contact the 
study manager concerned, Mr Lee Kellingray on 01603 255308 or 
lee.kellingray@ifr.ac.uk as stated on the enclosed participant information sheet. 
 
If, however, any of your details have changed or change in the future, or you would 
prefer to no longer remain on the database please could you inform the Human 
Nutrition Unit on 01603 255305. 
 
Thank you.  
 
Yours sincerely, 
 
 
 
 
Aliceon Blair 
HNU Senior Research Nurse   
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Invitation to take part in a Research Project 
 
 
Effects of Brassica on human gut Lactobacilli 
(EBL study)  
 
You are being invited to take part in a research study. Before you 
decide, it is important for you to understand why the research is being 
done and what it will involve for you. Please take time to read the 
following information carefully. Talk to others about the study if you 
wish. 
 
Part 1 tells you the purpose of this study and what will happen if you 
take part 
Part 2 gives you more detailed information about the conduct of the 
study 
 
Please ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. This 
information sheet is yours to keep. 
Thank you for reading this. 
 
This study is funded through the NAT4LIFE project with the Danish Council for Strategic 
Research.  
This study has been approved by a Local Research Ethics Committee. 
 
 
Chief Investigator 
Professor Richard Mithen 
 
Study Team 
Study Manager 
Mr Lee Kellingray 
Contact number: 01603 255308 
lee.kellingray@ifr.ac.uk 
 
Study Scientist 
     Dr Joanne F Doleman 
01603 251477 
            joanne.doleman@ifr.ac.uk 
 
Study Mobile number    07542 124238 
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PART 1 of the information sheet 
 
What is the purpose of the 
study? 
Brassica vegetables (see list 
on page 11 of this 
information sheet) are an 
important part of our diet. 
Unlike other vegetables 
which form part of our daily 
diet, they contain compounds which have a 
protective effect associated with a reduced risk of 
many chronic diseases, such as cancer. The 
protective effect may be as a result of the 
breakdown of these compounds, which are called 
glucosinolates (GSLs).  
 
In the vegetable, the GSLs are converted into 
active compounds called isothiocyanates (ITCs) 
by a protein called myrosinase. When we cook 
Brassica vegetables thoroughly the myrosinase 
in the vegetable stops working and the change 
from GSLs to ITCs is carried out by bacteria in 
our gut instead. It is the ITCs that are thought to 
be responsible for the protective effects against 
diseases.  
 
Our gut contains trillions of bacteria, many of 
which help us to unlock extra nutrients from the 
food we eat. Some bacteria, called lactobacilli, 
are often referred to as ‘good bacteria’ and are 
added to probiotic products, such as yoghurts. 
These bacteria are naturally found in our gut and 
some foods are thought to be able to increase 
their numbers, and therefore may increase the 
health benefits associated with them.  
 
In this study we will use the Brassica vegetables 
broccoli and cauliflower, as well as a broccoli and 
sweet potato soup. We are interested in whether 
eating Brassica causes an increase in lactobacilli 
in our gut. 
 
 
What we aim to 
do: 
We will look at 
whether a low or 
high Brassica 
vegetable diet 
causes a change in the number of gut lactobacilli. 
 
Additionally, as it has been shown that people 
are able to change GSLs to ITCs at different 
rates and in different amounts, we would like to 
look at the rate at which you get rid of ITCs from 
your body by collecting urine samples.  
 
Finally, we would like to look at your gut bacteria 
as an entire community to see what types we can 
find. We will do this by asking you to collect 
faecal samples. We will then extract the bacteria 
from these samples and use this to find out 
whether the different types of bacteria in your gut 
affect the rate and/or the amount of GSLs 
converted to ITCs by an individual. 
 
What will I have to do: 
Participants in the study will be asked to eat a 
low or high Brassica diet (one or nine portions of 
Brassica vegetables per week for 2 weeks), then 
following a 2 week break, they will be asked to 
consume the other Brassica diet. The order in 
which you eat the Brassica diets will be chosen 
by computer using a method called ‘random 
allocation’. This means that neither you nor the 
scientists will be able to decide in which order 
you eat the Brassica diets. 
 
During the study you will be asked to collect urine 
and faecal samples, and complete food diaries 
and stool charts (frequency and consistency of 
bowel movements). 
 
Who can take part in the study? 
We are aiming to recruit: 
 Men and women  
 Aged between 18 and 50 
 Smokers and non-smokers 
 Live within 40 miles of Norwich 
 Have a body mass index (BMI, kg/m2) 
between 19.5 and 30 
 
Who cannot take part in the study? 
Please note: You will not be able to take part if 
you: 
 are pregnant, have been pregnant 
in the last year or are lactating 
and/or breast feeding. 
 are currently suffering from, or 
have ever suffered from, any 
diagnosed gastrointestinal 
disease, gastrointestinal disorders including 
regular diarrhoea and constipation 
(excluding hiatus hernia unless 
symptomatic), and/or have undergone 
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gastrointestinal surgery, or the study 
intervention/procedure is contraindicated. 
 have been diagnosed with any long-term 
medical condition that may affect the study 
outcome (e.g. diabetes, haemophilia, 
cardiovascular disease, glaucoma, 
anaemia). These will be assessed on an 
individual basis. 
 have been diagnosed with any long-term 
medical condition requiring medication that 
may affect the study outcome. 
 regularly taking over the counter 
medications for digestive/gastrointestinal 
conditions. 
 are on long-term antibiotic therapy. You 
may be able to participate if 4 weeks has 
passed from the end of a course of 
antibiotics (this will be assessed on an 
individual basis). 
 regularly take laxatives (once a month or 
more). 
 take certain dietary supplements or herbal 
remedies and are unwilling to stop taking 
them for one month prior to and during 
study period. This will be assessed on an 
individual basis. 
 take pre- or pro-biotic drinks &/or yoghurts 
on an occasional basis, unless willing to 
abstain for one month prior to and during 
the study period. (if you regularly take pre 
&/or pro biotics (3+ times a week, and for 
more than one month) and will continue 
throughout the study then you will not be 
excluded). 
 on or plan to start a diet programme that 
may affect the study outcome (e.g. 5:2 
fasting diet) unless willing to abstain for 1 
month prior to and during study period. This 
will be assessed on an individual basis. 
 recently returned to the UK following a 
period abroad, and who have suffered 
gastric symptoms during the period abroad 
or on return to the UK. These will be 
assessed on an individual basis. 
 regular/recent (within 3 months) use of 
colonic irrigation or other bowel cleansing 
techniques. 
 are involved in another research project that 
includes dietary intervention and/or 
sampling of biological fluids/materials. 
Sampling of certain biological samples, 
such as saliva, may not affect the study and 
this will be assessed on an individual basis. 
 record blood in your stools or have two or 
more episodes of constipation or diarrhoea 
(type 1, 2, or 7 stools) during the study. 
 are unwilling to provide GPs contact details.  
 are unable to provide written informed 
consent. 
 are not suitable to take part in this study 
because of your eligibility screening results. 
 are related to or living with any member of 
the study team. 
 do not have access to a freezer. 
 regularly consume more than 15 units 
(women) or 22 units (men) of alcohol a 
week. 
 allergic to any of the foods/ingredients 
within the foods supplied. 
 
Why have I been invited? 
You have been sent this information sheet 
because: 
 You responded to an 
advertisement about the study. 
 Or your details currently 
held on the IFR Human Nutrition 
Unit (HNU) volunteers’ database 
suggest you may fit the study 
criteria.  
 
Do I have to take part? 
It is up to you to decide. We have described the 
study in this information sheet. If, after reading it, 
you are interested in participating, 
and you live in or within 40 miles of 
Norwich please complete and return 
the response form (page 15 of this 
information sheet) using the pre-paid 
envelope enclosed. On receipt of the 
response form a member of the study 
team will contact you by telephone to arrange a 
pre-study talk with you at the Human Nutrition 
Unit (HNU) in Norwich, and give you the 
Annex 2   EBL   Version 3   16/10/2014 
 312 
 
opportunity to ask any questions you may have 
at this time. 
You may also contact the study team by 
telephone, Lee Kellingray on 01603 255308; 
Joanne Doleman 01603 251477 or by email 
lee.kellingray@ifr.ac.uk or 
joanne.doleman@ifr.ac.uk if you have any 
questions before or during the study. 
Please feel free to say no simply by not 
responding to this letter. Do not worry, no one will 
contact you or try to persuade you to join the 
study.  
 
We aim to recruit a total of 10 participants to 
complete the study. If you register an interest in 
taking part, and we are near to the 10 participant 
point, we may ask you if you are happy to be 
placed on a standby list. If you are put on the list, 
there will be no guarantee that you will be 
required to take part in the study, but we will 
keep you informed and you are entitled to ask to 
be removed from the standby list at any time. 
 
Expressing an interest in the study, having a 
discussion about the study, or attending the 
screening does not mean you have to take 
part. 
You are entitled to withdraw at any time without 
giving a reason. 
 
What will happen to me if I take part? 
If you decide to take part, your involvement will 
last for approximately 11 weeks (dependent on 
whether you go on holiday, or a break is required 
for other reasons that will not affect the study), 
from first contact to the end of the study. During 
this period, the study team will keep in regular 
contact with you, or you can contact members of 
the study team, to answer any questions you 
may have about the study. 
 
For this study, you will have an informal talk with 
one of the study team at the HNU in Norwich 
(see below for more information) and you will  
then need to visit the unit on 3 separate 
occasions, although additional visits may be 
necessary for sample delivery;  
 
 Signing consent and the eligibility screening – 
Visit 1 
 To bring your baseline urine sample and 
collect the first Brassica diet – Visit 2 
 To bring a second baseline urine sample and 
collect the second Brassica diet after the 2 
week washout period with no Brassica – Visit 
3 
Where possible, appointments for screening will 
be made at your convenience but will take place 
on a weekday. 
 
Informal talk to discuss the study 
An appointment will be made for a member of the 
study team to discuss the study with you at the 
HNU. This will last up to one hour. The study 
team member will go through this information 
sheet with you and answer any questions you 
may have. 
 
After this conversation you will be given as long 
as you need but at least 72 hours (3 days) to 
decide whether or not you wish to take part in the 
study. During this time we will not contact you. 
After the 72 hours if you decide to take part you 
will need to contact a member of the study team 
to arrange an appointment for the eligibility 
screening visit. 
 
After the talk, you will be given a copy of the 
Bristol Stool Chart and a small container. Should 
you decide not to take part in the study, you may 
dispose of these as you see fit. If you do join the 
study, we would like you to use the Bristol Stool 
Chart to identify what your typical stool type is, as 
you will be asked this at your screening visit by 
the HNU nurse. The container will be used for a 
urine sample, which you will need to bring to your 
screening visit. It is important for the urine 
dipstick test results and study analysis that you 
do not use any containers other than the ones 
given to you during the study to collect your 
urine. If you lose the pots we will provide you with 
another at your appointment and give you the 
opportunity to provide another urine sample.  
Eligibility screening and informed consent – 
Visit 1 
This visit will last 
approximately 1 hour, and 
you will need to bring with 
you a midstream urine 
sample, produced within two 
hours of your screening 
appointment. This is 
necessary for the test to 
work.  
 
On arrival at the HNU you will be asked to sign a 
consent form, agreeing to participate in the 
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study. This form will also be signed by a member 
of the study team (study manager or study 
scientist) or the HNU Senior Research Nurse, 
and you will be given a copy to keep. Once you 
have signed the consent form you are still free to 
withdraw at any time without giving a reason. 
 
After you have signed the 
consent form, the nurse will carry 
out a urine dipstick patch test on 
your urine sample. The results of 
this will be known immediately 
and the HNU nurse will discuss 
the results with you. Depending 
on your urine dipstick test results 
you may be excluded from the 
study or offered a re-screen and 
advised to speak to your doctor or surgery nurse 
about your results. The HNU nurse will then 
complete a medical declaration form, which you 
will be given a copy of, and a screening 
questionnaire with you. At this point, the HNU 
nurse will explain the Bristol Stool Chart and ask 
you which type reflects your typical stool, using 
the Bristol Stool Chart as a guide. The HNU 
nurse will then measure and record your: 
 Blood pressure 
 Pulse rate 
 Height 
 Weight 
 Calculate your Body Mass Index (BMI, 
kg/m2) 
Your height and weight measurements are used 
to calculate your body mass index (BMI, kg/m2). 
Body Mass Index is a measure of whether you 
are a healthy weight for your height. If your BMI 
(kg/m2) is outside the range of 19.5 and 30kg/m2 
you will not be able to take part in the study. 
 
We will send copies of all your clinical results 
(urine results, blood pressure, pulse, Body Mass 
Index (BMI (kg/m2) and weight) to your GP. If any 
of your results are outside the study 
requirements you may not be able to take part in 
the study. 
 
After your screening appointment 
Following a successful screening appointment, a 
member of the study team will provide you with a 
faecal sample collection kit, along with a detailed 
sheet on how we would like you to collect and 
store your faecal sample until you can deliver it to 
us, or it can be collected by a member of the 
study team. Everything you need to collect the 
sample will be provided within the kit, including 
freezer blocks/ice cube bags as you will be 
required to freeze them to put into the insulated 
collection pot. This is so the sample can be kept 
cool until it is handed over to the study 
team/nurse. 
 
After you have given us your faecal sample, we 
will arrange a time and date for you to bring in a 
urine sample and to collect the first Brassica diet 
(Visit 2). You will be asked to stop eating any 
Brassica vegetables and ITC-containing 
foods, except those provided, for 8 weeks 
during your involvement on the study. Should 
the study break be required, this will increase to 
10 weeks. This includes 2 weeks before you 
collect the first Brassica diet (Visit 2). You will 
also be required to produce a second faecal 
sample, collected as before, following a minimum 
2 week period of the Brassica vegetable and ITC-
containing food diet restriction. Page 11 of this 
information sheet gives you a list of which foods 
you will not be able to eat during the study 
period, and if you are unsure whether you may 
eat a food item you can ask the study scientists. 
You will also be asked to complete food diaries 
and stool charts for 21 days during the study.  
 
 
 
First Brassica diet collection - Visit 2 
On the day you visit the HNU to pick up the first 
Brassica diet, you will be asked to: 
 
 Provide a faecal sample, if you have not 
done so already, following a minimum of 
2 weeks of the diet restriction. 
 
 Provide a small urine sample on the 
morning of your visit to collect the 
Brassica diet. This will provide a baseline 
sample in which there should be no ITCs. 
 
 Continue your diet restriction eating a 
diet that is free from Brassica vegetables 
and ITC-containing foods. 
On the morning of the Brassica diet collection, 
when you arrive at the HNU a nurse or member 
of the study team will collect your urine sample 
which you will have brought with you. You will be 
Annex 2   EBL   Version 3   16/10/2014 
 314 
 
asked if you are happy to continue with the study, 
and whether you have had any changes to your 
health or medication since your screening 
appointment which may affect the study data. 
You will also be reminded to continue with the 
Brassica vegetable and ITC-containing food diet 
restriction. 
 
If you are happy to continue, you will be given the 
first Brassica diet, cooking instructions, and a 
steamer to cook the vegetables with. Whilst 
steaming the Brassica we would appreciate it if 
you didn’t add anything else to the steamer. You 
will be asked to consume the supplied Brassica 
diet as part of your normal diet across the 2 week 
period. When on the low Brassica diet, you will 
be supplied with one 84g portion of frozen 
broccoli and one 84g portion of frozen 
cauliflower, and you will be required to eat one of 
these portions in week one and the other in week 
two, with a minimum of five days between eating 
each portion. When on the high Brassica diet, 
you will be supplied with six 84g portions of 
frozen broccoli, six 84g portions of frozen 
cauliflower, and six 300g portions of broccoli and 
sweet potato soup (each soup contains 84g of 
broccoli). You will be required to eat three 
portions of broccoli, three portions of cauliflower, 
and three broccoli and sweet potato soups each 
week for 2 weeks, eating at least one portion per 
day across this 2 week period. During each 
Brassica diet period you will be asked to record 
your vegetable and fruit intake for 7 days and to 
keep a diary about your stool consistency for 7 
days, and we will provide you with the Bristol 
Stool Chart as a guide for this. After eating the 
first portion of Brassica you will be asked to 
collect all the urine you produce for a full 24-hour 
period into the urine collection pot which we will 
provide, delivering it to the HNU once completed. 
Alternatively, transport can be arranged to collect 
it from you. 
 
Please note that the urine container will contain a 
white powder called ascorbic acid (vitamin C) 
which is needed to preserve the urine. The urine 
container should be kept out of reach of children 
and pets, and away from any heat source or 
direct sunlight. 
 
At the end of the 2 week Brassica diet 
intervention, you will be asked to collect a faecal 
sample in the faecal collection kit provided. When 
the sample has been produced, you will be asked 
to deliver it to the HNU, or collection from you will 
be arranged if required. 
 
When you deliver the faecal sample you will be 
reminded that you will still need to follow the 
Brassica and ITC-containing food free diet during 
the 2 week washout period between the two diet 
phases. You will also be given a faecal collection 
kit and, after a minimum of two weeks, you will 
be asked to bring a faecal sample to the HNU, 
collected as before. An appointment will be made 
for you to visit the HNU with a urine sample, in a 
container provided, which will be used as a 
baseline sample, and to collect the second 
Brassica diet (Visit 3). There may be a study 
break at this point if requested by you, e.g. due to 
a seasonal holiday period,prior to starting the 
initial diet restriction. This will allow you to cease 
the dietary restrictions for a maximum of 6 
weeks, providing you are willing to restrict your 
diet for 2 weeks and produce a faecal sample 
prior to continuing the study. 
 
Second Brassica diet collection - Visit 3 
On the day you visit the HNU to pick up the 
second Brassica diet, you will be asked to: 
 
 Provide a faecal sample, if you have not 
done so already, following a minimum of 
2 weeks of the diet restricted washout 
period. 
 
 Provide a small urine sample on the 
morning of your visit to collect the 
Brassica diet. This will provide a baseline 
sample in which there should be no ITCs. 
 
 Continue your diet restriction eating a 
diet that is free from Brassica vegetables 
and ITC-containing foods. 
As before, you will be asked if you are happy to 
continue on the study and whether you have had 
any health problems or change of medication 
which may affect the study data, since the first 
intervention period. If you are happy to continue, 
you will be supplied with the second Brassica 
diet, which will be the alternate diet to that eaten 
in the first intervention period.  
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Again, you will be reminded to continue following 
the diet restriction and asked to use the steamer 
to cook the Brassica vegetables and to follow the 
cooking instructions provided. You will be asked 
to consume the Brassica diet as part of your 
normal diet in the same manner as explained 
earlier in this information sheet. Once again, you 
will be asked to record your vegetable and fruit 
intake for 7 days and to keep a diary about your 
stool consistency for 7 days, referring to the 
Bristol Stool Chart as a guide. After eating the 
first portion of the supplied Brassica you will be 
asked to collect all the urine you produce for a 
full 24-hour period into the urine collection pot 
which we will provide. You will be asked to 
deliver this to the HNU once completed, or 
collection from you will be arranged if required.  
 
Once again, at the end of the 2 week Brassica 
diet intervention you will be asked to collect a 
faecal sample in the faecal collection kit 
provided. Once produced, you will be asked to 
deliver this to the HNU as before. On leaving the 
HNU you will be told that you no longer need to 
follow the Brassica-free diet. You will be given a 
faecal collection kit and, after a minimum of two 
weeks following your normal diet with no dietary 
restrictions, you will be asked to bring your final 
faecal sample to the HNU, or it will be collected 
as before. During the last week of this 2 week 
period you will be asked to record your vegetable 
and fruit intake for all 7 days and to keep a diary 
about your stool consistency for all 7 days, 
referring to the Bristol Stool Chart as a guide. 
When your final faecal sample is handed over we 
will also collect any outstanding food diaries and 
stool charts. This will signify the end of your 
involvement in the study. 
 
We understand that there is a lot of information 
here but please don’t worry, you will not have to 
remember every detail, we will provide you with 
step-by-step instructions throughout your 
involvement in the study. In addition, a brief 
summary of the study and a flowchart can be 
found on pages 12 and 13 of this information 
sheet. 
 
Access to your personal information 
When you are screened for the study, you will be 
given a code number. This code number is 
unique to you and will be used to protect your 
identity and make your samples anonymous. 
Access to any information about you will be 
restricted to the research team, nurses at the 
HNU, the HNU medical advisor and your GP. 
There is more information about this in Part 2. 
 
Expenses and payments 
Participating in these studies is on a voluntary 
basis. However, we do recognise that taking part 
can cause some inconvenience and there are 
associated travel costs. Thus, you will receive 
£335 as an inconvenience payment, however 
should the study break be required this will 
increase to £368; if you withdraw or are excluded 
from the study, payment will be pro-rata. 
Travelling expenses to and from the HNU will be 
reimbursed on presentation of a receipt for buses 
or trains, or the current IFR mileage rate for 
private cars, which is presently 45p per mile. If 
you require transport to and from the HNU, 
please let us know. We will arrange and pay for a 
taxi.  
 
All payments are liable to tax and you are 
responsible for declaring your own payments 
for tax purposes. 
 
Members of staff at IFR are free to participate 
in this study, however we would like to point 
out that their inconvenience payment will be 
taxed at source in accordance with BBSRC 
and IFR rules and HM Revenue and Customs 
(HMRC). 
 
If you are in receipt of benefits this payment 
may affect your benefits. 
 
What will I have to do next? 
If you are interested in learning more about this 
study please complete and return the response 
form (page 15 of this information sheet) using the 
pre-paid envelope enclosed. When we receive 
the response form, a member of the study team 
will contact you by telephone to arrange a pre-
study talk with you at the Human Nutrition Unit 
(HNU) in Norwich. If you wish to proceed, you will 
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then be able to book a screening appointment. 
Following a successful screening you will be 
recruited onto the study and you will be given a 
faecal collection kit. We will also arrange a date 
and time for the collection of the first Brassica 
diet. We will go over all the foods you will need to 
avoid for the two weeks before the study starts 
and a minimum of six weeks during the study 
(minimum of 8 weeks and a maximum of 10 
weeks in total) discussed above. You will be 
reminded that you are free to withdraw from the 
study at any time without giving a reason, 
however a call (or email) to a member of the 
study team would be appreciated if at all 
possible. 
 
What are the risks or side effects of 
participating in this study? 
As with any pressure measurement (like blood 
pressure) the inflation of the blood pressure cuffs 
may cause slight discomfort and a reddening of 
the arm where the cuff is placed, but this affects 
some people more than others.  
The HNU nurses will be happy to answer any 
questions you may have about any of the 
procedures involved. 
 
What are the potential benefits of taking part? 
For you, there are no direct benefits except 
receiving Brassica vegetables, which will 
contribute to your recommended 5-a-day. Our 
results will help us to understand:  
 whether eating Brassica vegetables can 
change your gut bacteria and help to 
increase beneficial bacteria/bacterial 
products in our gut; 
 whether the bacteria in your gut affects 
the rate at which you convert GSLs to 
ITCs;  
 which bacteria in your gut are responsible 
for converting GSLs to ITCs.  
 
The results from this study could also impact on 
future research into health benefits obtained from 
our diet, and the role our gut bacteria may play. 
  
What if there is a problem whilst I am on the 
study? 
Any complaint about the way you have been 
cared for during the study will be addressed. 
Detailed information about this is given in Part 2. 
 
Will my taking part be kept confidential? 
Yes – we follow Good Clinical Practice (GCP) 
and strict ethical and research governance rules. 
All information about you will be handled in 
confidence. More details about this are included 
in Part 2. 
 
This completes Part 1 of the information 
sheet. If the information in Part 1 has 
interested you and you are considering taking 
part, it is important that you read the 
additional information in Part 2 before making 
any decision.
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PART 2 of the information sheet 
What if relevant new information becomes 
available or changes to the study are made? 
If there are changes to the study or new 
information becomes available, we will tell you. If 
these changes are significant, you may be asked 
to sign another consent form. 
 
What will happen if I don’t want to carry on 
with the study? 
If you withdraw from the study, we will analyse 
your samples collected up to the point that you 
leave the study with those we obtain from all the 
volunteers, unless you decide otherwise. You will 
receive payment pro-rata for any samples, 
diaries etc. you have contributed. 
 
What if there is a problem? 
If you have any concerns about the study, you 
should ask to speak to the study manager Lee 
Kellingray: 01603 255308 who will do his best to 
answer your questions. If you are still unhappy, 
and wish to complain formally, you can do this 
through the chairperson of the Human Research 
Governance Committee (HRGC) – Dr Linda 
Harvey. 
 
The Institute of Food Research accepts 
responsibility for carrying out trials and as such 
will give consideration to claims from participants 
for any harm suffered by them as a result of 
participating in the trial, with the exception of 
those claims arising out of negligence by the 
participant. The Institute of Food Research has 
liability insurance in respect of research work 
involving human volunteers. 
 
Please note that the Institute will not fund any 
legal costs arising from any such action unless 
awarded by a court. 
 
Will my taking part in this study be kept 
confidential? 
All information collected about you during the 
course of the study will be kept strictly 
confidential. Any information leaving IFR, such as 
bacterial DNA/RNA extracted from stool samples 
for phylogenetic analysis and metatranscriptomic 
analysis will be anonymous. Study information 
will be stored in locked filing cabinets at the 
Institute of Food Research (IFR). Personal data 
collected will be processed by computer, 
however only personal information that is 
essential for the study will be collected. 
 
When you are screened for the study, you will be 
given a unique code number (volunteer code 
number). This number will be used to identify 
your samples and prevents anyone from working 
out whose samples are whose. Access to your 
personal records is restricted to the study team, 
the HNU nurses, the HNU medical advisor and 
your GP. Your data will be kept for 15 years in a 
secure archive, and will be destroyed after this 
time. Your personal information and the data 
collected will be handled to Good Clinical 
Practice standards.   
 
All research is subject to inspection and audit. 
Although your records may be accessed for this 
purpose, any personal information remains 
confidential. IFR has CCTV cameras in use for 
security purposes. However, provision has been 
made that volunteers attending the HNU are not 
identified. 
 
Will my General Practitioner (GP) be 
informed?  
Yes, it is routine practice to inform your GP that 
you are taking part in a study at the IFR and we 
will send them: 
 Details of the study  
 Your eligibility screening results including the 
dipstick urine patch test, blood pressure, 
pulse, weight and BMI (kg/m2) 
 Any stool charts that indicate abnormal stools 
or the presence of blood 
 
This is one of the things you agree to when 
signing the consent form. Any screening results 
which fall outside standard reference ranges will 
be assessed by the HNU nurses and medical 
advisor. We are unable to discuss test results 
with you, however you will be advised to speak to 
your GP about the results and sometimes the 
medical advisor may ask the HNU nurse to speak 
to you and/or your GP directly.  
 
What will happen to the samples I give? 
The urine sample at HNU Visit 1 (screening) will 
be used immediately for a urine dipstick patch 
test and then discarded. 
 
The urine samples (including 24-hour collection) 
you provide during the study will be analysed for 
ITC concentration. This will be done using a 
liquid chromatography/mass spectrometry 
(LC/MS) and a cyclocondensation method. 
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LC/MS uses a method that can separate 
components of a mixture. It will allow us to work 
out how much ITCs your body has excreted.  
 
The cyclocondensation method is a specific 
chemical reaction and will help us to find out the 
total amounts of ITCs in your urine samples.  
 
The bacteria from your faecal sample will be 
collected and the different types of bacteria and 
number of lactobacilli present will be determined. 
The faecal samples will also be used to examine 
changes in gut metabolites using nuclear 
magnetic resonance spectroscopy (NMR). NMR 
is another method that is able to separate the 
components of a mixture. Finally, should the 
results indicate that it is worthwhile, we will use 
faecal samples to examine any changes in 
bacterial gene expression through 
metatranscriptomic analysis using a Next 
Generation sequencing platform, such as 
Illumina. 
 
What will happen to the results of the 
research study? 
As a volunteer you are valuable to us but we are 
unable to tell you any of your individual results. 
The data resulting from the study may be 
published in scientific journals or presented at 
meetings with our funders. At the end of the 
study we will provide you with some feedback 
about what we have found as a result of your 
help and what it may mean for future research. 
 
Please note that data is presented as a whole 
and is anonymous. Your name will not appear 
anywhere in any of the results presented or 
published. 
 
Who is organising and funding this study? 
The study will be funded through the NAT4LIFE 
project with the Danish Council for Strategic 
Research. 
 
Who has reviewed this study? 
At IFR this research project has been reviewed 
by the Institute of Food Research Human 
Research Governance Committee (HRGC), as 
well as an external Local Research Ethics 
Committee. These are groups of independent 
people who review research to protect your 
safety, rights, well-being and dignity. This study 
has been reviewed by all committees, and given 
a favourable opinion. 
 
Further information-what we need you to tell 
us 
We need you to tell us some things for your 
safety and for the success of the study. 
 
Please tell us if you: 
 Have any episodes of illness, even if it is just 
a headache 
 Are injured in any way 
 Feel unwell during or after a visit to the Unit 
 Become pregnant 
 
Some medicines affect the information we are 
collecting. Please tell us if you take any 
medication including those you purchase at the 
chemist or supermarket (e.g. paracetamol). 
 
You should bring details of any medication (i.e. 
name of the medicine and the dose taken) you 
are taking when you come for your screening 
visit (Visit 1). 
 
Taking part in the research is entirely 
voluntary! You are free to withdraw from the 
study at any time without giving a reason. 
 
Thank you for your attention. 
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Effects of Brassica on human gut Lactobacilli 
(EBL study)  
 
 
A list of Brassica foods that are high in glucosinolates and ITCs 
that must be avoided: 
 
- Mustard: all types sauces, leaves and powders including Ethiopian mustard, 
Indian mustard, Chinese mustard, red giant mustard, wrapped heart mustard 
cabbage, yellow mustard, black mustard, broad beak mustard, purple stem 
mustard, mustard spinach. 
 
- Broccoli: all types including rapini or broccoli raab, alboglabra kai-ian (Chinese 
broccoli), romanesco broccoli, broccoli, broccoflower. 
 
- Sprouting broccoli  
 
- Brussels sprouts 
 
- Cauliflower  
 
- Cabbage: all types including white cabbage (drum), head cabbage, Savoy 
cabbage, red cabbage, green cabbage. 
 
- Kale: all types including curly kale, Chinese kale, sea kale, pabularia siberian 
kale, acephala Kale. 
 
- Kohl rabi 
 
- Turnip and turnip tops 
 
- Spring greens and Collard greens 
 
- Chinese cabbage; Pak Choi;  Bok choy and other Chinese brassica 
vegetables   
 
- Radish 
 
- Salad rocket 
 
- Horseradish: sauces and vegetables 
 
- Cress: all types, including watercress and garden cress 
 
- Papaya seeds 
 
- Wasabi  
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Brief summary of the study 
 
Days 1-4: 
Once you have discussed the study with a member of the study team, and should you 
wish to continue, you will be asked to bring a urine sample to the HNU Senior 
Research nurse. This will be tested as part of the screening appointment to determine 
whether you are suitable to take part in the study. If successful you will be given a 
container and you will be asked to return home and produce a faecal sample at your 
convenience. 
 
Days 5-19: 
Upon delivery of the faecal sample to the HNU, we will ask you to restrict certain foods 
from your diet (see page 11), which you will be required to maintain for approximately 8 
weeks. After a minimum of 2 weeks on the restricted diet you will be asked to produce 
and deliver another faecal sample. You will then need to bring a urine sample to the 
HNU and collect the frozen foods that we would like you to eat for the next 2 weeks as 
part of your normal diet (with the exception of the foods we have asked you to avoid). 
 
Days 20-34: 
During the first 2 week diet period you will be asked to record the fruit and vegetables 
you consume in food diaries for 7 consecutive days and, during the same 7 days, 
complete stool charts noting the frequency and consistency of your bowel movements. 
After eating the first portion of the supplied diet, we would need you to collect all of your 
urine for the next 24 hours in a container that we will supply, and bring this to the HNU. 
At the end of this 2 week diet period you will be asked to produce and deliver another 
faecal sample to the HNU. 
 
Days 35-49: 
Next you will be asked to maintain the dietary restrictions but otherwise eat your normal 
diet for a minimum of 2 weeks (called a washout phase), at the end of which, you will 
be asked to provide a faecal sample. 
There may be a study break at this point if requested by you, e.g. due to a seasonal 
holiday period, prior to starting the initial diet restriction. This will allow you to cease the 
dietary restrictions for a maximum of 6 weeks, providing you are willing to restrict your 
diet for 2 weeks and produce a faecal sample prior to continuing the study. 
 
Days 50-64: 
As before, you will be asked to produce a urine sample, and you will be given the foods 
required for the second 2 week diet period. Upon eating the first portion of the supplied 
diet you will be asked to collect all of your urine across the next 24 hours, and we will 
require you to complete both food diaries and stool charts for 7 consecutive days. On 
completing the second diet period we would like you to deliver another faecal sample to 
the HNU, and this will mark the end of the dietary restrictions. 
 
Days 65-79: 
Finally, we would require you to eat your normal diet for 2 weeks, completing further 
food diaries and stool charts for the last seven days, and producing a faecal sample at 
the end of the 2 week period. Upon delivery of the faecal sample, along with any 
outstanding food diaries or stool charts, you will have completed the study. 
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Day 1 
• Study talk 
Day 4 
• Produce urine sample for Eligibility screening 
Day 5 
• Produce/deliver faecal sample to the HNU 
• Start diet restriction (see page 11) 
Day 19 
• Produce/deliver faecal and urine sample to the HNU 
• Collect first Brassica diet from the HNU 
Day 20 
• Start first 2wk Brassica diet, complete food diary and stool chart for 7 consecutive days within this 
time 
• Collect urine for 24hr after eating 1st portion 
Day 21 
• Deliver 24hr urine collection to the HNU 
Day 34 
• Last day of first Brassica diet 
• Produce/deliver faecal sample to the HNU 
Day 35 
• Start 2wk washout period 
Day 49 
• Last day of washout period 
• Produce/deliver faecal sample to the HNU 
•Study break if required (maximum of 6 weeks) 
•Restart diet restriction 
•After 2 weeks of restricted diet, produce/deliver faecal sample to the HNU 
Day 50 
• Produce/deliver urine sample & collect second Brassica diet from the HNU 
• Start second 2wk Brassica diet, complete food diary and stool chart for 7 consecutive days within this 
time, and collect urine for 24hr after eating 1st portion 
Day 51 
• Deliver 24hr urine collection to the HNU 
Day 64 
• Last day of second Brassica diet 
• Produce/deliver faecal sample to the HNU 
Day 65 
• Start 2wk habitual diet period 
Day 72-79 
• Complete food diary and stool chart for seven days 
Day 79 
• End of Habitual diet period 
• Produce/deliver faecal sample to the HNU & the study is completed 
Flowchart of study 
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Effects of Brassica on human gut Lactobacilli 
(EBL study)  
 
I am interested in taking part and/or finding out more information 
about this study (please complete the personal details below). 
 
Name: 
………………………………………………………………………………
……………………………….. 
 
Address: ………………………………………………………… 
 
…………………………………………………………….............. 
 
 
Daytime telephone no.: ……………………………………………… 
 
Evening telephone no.: …………………………………………… 
 
Mobile no.: 
.............................................................................................................
. 
 
I am happy for a message to be left via my daytime/evening/mobile 
number: YES/NO 
*please circle as applicable 
 
Preferred number/time to call: ......................................................... 
 
E-mail address: ……………………………………………… 
 
Please return this form in the FREEPOST envelope provided, to: 
 
Mr Lee Kellingray 
Institute of Food Research 
FREEPOST NC 252 
Norwich Research Park 
Colney 
Norwich 
NR4 7UA 
 
Expressing an interest does not commit you to taking part in 
the study 
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WE NEED YOUR HELP ON 
Effects of Brassica on human gut Lactobacilli 
The EBL Study 
 
There is evidence that regularly 
eating Brassica vegetables, such 
as broccoli or cauliflower, may 
improve your health. 
 
Does it also increase the number 
of ‘good’ bacteria in your gut? 
We need to recruit: 
Men and women aged between 18 - 50 years old 
 
You would have to: 
 Eat portions of broccoli, cauliflower, and broccoli and sweet 
potato soups over 4 weeks, which we will provide 
 Eliminate Brassica vegetables from your diet for 8 weeks 
 Provide biological samples such as urine  
 
We will:    Reimburse your expenses 
         Provide recompense for taking part in the study 
 
If you live within 40 miles of Norwich and would like further 
information on the study, please contact:  
Mr Lee Kellingray 
01603 255308  
lee.kellingray@ifr.ac.uk  
        Dr Joanne Doleman  
     01603 251477 
         joanne.doleman@ifr.ac.uk 
This study is funded by the Danish Council For Strategic Research and has been approved by a 
Local Research Ethics Committee.  
An expression of interest does not commit you to participation.  
Study duration, September 2014- September 2015. 
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Date 
 
 
Dear_______________, 
 
 
Thank you for your interest in 
 
Effects of Brassica on human gut Lactobacilli 
(EBL study) 
 
at the Institute of Food Research. 
 
I have sent you the details of this study, which is in progress at present, as you have 
responded to an advert about the study and you may fit the criteria for this study. If you 
have any further questions about the study, please contact, Mr Lee Kellingray on 
01603 255308 or lee.kellingray@ifr.ac.uk as stated on the enclosed participant 
information sheet. 
 
If you are interested in taking part or getting more information about the study, please 
fill out the reply slip on page 15 of your participant information sheet, return it to the 
Institute of Food Research in the freepost envelope provided and a member of the 
study team will be in touch. 
 
Thank you.  
 
Yours sincerely, 
 
 
 
 
 
 
Mr Lee Kellingray,  
EBL study manager. 
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EBL APPOINTMENT CARDS 
 
 
Screening / Rescreening @ HNU    Day ____________________ 
Bring with you a midstream urine sample from    Date____________________ 
within 2 hours of your appointment time.    Time___________________ 
Also bring with you the name and address of your GP  and  
details of any medication and/or supplements taken. 
 
      
Start of Test phase 1 @ HNU     Day ____________________ 
Bring with you a midstream urine sample.    Date____________________ 
        Time____________________ 
          
           
 
Start of Test phase 2 @ HNU     Day____________________ 
Bring with you a midstream urine sample.   Date___________________ 
        Time___________________ 
 
 
If you are unable to make the appointment please contact  
Mr Lee Kellingray on 01603 255308 or the HNU nurse on 01603 255305  
Thank you.  
 
 
……………………………………………………………………………………………………………… 
 
 
EBL APPOINTMENT CARDS 
 
Screening / Rescreening @ HNU    Day ____________________ 
Bring with you a midstream urine sample from    Date____________________ 
within 2 hours of your appointment time.    Time____________________ 
Also bring with you the name and address of your GP  and  
details of any medication and/or supplements taken. 
 
      
Start of Test phase 1 @ HNU     Day ____________________ 
Bring with you a midstream urine sample.    Date____________________ 
                                Time____________________ 
          
           
 
Start of Test phase 2 @ HNU     Day____________________ 
Bring with you a midstream urine sample.   Date___________________ 
        Time__________________ 
 
 
 
If you are unable to make the appointment please contact  
Mr Lee Kellingray on 01603 255308 or the HNU nurse on 01603 255305  
Thank you.  
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                         EBL study 
CONSENT FORM FOR RESEARCH STUDY 
Volunteer please initial each box 
 
I confirm that I have read and understand the information sheet dated ………….; version no. 
………….; for the above study, and I have had the opportunity to consider the information, 
discuss the study and ask questions.   
 
I confirm that I have received satisfactory answers to my questions.  
      
I understand that my participation is voluntary, and I am free to withdraw from the study (1) at 
any time without giving a reason and (2) without my withdrawal affecting future participation 
in other research studies at IFR.  
 
With whom have you discussed the information for this research study? 
 
Name:  ………………………………………………………………………….. Role:  EBL Study Manager / Study 
Scientist / Nurse 
 
I understand that any of my personal information and data collected during the study may be 
looked at by individuals at IFR, where it is relevant to participation in this study.  
   
I give permission for these individuals to have access to my information and data. 
    
I understand that my personal information and data will be held confidentially at IFR and that 
it will be destroyed after 15 years.       
     
I agree to my GP being informed of my participation in the study, and for my clinical results to 
be sent to my GP.  
 
Name and address of your General Practitioner: 
…………………………………………………………………………………………………………………………………………………
…………………………………………..……………………………………………………………………………………………………… 
…………………………………………………………………………………………………..……………………………………………… 
I understand that all research is subject to inspection and audit.     
NB: although your records may be accessed for this purpose your personal information remains 
confidential 
 
I agree to take part in the above study. 
 
Signed:  ………………………………………………………………………….. (Name in BLOCK letters) 
 
Date:  …………………………………………            Date of Birth: ………………..………………………………………… 
 
I confirm that the participant above has been given a full verbal and written explanation of the 
study. 
Signed: ………………………………………………………………………… (Name in BLOCK letters)  
Role:  …………………………………. (BLOCK letters)               Date: ………….……………………………………… 
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CONFIDENTIAL Participant Eligibility Screening 
Questionnaire EBL 
 
Participant code number……………………..                    Sex: Male / Female 
 
Date of birth: …………………………………….     Age: years 
 
Height:………cms     Weight: …………Kg           Body Mass Index (BMI, kg/m2)……  
 
Blood Pressure: Right arm…………… Left arm…………………. Pulse: …………… 
 
Urinalysis: see page 4 
 
Have you ever had any of the following?  If yes give details below each relevant 
section. 
 
Angina/heart disease:   Y N  Thrombosis:    Y N 
……………………………………….                            ……………................................…. 
…………………………………........                            ………………………………............ 
 
High Blood Pressure:    Y N   High Cholesterol:    Y N 
…………………………………….....                          ……………………………..........…. 
…………………………………….....                            ………………………........………. 
 
Chest problems:           Y N  Diabetes:            Y        N 
………………………………………….             ……………………………...........… 
………………………………………….  ………………………………………. 
 
Depression or anxiety: Y N       Digestive/Gastrointestinal disorders:     Y    N                                                                                                                            
………………………………............    …………………………………….                                      
……………………………………….   …………………………….......…. 
Skin conditions:         Y N Inflammatory disease:  E.g. rheumatoid 
…………………………....................   arthritis                 Y         N 
……………………............................     ………………………………. 
        ………………………………. 
Liver problems:  Y N     
……………………………………….  Other medical conditions:   Y         N           
………………………….       ………………………...............................…. 
……………………………………       
Kidney/Renal problems:  Y N
 ………………………………………………………………. 
………………………………………………………………. 
……………………………………………………………….                                       
 
Are you currently on any of the following? 
If yes, give details below each relevant section of brand, dosage, frequency, when 
started etc. 
 
Prescribed medication:     Y         N   
……………………………………………………………….…………………………………… 
……………………………………………………………….…………………………………… 
Exclude if on medication for gastrointestinal problems 
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Colonic irrigation/bowel cleansing/ laxative/diarrhoea treatments:     Y         N   
…………………………………………………………………………………………………… 
…………………………………………………………………………………………………… 
Exclude if on medication/treatment for diarrhoea, constipation, bowel 
discomfort/disorder (includes over the counter medications). 
          
Dietary Supplements: Y N  Herbal remedies: Y N 
……………………………….         ………………………………………. 
………………………………………….  ………………………………………. 
…………………………………….   ………………………………………. 
If taking supplements/herbal remedies which may affect the study data and the participant is not 
willing to discontinue use for one month before and during the study, please exclude.  Check 
supplements/Herbal remedies with scientist 
 
WOMEN ONLY SECTION 
Are you/could you be pregnant?                                    Y         N          
Have you been pregnant within the last 12 months?    Y         N 
Are you breast-feeding?      Y         N 
End of women only section 
 
Have you had a major physical injury/operation? If yes give details below:        Y         N 
……………………………………………………………….…………………………………… 
……………………………………………………………….…………………………………… 
Are you currently suffering from any illness/injury? If yes give details below:    Y          N 
……………………………………………………………….…………………………………… 
……………………………………………………………….…………………………………… 
SMOKING:  
Are you currently a: Non-smoker / Current smoker / Ex-smoker / Lifelong smoker 
(circle appropriate) 
What do/did you smoke? (E.g. cigarettes, roll ups, cigars, pipe etc.)………….…… 
If a non-smoker/Ex smoker, have you ever smoked? Y N    
If yes, how long since you stopped smoking?.....How many did you smoke each day?... 
If currently a smoker/lifelong smoker: How many years have you been smoking?… 
DRINKING:  
Do you drink alcohol:   Y   N       How many units do you drink per week? ……………… 
A unit of alcohol is approximately half a pint of beer or lager, a single pub measure of 
spirit e.g. gin/vodka or a small glass of wine (125mL). 
Exclude participants who appear to binge drink or regularly consume >15 units (women) 
or >22 units (men) per week.  
 
DIETARY QUESTIONS: 
Are you a vegan or vegetarian?                             Y N 
Do you have any special dietary requirements:  Y N 
If yes state:……………………………………………………… …………… 
Have you any known allergies:                             Y N 
Food:……………………………… Drugs: ……………………………………………….         
Other: ……………………….…………………………………… 
Are you currently on/or plan to start a diet programme?                          Y   N 
If yes state 
which:…………………………………………………………………………………………… 
If on a diet programme which may affect the study data and the participant is not willing to 
discontinue for one month before and during the study, please exclude.  Check diet programmes 
with scientist                                                                                                                               2 of 4                                                                                                                                                                  
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BLOOD DONOR: 
Are you a regular blood donor?        Y   N 
If yes, when did you last donate blood? ………………………………. 
                                                                                                                                                                         
Do you take prebiotics or probiotics? These may be in a drink, yoghurt or other 
products. 
If yes, which products?...................................................................... 
How frequently?............................................................................................... 
If taking regularly (3+ times a week) and willing to continue throughout the study then 
include. 
If taking occasionally (<3 time a week), participant will have to discontinue use for at 
least 1 month before starting the intervention and throughout the study.  If participant 
not happy to do so, please exclude from study. 
 
GUT FUNCTION: 
On average, how many times do you open your bowels per day? ……………….. 
Do you typically need to strain when opening your bowels?                  Y    N 
What is the typical colour of your stools? ……………………………………….. 
What is your typical stool type? (refer to Bristol Stool Chart):  
Type:          1          2          3          4          5          6          7                    (circle appropriate)                                        
If participant typically passes stool types 1, 2, or 7, exclude from study. 
Do you typically suffer from any pain/discomfort when passing stools?             Y   N 
If yes, would you describe it as typically being:Mild/Moderate/Severe    (circle appropriate) 
Have you ever seen blood in your stools?                                          Y           N 
If yes, when did you last see blood in your stools? ……………………………….. 
If the participant did not seek medical advice on blood in their stools, exclude from 
study. 
 
GENERAL PRACTITIONER: 
Do you agree to us informing your General Practitioner of your participation in the study 
or of any results found?   
Y  N 
If you have answered NO to this question then we are unable to accept you on 
this study. 
 
Name and Address of your General Practitioner: 
……………………………………………………………………………………………………
……………………………………………………………………………………………………
…………………………………………………Telephone number:……………………………….. 
 
As far as you know are you related to or living with any member of study team?     Y                 N 
 
Are you currently participating in another research study?                                      Y                 N   
If yes check with participant whether it involves dietary intervention– refer to HNU Senior Research 
Nurse or scientist 
 
Are you currently undergoing any GP/Hospital investigations?                       Y                 N 
 
 
Form completed by (print name):……………… …….............Signature:……………… ………… 
 
Designation:………………………… ……….                      Date: ….........................……..  
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URINE DIPSTICK TEST RESULTS 
Attach to screening questionnaire to be kept at Study centre 
     
Study Title:     
 
Participant code number (NOT NAME):……………   Date of Birth:……………… ………    
Male/Female (circle) 
 
Date of sample:………………… ………    Time of sample:………………………………. 
 
Dipstick urine test reults:      
 
Protein:…………         Glucose:…………         Ketones:…………        Bilirubin:………..    
Urobilinogen:………...         Blood:…………… 
 
Specific Gravity………………   pH: ………………………………… 
             
 
Test performed by:……………………               Signature:………………… 
 
Date:……………                                    Time:…………….. 
 
Menstruating:     Y    N   N/A (circle as appropriate)  If menstruating do not refer to GP 
repeat urine test 5 days after finishing Menstruation. If blood indicated on this occasion refer to GP 
as flagged          
                                                                                                            urine. 
Repeat urine dipstick test results. 
 
pH………….Protein:…………Glucose:……………Ketones:………          
Bilirubin:…………. 
 
Urobilinogen:………..                       Blood:………….                  Specific 
Gravity…………. 
 
Test performed by:……………………… 
Signature:……………………Date:…………Time:……… 
 
Abnormal results referred to HNU protocol ‘for the referral of abnormal urinalysis 
results at screening’:     Y      N 
 
Comments:……………………………………………………………………………………… 
……………………………………………………………………………………………………
……………………………………………………………………………………………………
…………………………………………………………………………………………………… 
 
Please note a copy of these results must be sent to the participant’s G.P on the 
Eligibility Screening Results Form.   
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Date 
 
 
Dear Doctor …………………………………………………… 
 
This is to inform you that your patient ………………………………………..date of 
birth……………………….has consented to participate in a human nutrition study at the 
Institute of Food Research. The study,  
 
 
 
 
Effects of Brassica on human gut Lactobacilli 
(EBL study) 
 
 
 
has been approved by a Local Research Ethics Committee and the EBL Study 
Manager, 
Mr Lee Kellingray, can be contacted on 01603 255308 or lee.kellingray@ifr.ac.uk if 
you require further information. 
 
It is our policy to forward to the participant’s GP, copies of all screening results 
obtained during the study. 
 
We anticipate your patient will complete this study 
by………………………………………………………………….. 
 
Yours sincerely, 
 
 
 
 
 
 
 
Mr Lee Kellingray  
EBL Study Manager 
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Effects of Brassica on human gut Lactobacilli 
(EBL study) 
 
 
 You are receiving this study summary as one of your patients has consented to 
participate in the EBL study and has undergone screening (results enclosed). As their 
GP, you will be sent the results from their screening, which includes dipstick urine test 
results, BP, pulse, weight and BMI. In addition, copies of stool charts used during the 
study will be sent to you, should any significant changes to your patients stool type be 
recorded throughout the study period. 
 
 The main aim of this study is to examine whether eating Brassica vegetables can 
modulate the gut microbiota and cause an increase in the lactobacilli bacteria in our gut. 
 
 Additionally, we are interested in what role the gut bacteria may play in the metabolism 
of glucosinolates contained within these vegetables. 
 
 Lactobacilli are a normal part of our gut bacteria and have been linked with health 
benefits in humans. Some foods can increase their number and, therefore, increase 
these health benefits. We aim to determine whether Brassica vegetables can increase 
the numbers of these ‘good’ bacteria. 
 
 Glucosinolates (GSLs) are found in plant tissues of Brassica crops, such as broccoli, 
cauliflower and watercress. GSLs accumulate in these foods with glucoraphanin being 
the predominant glucosinolate found in broccoli. When the tissue is disrupted the 
glucosinolates are converted to ITCs by the plant enzyme myrosinase.  
 
 When cooked, the myrosinase has been inactivated. So when cooked Brassica 
vegetables are consumed, it is the myrosinase-like enzyme that the microflora in the 
colon produce that are responsible for converting glucosinolates to ITCs. 
 
 ITCs have been shown to exert diverse biological effects. Sulforaphane (SF) is the 
predominant ITC obtained from glucoraphanin in broccoli. SF has been linked to health 
benefits in humans, such as cancer chemoprevention and helping to maintain a healthy 
heart. 
 
 It has been shown that the extent of conversion of GSLs to ITCs by the human gut 
microbiota varies greatly between individuals. We aim to assess whether the 
differences in GSL metabolism rates can be explained by differences in the gut 
microbiota populations by faecal bacteria phylogeny analysis. 
 
 Your patient will be asked to eat a low Brassica diet (1 portion a week) for 2 weeks and 
a high Brassica diet (9 portions a week) for 2 weeks, in a random order, with a 2 week 
washout period separating these diets. During their involvement in the study, your 
patient will be asked to provide a total of 6 urine samples and 7 faecal samples for ITC 
& gut microbiota analysis, respectively. 
 
 This project is funded by the Danish Council for Strategic Research and has been 
approved by a local research ethics committee. 
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Study Title: Effects of Brassica on human gut Lactobacilli (EBL study)  
 
Participant’s Name:……………………………………………………………   
 
Date of Birth:………….               Male/Female:………….. 
                           
Dipstick urine test reults:     Multistix SG test strips used – Leucocytes and Nitrites 
not tested 
                                                 Tested as per test strip guide times 
 
pH………………Protein:…………Glucose:…………Ketones:………     Bilirubin:……….. 
60 seconds       60 seconds          30 seconds              40 seconds                30 seconds 
 
Urobilinogen:………...       Blood:………………..      Specific Gravity……………… 
60 seconds                                   60 seconds                   45 seconds 
 
Menstruating:     Y    N   N/A (circle as appropriate)    
 
Test performed by (print name):……….. Signature:……………. Date:……… Time:…… 
 
Repeat test required at surgery prior to re-screen:  Y    N    N/A    (circle as appropriate)   
 
Repeat urine dipstick test results (HNU).  Tested using Urine dipstick test 
strips/guide times as above  
 
pH………….Protein:…………Glucose:……………Ketones:………          
Bilirubin:…………. 
 
Urobilinogen:………..                       Blood:………….                  Specific 
Gravity…………. 
 
 
Test performed by (print name):……………….. Signature:…………………. Date:……… 
Time:…… 
 
Observations: 
 
Blood Pressure: Right arm:……………Left arm:……………. Pulse:    Rt………  Lt……. 
 
Weight(kg): ……………… BMI(kg/m2):……… Reference range for study:  >19.5 - <30  
 
Copies of screening blood results attached:   Yes            No           Not applicable   
(circle as appropriate) 
 
The ……………. (above/1st urine/repeat urine /BP/ BMI (kg/m2) –insert as appropriate) 
result(s) will / will not exclude your patient from this study. 
 
Date:………………………………………..   Signature:………………………………… 
Designation:……………………………………………….. 
 
Abnormal results are referred to the HNU Medical Advisor for comments regarding 
participation in the study. 
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Date 
 
 
Dear Doctor ………….. 
 
 
Your patient, ………………………………….., date of birth …………………………….. 
has consented to take part in a human nutrition study at the Institute of Food Research 
entitled,  
 
 
 
Effects of Brassica on human gut Lactobacilli (EBL 
study) 
 
 
Following consent it is our standard practice to screen the volunteers to exclude any 
health factors which may affect the study data or whose screening results may indicate 
an issue which may require further investigation.  We are looking for healthy people 
who have no chronic illness and are not taking any prescribed medication which may 
affect the study data.   
 
 
Some/none of your patient’s results fell outside the standard reference range on this 
occasion.   
 
 
These results will/will not affect the study data. 
 
 
Your patient will/will not be able to participate in the study. 
 
 
Yours sincerely, 
 
 
 
 
 
Mr Lee Kellingray  
EBL Study Manager 
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Effects of Brassica on human gut Lactobacilli 
(EBL study) 
 
Stool chart 
 
 This stool chart will allow us to monitor and record any changes to gut function 
during the study period.  
 
 Vegetables are a good source of fibre and this is fermented in the colon by your 
gut bacteria. This releases nutrients which we can use, however much of the 
fibre is bulky and not of use to us. 
 
 This fermentation process includes the release of gases, which are in turn 
released by us through flatulence (wind). 
 
 Increased fibre intake can sometimes lead to a larger number of bowel 
movements, discomfort and increased flatulence. 
 
 Therefore, during the periods outlined below we would like you to keep a record 
of each stool using the Bristol stool chart on page 2 to identify the type of stool. 
During these periods, we would also like you to record whether you see any 
blood or mucus on/in your stool and rate any experience of abdominal 
discomfort/pain, abdominal bloating, straining when opening your bowels 
(constipation), and/or flatulence for each day, leaving a gap to separate each 
day (example on page 2). 
 
 Ladies who are menstruating at the time entries are added to the stool chart 
should mark M in the box referring to stool type as this may help to interpret the 
data. 
 
 We would like you to keep this record for 7 days whilst consuming each of the 
supplied diets, and then for the 7 days which comprise the final week of the 
study. 
 
 You can choose which days to complete, but ideally it must be 7 consecutive 
days.  If this is not possible, then the 7 days should include one weekend. 
 
 Key to gastrointestinal sensations: 
              None – no discomfort. 
Mild – minimal discomfort but not interfering with everyday activities. 
Moderate - causes interference with everyday activities. 
Severe – prevents normal everyday activities. 
 
 
 
 
 
Please call Lee Kellingray on 01603 255308 
or Joanne Doleman on 01603 251477 
OR the study mobile on 07542 124238 
during normal working hours for any help. 
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Towards the bottom of the stool chart, which we would like you to complete, you will 
notice questions relating to any changes in medication. Should you have any changes 
to your medication, or start taking any medication of any kind, we would appreciate it if 
you could record what is being taken, any changes such as increased/decreased dose, 
date the medication was taken/changed, and the reason for taking/changing the 
medication. 
 
The HNU Senior Research Nurse may contact you by telephone to discuss information 
on the stool chart, and might advise you to speak to your GP should it be deemed 
necessary, as well as advising on your continuation or exclusion from the study.  
 
If you suffer from diarrhoea during the study, we would like you to contact a member of 
the study team and you will be asked to not collect a faecal sample for a minimum of 
48 hours after the last episode of diarrhoea. Should the diarrhoea persist for more than 
72hrs, you may be advised by the HNU Senior Research Nurse to speak to your GP 
and will be excluded from the study. 
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EBL study stool chart example: 
 
Date Time Type 
(refer 
to 
Bristol 
stool 
chart) 
Abdominal 
discomfort 
(none, 
mild, 
moderate, 
severe) 
Abdominal 
pain 
(none, 
mild, 
moderate, 
severe) 
Type of 
abdominal 
pain (dull 
ache, 
sharp pain, 
cramping) 
Bloating 
(none, 
mild, 
moderate, 
severe) 
Constipation 
(none, mild, 
moderate, 
severe) 
Flatulence 
(none, 
mild, 
moderate, 
severe) 
Colour  
(pale 
cream, 
light 
brown, 
dark 
brown, 
black) 
Blood Y/N 
If yes, 
what 
colour 
(bright 
red, dark 
red) 
Mucus 
Y/N 
01/06/14 09:05 3 none none none none none none Pale 
cream 
N Y 
01/06/14 14:25 2 none none none mild none moderate Light 
brown 
Y 
Bright red 
N 
            
02/06/14 10:50 4          
M 
none none none none none none Dark 
brown 
N N 
02/06/14 17:15 2          
M 
mild       none none none        none mild        Light 
brown 
N N 
            
03/06/14 All day none moderate moderate dull ache mild severe severe n/a n/a n/a 
 
Have there been any changes to your medication?   Y N 
What is the medication? Senokot………………………………………………………………………………………………… 
How has your medication changed? Took 2 tablets……………………………………………………………………………………. 
When did your medication change? Tuesday 3rd June 2014 at 10pm…………………………………………………………….... 
For what reason did your medication change? I was constipated and experiencing abdominal 
pain..........................................................................................................................................................................................................................
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 EBL FOOD DIARY  
 KEY INFORMATION FOR RECORDING FOOD AND DRINK CONSUMPTION 
 Food diaries are a very important part of the study because they help us to interpret the 
information we get from your study periods. It is however, essential that you eat as 
normal, apart from the foods we have asked you to avoid. 
 
 We would like you to record what fruits and vegetables you are eating during the 
periods outlined below. 
 
 Start each day on a new sheet. Use as many pages as you need for each day 
 
 Circle the day of the week and date at the top of each page. 
 
 You can choose which days to complete, but ideally it must be 7 consecutive days.  
If this is not possible, then the 7 days should include one weekend. 
 
 Try to write down what you eat at the time you eat it rather than from memory at a 
later date. Remember to add all fruits and vegetables eaten as snacks and nibbles as 
these can be easily forgotten. 
 
 Take a notebook with you if you eat out and try to include as much detail as possible. A 
portion size guide has been included to help you (please write which photo you are 
referring to by each portion of food).  Keep the labels of unusual foods containing 
fruits or vegetables if they are clean and put in the back of the record book. 
 
 Be as specific as possible, for example, Sainsbury’s ham and pineapple pizza Finest 
range. Use brand names and include details about food types such as Porcini 
mushrooms or button mushrooms. 
 
 For items that are rehydrated, e.g. dried apricots, it is important to state whether you are 
recording dry or soaked weight, if you do choose to weigh it out. 
 
 If you spill anything or don’t finish the fruit or vegetable, add this to the remarks section 
and include how much was spilt or left uneaten. 
 
 For any meals cooked from a recipe containing fruit or vegetables, complete the recipe 
sheet provided (example on page 8). State how much you ate as a proportion, e.g. one 
quarter, or half. 
 
 Record any fruit or vegetable supplements taken during diary recording days. 
 
 For items that are eaten and drunk on a very regular basis such as orange squash, 
record as much detail as possible the first time i.e. amount of water, amount of orange 
squash, brand of orange squash and then record ‘as usual’ for these items in future. 
 
 Record how you cooked your food (boiled, steamed, fried, grilled etc). If you fried the 
food, don’t forget to record what you fried it in (olive oil; butter; lard, beef dripping etc). 
 
 Record where you buy your food and drink when you eat away from home e.g. bacon, 
lettuce and tomato sandwich from Marks and Spencer.  Break down foods like salads, 
and sandwiches into individual ingredients. 
 
 If the weight is on the packaging of the food item, record that, noting down the individual 
ingredients and amounts. Write the weight of the portion that you actually ate on your 
food recording sheets.  
 
 An example of a record sheet is shown on page 7. 
Please call Lee Kellingray on 01603 255308 or Joanne Doleman on 01603 251477 at IFR 
OR the Study mobile on 07542 124238 during normal working hours for any help. 
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The table below lists common foods and drinks and gives examples of the words 
that you can use to describe these items. This list is an example, you will only 
need to do this for foods and drinks containing fruits or vegetables. 
 
(Note: You may wish to use other relevant words that are not on this list) 
 
Food / Drink Examples of Descriptions 
Alcoholic drinks 
Red wine / white wine / rosé wine / sparkling wine, alcopop, low alcohol. 
If measured in a pub: pint / half-pint, single / double, large / small/bottle.  
Soft drinks 
No added sugar, diet, diluted / undiluted volume. 
If measured in a pub: pint / half-pint. 
Biscuits 
Varieties: shortbread / digestive / rich tea / custard cream / etc. 
With / without chocolate / cream-filled.  
Bread 
Wholemeal / brown / white / 50:50 / seeded / granary / fruit.  
Not pre-sliced, medium / thick slice, small loaf, toasted.  
Crusty / soft, baguette / French stick, bagel, pitta.  
Breakfast Cereals 
Include details about milk and sugar (type & quantity). 
Porridge: instant / homemade, quantity of raw oats, toppings. 
Butter 
Hard / spreadable, salted / unsalted  
Check butter & not buttery spreads like I Can’t Believe It’s Not Butter 
Cakes & Buns 
Type: Victoria / chocolate / fruit / carrot, muffin / sponge / etc. 
Filling: frosting / royal icing / marzipan / buttercream / jam. 
Cheese 
Variety: Cheddar (mature, mild) / parmesan / brie / etc. 
Hard / soft / cream / cottage / processed / triangle. 
Half-fat / light. 
Cream 
Double / clotted / single / sour / long-life / spray / crème fraiche. 
Half-fat / light. 
Coffee & Tea 
Include details about milk and sugar / sweetener (type & quantity). 
Cup / mug. 
Fruit / herbal / green. 
Filter / instant / decaffeinated / cappuccino / espresso. 
Eggs 
Medium / large. 
Scrambled (include details for milk & butter) / boiled / fried 
(include details for oil). 
Fish & Shellfish 
Type: salmon, cod, sardines, king prawns. 
Fresh / canned (oil, brine or water) / frozen. 
Breadcrumbs / batter / cakes / fingers.  
Fruit, Vegetables 
& Fruit Juice 
Varieties: e.g. apples - braeburn, cox, gala. 
State If peeled and add the weight of the peeled item, 
e.g. apples, potatoes, kiwi, banana. 
Canned (juice or syrup) / fresh / stewed / dried / frozen. 
Fruit juice: freshly squeezed / fresh (e.g. from chilled section) / 
from concentrate (e.g. long-life). 
Gravies & Sauces 
Instant / sachet / jar / fresh. 
With meat juices / milk (type & amount), thick / thin. 
Meat & Poultry 
Type: pork, chicken, beef, lamb. 
With / without fat or skin, well-done / rare. 
Cut: chop / steak / leg / drumstick / mince (lean) / sausages  
(pork or beef, thick or thin, low-fat) / bacon (streaky or back). 
Milk Skimmed / 1% fat / semi-skimmed / whole (or full-fat). 
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UHT / soya / rice / flavoured / condensed. 
Nuts & Seeds 
Salted / unsalted / honey roasted / dry. 
Please state type of nuts & seeds, e.g. walnuts, peanuts, sesame seeds. 
Oils 
Varieties: olive oil / extra-virgin olive oil / vegetable oil / sunflower oil / rapeseed 
oil / sesame oil. 
Pasta, Rice, 
Noodles & 
Couscous 
Wholemeal / brown / white / pilau / egg-fried. 
It is important to state whether weight is for the dried or cooked ingredient. 
Pies & Quiches 
Short crust / puff pastry / suet. 
Individual / family-sized / party-sized. 
Provide details on filling, e.g. steak and kidney. 
Pizza 
Size: 8” / 10” / 12”.  Takeaway / chilled / frozen.   
Thick / thin / stuffed crust.  List toppings. 
Potatoes 
Chips: frozen / fresh, oven-baked / fried, thick-cut / crinkle cut / French fries. 
Mash: remember to include butter, milk, cheese, etc. 
Roast: remember to include type & amount of fat used.  
New & Baked: with / without skin, butter. 
Sandwiches 
Spread / no spread / mayonnaise. 
List all fillings.  
Spreads 
Varieties: buttery (e.g. I can’t believe it’s not butter, Clover), olive oil-spread 
(e.g. Bertolli), vegetable oil spread (e.g. Flora), sunflower spread, soya spread. 
Low fat / full-fat. 
Yoghurts 
Creamy / full-fat / low fat / fat-free. 
Natural / Greek / fruit / toffee / fromage frais 
  
 
 
 
 
 
 
 
Recipes 
What to do if you make a dish containing more than one portion, e.g. lasagne, 
casserole, meat pie, stir fry, apple crumble (please see the attached example). 
 
In the recipe section: 
o Name of dish 
o Date of when the meal was cooked and then eaten 
o Cooking method 
o Portion of recipe consumed, e.g. ¼.   
 Please add this as a fraction, not a weight.   
o Leftovers 
o Ingredients  
 List all ingredients-if you are able to weigh things, that would be 
very useful 
 It is important to include cooking oils/fats in your ingredients 
 
In the main diary: 
o Record the recipe name, e.g. Lasagne - recipe. 
o It is not necessary to re-write the quantity consumed or leftovers in this 
section 
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Food portion sizes
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Commonly used spoons, cups and glasses sizes 
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FOOD DIARY EXAMPLE 
EBL STUDY 
 
 
 
 
Volunteer 
Code:…EBL123……………………. 
 
 
 
 
 
 
 
 
 
7 days during the 2 week period of eating the 
Brassica diet in test phase 1 
 
 
 
 
 
7 days during the 2 week period of eating the 
Brassica diet in test phase 2 
 
 
 
 
 
The 7 days in the last week of the habitual diet phase 
 
 
 
 
 
 
 
(Circle as appropriate) 
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FOOD DIARY        EBL STUDY 
Food Intake example Page 
Volunteer Code: EBL123        Day: Mo    Tue    We    Th    Fr    Sa    Su   (please circle)      Date: 17/06/14 
 
TIME 
 
BRAND NAME 
FOOD/DRINK 
(description; how cooked; where 
bought; brand and any comments) 
AMOUNT 
SERVED  
LEFT 
OVER  
CODE AMOUNT 
08.00 Kelloggs Sultana bran  Small bowl (A)    
 Tesco Orange squash ~100ml    
 Robertson’s Marmalade orange (thick cut) 1 tablespoon    
10.30 
 Coffee (from machine), milk, no 
sugar 
small cup 
(190ml) teaspoon   
13.00 
Local grocer 
Cherry tomato 
small portion 
(about 70g) (A) 
   
 
 
Orange large 
Peel & 
pips  
  
 
Tesco Fanta 1 can (330ml)    
15.30 
PG Tips Green tea with lemon - see recipe 
sheets 
medium mug 
(220ml)    
18.00 
 
Chilli con carne – see recipe page 
medium 
portion 300g 
(B) 
   
 
 
Carrots, boiled in salted water 
small portion 
(about 70g) (A)  
  
 
 
Potatoes, roasted in vegetable oil 
small portion 
(about 70g) (A) 
   
 
Ski 
Low fat Strawberry yoghurt  
1 small 
yoghurt 
   
20.00 Blossom hill Red Wine – Italian Shiraz 1 small glass 
(175ml)    
       
  
  
   
  
  
   
  
  
   
 
 
  
   
 
 
  
   
       
       
       
       
       
       
       
       
       
       
       
 
Columns in green for official use only. 
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EBL STUDY  
Recipe Sheet - EXAMPLE 
Please use this sheet for any recipes that you use whilst recording your intake for us. In the “portion 
served” box tell us how much of the recipe you actually ate. Use this sheet also to tell us how you would 
usually take your tea/coffee on a regular basis. 
 
FOOD DIARY        
  
Volunteer Code: EBL123           Day: Mo    Tue    We    Th    Fr    Sa    Su   (please circle)    Date: 01/07/14 
 
NAME of RECIPE AND 
INGREDIENTS 
(description, brand etc) 
BRAND NAME AMOUNT IN 
RECIPE (g) 
PORTION 
SERVED 
Green tea (medium cup)   220ml 
water  200ml  
semi skimmed milk Tesco 30ml  
Tea bag  PG Tips strong infusion  
    
Chilli con carne   Medium 
portion 
(300 g) (B) 
1 large onion, diced   Large onion  
6 cloves of garlic, finely 
chopped  
 6 fat cloves  
tin of tomato puree  Tesco small tin  
tin chopped tomatoes  Napoli Large can (440g)  
tin red kidney beans, drained 
and washed  
Tesco Large can (440g)  
1 large red pepper, deseeded 
and chopped  
 1 large pepper  
A little vegetable oil -  
(enough to cover the bottom of 
the casserole dish) 
Waitrose 2 tablespoons  
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Effects of Brassica on human gut Lactobacilli (EBL study) 
 
Faecal Collection Kit: 
In order to collect your faecal sample we have provided you with a faecal collection kit. The kit should 
include: 
o An insulated container with a label on it 
o A plastic pot 
o A plastic bag  
o A nappy sack 
o Freezer blocks or ice cube bags 
o A plastic clip to close the plastic bag  
o When necessary, a urine sample collection bottle will be included and we would advise you 
to put this somewhere separate from the faecal collection kit until it is required. 
 
Please can you check your kit to ensure that you have all the items. Although we have checked the kit, if 
anything is missing please contact a member of the study team on the study mobile on 07542 124238, 
Lee Kellingray on 01603 255308 or Joanne Doleman on 01603 251477 before you collect your sample. 
 
The instructions as to how we would like you to collect your sample are on the other side of this piece of 
paper.  
 
Please ensure you have read and understood the instructions in advance of trying to collect your sample. If 
you have any questions please get in touch with a member of the study team.  
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Instructions for faecal collection: 
 
 
Day before sample collection 
 
Place the freezer blocks in the freezer so that they are ready to place into the bottom of the 
insulated container on the day of the sample collection. If you have ice cube bags please fill the 
bags with water and place in the freezer overnight. 
 
 
Day of the sample collection 
 
1. Place the labelled plastic bag into the plastic pot as though you were lining a bin, roll the excess bag 
down over the outsides of the plastic pot (note pot will be white not black as in picture).  
 
2. Just prior to collecting your sample, place the frozen freezer blocks or bags of ice cubes into the 
bottom of the insulated container (may not be as pictured). 
 
3. Collect your faecal sample directly into the labelled plastic bag in the pot. The pot is only used to 
make it easier to hold the bag. Please do not place any toilet paper into the pot and avoid collecting any 
urine in the pot if possible. 
 
4. Once the faeces is inside the labelled plastic bag, roll the top of the bag back up and seal the bag, 
close to but not touching the sample, using the plastic clip provided. Remove the sealed bag from the 
plastic pot and throw the plastic pot away in your normal domestic waste. 
 
5. Place the sealed bag inside the nappy sack and tie the nappy sack shut using the bag handles. 
 
6. Place the tied nappy sack with the freezer blocks/ice cubes into the insulated container. Close the 
lid of the insulated container and clip it shut to secure it. Wash your hands. 
 
7. Please write your volunteer number, and the date and time of collection on the label on the outside 
of the insulated container. 
 
8. Please call the study mobile on 07542 124238, or a study scientist Lee Kellingray on 01603 255308 or 
Joanne Doleman on 01603 251477 before you deliver your sample so that we can be ready to receive it.  
 
9. If for any reason a study scientist is unable to take your call, you can contact the Human Nutrition Unit 
(HNU) on 01603 255305. If you call the HNU and the answer phone is on it means there is no one at the 
HNU and you will need to contact one of the study scientists on the numbers above.   
Thank you very much. 
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Effects of Brassica on human gut Lactobacilli (EBL study) 
 
A list of foods that are high in glucosinolates and must be avoided: 
 
- Mustard : all types including ethiopian mustard, indian mustard, chinese mustard, red giant 
mustard, wrapped heart mustard cabbage, yellow mustard, black mustard, broad beak mustard, 
purple stem mustard, mustard spinach. 
 
- Broccoli: all types including rapini or broccoli raab, alboglabra kai-ian (chinese broccoli), 
romanesco broccoli, broccoli, broccoflower. 
 
- Sprouting broccoli  
 
- Brussels sprouts 
 
- Cabbage: all types including white cabbage (drum), head cabbage, savoy cabbage, red cabbage, 
green cabbage. 
 
- Kale: all types including curly kale, chinese kale, sea kale, pabularia siberian kale, acephala Kale. 
 
- Kohl rabi 
 
- Rutabaga: Swede, neep, turnip and turnip tops 
 
- Collard greens and spring greens 
 
- Chinese cabbage; Pak Choi; bok choi and other Chinese brassica vegetables   
 
- Radish 
 
- Salad rocket 
 
- Horseradish: sauces and vegetables 
 
- Cress: all types, including watercress and garden cress 
 
- Papaya seeds 
 
- Cauliflower  
 
- Wasabi  
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Brassica vegetables to avoid 
 
  
 
Kohlrabi Collard greens Collard greens 
 
 
 
Spring greens Kale Wasabi 
 
 
 
Cauliflower Cabbage Brussels Sprouts 
 
 
 
Chinese cabbage Pak Choi cabbage Bok Choy cabbage 
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Savoy cabbage Broccoli Salad rocket 
 
  
Sprouting Broccoli Turnip and turnip tops Radish 
  
 
Horseradish Mustard/mustard seeds Cress 
 
  
Watercress Watercress Papaya seed 
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 MEDICATION/MEDICAL CONDITIONS DECLARATION  
AGREEMENT 
 
 
Certain illnesses and medication may affect the outcome of research studies. 
Therefore, we would like you to inform the study organisers if you 
 start taking medication 
 suffer from any illness 
 
                                  OR 
 
 become pregnant 
 
 
Please sign below to confirm that you have agreed to this request. 
 
 
 
I……………………….consent to inform the study organiser of the 
 
      commencement of any medication/medical changes whilst participating in the 
 
      study 
 
 
                                                              OR 
 
 
    If I think I may be pregnant whilst participating on the study. 
 
 
 
 
   Signature of volunteer……………………………………………. 
 
 
   Date……………………….. 
 
 
 
  Signature of scientist…………………………………………………………. 
 
 
 
 
 
  AB/Vers.2/Rev. Nov.04 
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REPORT ON ADVERSE EVENT (AE)/REACTION (AR)/SERIOUS ADVERSE EVENT (SAE) 
(SAE/SUSAR-internal use only as the official NRES form will be used and signed off by Chief Investigator) 
 
 
Adverse Event / Adverse Reaction (circle as appropriate)  
 
Study Title: EBL 
 
REC reference:…………………………………..  
 
Participant Code Number:………………..   Date of Birth: ………………………...      Age: ……………………. 
 
Male/Female (delete as appropriate) 
 
Date/Time of occurrence: ………………………………..  Date/Time reported: ……………………………..... 
 
Reported to (initially): …………………………………….  Place of occurrence: ………………………………    
 
 
Description of AE/AR/SAE/SUSAR: 
 
Extent of Adverse Event (delete as appropriate):        Mild       Moderate     Severe 
 
Treatment/Action:……………………………………………………………………………………………………… 
 …………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………  
Outcome (delete as appropriate):      Recovered      Not yet recovered         Unknown 
 
Description of Trial Material:  
 
Drug Reaction (delete as appropriate):  Certain    Probable    Possible    Unlikely    Unclassified  
 
Reporter details (print name):……………………………….Title:…………………………………………… 
 
Signature:…………………………………………………………….. 
Date:………………………………………………………….. 
 
Professional Address:   HNU, IFR, Colney, Norwich, NR4 7UA    Tel. Number: 01603 255 305 
 
 
Chief Investigator   Professor Richard Mithen 
 
Signature:                                                          Date:        
 
 
Professional Address:  HNU, IFR, Colney, Norwich, NR4 7UA    Tel. Number: 01603 255 305 
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Comments by IFR Medical Advisor:  
 
………………………………………………………………………………………………………………………….. 
…………………………………………………………………………………………………………………………..  
………………………………………………………………………………………………………………………….. 
…………………………………………………………………………………………………………………………..  
………………………………………………………………………………………………………………………….. 
…………………………………………………………………………………………………………………………..  
 
Participant’s screening questionnaire attached (circle as appropriate):   Yes   No 
 
If ‘No’ state reason:……………………………………………………………………………………….. 
 
N.B. please ensure any relevant paperwork is attached  
 
 
IFR Medical Advisor 
 
Name:............................................................................................................................................... 
 
Professional Address: 
 
…………………………………………………………………………………………………………………………..  
………………………………………………………………………………………………………………………….. 
…………………………………………………………………………………………………………………………..  
Telephone No.: ……………………………………………………………………………………………. 
 
 
Signature:……………………………………… Date:………………………………………………… 
 
 
 
                                                            
 
 
 
 
 
 
   Based on Version 4/Aliceon Blair/Rev. Mar 2006       
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EBL 
 
Cooking Instructions 
 
 
 
 Cook the vegetable portions from frozen; DO NOT DEFROST 
 Fill the base of the steamer to the low fill level with water 
 Plug in and switch on.  Set the timer to 10 minutes 
 Wait until steam can be seen rising from the vent at the top. 
 Use the top tier to steam your broccoli or cauliflower  
Brassica florets: Steam Brassica florets for 4-5 minutes 
 
We ask that you do not cook the Brassica vegetables any more, but 
feel free to incorporate your portions of Brassica vegetables into 
your meal at the end of its cooking time.  
 
Should the steamer stop working, please contact 
Lee Kellingray on 01603 255 308  
Joanne Doleman on 01603 251 477 
or the study mobile on 07542 124238 
 during normal working hours. 
THANK YOU 
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Soup storage and cooking guidelines  
 
 
 
 
 
 
 
Storage instructions 
Frozen soups collected by/delivered to you should be stored in the freezer on 
receipt. Please DO NOT re-freeze soups once they have thawed.  
 
 
 
Cooking instructions 
Hob: Empty chilled contents into a pan. Heat gently, 
stirring occasionally for 4 minutes. Ensure soup is piping 
hot. 
Microwave: Can be heated from chilled or frozen. Remove 
lid. Lay lid back on the pot and place pot on microwaveable 
plate and heat for the times below, stirring halfway through 
the cooking time. Allow to stand for 2 minutes after 
heating.   
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